RU2810326C2 - Antibodies against hla-g, compositions containing antibodies against hla-g, and methods of use of antibodies against hla-g - Google Patents

Abstract

FIELD: biotechnology.

SUBSTANCE: invention relates to an antibody that specifically binds to human HLA-G (hHLA-G), a method for its production, as well as a composition and a kit containing it. Also an isolated nucleic acid encoding the above antibody is disclosed, as well as a vector and a cell containing it is disclosed.

EFFECT: invention is effective for the treatment of a disease or condition in which HLA-G is involved.

20 cl, 10 dwg, 1 tbl, 12 ex

Description

RELATED APPLICATIONS

[0001] This application claims priority to U.S. Provisional Patent Application No. 62/737,666, filed September 27, 2018, which is incorporated by reference herein in its entirety.

TECHNICAL FIELD

[0002] The present invention provides antibodies having binding specificity for HLA-G and compositions containing said antibodies, including pharmaceutical compositions, diagnostic compositions and kits. Methods of using antibodies against HLA-G for therapeutic and diagnostic purposes are also proposed.

BACKGROUND OF THE ART

[0003] Class IG histocompatibility antigen, HLA-G, also known as human leukocyte antigen G (HLA-G), is a protein that in humans encodes the HLA-G gene. HLA-G belongs to the non-classical heavy chain paralogues of HLA class I. HLA-G is a heterodimer consisting of a heavy chain and a light chain (beta-2-microglobulin). There are membrane-bound and soluble forms of HLA-G.

[0004] HLA-G is normally expressed at the transplacental barrier and other immunologically privileged sites. HLA-G may play a role in immunotolerance in pregnancy because it is expressed in the placenta by extravillous trophoblast cells, whereas the classical MHC class I genes (HLA-A and HLA-B) are not expressed. Since HLA-G was first identified in placental samples, many studies have assessed its role in pregnancy disorders such as preeclampsia and recurrent miscarriage. See source: Michita, Rafael Tomoya et al., Human Immunology. 2016, 77 (10): 892-897, which is incorporated by reference herein in its entirety with all drawings.

[0005] HLA-G has been shown to be immunosuppressive. By binding to receptors expressed on various myeloid and lymphoid cells, HLA-G can directly inhibit the functions of NK cells, cytotoxic T lymphocytes, B cells, neutrophils, monocytes, macrophages and dendritic cells. HLA-G also inhibits T and NK cell proliferation and cytolytic activity. HLA-G inhibits phagocytosis and induces the formation or expansion of regulatory T cells.

[0006] HLA-G mediates immune function through at least three ITIM-containing inhibitory receptors, ILT2, ILT4 and KIR2DL4. On lymphoid and myeloid cells, for example, HLA-G mediates function through ILT2. On myeloid cells, HLA-G mediates function through ILT4. On decidual NK cells, HLA-G mediates immune function through KIR2DL4 and ILT2.

[0007] HLA-G is an immune checkpoint target. HLA-G can directly suppress immune cell function through receptor binding and/or trogocytosis and disruption of chemotaxis. HLA-G can enhance the invasive and metastatic potential of tumor cells. HLA-G promotes tumor evasion from immunological surveillance, enhances metastasis and progression of malignant neoplasms. During tumor progression, HLA-G has other effects such as inhibition of immune cell cytolysis, induction of immune cell apoptosis, and/or acquisition of regulatory cells through receptor binding and/or trogocytosis.

[0008] Upregulation of HLA-G expression occurs in a variety of tumors and is associated with poor prognosis and disease progression. Serum HLA-G levels are elevated in breast, lung, colorectal (CRC), gastric, esophageal, neuroblastoma, cervical, and hematologic cancers. HLA-G has also been found to correlate with clinical indicators in advanced stage diseases, such as tumor metastasis, poor prognosis, immunosurveillance evasion, and tumor invasiveness.

[0009] HLA-G is a promising target in diseases such as cancer.

BRIEF DESCRIPTION OF THE INVENTION

[0010] The present invention provides antibodies that selectively bind HLA-G. In some embodiments, the antibodies bind human HLA-G. In some embodiments, the antibodies comprise at least one CDR sequence defined by a consensus sequence set forth herein. In some embodiments, the antibodies comprise one or more of the exemplary CDR, V _H or V _L sequences described herein, or variants thereof. In some aspects, the variant is a variant with one or more conservative amino acid substitutions.

[0011] Compositions and kits containing these antibodies are also provided. In some embodiments, the compositions are pharmaceutical compositions. Any suitable pharmaceutical composition may be used. In some embodiments, the pharmaceutical composition is a composition for parenteral administration.

[0012] Methods of using anti-HLA-G antibodies according to the present invention are also described herein. In some embodiments, the method is a method of treatment. In some embodiments, the method is an analytical method. In some embodiments, the method is a method for purifying and/or quantifying HLA-G.

[0013] In some embodiments, the method is a diagnostic method. In some embodiments, the diagnostic method includes or consists of detecting tumor-expressed HLA-G. In some embodiments, the diagnostic method includes or consists of detecting soluble HLA-G. In some embodiments, the detection method includes or consists of detecting HLA-G expression on immune cells.

[0014] In some embodiments, the antibodies are used to treat a disease or condition. In some aspects, said disease or condition is selected from cancer, autoimmune disease, and infection. In some aspects, the use of any of the antibodies or pharmaceutical compositions of the present invention is provided for the treatment of a disease or condition selected from cancer, autoimmune disease, and infection.

BRIEF DESCRIPTION OF THE DRAWINGS

[0015] In FIG. Figure 1 shows a table with the avidity and monomer affinity values of anti-HLA-G antibodies for the recombinant HLA-G protein.

[0016] In FIG. 2A and FIG. 2B shows biolayer interferometry sensograms for anti-HLA-G antibodies that bind to HLA-G and can be divided into three biochemical groups based on their ability to cross-block in pairwise binding testing.

[0017] In FIG. Figure 3 shows sensograms obtained by biolayer interferometry for antibodies that bind and block the interaction of HLA-G with ILT2 and ILT4 at different levels of effectiveness.

[0018] In FIG. 4 shows an assessment of the binding of anti-HLA-G antibodies to naturally expressed HLA-G found on JEG-3 tumor cells.

[0019] In FIG. 5A, FIG. 5B, FIG. 5C and FIG. 5D shows data for Fab and anti-HLA-G antibodies that restore NKL killing activity by blocking suppression mediated by the interaction of HLA-G with ILT2 or ILT4.

[0020] In FIG. 6 shows an assessment of anti-HLA-G antibody reversal of HLA-G-mediated suppression of primary human cells. In fig. 6A and FIG. 6B shows an assessment of phagocytosis in a human macrophage assay. In fig. 6C shows an assessment of the cytotoxic activity of primary human NK cells. In fig. 6D shows an assessment of the function of primary human CD8+ T cells.

[0021] In FIG. 7A and FIG. 7B shows results corresponding to values for binding of anti-HLA-G antibodies to individual recombinant HLA class Ia antigens immobilized on beads.

[0022] In FIG. 8 shows an assessment of the binding of anti-HLA-G antibodies to a panel of B-lymphoblastoid cells (B-LCL) of 28 HLA-typed lines.

[0023] In FIG. 9A and FIG. 9B shows an assessment of the binding of anti-HLA-G antibodies to various forms of HLA-G after site-directed mutagenesis.

[0024] In FIG. 10 shows data confirming the inhibition of tumor growth by an anti-HLA-G antibody with Fc effector function in a tumor xenograft mouse model using 721.221 cells expressing HLA-G.

DETAILED DESCRIPTION OF THE INVENTION

1. Definitions

[0025] Unless otherwise indicated, all terms, symbols and other scientific terms used herein are intended to have meanings well known to those skilled in the art to which this invention relates. In some cases, terms with commonly known meanings are defined herein for clarity of understanding and/or ease of reference; the inclusion of such definitions herein does not necessarily imply any difference from the meanings customary in the art. The techniques and procedures described or referred to herein are generally well known and are often used using standard techniques by those skilled in the art, such as the widely used molecular cloning methods described in Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd ed. (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. If necessary, procedures involving the use of commercially available kits and reagents are performed, generally in accordance with manufacturer-provided protocols and/or parameters unless otherwise specified.

[0026] As used herein, terms used in the singular include their plural equivalents unless the context clearly indicates otherwise.

[0027] The term “about” refers to a given value and covers the given value as well as a range of smaller and larger values relative to it. In some embodiments, the term “about” indicates a specified value of ±10%, ±5%, or ±1%. In some embodiments, the term “about” indicates a specified value ± a standard deviation from the specified value.

[0028] The term “combinations thereof” includes all possible combinations of elements to which the term refers.

[0029] The term "immunoglobulin" refers to a class of structurally related proteins typically containing two pairs of polypeptide chains: one pair of light (L) chains and one pair of heavy (H) chains. In “intact immunoglobulin” all four of these chains are connected to each other by disulfide bonds. The structure of immunoglobulins has been described in detail. See, for example, Paul, Fundamental Immunology 7th ed., Ch. 5 (2013) Lippincott Williams & Wilkins, Philadelphia, PA. Briefly, each heavy chain typically contains a heavy chain variable region ( _VH ) and a heavy chain constant region (CH). The heavy chain constant region typically contains three domains, _CH1 , _CH2 and _CH3 . Each light chain typically contains a light chain variable region (V _L ) and a light chain constant region. The light chain constant region typically contains one domain, abbreviated CL.

[0030] The term “antibody” describes a type of immunoglobulin molecule and is used herein in its broadest sense. Antibody specifically includes intact antibodies (eg, intact immunoglobulins), as well as antibody fragments and antigen-binding proteins. Antibodies contain at least one antigen binding domain. One example of an antigen binding domain is the antigen binding domain formed by the V _H -V _L dimer. "Anti-HLA-G antibody", "anti-HLA-G antibody", "HLA-G-Ab", "HLA-G-specific antibody", or "anti-HLA-G Ab" is an antibody as described herein, which specifically binds to the HLA-G antigen.

[0031] The V _H and V _L regions can be further subdivided into regions of hypervariability (“hypervariable regions (HVRs)”; also called “complementarity determining regions” (CDRs)) interspersed with more conserved regions. These more conserved regions are called framework regions (FR). Each of the V _H and V _L regions typically contains three CDRs and four FRs, arranged in the following order (from N-terminus to C-terminus): FR1 - CDR1 - FR2 - CDR2 - FR3 - CDR3 - FR4. These CDRs are involved in antigen binding and impart antigen specificity and binding affinity to the antibody. See source: Kabat et al., Sequences of Proteins of Immunological Interest 5th ed. (1991) Public Health Service, National Institutes of Health, Bethesda, MD, incorporated herein by reference in its entirety.

[0032] The light chain of any vertebrate species can be classified into one of two types, called kappa and lambda, based on the sequence of the constant domain.

[0033] The heavy chain of any vertebrate species can be classified into one of five distinct classes (or isotypes): IgA, IgD, IgE, IgG, and IgM. These classes are also called α, δ, ε, γ and μ, respectively. The IgG and IgA classes are further divided into subclasses based on differences in sequence and function. In humans, the following subclasses are expressed: IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2.

[0034] CDR amino acid sequence boundaries can be determined by one skilled in the art using any of a number of known numbering schemes, including those described in Kabat et al., supra ("Kabat" numbering scheme); Al-Lazikani et al., 1997, J. Mol. Biol., 273:927-948 (Chothia numbering scheme); MacCallum et al., 1996, J. Mol. Biol. 262:732-745 (numbering scheme “contact”); Lefranc et al., Dev. Comp. Immunol., 2003, 27:55-77 (numbering scheme “IMGT”); and Honegge and Plückthun, J. Mol. Biol., 2001, 309:657-70 (numbering scheme “AHo”), each of which is incorporated herein by reference in its entirety.

[0035] Table 1 shows the positions included in CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2 and CDR-H3, identified by the Kabat and Chothia schemes. For CDR-H1, residue numbering is provided using both Kabat and Chothia numbering schemes.

[0036] Unless otherwise specified, the Kabat/Chothia numbering scheme is used herein to identify a specific CDR. In cases where the residues defined by the two numbering schemes are different, it is specified which numbering scheme is used, Kabat or Chothia.

Table 1. CDR remnants according to Kabat and Chothia numbering schemes.

CDR Kabat Chothia L1 L24-L34 L24-L34 L2 L50-L56 L50-L56 L3 L89-L97 L89-L97 H1 (Kabat numbering) H31-H35B H26-H32 or H34* H1 (Chothia Numbering) H31-H35 H26-H32 H2 H50-H65 H52-H56 H3 H95-H102 H95-H102

* The C-terminus of CDR-H1, when numbered using the Kabat numbering system, varies to correspond to residue H32 or H34, depending on the length of the CDR.

[0037] The "EU numbering scheme" is typically used when describing the constant region residues of an antibody heavy chain (eg, as described by Kabat et al., supra). Unless otherwise noted, the EU numbering scheme is used to describe the heavy chain constant region residues of the antibodies described herein.

[0038] An "antibody fragment" contains a portion of an intact antibody, such as an antigen binding or variable region of an intact antibody. Antibody fragments include, for example, Fv fragments, Fab fragments, F(abˊ) ₂ fragments, Fabˊ fragments, scFv (sFv) fragments and scFv-Fc fragments.

[0039] "Fv" fragments contain a non-covalently linked dimer containing one heavy chain variable domain and one light chain variable domain.

[0040] "Fab" fragments contain, in addition to heavy and light chain variable domains, a light chain constant domain and a first heavy chain constant domain ( _CH1 ). Fab fragments can be obtained, for example, by digesting the full-length antibody with papain.

[0041] "F(abˊ) ₂ " fragments contain two Fab' fragments connected near the hinge region by disulfide bonds. F(abˊ) ₂ fragments can be obtained, for example, by cleavage of the intact antibody with pepsin. F(abˊ) fragments can be dissociated, for example, by treatment with β-mercaptoethanol.

[0042] “Single chain Fv” or “sFv” or “scFv” antibody fragments contain a V _H domain and a V _L domain in a single polypeptide chain. V _H and V _L are usually connected by a peptide linker. See Plückthun A. (1994). Antibodies from Escherichia coli., in Rosenberg M. & Moore GP (Eds.), The Pharmacology of Monoclonal Antibodies vol. 113 (pp. 269-315). Springer-Verlag, New York, which is incorporated herein by reference in its entirety. "scFv-Fc" fragments contain scFv attached to an Fc domain. For example, the Fc domain may be attached to the C-terminus of the scFv. The Fc domain may follow V _H or V _L , depending on the orientation of the variable domains in scFv (ie, V _H -V _L or V _L -V _H ). Any suitable Fc domain known in the art or described herein can be used.

[0043] The term "monoclonal antibody" refers to an antibody from a population of essentially homogeneous antibodies. A population of substantially homogeneous antibodies contains antibodies that are substantially similar and bind the same epitope(s), excluding variations that may normally occur when a monoclonal antibody is produced. Such variants are usually present in small quantities. A monoclonal antibody is typically produced by a process that involves selecting a single antibody from a plurality of antibodies. For example, the selection method may be selecting a unique clone from a plurality of clones, such as a pool of hybridoma clones, phage clones, yeast clones, bacterial clones, or other recombinant DNA clones. The selected antibody may be further modified, for example, to improve affinity for the target (“affinity maturation”), to humanize the antibody, to improve its production in cell culture, and/or to reduce immunogenicity in a subject.

[0044] The term “chimeric antibody” refers to an antibody in which a portion of the heavy and/or light chain is derived from a particular source or species and the remainder of the heavy and/or light chain is derived from a different source or species.

[0045] "Humanized" forms of non-human antibodies are chimeric antibodies that contain minimal sequence derived from the non-human antibody. A humanized antibody is typically a human immunoglobulin (recipient antibody) in which residues from one or more CDRs are replaced by residues from one or more CDRs of a non-human antibody (donor antibody). Said donor antibody may be any suitable non-human antibody, for example a mouse, rat, rabbit, chicken or non-human primate antibody, with the desired specificity, affinity or biological effect. In some cases, selected framework residues of the recipient antibody are replaced with corresponding framework residues from the donor antibody. Humanized antibodies may also contain residues not found in either the recipient antibody or the donor antibody. Such modifications can be implemented to further improve the function of the antibody. Additional information can be found in: Jones et al., Nature, 1986, 321:522-525; Riechmann et al., Nature, 1988, 332:323-329; and Presta, Curr. Op. Struct. Biol., 1992, 2:593-596, each of which is incorporated herein by reference in its entirety.

[0046] A “human antibody” is an antibody that has an amino acid sequence corresponding to that of an antibody produced by a human or a human cell, or is derived from a non-human source involving the human antibody repertoire or human antibody coding sequences (e.g., from a human sources or developed de novo). Humanized antibodies are specifically excluded from human antibodies.

[0047] An "isolated antibody" is an antibody that has been separated from and/or isolated from a component of its natural environment. Components of the natural environment may include enzymes, hormones, and other protein or non-protein materials. In some embodiments, the isolated antibody is purified to an extent sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence, for example, using a rotating beaker sequencer. In some embodiments, the isolated antibody is purified to homogeneity by gel electrophoresis (eg, SDS-PAGE) under reducing or non-reducing conditions, with Coomassie Blue or Silver detection. The isolated antibody includes the antibody in situ within the recombinant cells since at least one component of the antibody's natural environment is missing. In some aspects, the isolated antibody is obtained using at least one purification step.

[0048] In some embodiments, the isolated antibody is purified to at least 80%, 85%, 90%, 95%, or 99% by weight. In some embodiments, the isolated antibody is provided in the form of a solution containing at least 85%, 90%, 95%, 98%, 99%, and up to 100% of the antibody by weight, with the remainder being other substances dissolved in the solvent.

[0049] “Affinity” refers to the strength of the total sum of non-covalent interactions between one binding site of a molecule (eg, an antibody) and its binding partner (eg, an antigen). Unless otherwise specified, as used herein, “binding affinity” refers to the true binding affinity, which reflects the 1:1 interaction between members of a binding pair (eg, antibody and antigen). The affinity of a molecule X for its partner Y can usually be expressed in terms of the dissociation constant ( _KD ). Affinity can be measured by conventional methods known in the art, including those described herein. Affinity can be determined, for example, using surface plasmon resonance (SPR) technology, such as the ^Biacore® instrument, or using biolayer interferometry technology, using the ^Octet® instrument.

[0050] In the context of binding of an antibody to a target molecule, the terms "specifically binds", "specifically binds to", "specifically for", "selectively binds" and "selectively for" as applied to a particular antigen (e.g., polypeptide target) or epitope on a specific antigen means binding that is measurably different from a nonspecific or nonselective interaction. Specific binding can be measured, for example, by determining the binding of a molecule and comparing it with the binding of a control molecule. Specific binding can also be determined using competition with a control molecule similar to the target, for example, an excess of unlabeled target. In this case, specific binding is indicated by competitive inhibition of the binding of the labeled target to the probe by an excess of unlabeled target.

[0051] The term “k _d ” (c ^-1 ) as used herein refers to the dissociation rate constant of a particular antibody-antigen interaction. The specified value is also called the k _off value.

[0052] The term " _ka " (M ^-1 ×c ^-1 ) as used herein refers to the binding rate constant of a particular antibody-antigen interaction. The specified value is also called the k _on value.

[0053] The term "K _D " (M) as used herein refers to the dissociation equilibrium constant for a particular antibody-antigen interaction. K _D = k _d /k _a .

[0054] The term "K _A " (M ^-1 ), as used herein, refers to the binding equilibrium constant for a particular antibody-antigen interaction. K _A = k _a /k _d .

[0055] An “affinity matured” antibody is an antibody with one or more changes in one or more CDRs or FRs that result in an improvement in the antibody's affinity for an antigen compared to a parent antibody that does not contain the change (or changes). In one embodiment, the affinity matured antibody has an affinity for the target antigen in the nanomolar or picomolar range. Affinity matured antibodies can be prepared using various methods known in the art. For example, Marks et al. ( source : Marks et al. Bio/Technology, 1992, 10:779-783, incorporated by reference in its entirety) describe affinity maturation by swapping the _VH and _VL domains. Random mutagenesis of CDRs and/or framework residues is described, for example, in the sources: Barbas et al. (Proc. Nat. Acad. Sci. USA, 1994, 91:3809-3813); Schier et al., Gene, 1995, 169:147-155; Yelton et al., J. Immunol., 1995, 155:1994-2004; Jackson et al., J. Immunol., 1995, 154:3310-33199; and Hawkins et al, J. Mol. Biol., 1992, 226:889-896, each of which is incorporated by reference in its entirety.

[0056] As used herein, in the context of two or more antibodies, the term “competes with” or “cross-competes with” indicates that the two or more antibodies compete for binding to an antigen (eg, HLA-G). In one example of the assay, HLA-G is applied to a plate and allowed to bind to the first antibody, after which a second, labeled antibody is added. If the presence of the first antibody reduces the binding of the second antibody, this means that these antibodies are competing. The term “competes with” also includes combinations of antibodies in which one antibody reduces the binding of another antibody, but when said antibodies are added in the reverse order, competition is not observed. Moreover, in some embodiments, the first and second antibodies mutually inhibit binding, regardless of the order in which they are added. In some embodiments, one antibody reduces the binding of another antibody to its antigen by at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%.

[0057] The term "epitope" means the portion of an antigen that is capable of specific binding to an antibody. Epitopes often consist of surface accessible amino acid residues and/or sugar side chains and may have specific three-dimensional structural characteristics as well as specific charging characteristics. Conformational and non-conformational epitopes differ in that binding to the former, but not to the latter, is lost in the presence of denaturing solvents. An epitope may contain amino acid residues that are directly involved in binding and other amino acid residues that are not directly involved in binding. The epitope to which the antibody binds can be determined using known epitope detection techniques, such as, for example, testing the antibody for binding to HLA-G variants with different point mutations.

[0058] The percentage of “identity” between a polypeptide sequence and a reference sequence is defined as the percentage of amino acid residues in the specified polypeptide sequence that are identical to the amino acid residues in the reference sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percentage of sequence identity. Alignment to determine percent amino acid identity can be accomplished in a variety of ways known in the art, for example, using publicly available software such as BLAST, BLAST-2, ALIGN, MEGALIGN (DNASTAR), CLUSTALW software or CLUSTAL OMEGA. Those skilled in the art can determine appropriate parameters for sequence alignment, including any algorithms necessary to achieve maximum alignment over the entire length of the sequences being compared.

[0059] "Conservative substitution" or "conservative amino acid substitution" refers to the replacement of one or more amino acids with one or more chemically or functionally similar amino acids. Conservative substitution tables listing analogous amino acids are well known in the art. Polypeptide sequences containing such substitutions are known as "conservatively modified variants". For example, the following groups of amino acids are considered conservative substitutions for each other.

Acidic residues D and E Main balances K, R and H Hydrophilic uncharged residues S, T, N and Q Aliphatic uncharged residues G,A,V,L and I Non-polar uncharged residues C, M and P Aromatic residues F, Y and W

Residues containing an alcohol group S and T Aliphatic residues I, L, V and M Cycloalkenyl-associated residues F, H, W and Y Hydrophobic residues A, C, F, G, H, I, L, M, V, W and Y Negatively charged residues D and E Polar residues C, D, E, H, K, N, Q, R, S and T Positively charged residues H, K and R Small leftovers A, C, D, G, N, P, S, T and V Very small leftovers A, G and S Residues involved in coil formation A, C, D, E, G, H, K, N, Q, R, S, P and T Flexible balances Q, T, K, S, G, P, D, E and R

Group 1 A, S and T Group 2 D and E Group 3 N and Q Group 4 R and K Group 5 I, L and M Group 6 F, Y and W

Group A A and G Group B D and E Group C N and Q Group D R, K and H Group E I, L, M, V Group F F, Y and W Group G S and T Group H C and M

Additional conservative substitutions are described, for example, in Creighton, Proteins: Structures and Molecular Properties 2nd ed. (1993) W. H. Freeman & Co., New York, NY. An antibody produced by introducing one or more conservative substitutions of amino acid residues into the parent antibody is called a “conservatively modified variant.”

[0060] The term "amino acid" refers to twenty common naturally occurring amino acids. Naturally occurring amino acids include alanine (Ala;A), arginine (Arg;R), asparagine (Asn;N), aspartic acid (Asp;D), cysteine (Cys;C); glutamic acid (Glu; E), glutamine (Gln; Q), glycine (Gly; G); histidine (His; H), isoleucine (Ile; I), leucine (Leu; L), lysine (Lys; K), methionine (Met; M), phenylalanine (Phe; F), proline (Pro; P), serine (Ser;S), threonine (Thr;T), tryptophan (Trp;W), tyrosine (Tyr;Y) and valine (Val;V).

[0061] “Treat” or “treating” with respect to any disease or disorder refers, in some embodiments, to alleviating the disease or disorder present in a subject. In another embodiment, “treat” or “treating” includes alleviating at least one physical parameter that may not be discernible to the subject. In yet another embodiment, “treat” or “treating” includes modulating a disease or disorder either physically (eg, stabilizing a discernible symptom), physiologically (eg, stabilizing a physical measure), or both. In another embodiment, “treat” or “treating” includes delaying or preventing the onset of a disease or disorder.

[0062] As used herein, the term “therapeutically effective amount” or “effective amount” refers to an amount of an antibody or composition that, when administered to a subject, is effective to treat a disease or disorder.

[0063] As used herein, the term “subject” means a mammalian subject. Examples of subjects include, but are not limited to, humans, monkeys, dogs, cats, mice, rats, cows, horses, camels, birds, goats and sheep. In some embodiments, the subject is a human. In some embodiments, the subject suffers from cancer, an autoimmune disease or condition, and/or infection, which can be treated with an antibody of the present invention. In some embodiments, the subject is a person believed to be suffering from cancer, an autoimmune disease or condition, and/or an acute infection and a chronic infection.

1. Antibodies

[0064] The present invention provides antibodies that selectively bind human HLA-G. In some aspects, the antibody selectively binds to the extracellular domain of human HLA-G.

[0065] In some embodiments, the antibody comprises one or more CDRs of a specific length in terms of the number of amino acid residues. In some embodiments, the Chothia CDR-H1 length of the antibody is 6, 7, 8, or 9 residues. In some embodiments, the Kabat CDR-H1 length of the antibody is 4, 5, 6, or 7 residues. In some embodiments, the Chothia CDR-H2 length of the antibody is 5, 6, or 7 residues. In some embodiments, the Kabat CDR-H2 length of the antibody is 15, 16, 17, or 18 residues. In some embodiments, the Kabat/Chothia CDR-H3 length of the antibody is 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 residues.

[0066] In some aspects, the Kabat/Chothia CDR-L1 length of the antibody is 9, 10, 11, 12, 13, 14, 15, or 16 residues. In some aspects, the Kabat/Chothia CDR-L2 length of the antibody is 6, 7, or 8 residues. In some aspects, the Kabat/Chothia CDR-L3 length of the antibody is 8, 9, 10, 11, or 12 residues.

[0067] In some embodiments, the antibody comprises a light chain. In some aspects, said light chain is a kappa light chain. In some aspects, said light chain is a lambda light chain.

[0068] In some embodiments, the antibody comprises a heavy chain. In some aspects, said heavy chain is an IgA chain. In some aspects, said heavy chain is an IgD chain. In some aspects, said heavy chain is an IgE chain. In some aspects, said heavy chain is an IgG chain. In some aspects, said heavy chain is an IgM chain. In some aspects, said heavy chain is an IgG1 chain. In some aspects, said heavy chain is an IgG2 chain. In some aspects, said heavy chain is an IgG3 chain. In some aspects, said heavy chain is an IgG4 chain. In some aspects, said heavy chain is an IgA1 chain. In some aspects, said heavy chain is an IgA2 chain.

[0069] In some embodiments, the antibody is an antibody fragment. In some aspects, said antibody fragment is an Fv fragment. In some aspects, said antibody fragment is a Fab fragment. In some aspects, said antibody fragment is an F(abˊ) ₂ fragment. In some aspects, said antibody fragment is a Fab' fragment. In some aspects, said antibody fragment is a scFv (sFv) fragment. In some aspects, said antibody fragment is a scFv-Fc fragment.

[0070] In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the antibody is a polyclonal antibody.

[0071] In some embodiments, the antibody is a chimeric antibody. In some embodiments, the antibody is a humanized antibody. In some embodiments, the antibody is a human antibody.

[0072] In some embodiments, the antibody is an affinity matured antibody. In some aspects, the antibody is an affinity matured antibody derived from an exemplary sequence set forth herein.

[0073] In some embodiments, the antibody blocks the interaction and/or binding of HLA-G to an inhibitory ITIM receptor. In some embodiments, the antibody blocks the interaction and/or binding of HLA-G to ILT2. In some embodiments, the antibody blocks the interaction and/or binding of HLA-G to ILT4. In some embodiments, the antibody blocks the interaction and/or binding of HLA-G to KIR2DL4. In embodiments, the antibody binds HLA-G but does not block the interaction between HLA-G and ILT2, ILT4, and/or KIRDL4. In some embodiments, the antibody disrupts the HLA-G heterodimer and/or prevents HLA-G dimerization.

[0074] In some embodiments, the antibody inhibits immunosuppressive function. In some embodiments, the antibody inhibits HLA-G-mediated suppression of NK cells. In some embodiments, the antibody inhibits HLA-G-mediated suppression of cytotoxic T lymphocytes. In some embodiments, the antibody inhibits HLA-G-mediated suppression of B cells. In some embodiments, the antibody inhibits HLA-G-mediated suppression of neutrophils. In some embodiments, the antibody inhibits HLA-G-mediated suppression of dendritic cells. In some embodiments, the antibody inhibits HLA-G-mediated suppression of macrophages. In some embodiments, the antibody inhibits HLA-G-mediated suppression of monocytes. In some embodiments, the antibody inhibits HLA-G-mediated suppression of cytolysis and/or proliferation of NK and/or T cells.

[0075] In some embodiments, the antibody prevents or inhibits HLA-G-mediated suppression of phagocytosis. In some embodiments, the antibody mediates HLA-G-mediated induction of regulatory T cells. In some embodiments, the antibody prevents or inhibits the formation or expansion of regulatory T cells.

[0076] The antibodies provided by the present invention may be suitable for the treatment of various diseases and conditions, including cancer, autoimmune diseases and infections. In some embodiments, the antibody inhibits HLA-G function on tumor cells. In some embodiments, the antibody inhibits HLA-G function on immune cells. In some embodiments, the antibody inhibits HLA-G function on myeloid cells. In some embodiments, the antibody inhibits HLA-G function on subsets of T cells. In some embodiments, the antibody inhibits metastasis. In some embodiments, the antibody inhibits angiogenesis.

[0077] In some embodiments, the antibody competes or is capable of competing for binding to human HLA-G with another antibody. In some embodiments, said antibody comprises or includes an antibody that is capable of competing for binding of human HLA-G to a reference antibody, characterized in that said reference antibody binds to an epitope comprising positions 195, 197, and/or 198 of SEQ ID NO: 342 , on the human HLA-G polypeptide. In some embodiments, the antibody and the reference antibody cross-compete or are capable of cross-competing for binding human HLA-G to another antibody.

[0078] In some embodiments, the antibody binds to an epitope comprising position 195, 197 and/or 198 of SEQ ID NO: 342 on a human HLA-G polypeptide. In some aspects, the epitope comprises or consists of a continuous or discontinuous stretch of amino acids comprising residues 195, 197 and/or 198 of the sequence set forth in SEQ ID NO: 342. In some aspects, said epitope contains a sequence identical to or corresponding to residues 195, 197, and/or 198 of the sequence set forth in SEQ ID NO: 342. In some aspects, said epitope has a sequence that is 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% identical to the sequence set forth in SEQ ID NO: 342. In some aspects, the epitope contains 1, 2, 3, 4, 5, 6 , 7, 8, or 9 substitutions relative to the sequence included in the sequence set forth in SEQ ID NO: 342. In some aspects, the epitope contains 1, 2, or 3 substitutions relative to the residues included in the sequence set forth in SEQ ID NO: 342. In some aspects, the antibody contacts any of the moieties shown in FIG. 9.

1.1. CDR-H3 sequences

[0079] In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or essentially consisting of a sequence selected from SEQ ID NO: 76-101. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 76. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 77. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 78. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 79. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 80. In some aspects, the antibody contains a CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 81. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 82. In some aspects, the antibody contains a CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 83. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 84. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 85. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 86. In some aspects, the antibody contains a CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 87. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 88. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 89. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 90. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 91. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 92. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 93. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 94. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 95. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 96. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 97. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 98. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 99. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 100. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 101.

[0080] In some aspects, the CDR-H3 sequence comprises a variant of, consists of, or consists essentially of a variant of an exemplary CDR-H3 sequence set forth herein. In some aspects, the CDR-H3 sequence comprises, consists of, or consists essentially of a sequence that is at least 70%, 75%, 80%, 85%, 90%, or 95% identical to any of the exemplary CDR-H3 sequences given in the present description. In some aspects, the CDR-H3 sequence comprises, consists of, or consists essentially of any of the exemplary CDR-H3 sequences provided herein with 1, 2, or 3 amino acid substitutions. In some aspects, these amino acid substitutions are conservative amino acid substitutions.

1.2. _VH sequences containing illustrative CDRs

[0081] In some embodiments, the antibody comprises a V _H sequence comprising one or more CDR-H sequences containing, consisting of, or essentially consisting of one or more exemplary CDR-H sequences provided herein and variants thereof.

1.2.1. _VH sequences containing illustrative CDRs by Kabat

[0082] In some embodiments, the antibody comprises a _VH sequence comprising one or more Kabat CDR-H sequences containing, consisting of, or substantially consisting of one or more exemplary Kabat CDR-H sequences set forth herein, and their options.

1.2.1.1. CDR-H3 by Kabat

[0083] In some embodiments, the antibody comprises a V _H sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or essentially consisting of a sequence selected from SEQ ID NO: 76-101. In some aspects, said antibody comprises a _VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 76. In some aspects, said antibody comprises a _VH sequence comprising a Kabat CDR-H3 sequence, comprising, consisting of, or essentially consisting of SEQ ID NO: 77. In some aspects, said antibody comprises a V _H sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 78. In some aspects, said the antibody comprises a V _H sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 79. In some aspects, the antibody comprises a V _H sequence comprising a Kabat CDR-H3 sequence comprising, consisting of or essentially consisting of SEQ ID NO: 80. In some aspects, said antibody comprises a _VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 81. In some aspects, said antibody comprises a V sequence _H containing a Kabat CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 82. In some aspects, said antibody comprises a V _H sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 83. In some aspects, said antibody comprises a _VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 84. In some aspects, said antibody comprises a _VH sequence comprising the sequence Kabat CDR-H3 comprising, consisting of, or essentially consisting of SEQ ID NO: 85. In some aspects, said antibody comprises a V _H sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 86. In some aspects, said antibody comprises a V _H sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 87. In some aspects, said antibody comprises a V _H sequence comprising a Kabat CDR-H3 sequence Kabat, comprising, consisting of, or essentially consisting of SEQ ID NO: 88. In some aspects, said antibody comprises a V _H sequence comprising a Kabat CDR-H3 sequence, comprising, consisting of, or essentially consisting of SEQ ID NO: 89. In some aspects In some aspects, said antibody comprises a _VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 90. In some aspects, said antibody comprises a _VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of or essentially consisting of SEQ ID NO: 91. In some aspects, said antibody comprises a V _H sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 92. In some aspects, said antibody comprises a _VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of or essentially consisting of SEQ ID NO: 94. In some aspects, said antibody comprises a _VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of or essentially consisting of SEQ ID NO: 95. In some aspects, said antibody comprises a _VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 96. In some aspects, said antibody comprises a _VH sequence, comprising a Kabat CDR-H3 sequence comprising, consisting of or essentially consisting of SEQ ID NO: 97. In some aspects, said antibody comprises a V _H sequence comprising a Kabat CDR-H3 sequence comprising, consisting of or essentially consisting of SEQ ID NO: 98. In some aspects, said antibody comprises a V _H sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 99. In some aspects, said antibody comprises a V _H sequence comprising a CDR- sequence Kabat H3 comprising, consisting of, or essentially consisting of SEQ ID NO: 100. In some aspects, said antibody comprises a V _H sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 101.

1.2.1.2. CDR-H2 by Kabat

[0084] In some embodiments, the antibody comprises a V _H sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or essentially consisting of a sequence selected from SEQ ID NOs: 54-71. In some aspects, said antibody comprises a _VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 54. In some aspects, said antibody comprises a _VH sequence comprising a Kabat CDR-H2 sequence, comprising, consisting of, or essentially consisting of SEQ ID NO: 55. In some aspects, said antibody comprises a V _H sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 56. In some aspects, said the antibody comprises a _VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 57. In some aspects, the antibody comprises a _VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of or essentially consisting of SEQ ID NO: 58. In some aspects, said antibody comprises a _VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 59. In some aspects, said antibody comprises a V sequence _H containing a Kabat CDR-H2 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 60. In some aspects, said antibody comprises a V _H sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 61. In some aspects, said antibody comprises a _VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 62. In some aspects, said antibody comprises a _VH sequence comprising the sequence Kabat CDR-H2 comprising, consisting of, or essentially consisting of SEQ ID NO: 63. In some aspects, said antibody comprises a V _H sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 64. In some aspects, said antibody comprises a V _H sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 65. In some aspects, said antibody comprises a V _H sequence comprising a Kabat CDR-H2 sequence Kabat, comprising, consisting of, or essentially consisting of SEQ ID NO: 66. In some aspects, said antibody comprises a V _H sequence comprising a Kabat CDR-H2 sequence, comprising, consisting of, or essentially consisting of SEQ ID NO: 67. In some aspects In some aspects, said antibody comprises a V _H sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 68. In some aspects, said antibody comprises a V _H sequence comprising a Kabat CDR-H2 sequence comprising, consisting of or essentially consisting of SEQ ID NO: 69. In some aspects, said antibody comprises a _VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 70. In some aspects, said antibody comprises a _VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 71.

1.2.1.3. CDR-H1 by Kabat

[0085] In some embodiments, the antibody comprises a V _H sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or essentially consisting of a sequence selected from SEQ ID NOs: 18-34. In some aspects, said antibody comprises a _VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 18. In some aspects, said antibody comprises a _VH sequence comprising a Kabat CDR-H1 sequence, comprising, consisting of, or essentially consisting of SEQ ID NO: 19. In some aspects, said antibody comprises a _VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 20. In some aspects, said the antibody comprises a V _H sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 21. In some aspects, the antibody comprises a V _H sequence comprising a Kabat CDR-H1 sequence comprising, consisting of or essentially consisting of SEQ ID NO: 22. In some aspects, said antibody comprises a _VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 23. In some aspects, said antibody comprises a V sequence _H containing a Kabat CDR-H1 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 24. In some aspects, said antibody comprises a V _H sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 25. In some aspects, said antibody comprises a _VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 26. In some aspects, said antibody comprises a _VH sequence comprising the sequence Kabat CDR-H1 comprising, consisting of, or essentially consisting of SEQ ID NO: 27. In some aspects, said antibody comprises a _VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 28. In some aspects, said antibody comprises a V _H sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 29. In some aspects, said antibody comprises a V _H sequence comprising a Kabat CDR-H1 sequence Kabat, comprising, consisting of, or essentially consisting of SEQ ID NO: 30. In some aspects, said antibody comprises a V _H sequence comprising a Kabat CDR-H1 sequence, comprising, consisting of, or essentially consisting of SEQ ID NO: 31. In some aspects, In some aspects, said antibody comprises a _VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 32. In some aspects, said antibody comprises a _VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of or essentially consisting of SEQ ID NO: 33. In some aspects, said antibody comprises a V _H sequence comprising a Kabat CDR-H1 sequence comprising, consisting of or essentially consisting of SEQ ID NO: 34.

1.2.1.4. CDR-H3 by Kabat + CDR-H2 by Kabat

[0086] In some embodiments, the antibody comprises a V _H sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or essentially consisting of a sequence selected from SEQ ID NOs: 76-101, and a Kabat CDR-H2 sequence, comprising, consisting of, or essentially consisting of a sequence selected from SEQ ID NO: 54-71. In some aspects, both Kabat CDR-H3 and Kabat CDR-H2 are taken from the same exemplary _VH sequence provided herein. For example, in some aspects, both Kabat CDR-H3 and Kabat CDR-H2 are taken from the same exemplary V _H sequence selected from SEQ ID NO: 170-200.

1.2.1.5. CDR-H3 by Kabat + CDR-H1 by Kabat

[0087] In some embodiments, the antibody comprises a V _H sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or essentially consisting of a sequence selected from SEQ ID NO: 76-101, and a Kabat CDR-H1 sequence, comprising, consisting of, or essentially consisting of a sequence selected from SEQ ID NO: 18-34. In some aspects, both Kabat CDR-H3 and Kabat CDR-H1 are taken from the same exemplary _VH sequence provided herein. For example, in some aspects, both Kabat CDR-H3 and Kabat CDR-H1 are taken from the same exemplary V _H sequence selected from SEQ ID NO: 170-200.

1.2.1.6. CDR-H1 by Kabat + CDR-H2 by Kabat

[0088] In some embodiments, the antibody comprises a _VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or essentially consisting of a sequence selected from SEQ ID NOs: 18-34, and a Kabat CDR-H2 sequence, comprising, consisting of, or essentially consisting of a sequence selected from SEQ ID NO: 54-71. In some aspects, both Kabat CDR-H1 and Kabat CDR-H2 are taken from the same exemplary _VH sequence provided herein. For example, in some aspects, both Kabat CDR-H1 and Kabat CDR-H2 are taken from the same exemplary V _H sequence selected from SEQ ID NO: 170-200.

1.2.1.7 CDR-H1 by Kabat + CDR-H2 by Kabat + CDR-H3 by Kabat

[0089] In some embodiments, the antibody comprises a _VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or essentially consisting of a sequence selected from SEQ ID NOs: 18-34, a Kabat CDR-H2 sequence comprising , consisting of or essentially consisting of a sequence selected from SEQ ID NO: 54-71, and a Kabat CDR-H3 sequence containing, consisting of or essentially consisting of a sequence selected from SEQ ID NO: 76-101. In some aspects, the Kabat CDR-H1, Kabat CDR-H2, and Kabat CDR-H3 sequences are all taken from a single exemplary _VH sequence provided herein. For example, in some aspects, the Kabat CDR-H1, Kabat CDR-H2, and Kabat CDR-H3 sequences are all taken from a single exemplary V _H sequence selected from SEQ ID NOs: 170-200.

[0090] In some aspects, the antibody comprises a V _H sequence comprising a Kabat CDR-H1 sequence containing SEQ ID NO: 18, a Kabat CDR-H2 sequence containing SEQ ID NO: 54, and a Kabat CDR-H3 sequence, comprising SEQ ID NO: 76. In some aspects, said antibody comprises a _VH sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 19, a Kabat CDR-H2 sequence comprising SEQ ID NO: 55, and a CDR- Kabat H3 comprising SEQ ID NO: 77. In some aspects, said antibody comprises a V _H sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 20, a Kabat CDR-H2 sequence comprising SEQ ID NO: 56, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 78. In some aspects, said antibody comprises a _VH sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 21, a Kabat CDR-H2 sequence comprising SEQ ID NO: 57, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 79. In some aspects, the antibody comprises a V _H sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 22, a Kabat CDR-H2 sequence comprising SEQ ID NO: 58, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 80. In some aspects, said antibody comprises a _VH sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 21, a CDR sequence Kabat -H2 comprising SEQ ID NO: 57, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 76. In some aspects, said antibody comprises a _VH sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 23, a Kabat CDR-H2 sequence comprising SEQ ID NO: 59, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 76. In some aspects, said antibody comprises a V _H sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 23, a Kabat CDR-H2 sequence comprising SEQ ID NO: 60, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 81. In some aspects, said antibody comprises a _VH sequence comprising a CDR-H1 sequence Kabat comprising SEQ ID NO: 23, a Kabat CDR-H2 sequence comprising SEQ ID NO: 59, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 82. In some aspects, said antibody comprises a _VH sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 23, a Kabat CDR-H2 sequence comprising SEQ ID NO: 59, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 76. In some aspects, said antibody comprises the sequence V _H comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 23, a Kabat CDR-H2 sequence comprising SEQ ID NO: 59, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 81. In some aspects said antibody contains a V _H sequence containing a Kabat CDR-H1 sequence containing SEQ ID NO: 21, a Kabat CDR-H2 sequence containing SEQ ID NO: 57, and a Kabat CDR-H3 sequence containing SEQ ID NO: 83 In some aspects, said antibody comprises a V _H sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 21, a Kabat CDR-H2 sequence comprising SEQ ID NO: 57, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 84. In some aspects, the antibody comprises a V _H sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 24, a Kabat CDR-H2 sequence comprising SEQ ID NO: 61, and a CDR-H3 sequence of Kabat comprising SEQ ID NO: 85. In some aspects, said antibody comprises a V _H sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 24, a Kabat CDR-H2 sequence comprising SEQ ID NO: 61, and a Kabat CDR-H3 comprising SEQ ID NO: 86. In some aspects, said antibody comprises a V _H sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 25, a Kabat CDR-H2 sequence comprising SEQ ID NO: 62, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 87. In some aspects, said antibody comprises a V _H sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 26, a Kabat CDR-H2 sequence comprising SEQ ID NO: 63, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 88. In some aspects, the antibody comprises a _VH sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 26, a CDR-H2 sequence Kabat comprising SEQ ID NO: 63, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 89. In some aspects, said antibody comprises a V _H sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 25, a Kabat CDR-H2 sequence comprising SEQ ID NO: 63, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 90. In some aspects, said antibody comprises a _VH sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 27, a Kabat CDR-H2 sequence comprising SEQ ID NO: 64, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 90. In some aspects, said antibody comprises a V _H sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 28, a Kabat CDR-H2 sequence comprising SEQ ID NO: 62, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 91. In some aspects, said antibody comprises a V _H sequence comprising a CDR sequence Kabat -H1 comprising SEQ ID NO: 29, Kabat CDR-H2 sequence comprising SEQ ID NO: 64, and Kabat CDR-H3 sequence comprising SEQ ID NO: 92. In some aspects, said antibody comprises a V _H sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 25, a Kabat CDR-H2 sequence comprising SEQ ID NO: 65, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 93. In some aspects, said antibody contains a V _H sequence containing a Kabat CDR-H1 sequence containing SEQ ID NO: 30, a Kabat CDR-H2 sequence containing SEQ ID NO: 66, and a Kabat CDR-H3 sequence containing SEQ ID NO: 94. According to In some aspects, said antibody comprises a _VH sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 31, a Kabat CDR-H2 sequence comprising SEQ ID NO: 67, and a Kabat CDR-H3 sequence comprising SEQ ID NO: : 95. In some aspects, said antibody comprises a _VH sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 32, a Kabat CDR-H2 sequence comprising SEQ ID NO: 68, and a Kabat CDR-H3 sequence, comprising SEQ ID NO: 96. In some aspects, said antibody comprises a _VH sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 33, a Kabat CDR-H2 sequence comprising SEQ ID NO: 69, and a CDR- Kabat H3 comprising SEQ ID NO: 97. In some aspects, said antibody comprises a _VH sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 34, a Kabat CDR-H2 sequence comprising SEQ ID NO: 70, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 98. In some aspects, said antibody comprises a _VH sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 18, a Kabat CDR-H2 sequence comprising SEQ ID NO: 54, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 99. In some aspects, the antibody comprises a _VH sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 31, a Kabat CDR-H2 sequence comprising SEQ ID NO: 71, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 100. In some aspects, said antibody comprises a _VH sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 24, a CDR sequence Kabat -H2 containing SEQ ID NO: 61, and Kabat CDR-H3 sequence containing SEQ ID NO: 101.

1.2.1.8. Variants of _VH sequences containing illustrative CDRs by Kabat

[0091] In some embodiments, the V _H sequences provided by the present invention comprise a variant of the exemplary Kabat CDR-H3, CDR-H2, and/or CDR-H1 sequence set forth herein.

[0092] In some aspects, the Kabat CDR-H3 sequence comprises, consists of, or consists essentially of a variant of the exemplary Kabat CDR-H3 sequence set forth herein. In some aspects, the Kabat CDR-H3 sequence comprises, consists of, or consists essentially of a sequence that is at least 70%, 75%, 80%, 85%, 90%, or 95% identical to any of the exemplary CDR-H sequences according to Kabat3 given in this description. In some aspects, the Kabat CDR-H3 sequence comprises, consists of, or consists essentially of any of the exemplary Kabat3 CDR-H sequences provided herein, with 1, 2, or 3 amino acid substitutions. In some aspects, these amino acid substitutions are conservative amino acid substitutions.

[0093] In some aspects, the Kabat CDR-H2 sequence comprises a variant of, consists of, or consists essentially of a variant of the exemplary Kabat CDR-H2 sequence set forth herein. In some aspects, the Kabat CDR-H2 sequence comprises, consists of, or consists essentially of a sequence that is at least 70%, 75%, 80%, 85%, 90%, or 95% identical to any of the exemplary Kabat CDR-H2 sequences. Kabat sequences given herein. In some aspects, the Kabat CDR-H2 sequence comprises, consists of, or consists essentially of any of the exemplary Kabat CDR-H2 sequences provided herein, with 1, 2, or 3 amino acid substitutions. In some aspects, these amino acid substitutions are conservative amino acid substitutions.

[0094] In some aspects, the Kabat CDR-H1 sequence comprises a variant of, consists of, or consists essentially of a variant of the exemplary Kabat CDR-H1 sequence set forth herein. In some aspects, the Kabat CDR-H1 sequence comprises, consists of, or consists essentially of a sequence that is at least 70%, 75%, 80%, 85%, 90%, or 95% identical to any of the exemplary CDR-H1 sequences according to Kabat, given in this description. In some aspects, the Kabat CDR-H1 sequence comprises, consists of, or consists essentially of any of the exemplary Kabat CDR-H1 sequences provided herein, with 1, 2, or 3 amino acid substitutions. In some aspects, these amino acid substitutions are conservative amino acid substitutions.

1.2.2. _VH sequences containing illustrative Chothia CDRs

[0095] In some embodiments, the antibody comprises a V _H sequence comprising one or more Chothia CDR-H sequences containing, consisting of, or substantially consisting of one or more exemplary Chothia CDR-H sequences provided herein, and their options.

1.2.2.1. CDR-H3 by Chothia

[0096] In some embodiments, the antibody comprises a V _H sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or essentially consisting of a sequence selected from SEQ ID NO: 76-101. In some aspects, said antibody comprises a V _H sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 76. In some aspects, said antibody comprises a V _H sequence comprising a Chothia CDR-H3 sequence, comprising, consisting of, or essentially consisting of SEQ ID NO: 77. In some aspects, said antibody comprises a V _H sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 78. In some aspects, said the antibody comprises a _VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 79. In some aspects, said antibody comprises a _VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of or essentially consisting of SEQ ID NO: 80. In some aspects, said antibody comprises a _VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 81. In some aspects, said antibody comprises a V sequence _H containing a Chothia CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 82. In some aspects, said antibody comprises a V _H sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 83. In some aspects, the antibody comprises a V _H sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 84. In some aspects, the antibody comprises a V _H sequence comprising the sequence A Chothia CDR-H3 comprising, consisting of, or essentially consisting of SEQ ID NO: 85. In some aspects, said antibody comprises a _VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or essentially consisting of a SEQ ID NO: 86. In some aspects, said antibody comprises a _VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 87. In some aspects, said antibody comprises a _VH sequence comprising a Chothia CDR-H3 sequence Chothia comprising, consisting of, or essentially consisting of SEQ ID NO: 88. In some aspects, said antibody comprises a V _H sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 89. In some aspects In some aspects, said antibody comprises a _VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 90. In some aspects, said antibody comprises a _VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of or essentially consisting of SEQ ID NO: 91. In some aspects, said antibody comprises a V _H sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 92. In some aspects, said antibody comprises a _VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of or essentially consisting of SEQ ID NO: 93. In some aspects, said antibody comprises a _VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of or essentially consisting of SEQ ID NO: 94. In some aspects, said antibody comprises a _VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 95. In some aspects, said antibody comprises a _VH sequence, comprising a Chothia CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 96. In some aspects, said antibody comprises a V _H sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 97. In some aspects, said antibody comprises a V _H sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 98. In some aspects, said antibody comprises a V _H sequence comprising a CDR- sequence Chothia H3 comprising, consisting of, or essentially consisting of SEQ ID NO: 99. In some aspects, said antibody comprises a V _H sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 100. In some aspects, said antibody comprises a _VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 101.

1.2.2.2. CDR-H2 by Chothia

[0097] In some embodiments, the antibody comprises a V _H sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or essentially consisting of a sequence selected from SEQ ID NOs: 38-50. In some aspects, said antibody comprises a _VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 38. In some aspects, said antibody comprises a _VH sequence comprising a Chothia CDR-H2 sequence, comprising, consisting of, or essentially consisting of SEQ ID NO: 39. In some aspects, said antibody comprises a _VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 40. In some aspects, said the antibody comprises a V _H sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 41. In some aspects, said antibody comprises a V _H sequence comprising a Chothia CDR-H2 sequence comprising, consisting of or essentially consisting of SEQ ID NO: 42. In some aspects, said antibody comprises a _VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 43. In some aspects, said antibody comprises a V sequence _H containing a Chothia CDR-H2 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 44. In some aspects, said antibody comprises a V _H sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 45. In some aspects, said antibody comprises a _VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 46. In some aspects, said antibody comprises a _VH sequence comprising the sequence A Chothia CDR-H2 comprising, consisting of, or essentially consisting of SEQ ID NO: 47. In some aspects, said antibody comprises a _VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or essentially consisting of a SEQ ID NO: 48. In some aspects, said antibody comprises a V _H sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 49. In some aspects, said antibody comprises a V _H sequence comprising a Chothia CDR-H2 sequence Chothia, containing, consisting of or essentially consisting of SEQ ID NO: 50.

1.2.2.3. CDR-H1 by Chothia

[0098] In some embodiments, the antibody comprises a V _H sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or essentially consisting of a sequence selected from SEQ ID NOs: 1-14. In some aspects, said antibody comprises a _VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 1. In some aspects, said antibody comprises a _VH sequence comprising a Chothia CDR-H1 sequence, comprising, consisting of, or essentially consisting of SEQ ID NO: 2. In some aspects, said antibody comprises a V _H sequence comprising a Chothia CDR-H1 sequence, comprising, consisting of, or essentially consisting of SEQ ID NO: 3. In some aspects, said the antibody comprises a _VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 4. In some aspects, said antibody comprises a _VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of or essentially consisting of SEQ ID NO: 5. In some aspects, said antibody comprises a _VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 6. In some aspects, said antibody comprises a V sequence _H containing a Chothia CDR-H1 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 7. In some aspects, said antibody comprises a V _H sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 8. In some aspects, said antibody comprises a _VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 9. In some aspects, said antibody comprises a _VH sequence comprising the sequence A Chothia CDR-H1 comprising, consisting of, or essentially consisting of SEQ ID NO: 10. In some aspects, said antibody comprises a _VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 11. In some aspects, said antibody comprises a _VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 12. In some aspects, said antibody comprises a _VH sequence comprising a Chothia CDR-H1 sequence Chothia comprising, consisting of, or essentially consisting of SEQ ID NO: 13. In some aspects, said antibody comprises a _VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 14.

1.2.2.4. CDR-H3 by Chothia + CDR-H2 by Chothia

[0099] In some embodiments, the antibody comprises a V _H sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or essentially consisting of a sequence selected from SEQ ID NO: 76-101, and a Chothia CDR-H2 sequence, comprising, consisting of, or essentially consisting of a sequence selected from SEQ ID NO: 38-50. In some aspects, both the Chothia CDR-H3 sequence and the Chothia CDR-H2 sequence are taken from the same exemplary _VH sequence provided herein. For example, in some aspects, both Chothia CDR-H3 and Chothia CDR-H2 are taken from the same exemplary V _H sequence selected from SEQ ID NO: 170-200.

1.2.2.5. CDR-H3 by Chothia + CDR-H1 by Chothia

[00100] In some embodiments, the antibody comprises a _VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or essentially consisting of a sequence selected from SEQ ID NOs: 76-101, and a Chothia CDR-H1 sequence, comprising, consisting of, or essentially consisting of a sequence selected from SEQ ID NO: 1-14. In some aspects, both the Chothia CDR-H3 sequence and the Chothia CDR-H1 sequence are taken from the same exemplary _VH sequence provided herein. For example, in some aspects, both Chothia CDR-H3 and Chothia CDR-H1 are taken from the same exemplary V _H sequence selected from SEQ ID NO: 170-200.

1.2.2.6. CDR-H1 by Chothia + CDR-H2 by Chothia

[00101] In some embodiments, the antibody comprises a V _H sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or essentially consisting of a sequence selected from SEQ ID NOs: 1-14, and a Chothia CDR-H2 sequence, comprising, consisting of, or essentially consisting of a sequence selected from SEQ ID NO: 38-50. In some aspects, both the Chothia CDR-H1 sequence and the Chothia CDR-H2 sequence are taken from the same exemplary V _H sequence provided herein. For example, in some aspects, both Chothia CDR-H1 and Chothia CDR-H2 are taken from the same exemplary V _H sequence selected from SEQ ID NO: 170-200.

1.2.2.7. CDR-H1 by Chothia + CDR-H2 by Chothia + CDR-H3 by Chothia

[00102] In some embodiments, the antibody comprises a _VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or essentially consisting of a sequence selected from SEQ ID NOs: 1-14, a Chothia CDR-H2 sequence consisting or essentially consisting of a sequence selected from SEQ ID NO: 38-50, and a Chothia CDR-H3 sequence comprising, consisting of, or essentially consisting of a sequence selected from SEQ ID NO: 76-101. In some aspects, both the Chothia CDR-H1 sequence, the Chothia CDR-H2 sequence, and the Chothia CDR-H3 sequence are taken from the same exemplary V _H sequence provided herein. For example, in some aspects, both Chothia CDR-H1, Chothia CDR-H2, and Chothia CDR-H3 are taken from the same exemplary V _H sequence selected from SEQ ID NO: 170-200.

[00103] In some embodiments, the antibody comprises a _VH sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO: 1, a Chothia CDR-H2 sequence comprising SEQ ID NO: 38, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 76. In some embodiments, said antibody comprises a V _H sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO: 2, a Chothia CDR-H2 sequence comprising SEQ ID NO: 39, and a sequence Chothia CDR-H3 comprising SEQ ID NO: 77. In some embodiments, said antibody comprises a _VH sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO: 2, a Chothia CDR-H2 sequence comprising SEQ ID NO : 40, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 78. In some embodiments, the antibody comprises a _VH sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO: 3, a Chothia CDR-H2 sequence , comprising SEQ ID NO: 41, and a Chothia CDR-H3 sequence, comprising SEQ ID NO: 79. In some embodiments, said antibody comprises a V _H sequence comprising a Chothia CDR-H1 sequence, comprising SEQ ID NO: 4, sequence A Chothia CDR-H2 comprising SEQ ID NO: 41 and a Chothia CDR-H3 sequence comprising SEQ ID NO: 80. In some embodiments, the antibody comprises a _VH sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO: 3, a Chothia CDR-H2 sequence comprising SEQ ID NO: 41, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 76. In some embodiments, the antibody comprises a V _H sequence comprising a CDR-H1 sequence Chothia comprising SEQ ID NO: 2, a Chothia CDR-H2 sequence containing SEQ ID NO: 42, and a Chothia CDR-H3 sequence containing SEQ ID NO: 76. In some embodiments, the antibody comprises a V _H sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO: 2, a Chothia CDR-H2 sequence comprising SEQ ID NO: 43, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 81. In some embodiments, the antibody comprises a V _H sequence containing a Chothia CDR-H1 sequence containing SEQ ID NO: 2, a Chothia CDR-H2 sequence containing SEQ ID NO: 42, and a Chothia CDR-H3 sequence containing SEQ ID NO: 82. According to some In embodiments, said antibody comprises a V _H sequence comprising a Chothia CDR-H1 sequence containing SEQ ID NO: 5, a Chothia CDR-H2 sequence containing SEQ ID NO: 42, and a Chothia CDR-H3 sequence containing SEQ ID NO: : 76. In some embodiments, the antibody comprises a _VH sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO: 2, a Chothia CDR-H2 sequence comprising SEQ ID NO: 42, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 81. In some embodiments, said antibody comprises a V _H sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO: 3, a Chothia CDR-H2 sequence comprising SEQ ID NO: 41, and a sequence Chothia CDR-H3 comprising SEQ ID NO: 83. In some embodiments, said antibody comprises a _VH sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO: 3, a Chothia CDR-H2 sequence comprising SEQ ID NO : 41, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 84. In some embodiments, the antibody comprises a _VH sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO: 6, a Chothia CDR-H2 sequence , comprising SEQ ID NO: 44, and a Chothia CDR-H3 sequence, comprising SEQ ID NO: 85. In some embodiments, said antibody comprises a _VH sequence comprising a Chothia CDR-H1 sequence, comprising SEQ ID NO: 6, sequence A Chothia CDR-H2 comprising SEQ ID NO: 44 and a Chothia CDR-H3 sequence comprising SEQ ID NO: 86. In some embodiments, the antibody comprises a _VH sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO: 7, a Chothia CDR-H2 sequence comprising SEQ ID NO: 45, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 87. In some embodiments, the antibody comprises a V _H sequence comprising a CDR-H1 sequence Chothia containing SEQ ID NO: 8, a Chothia CDR-H2 sequence containing SEQ ID NO: 44, and a Chothia CDR-H3 sequence containing SEQ ID NO: 88. In some embodiments, the antibody comprises a V _H sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO: 8, a Chothia CDR-H2 sequence comprising SEQ ID NO: 44, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 89. In some embodiments, the antibody comprises a V _H sequence containing a Chothia CDR-H1 sequence containing SEQ ID NO: 7, a Chothia CDR-H2 sequence containing SEQ ID NO: 44, and a Chothia CDR-H3 sequence containing SEQ ID NO: 90. According to some In embodiments, said antibody comprises a V _H sequence comprising a Chothia CDR-H1 sequence containing SEQ ID NO: 9, a Chothia CDR-H2 sequence containing SEQ ID NO: 44, and a Chothia CDR-H3 sequence containing SEQ ID NO: : 90. In some embodiments, the antibody comprises a _VH sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO: 6, a Chothia CDR-H2 sequence comprising SEQ ID NO: 45, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 91. In some embodiments, said antibody comprises a V _H sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO: 8, a Chothia CDR-H2 sequence comprising SEQ ID NO: 44, and a Chothia CDR-H3 comprising SEQ ID NO: 92. In some embodiments, said antibody comprises a _VH sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO: 7, a Chothia CDR-H2 sequence comprising SEQ ID NO : 44, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 93. In some embodiments, the antibody comprises a _VH sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO: 10, a Chothia CDR-H2 sequence , comprising SEQ ID NO: 46, and a Chothia CDR-H3 sequence, comprising SEQ ID NO: 94. In some embodiments, said antibody comprises a _VH sequence comprising a Chothia CDR-H1 sequence, comprising SEQ ID NO: 11, sequence A Chothia CDR-H2 comprising SEQ ID NO: 47 and a Chothia CDR-H3 sequence comprising SEQ ID NO: 95. In some embodiments, the antibody comprises a _VH sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO: 12, a Chothia CDR-H2 sequence comprising SEQ ID NO: 48, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 96. In some embodiments, the antibody comprises a V _H sequence comprising a CDR-H1 sequence Chothia sequence comprising SEQ ID NO: 13, a Chothia CDR-H2 sequence comprising SEQ ID NO: 44, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 97. In some embodiments, said antibody comprises a _VH sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO: 14, a Chothia CDR-H2 sequence comprising SEQ ID NO: 49, and a Chothia CDR-H3 sequence comprising SEQ ID NO: 98. In some embodiments, the antibody comprises a V _H sequence containing a Chothia CDR-H1 sequence containing SEQ ID NO: 1, a Chothia CDR-H2 sequence containing SEQ ID NO: 38, and a Chothia CDR-H3 sequence containing SEQ ID NO: 99. According to some In embodiments, said antibody comprises a V _H sequence comprising a Chothia CDR-H1 sequence containing SEQ ID NO: 11, a Chothia CDR-H2 sequence containing SEQ ID NO: 50, and a Chothia CDR-H3 sequence containing SEQ ID NO: : 100. In some embodiments, the antibody comprises a _VH sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO: 6, a Chothia CDR-H2 sequence comprising SEQ ID NO: 44, and a Chothia CDR-H3 sequence containing SEQ ID NO: 101.

1.2.2.8. _VH sequence variants containing illustrative Chothia CDRs

[00104] In some embodiments, the V _H sequences provided by the present invention comprise a variant of the exemplary Chothia CDR-H3, CDR-H2, and/or CDR-H1 sequence set forth herein.

[00105] In some aspects, the Chothia CDR-H3 sequence comprises, consists of, or consists essentially of a variant of an exemplary Chothia CDR-H3 sequence set forth herein. In some aspects, the Chothia CDR-H3 sequence comprises, consists of, or consists essentially of a sequence that is at least 70%, 75%, 80%, 85%, 90%, or 95% identical to any of the exemplary CDR-H3 sequences according to Chothia, given in this description. In some aspects, the Chothia CDR-H3 sequence comprises, consists of, or consists essentially of any of the exemplary Chothia CDR-H3 sequences provided herein, with 1, 2, or 3 amino acid substitutions. In some aspects, these amino acid substitutions are conservative amino acid substitutions.

[00106] In some aspects, the Chothia CDR-H2 sequence comprises a variant of, consists of, or consists essentially of a variant of the exemplary Chothia CDR-H2 sequence set forth herein. In some aspects, the Chothia CDR-H2 sequence comprises, consists of, or consists essentially of a sequence that is at least 70%, 75%, 80%, 85%, 90%, or 95% identical to any of the exemplary CDR-H2 sequences according to Chothia, given in this description. In some aspects, the Chothia CDR-H2 sequence comprises, consists of, or consists essentially of any of the exemplary Chothia CDR-H2 sequences provided herein, with 1, 2, or 3 amino acid substitutions. In some aspects, these amino acid substitutions are conservative amino acid substitutions.

[00107] In some aspects, the Chothia CDR-H1 sequence comprises a variant of, consists of, or consists essentially of a variant of the exemplary Chothia CDR-H1 sequence set forth herein. In some aspects, the Chothia CDR-H1 sequence comprises, consists of, or consists essentially of a sequence that is at least 70%, 75%, 80%, 85%, 90%, or 95% identical to any of the exemplary CDR-H1 sequences according to Chothia, given in this description. In some aspects, the Chothia CDR-H1 sequence comprises, consists of, or consists essentially of any of the exemplary Chothia CDR-H1 sequences provided herein, with 1, 2, or 3 amino acid substitutions. In some aspects, these amino acid substitutions are conservative amino acid substitutions.

1.3. Sequences V _H

[00108] In some embodiments, the antibody comprises a V _H sequence comprising, consisting of, or essentially consisting of a sequence selected from SEQ ID NOs: 170-200. In some aspects, the antibody comprises a V _H sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 170. In some aspects, the antibody contains a V _{H sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 171. In some aspects, the antibody contains a V H} sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 171. In some aspects, said antibody comprises a _VH sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 172. In some aspects, said antibody comprises a VH sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 173. In some aspects, said antibody comprises a _VH sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 173. In some aspects, said antibody the antibody comprises a _VH sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 174. In some aspects, said antibody comprises a _VH sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 175. In some aspects, said antibody comprises a V _H sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 176. In some aspects, said antibody comprises a V _H sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 177. In some aspects, said antibody comprises a V sequence _H containing, consisting of, or essentially consisting of SEQ ID NO: 178. In some aspects, said antibody comprises a V _H sequence containing, consisting of, or essentially consisting of SEQ ID NO: 179. In some aspects, said antibody comprises a V _H sequence, comprising, consisting of, or essentially consisting of SEQ ID NO: 180. In some aspects, said antibody comprises a V _H sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 181. In some aspects, said antibody comprises a V _H sequence comprising, consisting of or essentially consisting of SEQ ID NO: 182. In some aspects, said antibody comprises a V _H sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 183. In some aspects, said antibody contains a V _H sequence comprising, consisting of or essentially consisting of SEQ ID NO: 184. In some aspects, said antibody comprises a V _H sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 185. In some aspects, said antibody comprises a V _H sequence comprising, consisting of, or essentially consisting of consisting of SEQ ID NO: 186. In some aspects, said antibody contains a V _H sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 187. In some aspects, said antibody contains a V _H sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 188. In some aspects, the antibody comprises a _VH sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 189. In some aspects, the antibody comprises a _VH sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 190. In some aspects, the antibody contains a _VH sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 191. In some aspects, the antibody contains a _VH sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 191. 192. In some aspects, the antibody contains a _VH sequence containing, consisting of, or essentially consisting of SEQ ID NO: 193. In some aspects, the antibody contains a _VH sequence containing, consisting of, or essentially consisting of SEQ ID NO: 194. In some aspects, the antibody comprises a _VH sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 195. In some aspects, the antibody contains a VH sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 196. In some aspects, the antibody comprises a _VH sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 196. In some aspects, said antibody comprises a V _H sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 197. In some aspects, said antibody comprises a V _{H sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 198. In some aspects, said antibody comprises a V H} sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 198. In some aspects, said antibody the antibody contains a _VH sequence containing, consisting of, or essentially consisting of SEQ ID NO: 199. In some aspects, the antibody contains a _VH sequence containing, consisting of, or essentially consisting of SEQ ID NO: 200.

1.3.1. V _H sequence variants

[00109] In some embodiments, the V _H sequences provided by the present invention comprise, consist of, or consist essentially of a variant of the exemplary V _H sequence set forth herein.

[00110] In some aspects, the V _H sequence comprises, consists of, or consists essentially of a variant of the exemplary V _H sequence described herein. In some aspects, the V _H sequence comprises, consists of, or consists essentially of a sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% identical to any of illustrative V _H sequences given herein.

[00111] In some embodiments, the V _H sequence contains, consists of, or consists essentially of any of the exemplary V _H sequences provided herein, with 20 or less, 19 or less, 18 or less, 17 or less, 16 or less , 15 or less, 14 or less, 13 or less, 12 or less, 11 or less, 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, 2 or less, or 1 or less amino acid substitutions. In some aspects, these amino acid substitutions are conservative amino acid substitutions.

1.4. CDR-L3 sequences

[00112] In some embodiments, the antibody comprises a CDR-L3 sequence comprising, consisting of, or essentially consisting of a sequence selected from SEQ ID NOs: 149-166. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 149. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 150. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 151. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 152. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 153. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 154. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 155. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 156. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 157. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 158. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 159. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 160. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 161. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 162. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 163. In some aspects, the antibody contains a CDR-L3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 164. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 165. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 166.

[00113] In some aspects, the CDR-L3 sequence comprises a variant of, consists of, or consists essentially of a variant of an exemplary CDR-L3 sequence set forth herein. In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of a sequence that is at least 70%, 75%, 80%, 85%, 90%, or 95% identical to any of the exemplary CDR-L3 sequences given in the present description. In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of any of the exemplary CDR-L3 sequences provided herein, with 1, 2, or 3 amino acid substitutions. In some aspects, these amino acid substitutions are conservative amino acid substitutions.

1.5. V _L Sequences containing illustrative CDRs

[00114] In some embodiments, the antibody comprises a V _L sequence comprising one or more CDR-L sequences containing, consisting of, or substantially consisting of one or more exemplary CDR-L sequences provided herein and variants thereof.

1.5.1. CDR-L3

[00115] In some embodiments, the antibody comprises a V _L sequence comprising a CDR-L3 sequence comprising, consisting of, or essentially consisting of a sequence selected from SEQ ID NOs: 149-166. In some aspects, said antibody comprises a V _L sequence comprising a CDR-L3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 149. In some aspects, said antibody comprises a V _L sequence comprising a CDR-L3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 150. In some aspects, said antibody comprises a _VL sequence comprising a CDR-L3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 151. In some aspects, said antibody comprises a _VL sequence, comprising a CDR-L3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 152. In some aspects, said antibody comprises a V _L sequence comprising a CDR-L3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 153. In some aspects, the antibody comprises a _VL sequence comprising a CDR-L3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 154. In some aspects, the antibody comprises a _VL sequence comprising a CDR-L3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 155. In some aspects, said antibody comprises a _VL sequence comprising a CDR-L3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 156. In some aspects, said antibody comprises a _VL sequence, comprising a CDR-L3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 157. In some aspects, said antibody comprises a V _L sequence comprising a CDR-L3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 158. In some aspects, said antibody comprises a V _L sequence comprising a CDR-L3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 159. In some aspects, said antibody comprises a V _L sequence comprising a CDR-L3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 160. In some aspects, said antibody comprises a _VL sequence comprising a CDR-L3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 161. In some aspects, said antibody comprises a _VL sequence, comprising a CDR-L3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 162. In some aspects, said antibody comprises a V _L sequence comprising a CDR-L3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 163. In some aspects, said antibody comprises a V _L sequence comprising a CDR-L3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 164. In some aspects, said antibody comprises a V _L sequence comprising a CDR-L3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 165. In some aspects, said antibody comprises a V _L sequence comprising a CDR-L3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 166.

1.5.2. CDR-L2

[00116] In some embodiments, the antibody comprises a V _L sequence comprising a CDR-L2 sequence comprising, consisting of, or essentially consisting of a sequence selected from SEQ ID NOs: 128-145. In some aspects, said antibody comprises a V _L sequence comprising a CDR-L2 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 128. In some aspects, said antibody comprises a V _L sequence comprising a CDR-L2 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 129. In some aspects, said antibody comprises a _VL sequence comprising a CDR-L2 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 130. In some aspects, said antibody comprises a _VL sequence, comprising a CDR-L2 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 131. In some aspects, said antibody comprises a V _L sequence comprising a CDR-L2 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 132. In some aspects, said antibody comprises a V _L sequence comprising a CDR-L2 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 133. In some aspects, said antibody comprises a V _L sequence comprising a CDR-L2 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 134. In some aspects, said antibody comprises a _VL sequence comprising a CDR-L2 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 135. In some aspects, said antibody comprises a _VL sequence, comprising a CDR-L2 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 136. In some aspects, said antibody comprises a V _L sequence comprising a CDR-L2 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 137. In some aspects, said antibody comprises a V _L sequence comprising a CDR-L2 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 138. In some aspects, said antibody comprises a V _L sequence comprising a CDR-L2 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 139. In some aspects, said antibody comprises a _VL sequence comprising a CDR-L2 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 140. In some aspects, said antibody comprises a _VL sequence, comprising a CDR-L2 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 141. In some aspects, said antibody comprises a V _L sequence comprising a CDR-L2 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 142. In some aspects, said antibody comprises a V _L sequence comprising a CDR-L2 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 143. In some aspects, said antibody comprises a V _L sequence comprising a CDR-L2 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 144. In some aspects, said antibody comprises a V _L sequence comprising a CDR-L2 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 145.

1.5.3. CDR-L1

[00117] In some embodiments, the antibody comprises a V _L sequence comprising a CDR-L1 sequence comprising, consisting of, or essentially consisting of a sequence selected from SEQ ID NOs: 105-124. In some aspects, the antibody comprises a _VL sequence comprising a CDR-L1 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 105. In some aspects, the antibody comprises a _VL sequence comprising a CDR-L1 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 106. In some aspects, said antibody comprises a _VL sequence comprising a CDR-L1 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 107. In some aspects, said antibody comprises a _VL sequence, comprising a CDR-L1 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 108. In some aspects, said antibody comprises a V _L sequence comprising a CDR-L1 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 109. In some aspects, said antibody comprises a V _L sequence comprising a CDR-L1 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 110. In some aspects, said antibody comprises a V _L sequence comprising a CDR-L1 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 111. In some aspects, said antibody comprises a _VL sequence comprising a CDR-L1 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 112. In some aspects, said antibody comprises a _VL sequence, comprising a CDR-L1 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 113. In some aspects, said antibody comprises a V _L sequence comprising a CDR-L1 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 114. In some aspects, the antibody comprises a _VL sequence comprising a CDR-L1 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 115. In some aspects, the antibody comprises a _VL sequence comprising a CDR-L1 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 116. In some aspects, said antibody comprises a _VL sequence comprising a CDR-L1 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 117. In some aspects, said antibody comprises a _VL sequence, comprising a CDR-L1 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 118. In some aspects, said antibody comprises a V _L sequence comprising a CDR-L1 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 119. In some aspects, the antibody comprises a _VL sequence comprising a CDR-L1 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 120. In some aspects, the antibody comprises a _VL sequence comprising a CDR-L1 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 121. In some aspects, said antibody comprises a _VL sequence comprising a CDR-L1 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 122. In some aspects, said antibody comprises a _VL sequence, comprising a CDR-L1 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 123. In some aspects, said antibody comprises a V _L sequence comprising a CDR-L1 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 124.

1.5.4. CDR-L3 + CDR-L2

[00118] In some embodiments, the antibody comprises a V _L sequence comprising a CDR-L3 sequence comprising, consisting of, or essentially consisting of a sequence selected from SEQ ID NOs: 149-166, and a CDR-L2 sequence comprising, consisting of, or essentially consisting of a sequence selected from SEQ ID NO: 128-145. In some aspects, both the CDR-L3 sequence and the CDR-L2 sequence are taken from the same exemplary V _L sequence provided herein. For example, in some aspects, both CDR-L3 and CDR-L2 are taken from the same exemplary V _L sequence selected from SEQ ID NOs: 204-228.

1.5.5. CDR-L3 + CDR-L1

[00119] In some embodiments, the antibody comprises a V _L sequence comprising a CDR-L3 sequence comprising, consisting of, or essentially consisting of a sequence selected from SEQ ID NOs: 149-166, and a CDR-L1 sequence comprising, consisting of, or essentially consisting of a sequence selected from SEQ ID NO: 105-124. In some aspects, both the CDR-L3 sequence and the CDR-L1 sequence are taken from the same exemplary V _L sequence provided herein. For example, in some aspects, both CDR-L3 and CDR-L1 are taken from the same exemplary V _L sequence selected from SEQ ID NOs: 204-228.

1.5.6. CDR-L1 + CDR-L2

[00120] In some embodiments, the antibody comprises a V _L sequence comprising a CDR-L1 sequence comprising, consisting of, or essentially consisting of a sequence selected from SEQ ID NOs: 105-124, and a CDR-L2 sequence comprising, consisting of or essentially consisting of a sequence selected from SEQ ID NO: 128-145. In some aspects, both CDR-L1 and CDR-L2 sequences are taken from the same exemplary V _L sequence provided herein. For example, in some aspects, both the CDR-L1 and CDR-L2 sequences are taken from the same exemplary V _L sequence selected from SEQ ID NOs: 204-228.

1.5.7. CDR-L1 + CDR-L2 + CDR-L3

[00121] In some embodiments, said antibody comprises a V _L sequence comprising a CDR-L1 sequence comprising, consisting of, or essentially consisting of a sequence selected from SEQ ID NOs: 105-124, a CDR-L2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 128-145, and a CDR-L3 sequence comprising, consisting of, or essentially consisting of a sequence selected from SEQ ID NOs: 149-166. In some aspects, the sequences, CDR-L1, CDR-L2, and CDR-L3, are all taken from a single exemplary V _L sequence provided herein. For example, in some aspects, all of the above sequences, CDR-L1, CDR-L2, and CDR-L3, are taken from a single exemplary V _L sequence selected from SEQ ID NOs: 204-228.

[00122] In some aspects, said antibody comprises a V _L sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 105, a CDR-L2 sequence comprising SEQ ID NO: 128, and a CDR-L3 sequence comprising SEQ ID NO: 149. According to In some aspects, said antibody comprises a V _L sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 106, a CDR-L2 sequence comprising SEQ ID NO: 129, and a CDR-L3 sequence comprising SEQ ID NO: 150. In some aspects, said antibody contains a V _L sequence containing a CDR-L1 sequence containing SEQ ID NO: 107, a CDR-L2 sequence containing SEQ ID NO: 128, and a CDR-L3 sequence SEQ ID NO: 151. In some aspects, said antibody contains a V _L sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 108, a CDR-L2 sequence comprising SEQ ID NO: 130, and a CDR-L3 sequence SEQ ID NO: 151. In some aspects, said antibody comprises a V _L sequence comprising a CDR sequence -L1 comprising SEQ ID NO: 109, a CDR-L2 sequence comprising SEQ ID NO: 131, and a CDR-L3 sequence SEQ ID NO: 152. In some aspects, said antibody comprises a V _L sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 107, a CDR-L2 sequence comprising SEQ ID NO: 132, and a CDR-L3 sequence SEQ ID NO: 153. In some aspects, said antibody comprises a V _L sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 153. 110, a CDR-L2 sequence comprising SEQ ID NO: 132, and a CDR-L3 sequence SEQ ID NO: 151. In some aspects, said antibody comprises a V _L sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 111, a CDR sequence -L2 comprising SEQ ID NO: 133, and a CDR-L3 sequence SEQ ID NO: 151. In some aspects, said antibody comprises a V _L sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 105, a CDR-L2 sequence comprising SEQ ID NO: 128, and a CDR-L3 sequence SEQ ID NO: 154. In some aspects, said antibody comprises a V _L sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 112, a CDR-L2 sequence comprising SEQ ID NO: 134, and a CDR-L3 sequence of SEQ ID NO: 155. In some aspects, said antibody comprises a V _L sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 113, a CDR-L2 sequence comprising SEQ ID NO: 135, and a sequence CDR-L3 SEQ ID NO: 156. In some aspects, the antibody comprises a V _L sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 114, a CDR-L2 sequence comprising SEQ ID NO: 136, and a CDR-L3 sequence SEQ ID NO: 157. In some aspects, said antibody comprises a V _L sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 115, a CDR-L2 sequence comprising SEQ ID NO: 135, and a CDR-L3 sequence SEQ ID NO: 157 In some aspects, said antibody comprises a V _L sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 116, a CDR-L2 sequence comprising SEQ ID NO: 128, and a CDR-L3 sequence SEQ ID NO: 155. In some aspects said antibody comprises a V _L sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 117, a CDR-L2 sequence comprising SEQ ID NO: 137, and a CDR-L3 sequence SEQ ID NO: 155. In some aspects, said antibody comprises the sequence V _L containing the CDR-L1 sequence containing SEQ ID NO: 118, the CDR-L2 sequence containing SEQ ID NO: 137, and the CDR-L3 sequence SEQ ID NO: 158. In some aspects, the antibody contains a V _L sequence containing a CDR-L1 sequence comprising SEQ ID NO: 118, a CDR-L2 sequence comprising SEQ ID NO: 138, and a CDR-L3 sequence SEQ ID NO: 155. In some aspects, said antibody comprises a V _L sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 119, a CDR-L2 sequence comprising SEQ ID NO: 139, and a CDR-L3 sequence SEQ ID NO: 159. In some aspects, said antibody comprises a V _L sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 120, a CDR-L2 sequence comprising SEQ ID NO: 140, and a CDR-L3 sequence SEQ ID NO: 160. In some aspects, said antibody comprises a V _L sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 121, a CDR-L2 sequence comprising SEQ ID NO: 141, and a CDR-L3 sequence SEQ ID NO: 161. In some aspects, said antibody comprises a V _L sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 122, a CDR-L2 sequence comprising SEQ ID NO: 142, and a CDR-L3 sequence SEQ ID NO: 162. In some aspects, said antibody comprises a V _L sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 105, a CDR-L2 sequence comprising SEQ ID NO: 143, and a CDR-L3 sequence of SEQ ID NO: 163. In some aspects, said antibody comprises a V _L sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 105, a CDR-L2 sequence comprising SEQ ID NO: 143, and a CDR-L3 sequence of SEQ ID NO: 164. In some aspects, said antibody comprises a V _L sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 123, a CDR-L2 sequence comprising SEQ ID NO: 144, and a CDR- L3 SEQ ID NO: 165. In some aspects, said antibody comprises a V _L sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 124, a CDR-L2 sequence comprising SEQ ID NO: 145, and a CDR-L3 sequence SEQ ID NO: 124. : 166.

1.5.8. V _L sequence variants containing illustrative CDR-Ls

[00123] In some embodiments, the V _L sequences provided by the present invention comprise a variant of the exemplary CDR-L3, CDR-L2, and/or CDR-L1 sequence set forth herein.

[00124] In some aspects, the CDR-L3 sequence comprises a variant of, consists of, or consists essentially of a variant of an exemplary CDR-L3 sequence described herein. In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of a sequence that is at least 70%, 75%, 80%, 85%, 90%, or 95% identical to any of the exemplary CDR-L3 sequences given in the present description. In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of any of the exemplary CDR-L3 sequences provided herein, with 1, 2, or 3 amino acid substitutions. In some aspects, these amino acid substitutions are conservative amino acid substitutions.

[00125] In some aspects, the CDR-L2 sequence comprises, consists of, or consists essentially of a variant of an exemplary CDR-L2 sequence set forth herein. In some aspects, the CDR-L2 sequence comprises, consists of, or consists essentially of a sequence that is at least 70%, 75%, 80%, 85%, 90%, or 95% identical to any of the exemplary CDR-L2 sequences given in the present description. In some aspects, the CDR-L2 sequence comprises, consists of, or consists essentially of any of the exemplary CDR-L2 sequences provided herein, with 1, 2, or 3 amino acid substitutions. In some aspects, these amino acid substitutions are conservative amino acid substitutions.

[00126] In some aspects, the CDR-L1 sequence comprises a variant of, consists of, or consists essentially of a variant of the exemplary CDR-L1 sequence described herein. In some aspects, the CDR-L1 sequence comprises, consists of, or consists essentially of a sequence that is at least 70%, 75%, 80%, 85%, 90%, or 95% identical to any of the exemplary CDR-L1 sequences given in the present description. In some aspects, the CDR-L1 sequence comprises, consists of, or consists essentially of any of the exemplary CDR-L1 sequences provided herein, with 1, 2, or 3 amino acid substitutions. In some aspects, these amino acid substitutions are conservative amino acid substitutions.

1.6. Sequences V _L

[00127] In some embodiments, the antibody comprises a V _L sequence comprising, consisting of, or essentially consisting of a sequence selected from SEQ ID NOs: 204-228. In some aspects, the antibody comprises a V _L sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 204. In some aspects, the antibody contains a V _{L sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 205. In some aspects, the antibody contains a V L} sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 205. In some aspects, said antibody comprises a V _L sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 206. In some aspects, said antibody comprises a V _{L sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 207. In some aspects, said antibody comprises a V L} sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 207. In some aspects, said antibody the antibody contains a V _L sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 208. In some aspects, the antibody contains a V _L sequence containing, consisting of, or essentially consisting of SEQ ID NO: 209. In some aspects, the antibody contains a V _L sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 210. In some aspects, said antibody comprises a V _L sequence containing, consisting of, or essentially consisting of SEQ ID NO: 211. In some aspects, said antibody comprises a V sequence _L , containing, consisting of, or essentially consisting of SEQ ID NO: 212. In some aspects, said antibody comprises a V _L sequence, containing, consisting of, or essentially consisting of SEQ ID NO: 213. In some aspects, said antibody comprises a V _L sequence, comprising, consisting of, or essentially consisting of SEQ ID NO: 214. In some aspects, said antibody comprises a V _L sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 215. In some aspects, said antibody comprises a V _L sequence comprising, consisting of or essentially consisting of SEQ ID NO: 216. In some aspects, said antibody comprises a V _L sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 217. In some aspects, said antibody contains a V _L sequence comprising, consisting of or essentially consisting of SEQ ID NO: 218. In some aspects, said antibody contains a V _L sequence containing, consisting of, or essentially consisting of SEQ ID NO: 219. In some aspects, said antibody contains a V _L sequence containing, consisting of, or essentially consisting of consisting of SEQ ID NO: 220. In some aspects, said antibody contains a V _L sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 221. In some aspects, said antibody contains a V _L sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 222. In some aspects, the antibody contains a V _L sequence containing, consisting of, or essentially consisting of SEQ ID NO: 223. In some aspects, the antibody contains a V _L sequence containing, consisting of, or essentially consisting of SEQ ID NO: 224. In some aspects, the antibody contains a V _L sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 225. In some aspects, the antibody contains a V _L sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 225. 226. In some aspects, the antibody contains a V _L sequence containing, consisting of, or essentially consisting of SEQ ID NO: 227. In some aspects, the antibody contains a V _L sequence containing, consisting of, or essentially consisting of SEQ ID NO: 228.

1.6.1. Sequence variants V _L

[00128] In some embodiments, the V _L sequences provided by the present invention contain, consist of, or consist essentially of a variant of the exemplary V _L sequence set forth herein.

[00129] In some aspects, the V _L sequence comprises, consists of, or consists essentially of a variant of the exemplary V _L sequence described herein. In some aspects, the sequence V _L comprises, consists of, or consists of a sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.05% identical to any of the illustrative sequences V _L given in the present description.

[00130] In some embodiments, the V _L sequence contains, consists of, or consists essentially of any of the exemplary V _L sequences provided herein, with 20 or less, 19 or less, 18 or less, 17 or less, 16 or less , 15 or less, 14 or less, 13 or less, 12 or less, 11 or less, 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, 2 or less, or 1 or less amino acid substitutions. In some aspects, these amino acid substitutions are conservative amino acid substitutions.

1.7. Couples

1.7.1. CDR-H3 - CDR-L3 pairs

[00131] In some embodiments, the antibody comprises a CDR-H3 sequence, and a CDR-L3 sequence. In some aspects, the CDR-H3 sequence is included in V _H and the CDR-L3 sequence is included in V _L .

[00132] In some aspects, the CDR-H3 sequence is a CDR-H3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 76-101, and the CDR-L3 sequence is a CDR-L3 sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 149-166.

[00133] In some aspects, the CDR-H3 sequence is SEQ ID NO: 76, and the CDR-L3 sequence is selected from SEQ ID NO: 149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[00134] In some aspects, the CDR-H3 sequence is SEQ ID NO: 77, and the CDR-L3 sequence is selected from SEQ ID NO: 149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[00135] In some aspects, the CDR-H3 sequence is SEQ ID NO: 78, and the CDR-L3 sequence is selected from SEQ ID NO: 149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[00136] In some aspects, the CDR-H3 sequence is SEQ ID NO: 79, and the CDR-L3 sequence is selected from SEQ ID NO: 149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[00137] In some aspects, the CDR-H3 sequence is SEQ ID NO: 80, and the CDR-L3 sequence is selected from SEQ ID NO: 149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[00138] In some aspects, the CDR-H3 sequence is SEQ ID NO: 81, and the CDR-L3 sequence is selected from SEQ ID NO: 149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[00139] In some aspects, the CDR-H3 sequence is SEQ ID NO: 82, and the CDR-L3 sequence is selected from SEQ ID NO: 149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[00140] In some aspects, the CDR-H3 sequence is SEQ ID NO: 83, and the CDR-L3 sequence is selected from SEQ ID NO: 149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[00141] In some aspects, the CDR-H3 sequence is SEQ ID NO: 84, and the CDR-L3 sequence is selected from SEQ ID NO: 149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[00142] In some aspects, the CDR-H3 sequence is SEQ ID NO: 85, and the CDR-L3 sequence is selected from SEQ ID NO: 149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[00143] In some aspects, the CDR-H3 sequence is SEQ ID NO: 86, and the CDR-L3 sequence is selected from SEQ ID NO: 149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[00144] In some aspects, the CDR-H3 sequence is SEQ ID NO: 87, and the CDR-L3 sequence is selected from SEQ ID NO: 149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[00145] In some aspects, the CDR-H3 sequence is SEQ ID NO: 88, and the CDR-L3 sequence is selected from SEQ ID NO: 149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[00146] In some aspects, the CDR-H3 sequence is SEQ ID NO: 89, and the CDR-L3 sequence is selected from SEQ ID NO: 149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[00147] In some aspects, the CDR-H3 sequence is SEQ ID NO: 90, and the CDR-L3 sequence is selected from SEQ ID NO: 149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[00148] In some aspects, the CDR-H3 sequence is SEQ ID NO: 91, and the CDR-L3 sequence is selected from SEQ ID NO: 149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[00149] In some aspects, the CDR-H3 sequence is SEQ ID NO: 92, and the CDR-L3 sequence is selected from SEQ ID NO: 149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[00150] In some aspects, the CDR-H3 sequence is SEQ ID NO: 93, and the CDR-L3 sequence is selected from SEQ ID NO: 149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[00151] In some aspects, the CDR-H3 sequence is SEQ ID NO: 94, and the CDR-L3 sequence is selected from SEQ ID NO: 149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[00152] In some aspects, the CDR-H3 sequence is SEQ ID NO: 95, and the CDR-L3 sequence is selected from SEQ ID NO: 149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[00153] In some aspects, the CDR-H3 sequence is SEQ ID NO: 96, and the CDR-L3 sequence is selected from SEQ ID NO: 149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[00154] In some aspects, the CDR-H3 sequence is SEQ ID NO: 97, and the CDR-L3 sequence is selected from SEQ ID NO: 149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[00155] In some aspects, the CDR-H3 sequence is SEQ ID NO: 98, and the CDR-L3 sequence is selected from SEQ ID NO: 149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[00156] In some aspects, the CDR-H3 sequence is SEQ ID NO: 99, and the CDR-L3 sequence is selected from SEQ ID NO: 149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[00157] In some aspects, the CDR-H3 sequence is SEQ ID NO: 100, and the CDR-L3 sequence is selected from SEQ ID NO: 149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

[00158] In some aspects, the CDR-H3 sequence is SEQ ID NO: 101, and the CDR-L3 sequence is selected from SEQ ID NO: 149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO: 149. In some aspects, the CDR-L3 sequence is SEQ ID NO: 150. In some aspects, the CDR-L3 sequence is SEQ ID NO: 151. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 152. In some aspects, the CDR-L3 sequence is SEQ ID NO: 153. In some aspects, the CDR-L3 sequence is SEQ ID NO: 154. In some aspects, the CDR-L3 sequence is SEQ ID NO: 155. In some aspects, the CDR-L3 sequence is SEQ ID NO: 156. In some aspects, the CDR-L3 sequence is SEQ ID NO: 157. In some aspects, the CDR-L3 sequence is SEQ ID NO: 158. In some aspects, the CDR-L3 sequence is SEQ ID NO: 159. In some aspects, the CDR-L3 sequence is SEQ ID NO: 160. In some aspects, the CDR-L3 sequence is SEQ ID NO: 161. In some aspects, the CDR sequence is -L3 is SEQ ID NO: 162. In some aspects, the CDR-L3 sequence is SEQ ID NO: 163. In some aspects, the CDR-L3 sequence is SEQ ID NO: 164. In some aspects, the CDR-L3 sequence is SEQ ID NO: 165. In some aspects, the CDR-L3 sequence is SEQ ID NO: 166.

1.7.1.1. Pair options CDR-H3 - CDR-L3

[00159] In some embodiments, the CDR-H3-CDR-L3 pairs provided by the present invention comprise a variant of the exemplary CDR-H3 and/or CDR-L1 sequence described herein.

[00160] In some aspects, the CDR-H3 sequence comprises a variant of, consists of, or consists essentially of a variant of an exemplary CDR-H3 sequence set forth herein. In some aspects, the CDR-H3 sequence comprises, consists of, or consists essentially of a sequence that is at least 70%, 75%, 80%, 85%, 90%, or 95% identical to any of the exemplary CDR-H3 sequences given in the present description. In some aspects, the CDR-H3 sequence comprises, consists of, or consists essentially of any of the exemplary CDR-H3 sequences provided herein with 1, 2, or 3 amino acid substitutions. In some aspects, these amino acid substitutions are conservative amino acid substitutions.

[00161] In some aspects, the CDR-L3 sequence comprises a variant of, consists of, or consists essentially of a variant of an exemplary CDR-L3 sequence described herein. In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of a sequence that is at least 70%, 75%, 80%, 85%, 90%, or 95% identical to any of the exemplary CDR-L3 sequences given in the present description. In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of any of the exemplary CDR-L3 sequences provided herein, with 1, 2, or 3 amino acid substitutions. In some aspects, these amino acid substitutions are conservative amino acid substitutions.

1.7.2. Pairs V _H - V _L

[00162] In some embodiments, the antibody comprises a V _H sequence and a V _L sequence.

[00163] In some aspects, the V _H sequence is a V _H sequence containing, consisting of, or essentially consisting of SEQ ID NO: 170-200, and the V _L sequence is a V _L sequence containing, consisting of, or essentially consisting of SEQ ID NO: 204-228.

[00164] In some aspects, the V _H sequence is SEQ ID NO: 170, and the V _L sequence is selected from SEQ ID NO: 204-228. In some aspects, the V _L sequence is SEQ ID NO: 204. In some aspects, the V _L sequence is SEQ ID NO: 205. In some aspects, the V _L sequence is SEQ ID NO: 206. In some aspects, the V _L sequence is SEQ ID NO: 207. In some aspects, the V _L sequence is SEQ ID NO: 208. In some aspects, the V _L sequence is SEQ ID NO: 209. In some aspects, the V _L sequence is SEQ ID NO: 210. In some aspects, In some aspects, the V _L sequence is SEQ ID NO: 211. In some aspects, the V _L sequence is SEQ ID NO: 212. In some aspects, the V _L sequence is SEQ ID NO: 213. In some aspects, the V _L sequence is SEQ ID NO: 214. In some aspects, the sequence V _L is SEQ ID NO: 215. In some aspects, the sequence V _L is SEQ ID NO: 216. In some aspects, the sequence V _L is SEQ ID NO: 217. In some aspects, the sequence V _L is SEQ ID NO: 218. In some aspects, the sequence V _L is SEQ ID NO: 219. In some aspects, the sequence V _L is SEQ ID NO: 220. In some aspects, the sequence V _L is SEQ ID NO: 221. In some aspects, the V _L sequence is SEQ ID NO: 222. In some aspects, the V _L sequence is SEQ ID NO: 223. In some aspects, the V _L sequence is SEQ ID NO: 224. In some aspects, the V _L sequence is is SEQ ID NO: 225. In some aspects, the V _L sequence is SEQ ID NO: 226. In some aspects, the V _L sequence is SEQ ID NO: 227. In some aspects, the V _L sequence is SEQ ID NO: 228.

[00165] In some aspects, the V _H sequence is SEQ ID NO: 171, and the V _L sequence is selected from SEQ ID NO: 204-228. In some aspects, the V _L sequence is SEQ ID NO: 204. In some aspects, the V _L sequence is SEQ ID NO: 205. In some aspects, the V _L sequence is SEQ ID NO: 206. In some aspects, the V _L sequence is SEQ ID NO: 207. In some aspects, the V _L sequence is SEQ ID NO: 208. In some aspects, the V _L sequence is SEQ ID NO: 209. In some aspects, the V _L sequence is SEQ ID NO: 210. In some aspects, In some aspects, the V _L sequence is SEQ ID NO: 211. In some aspects, the V _L sequence is SEQ ID NO: 212. In some aspects, the V _L sequence is SEQ ID NO: 213. In some aspects, the V _L sequence is SEQ ID NO: 214. In some aspects, the sequence V _L is SEQ ID NO: 215. In some aspects, the sequence V _L is SEQ ID NO: 216. In some aspects, the sequence V _L is SEQ ID NO: 217. In some aspects, the sequence V _L is SEQ ID NO: 218. In some aspects, the sequence V _L is SEQ ID NO: 219. In some aspects, the sequence V _L is SEQ ID NO: 220. In some aspects, the sequence V _L is SEQ ID NO: 221. In some aspects, the V _L sequence is SEQ ID NO: 222. In some aspects, the V _L sequence is SEQ ID NO: 223. In some aspects, the V _L sequence is SEQ ID NO: 224. In some aspects, the V _L sequence is is SEQ ID NO: 225. In some aspects, the V _L sequence is SEQ ID NO: 226. In some aspects, the V _L sequence is SEQ ID NO: 227. In some aspects, the V _L sequence is SEQ ID NO: 228.

[00166] In some aspects, the V _H sequence is SEQ ID NO: 172 and the V _L sequence is selected from SEQ ID NO: 204-228. In some aspects, the V _L sequence is SEQ ID NO: 204. In some aspects, the V _L sequence is SEQ ID NO: 205. In some aspects, the V _L sequence is SEQ ID NO: 206. In some aspects, the V _L sequence is SEQ ID NO: 207. In some aspects, the V _L sequence is SEQ ID NO: 208. In some aspects, the V _L sequence is SEQ ID NO: 209. In some aspects, the V _L sequence is SEQ ID NO: 210. In some aspects, In some aspects, the V _L sequence is SEQ ID NO: 211. In some aspects, the V _L sequence is SEQ ID NO: 212. In some aspects, the V _L sequence is SEQ ID NO: 213. In some aspects, the V _L sequence is SEQ ID NO: 214. In some aspects, the sequence V _L is SEQ ID NO: 215. In some aspects, the sequence V _L is SEQ ID NO: 216. In some aspects, the sequence V _L is SEQ ID NO: 217. In some aspects, the sequence V _L is SEQ ID NO: 218. In some aspects, the sequence V _L is SEQ ID NO: 219. In some aspects, the sequence V _L is SEQ ID NO: 220. In some aspects, the sequence V _L is SEQ ID NO: 221. In some aspects, the V _L sequence is SEQ ID NO: 222. In some aspects, the V _L sequence is SEQ ID NO: 223. In some aspects, the V _L sequence is SEQ ID NO: 224. In some aspects, the V _L sequence is is SEQ ID NO: 225. In some aspects, the V _L sequence is SEQ ID NO: 226. In some aspects, the V _L sequence is SEQ ID NO: 227. In some aspects, the V _L sequence is SEQ ID NO: 228.

[00167] In some aspects, the V _H sequence is SEQ ID NO: 173 and the V _L sequence is selected from SEQ ID NO: 204-228. In some aspects, the V _L sequence is SEQ ID NO: 204. In some aspects, the V _L sequence is SEQ ID NO: 205. In some aspects, the V _L sequence is SEQ ID NO: 206. In some aspects, the V _L sequence is SEQ ID NO: 207. In some aspects, the V _L sequence is SEQ ID NO: 208. In some aspects, the V _L sequence is SEQ ID NO: 209. In some aspects, the V _L sequence is SEQ ID NO: 210. In some aspects, In some aspects, the V _L sequence is SEQ ID NO: 211. In some aspects, the V _L sequence is SEQ ID NO: 212. In some aspects, the V _L sequence is SEQ ID NO: 213. In some aspects, the V _L sequence is SEQ ID NO: 214. In some aspects, the sequence V _L is SEQ ID NO: 215. In some aspects, the sequence V _L is SEQ ID NO: 216. In some aspects, the sequence V _L is SEQ ID NO: 217. In some aspects, the sequence V _L is SEQ ID NO: 218. In some aspects, the sequence V _L is SEQ ID NO: 219. In some aspects, the sequence V _L is SEQ ID NO: 220. In some aspects, the sequence V _L is SEQ ID NO: 221. In some aspects, the V _L sequence is SEQ ID NO: 222. In some aspects, the V _L sequence is SEQ ID NO: 223. In some aspects, the V _L sequence is SEQ ID NO: 224. In some aspects, the V _L sequence is is SEQ ID NO: 225. In some aspects, the V _L sequence is SEQ ID NO: 226. In some aspects, the V _L sequence is SEQ ID NO: 227. In some aspects, the V _L sequence is SEQ ID NO: 228.

[00168] In some aspects, the V _H sequence is SEQ ID NO: 174, and the V _L sequence is selected from SEQ ID NO: 204-228. In some aspects, the V _L sequence is SEQ ID NO: 204. In some aspects, the V _L sequence is SEQ ID NO: 205. In some aspects, the V _L sequence is SEQ ID NO: 206. In some aspects, the V _L sequence is SEQ ID NO: 207. In some aspects, the V _L sequence is SEQ ID NO: 208. In some aspects, the V _L sequence is SEQ ID NO: 209. In some aspects, the V _L sequence is SEQ ID NO: 210. In some aspects, In some aspects, the V _L sequence is SEQ ID NO: 211. In some aspects, the V _L sequence is SEQ ID NO: 212. In some aspects, the V _L sequence is SEQ ID NO: 213. In some aspects, the V _L sequence is SEQ ID NO: 214. In some aspects, the sequence V _L is SEQ ID NO: 215. In some aspects, the sequence V _L is SEQ ID NO: 216. In some aspects, the sequence V _L is SEQ ID NO: 217. In some aspects, the sequence V _L is SEQ ID NO: 218. In some aspects, the sequence V _L is SEQ ID NO: 219. In some aspects, the sequence V _L is SEQ ID NO: 220. In some aspects, the sequence V _L is SEQ ID NO: 221. In some aspects, the V _L sequence is SEQ ID NO: 222. In some aspects, the V _L sequence is SEQ ID NO: 223. In some aspects, the V _L sequence is SEQ ID NO: 224. In some aspects, the V _L sequence is is SEQ ID NO: 225. In some aspects, the V _L sequence is SEQ ID NO: 226. In some aspects, the V _L sequence is SEQ ID NO: 227. In some aspects, the V _L sequence is SEQ ID NO: 228.

[00169] In some aspects, the V _H sequence is SEQ ID NO: 175 and the V _L sequence is selected from SEQ ID NO: 204-228. In some aspects, the V _L sequence is SEQ ID NO: 204. In some aspects, the V _L sequence is SEQ ID NO: 205. In some aspects, the V _L sequence is SEQ ID NO: 206. In some aspects, the V _L sequence is SEQ ID NO: 207. In some aspects, the V _L sequence is SEQ ID NO: 208. In some aspects, the V _L sequence is SEQ ID NO: 209. In some aspects, the V _L sequence is SEQ ID NO: 210. In some aspects, In some aspects, the V _L sequence is SEQ ID NO: 211. In some aspects, the V _L sequence is SEQ ID NO: 212. In some aspects, the V _L sequence is SEQ ID NO: 213. In some aspects, the V _L sequence is SEQ ID NO: 214. In some aspects, the sequence V _L is SEQ ID NO: 215. In some aspects, the sequence V _L is SEQ ID NO: 216. In some aspects, the sequence V _L is SEQ ID NO: 217. In some aspects, the sequence V _L is SEQ ID NO: 218. In some aspects, the sequence V _L is SEQ ID NO: 219. In some aspects, the sequence V _L is SEQ ID NO: 220. In some aspects, the sequence V _L is SEQ ID NO: 221. In some aspects, the V _L sequence is SEQ ID NO: 222. In some aspects, the V _L sequence is SEQ ID NO: 223. In some aspects, the V _L sequence is SEQ ID NO: 224. In some aspects, the V _L sequence is is SEQ ID NO: 225. In some aspects, the V _L sequence is SEQ ID NO: 226. In some aspects, the V _L sequence is SEQ ID NO: 227. In some aspects, the V _L sequence is SEQ ID NO: 228.

[00170] In some aspects, the V _H sequence is SEQ ID NO: 176, and the V _L sequence is selected from SEQ ID NO: 204-228. In some aspects, the V _L sequence is SEQ ID NO: 204. In some aspects, the V _L sequence is SEQ ID NO: 205. In some aspects, the V _L sequence is SEQ ID NO: 206. In some aspects, the V _L sequence is SEQ ID NO: 207. In some aspects, the V _L sequence is SEQ ID NO: 208. In some aspects, the V _L sequence is SEQ ID NO: 209. In some aspects, the V _L sequence is SEQ ID NO: 210. In some aspects, In some aspects, the V _L sequence is SEQ ID NO: 211. In some aspects, the V _L sequence is SEQ ID NO: 212. In some aspects, the V _L sequence is SEQ ID NO: 213. In some aspects, the V _L sequence is SEQ ID NO: 214. In some aspects, the sequence V _L is SEQ ID NO: 215. In some aspects, the sequence V _L is SEQ ID NO: 216. In some aspects, the sequence V _L is SEQ ID NO: 217. In some aspects, the sequence V _L is SEQ ID NO: 218. In some aspects, the sequence V _L is SEQ ID NO: 219. In some aspects, the sequence V _L is SEQ ID NO: 220. In some aspects, the sequence V _L is SEQ ID NO: 221. In some aspects, the V _L sequence is SEQ ID NO: 222. In some aspects, the V _L sequence is SEQ ID NO: 223. In some aspects, the V _L sequence is SEQ ID NO: 224. In some aspects, the V _L sequence is is SEQ ID NO: 225. In some aspects, the V _L sequence is SEQ ID NO: 226. In some aspects, the V _L sequence is SEQ ID NO: 227. In some aspects, the V _L sequence is SEQ ID NO: 228.

[00171] In some aspects, the V _H sequence is SEQ ID NO: 177, and the V _L sequence is selected from SEQ ID NO: 204-228. In some aspects, the V _L sequence is SEQ ID NO: 204. In some aspects, the V _L sequence is SEQ ID NO: 205. In some aspects, the V _L sequence is SEQ ID NO: 206. In some aspects, the V _L sequence is SEQ ID NO: 207. In some aspects, the V _L sequence is SEQ ID NO: 208. In some aspects, the V _L sequence is SEQ ID NO: 209. In some aspects, the V _L sequence is SEQ ID NO: 210. In some aspects, In some aspects, the V _L sequence is SEQ ID NO: 211. In some aspects, the V _L sequence is SEQ ID NO: 212. In some aspects, the V _L sequence is SEQ ID NO: 213. In some aspects, the V _L sequence is SEQ ID NO: 214. In some aspects, the sequence V _L is SEQ ID NO: 215. In some aspects, the sequence V _L is SEQ ID NO: 216. In some aspects, the sequence V _L is SEQ ID NO: 217. In some aspects, the sequence V _L is SEQ ID NO: 218. In some aspects, the sequence V _L is SEQ ID NO: 219. In some aspects, the sequence V _L is SEQ ID NO: 220. In some aspects, the sequence V _L is SEQ ID NO: 221. In some aspects, the V _L sequence is SEQ ID NO: 222. In some aspects, the V _L sequence is SEQ ID NO: 223. In some aspects, the V _L sequence is SEQ ID NO: 224. In some aspects, the V _L sequence is is SEQ ID NO: 225. In some aspects, the V _L sequence is SEQ ID NO: 226. In some aspects, the V _L sequence is SEQ ID NO: 227. In some aspects, the V _L sequence is SEQ ID NO: 228.

[00172] In some aspects, the V _H sequence is SEQ ID NO: 178, and the V _L sequence is selected from SEQ ID NO: 204-228. In some aspects, the V _L sequence is SEQ ID NO: 204. In some aspects, the V _L sequence is SEQ ID NO: 205. In some aspects, the V _L sequence is SEQ ID NO: 206. In some aspects, the V _L sequence is SEQ ID NO: 207. In some aspects, the V _L sequence is SEQ ID NO: 208. In some aspects, the V _L sequence is SEQ ID NO: 209. In some aspects, the V _L sequence is SEQ ID NO: 210. In some aspects, In some aspects, the V _L sequence is SEQ ID NO: 211. In some aspects, the V _L sequence is SEQ ID NO: 212. In some aspects, the V _L sequence is SEQ ID NO: 213. In some aspects, the V _L sequence is SEQ ID NO: 214. In some aspects, the sequence V _L is SEQ ID NO: 215. In some aspects, the sequence V _L is SEQ ID NO: 216. In some aspects, the sequence V _L is SEQ ID NO: 217. In some aspects, the sequence V _L is SEQ ID NO: 218. In some aspects, the sequence V _L is SEQ ID NO: 219. In some aspects, the sequence V _L is SEQ ID NO: 220. In some aspects, the sequence V _L is SEQ ID NO: 221. In some aspects, the V _L sequence is SEQ ID NO: 222. In some aspects, the V _L sequence is SEQ ID NO: 223. In some aspects, the V _L sequence is SEQ ID NO: 224. In some aspects, the V _L sequence is is SEQ ID NO: 225. In some aspects, the V _L sequence is SEQ ID NO: 226. In some aspects, the V _L sequence is SEQ ID NO: 227. In some aspects, the V _L sequence is SEQ ID NO: 228.

[00173] In some aspects, the V _H sequence is SEQ ID NO: 179, and the V _L sequence is selected from SEQ ID NO: 204-228. In some aspects, the V _L sequence is SEQ ID NO: 204. In some aspects, the V _L sequence is SEQ ID NO: 205. In some aspects, the V _L sequence is SEQ ID NO: 206. In some aspects, the V _L sequence is SEQ ID NO: 207. In some aspects, the V _L sequence is SEQ ID NO: 208. In some aspects, the V _L sequence is SEQ ID NO: 209. In some aspects, the V _L sequence is SEQ ID NO: 210. In some aspects, In some aspects, the V _L sequence is SEQ ID NO: 211. In some aspects, the V _L sequence is SEQ ID NO: 212. In some aspects, the V _L sequence is SEQ ID NO: 213. In some aspects, the V _L sequence is SEQ ID NO: 214. In some aspects, the sequence V _L is SEQ ID NO: 215. In some aspects, the sequence V _L is SEQ ID NO: 216. In some aspects, the sequence V _L is SEQ ID NO: 217. In some aspects, the sequence V _L is SEQ ID NO: 218. In some aspects, the sequence V _L is SEQ ID NO: 219. In some aspects, the sequence V _L is SEQ ID NO: 220. In some aspects, the sequence V _L is SEQ ID NO: 221. In some aspects, the V _L sequence is SEQ ID NO: 222. In some aspects, the V _L sequence is SEQ ID NO: 223. In some aspects, the V _L sequence is SEQ ID NO: 224. In some aspects, the V _L sequence is is SEQ ID NO: 225. In some aspects, the V _L sequence is SEQ ID NO: 226. In some aspects, the V _L sequence is SEQ ID NO: 227. In some aspects, the V _L sequence is SEQ ID NO: 228.

[00174] In some aspects, the V _H sequence is SEQ ID NO: 180, and the V _L sequence is selected from SEQ ID NO: 204-228. In some aspects, the V _L sequence is SEQ ID NO: 204. In some aspects, the V _L sequence is SEQ ID NO: 205. In some aspects, the V _L sequence is SEQ ID NO: 206. In some aspects, the V _L sequence is SEQ ID NO: 207. In some aspects, the V _L sequence is SEQ ID NO: 208. In some aspects, the V _L sequence is SEQ ID NO: 209. In some aspects, the V _L sequence is SEQ ID NO: 210. In some aspects, In some aspects, the V _L sequence is SEQ ID NO: 211. In some aspects, the V _L sequence is SEQ ID NO: 212. In some aspects, the V _L sequence is SEQ ID NO: 213. In some aspects, the V _L sequence is SEQ ID NO: 214. In some aspects, the sequence V _L is SEQ ID NO: 215. In some aspects, the sequence V _L is SEQ ID NO: 216. In some aspects, the sequence V _L is SEQ ID NO: 217. In some aspects, the sequence V _L is SEQ ID NO: 218. In some aspects, the sequence V _L is SEQ ID NO: 219. In some aspects, the sequence V _L is SEQ ID NO: 220. In some aspects, the sequence V _L is SEQ ID NO: 221. In some aspects, the V _L sequence is SEQ ID NO: 222. In some aspects, the V _L sequence is SEQ ID NO: 223. In some aspects, the V _L sequence is SEQ ID NO: 224. In some aspects, the V _L sequence is is SEQ ID NO: 225. In some aspects, the V _L sequence is SEQ ID NO: 226. In some aspects, the V _L sequence is SEQ ID NO: 227. In some aspects, the V _L sequence is SEQ ID NO: 228.

[00175] In some aspects, the V _H sequence is SEQ ID NO: 181, and the V _L sequence is selected from SEQ ID NO: 204-228. In some aspects, the V _L sequence is SEQ ID NO: 204. In some aspects, the V _L sequence is SEQ ID NO: 205. In some aspects, the V _L sequence is SEQ ID NO: 206. In some aspects, the V _L sequence is SEQ ID NO: 207. In some aspects, the V _L sequence is SEQ ID NO: 208. In some aspects, the V _L sequence is SEQ ID NO: 209. In some aspects, the V _L sequence is SEQ ID NO: 210. In some aspects, In some aspects, the V _L sequence is SEQ ID NO: 211. In some aspects, the V _L sequence is SEQ ID NO: 212. In some aspects, the V _L sequence is SEQ ID NO: 213. In some aspects, the V _L sequence is SEQ ID NO: 214. In some aspects, the sequence V _L is SEQ ID NO: 215. In some aspects, the sequence V _L is SEQ ID NO: 216. In some aspects, the sequence V _L is SEQ ID NO: 217. In some aspects, the sequence V _L is SEQ ID NO: 218. In some aspects, the sequence V _L is SEQ ID NO: 219. In some aspects, the sequence V _L is SEQ ID NO: 220. In some aspects, the sequence V _L is SEQ ID NO: 221. In some aspects, the V _L sequence is SEQ ID NO: 222. In some aspects, the V _L sequence is SEQ ID NO: 223. In some aspects, the V _L sequence is SEQ ID NO: 224. In some aspects, the V _L sequence is is SEQ ID NO: 225. In some aspects, the V _L sequence is SEQ ID NO: 226. In some aspects, the V _L sequence is SEQ ID NO: 227. In some aspects, the V _L sequence is SEQ ID NO: 228.

[00176] In some aspects, the V _H sequence is SEQ ID NO: 182 and the V _L sequence is selected from SEQ ID NO: 204-228. In some aspects, the V _L sequence is SEQ ID NO: 204. In some aspects, the V _L sequence is SEQ ID NO: 205. In some aspects, the V _L sequence is SEQ ID NO: 206. In some aspects, the V _L sequence is SEQ ID NO: 207. In some aspects, the V _L sequence is SEQ ID NO: 208. In some aspects, the V _L sequence is SEQ ID NO: 209. In some aspects, the V _L sequence is SEQ ID NO: 210. In some aspects, In some aspects, the V _L sequence is SEQ ID NO: 211. In some aspects, the V _L sequence is SEQ ID NO: 212. In some aspects, the V _L sequence is SEQ ID NO: 213. In some aspects, the V _L sequence is SEQ ID NO: 214. In some aspects, the sequence V _L is SEQ ID NO: 215. In some aspects, the sequence V _L is SEQ ID NO: 216. In some aspects, the sequence V _L is SEQ ID NO: 217. In some aspects, the sequence V _L is SEQ ID NO: 218. In some aspects, the sequence V _L is SEQ ID NO: 219. In some aspects, the sequence V _L is SEQ ID NO: 220. In some aspects, the sequence V _L is SEQ ID NO: 221. In some aspects, the V _L sequence is SEQ ID NO: 222. In some aspects, the V _L sequence is SEQ ID NO: 223. In some aspects, the V _L sequence is SEQ ID NO: 224. In some aspects, the V _L sequence is is SEQ ID NO: 225. In some aspects, the V _L sequence is SEQ ID NO: 226. In some aspects, the V _L sequence is SEQ ID NO: 227. In some aspects, the V _L sequence is SEQ ID NO: 228.

[00177] In some aspects, the V _H sequence is SEQ ID NO: 183 and the V _L sequence is selected from SEQ ID NO: 204-228. In some aspects, the V _L sequence is SEQ ID NO: 204. In some aspects, the V _L sequence is SEQ ID NO: 205. In some aspects, the V _L sequence is SEQ ID NO: 206. In some aspects, the V _L sequence is SEQ ID NO: 207. In some aspects, the V _L sequence is SEQ ID NO: 208. In some aspects, the V _L sequence is SEQ ID NO: 209. In some aspects, the V _L sequence is SEQ ID NO: 210. In some aspects, In some aspects, the V _L sequence is SEQ ID NO: 211. In some aspects, the V _L sequence is SEQ ID NO: 212. In some aspects, the V _L sequence is SEQ ID NO: 213. In some aspects, the V _L sequence is SEQ ID NO: 214. In some aspects, the sequence V _L is SEQ ID NO: 215. In some aspects, the sequence V _L is SEQ ID NO: 216. In some aspects, the sequence V _L is SEQ ID NO: 217. In some aspects, the sequence V _L is SEQ ID NO: 218. In some aspects, the sequence V _L is SEQ ID NO: 219. In some aspects, the sequence V _L is SEQ ID NO: 220. In some aspects, the sequence V _L is SEQ ID NO: 221. In some aspects, the V _L sequence is SEQ ID NO: 222. In some aspects, the V _L sequence is SEQ ID NO: 223. In some aspects, the V _L sequence is SEQ ID NO: 224. In some aspects, the V _L sequence is is SEQ ID NO: 225. In some aspects, the V _L sequence is SEQ ID NO: 226. In some aspects, the V _L sequence is SEQ ID NO: 227. In some aspects, the V _L sequence is SEQ ID NO: 228.

[00178] In some aspects, the V _H sequence is SEQ ID NO: 184, and the V _L sequence is selected from SEQ ID NO: 204-228. In some aspects, the V _L sequence is SEQ ID NO: 204. In some aspects, the V _L sequence is SEQ ID NO: 205. In some aspects, the V _L sequence is SEQ ID NO: 206. In some aspects, the V _L sequence is SEQ ID NO: 207. In some aspects, the V _L sequence is SEQ ID NO: 208. In some aspects, the V _L sequence is SEQ ID NO: 209. In some aspects, the V _L sequence is SEQ ID NO: 210. In some aspects, In some aspects, the V _L sequence is SEQ ID NO: 211. In some aspects, the V _L sequence is SEQ ID NO: 212. In some aspects, the V _L sequence is SEQ ID NO: 213. In some aspects, the V _L sequence is SEQ ID NO: 214. In some aspects, the sequence V _L is SEQ ID NO: 215. In some aspects, the sequence V _L is SEQ ID NO: 216. In some aspects, the sequence V _L is SEQ ID NO: 217. In some aspects, the sequence V _L is SEQ ID NO: 218. In some aspects, the sequence V _L is SEQ ID NO: 219. In some aspects, the sequence V _L is SEQ ID NO: 220. In some aspects, the sequence V _L is SEQ ID NO: 221. In some aspects, the V _L sequence is SEQ ID NO: 222. In some aspects, the V _L sequence is SEQ ID NO: 223. In some aspects, the V _L sequence is SEQ ID NO: 224. In some aspects, the V _L sequence is is SEQ ID NO: 225. In some aspects, the V _L sequence is SEQ ID NO: 226. In some aspects, the V _L sequence is SEQ ID NO: 227. In some aspects, the V _L sequence is SEQ ID NO: 228.

[00179] In some aspects, the V _H sequence is SEQ ID NO: 185 and the V _L sequence is selected from SEQ ID NO: 204-228. In some aspects, the V _L sequence is SEQ ID NO: 204. In some aspects, the V _L sequence is SEQ ID NO: 205. In some aspects, the V _L sequence is SEQ ID NO: 206. In some aspects, the V _L sequence is SEQ ID NO: 207. In some aspects, the V _L sequence is SEQ ID NO: 208. In some aspects, the V _L sequence is SEQ ID NO: 209. In some aspects, the V _L sequence is SEQ ID NO: 210. In some aspects, In some aspects, the V _L sequence is SEQ ID NO: 211. In some aspects, the V _L sequence is SEQ ID NO: 212. In some aspects, the V _L sequence is SEQ ID NO: 213. In some aspects, the V _L sequence is SEQ ID NO: 214. In some aspects, the sequence V _L is SEQ ID NO: 215. In some aspects, the sequence V _L is SEQ ID NO: 216. In some aspects, the sequence V _L is SEQ ID NO: 217. In some aspects, the sequence V _L is SEQ ID NO: 218. In some aspects, the sequence V _L is SEQ ID NO: 219. In some aspects, the sequence V _L is SEQ ID NO: 220. In some aspects, the sequence V _L is SEQ ID NO: 221. In some aspects, the V _L sequence is SEQ ID NO: 222. In some aspects, the V _L sequence is SEQ ID NO: 223. In some aspects, the V _L sequence is SEQ ID NO: 224. In some aspects, the V _L sequence is is SEQ ID NO: 225. In some aspects, the V _L sequence is SEQ ID NO: 226. In some aspects, the V _L sequence is SEQ ID NO: 227. In some aspects, the V _L sequence is SEQ ID NO: 228.

[00180] In some aspects, the V _H sequence is SEQ ID NO: 186 and the V _L sequence is selected from SEQ ID NO: 204-228. In some aspects, the V _L sequence is SEQ ID NO: 204. In some aspects, the V _L sequence is SEQ ID NO: 205. In some aspects, the V _L sequence is SEQ ID NO: 206. In some aspects, the V _L sequence is SEQ ID NO: 207. In some aspects, the V _L sequence is SEQ ID NO: 208. In some aspects, the V _L sequence is SEQ ID NO: 209. In some aspects, the V L sequence is SEQ ID NO: 210. In some aspects, the V _L sequence is SEQ ID NO: 210. In some aspects, the V _L sequence is SEQ ID NO: 211. In some aspects, the V _L sequence is SEQ ID NO: 212. In some aspects, the V _L sequence is SEQ ID NO: 213. In some aspects, the V _L sequence is SEQ ID NO: 214. In some aspects, the sequence V _L is SEQ ID NO: 215. In some aspects, the sequence V _L is SEQ ID NO: 216. In some aspects, the sequence V _L is SEQ ID NO: 217. In some aspects, the sequence V _L is SEQ ID NO: 218. In some aspects, the sequence V _L is SEQ ID NO: 219. In some aspects, the sequence V _L is SEQ ID NO: 220. In some aspects, the sequence V _L is SEQ ID NO: 221. In some aspects, the V _L sequence is SEQ ID NO: 222. In some aspects, the V _L sequence is SEQ ID NO: 223. In some aspects, the V _L sequence is SEQ ID NO: 224. In some aspects, the V _L sequence is is SEQ ID NO: 225. In some aspects, the V _L sequence is SEQ ID NO: 226. In some aspects, the V _L sequence is SEQ ID NO: 227. In some aspects, the V _L sequence is SEQ ID NO: 228.

[00181] In some aspects, the V _H sequence is SEQ ID NO: 187, and the V _L sequence is selected from SEQ ID NO: 204-228. In some aspects, the V _L sequence is SEQ ID NO: 204. In some aspects, the V _L sequence is SEQ ID NO: 205. In some aspects, the V _L sequence is SEQ ID NO: 206. In some aspects, the V _L sequence is SEQ ID NO: 207. In some aspects, the V _L sequence is SEQ ID NO: 208. In some aspects, the V _L sequence is SEQ ID NO: 209. In some aspects, the V L sequence is SEQ ID NO: 210. In some aspects, the V _L sequence is SEQ ID NO: 210. In some aspects, the V _L sequence is SEQ ID NO: 211. In some aspects, the V _L sequence is SEQ ID NO: 212. In some aspects, the V _L sequence is SEQ ID NO: 213. In some aspects, the V _L sequence is SEQ ID NO: 214. In some aspects, the sequence V _L is SEQ ID NO: 215. In some aspects, the sequence V _L is SEQ ID NO: 216. In some aspects, the sequence V _L is SEQ ID NO: 217. In some aspects, the sequence V _L is SEQ ID NO: 218. In some aspects, the sequence V _L is SEQ ID NO: 219. In some aspects, the sequence V _L is SEQ ID NO: 220. In some aspects, the sequence V _L is SEQ ID NO: 221. In some aspects, the V _L sequence is SEQ ID NO: 222. In some aspects, the V _L sequence is SEQ ID NO: 223. In some aspects, the V _L sequence is SEQ ID NO: 224. In some aspects, the V _L sequence is is SEQ ID NO: 225. In some aspects, the V _L sequence is SEQ ID NO: 226. In some aspects, the V _L sequence is SEQ ID NO: 227. In some aspects, the V _L sequence is SEQ ID NO: 228.

[00182] In some aspects, the V _H sequence is SEQ ID NO: 188, and the V _L sequence is selected from SEQ ID NO: 204-228. In some aspects, the V _L sequence is SEQ ID NO: 204. In some aspects, the V _L sequence is SEQ ID NO: 205. In some aspects, the V _L sequence is SEQ ID NO: 206. In some aspects, the V _L sequence is SEQ ID NO: 207. In some aspects, the V _L sequence is SEQ ID NO: 208. In some aspects, the V _L sequence is SEQ ID NO: 209. In some aspects, the V _L sequence is SEQ ID NO: 210. In some aspects, In some aspects, the V _L sequence is SEQ ID NO: 211. In some aspects, the V _L sequence is SEQ ID NO: 212. In some aspects, the V _L sequence is SEQ ID NO: 213. In some aspects, the V _L sequence is SEQ ID NO: 214. In some aspects, the sequence V _L is SEQ ID NO: 215. In some aspects, the sequence V _L is SEQ ID NO: 216. In some aspects, the sequence V _L is SEQ ID NO: 217. In some aspects, the sequence V _L is SEQ ID NO: 218. In some aspects, the sequence V _L is SEQ ID NO: 219. In some aspects, the sequence V _L is SEQ ID NO: 220. In some aspects, the sequence V _L is SEQ ID NO: 221. In some aspects, the V _L sequence is SEQ ID NO: 222. In some aspects, the V _L sequence is SEQ ID NO: 223. In some aspects, the V _L sequence is SEQ ID NO: 224. In some aspects, the V _L sequence is is SEQ ID NO: 225. In some aspects, the V _L sequence is SEQ ID NO: 226. In some aspects, the V _L sequence is SEQ ID NO: 227. In some aspects, the V _L sequence is SEQ ID NO: 228.

[00183] In some aspects, the V _H sequence is SEQ ID NO: 189, and the V _L sequence is selected from SEQ ID NO: 204-228. In some aspects, the V _L sequence is SEQ ID NO: 204. In some aspects, the V _L sequence is SEQ ID NO: 205. In some aspects, the V _L sequence is SEQ ID NO: 206. In some aspects, the V _L sequence is SEQ ID NO: 207. In some aspects, the V _L sequence is SEQ ID NO: 208. In some aspects, the V _L sequence is SEQ ID NO: 209. In some aspects, the V _L sequence is SEQ ID NO: 210. In some aspects, In some aspects, the V _L sequence is SEQ ID NO: 211. In some aspects, the V _L sequence is SEQ ID NO: 212. In some aspects, the V _L sequence is SEQ ID NO: 213. In some aspects, the V _L sequence is SEQ ID NO: 214. In some aspects, the sequence V _L is SEQ ID NO: 215. In some aspects, the sequence V _L is SEQ ID NO: 216. In some aspects, the sequence V _L is SEQ ID NO: 217. In some aspects, the sequence V _L is SEQ ID NO: 218. In some aspects, the sequence V _L is SEQ ID NO: 219. In some aspects, the sequence V _L is SEQ ID NO: 220. In some aspects, the sequence V _L is SEQ ID NO: 221. In some aspects, the V _L sequence is SEQ ID NO: 222. In some aspects, the V _L sequence is SEQ ID NO: 223. In some aspects, the V _L sequence is SEQ ID NO: 224. In some aspects, the V _L sequence is is SEQ ID NO: 225. In some aspects, the V _L sequence is SEQ ID NO: 226. In some aspects, the V _L sequence is SEQ ID NO: 227. In some aspects, the V _L sequence is SEQ ID NO: 228.

[00184] In some aspects, the V _H sequence is SEQ ID NO: 190, and the V _L sequence is selected from SEQ ID NO: 204-228. In some aspects, the V _L sequence is SEQ ID NO: 204. In some aspects, the V _L sequence is SEQ ID NO: 205. In some aspects, the V _L sequence is SEQ ID NO: 206. In some aspects, the V _L sequence is SEQ ID NO: 207. In some aspects, the V _L sequence is SEQ ID NO: 208. In some aspects, the V _L sequence is SEQ ID NO: 209. In some aspects, the V _L sequence is SEQ ID NO: 210. In some aspects, In some aspects, the V _L sequence is SEQ ID NO: 211. In some aspects, the V _L sequence is SEQ ID NO: 212. In some aspects, the V _L sequence is SEQ ID NO: 213. In some aspects, the V _L sequence is SEQ ID NO: : 214. In some aspects, the sequence V _L is SEQ ID NO: 215. In some aspects, the sequence V _L is SEQ ID NO: 216. In some aspects, the sequence V _L is SEQ ID NO: 217. In some aspects, the sequence V _L is SEQ ID NO: 218. In some aspects, the sequence V _L is SEQ ID NO: 219. In some aspects, the sequence V _L is SEQ ID NO: 220. In some aspects, the sequence V _L is SEQ ID NO: 221 In some aspects, the V _L sequence is SEQ ID NO: 222. In some aspects, the V _L sequence is SEQ ID NO: 223. In some aspects, the V _L sequence is SEQ ID NO: 224. In some aspects, the V _L sequence is is SEQ ID NO: 225. In some aspects, the V _L sequence is SEQ ID NO: 226. In some aspects, the V _L sequence is SEQ ID NO: 227. In some aspects, the V _L sequence is SEQ ID NO: 228.

[00185] In some aspects, the V _H sequence is SEQ ID NO: 191, and the V _L sequence is selected from SEQ ID NO: 204-228. In some aspects, the V _L sequence is SEQ ID NO: 204. In some aspects, the V _L sequence is SEQ ID NO: 205. In some aspects, the V _L sequence is SEQ ID NO: 206. In some aspects, the V _L sequence is SEQ ID NO: 207. In some aspects, the V _L sequence is SEQ ID NO: 208. In some aspects, the V _L sequence is SEQ ID NO: 209. In some aspects, the V _L sequence is SEQ ID NO: 210. In some aspects, In some aspects, the V _L sequence is SEQ ID NO: 211. In some aspects, the V _L sequence is SEQ ID NO: 212. In some aspects, the V _L sequence is SEQ ID NO: 213. In some aspects, the V _L sequence is SEQ ID NO: 214. In some aspects, the sequence V _L is SEQ ID NO: 215. In some aspects, the sequence V _L is SEQ ID NO: 216. In some aspects, the sequence V _L is SEQ ID NO: 217. In some aspects, the sequence V _L is SEQ ID NO: 218. In some aspects, the sequence V _L is SEQ ID NO: 219. In some aspects, the sequence V _L is SEQ ID NO: 220. In some aspects, the sequence V _L is SEQ ID NO: 221. In some aspects, the V _L sequence is SEQ ID NO: 222. In some aspects, the V _L sequence is SEQ ID NO: 223. In some aspects, the V _L sequence is SEQ ID NO: 224. In some aspects, the V _L sequence is is SEQ ID NO: 225. In some aspects, the V _L sequence is SEQ ID NO: 226. In some aspects, the V _L sequence is SEQ ID NO: 227. In some aspects, the V _L sequence is SEQ ID NO: 228.

[00186] In some aspects, the V _H sequence is SEQ ID NO: 192, and the V _L sequence is selected from SEQ ID NO: 204-228. In some aspects, the V _L sequence is SEQ ID NO: 204. In some aspects, the V _L sequence is SEQ ID NO: 205. In some aspects, the V _L sequence is SEQ ID NO: 206. In some aspects, the V _L sequence is SEQ ID NO: 207. In some aspects, the V _L sequence is SEQ ID NO: 208. In some aspects, the V _L sequence is SEQ ID NO: 209. In some aspects, the V _L sequence is SEQ ID NO: 210. In some aspects, In some aspects, the V _L sequence is SEQ ID NO: 211. In some aspects, the V _L sequence is SEQ ID NO: 212. In some aspects, the V _L sequence is SEQ ID NO: 213. In some aspects, the V _L sequence is SEQ ID NO: 214. In some aspects, the sequence V _L is SEQ ID NO: 215. In some aspects, the sequence V _L is SEQ ID NO: 216. In some aspects, the sequence V _L is SEQ ID NO: 217. In some aspects, the sequence V _L is SEQ ID NO: 218. In some aspects, the sequence V _L is SEQ ID NO: 219. In some aspects, the sequence V _L is SEQ ID NO: 220. In some aspects, the sequence V _L is SEQ ID NO: 221. In some aspects, the V _L sequence is SEQ ID NO: 222. In some aspects, the V _L sequence is SEQ ID NO: 223. In some aspects, the V _L sequence is SEQ ID NO: 224. In some aspects, the V _L sequence is is SEQ ID NO: 225. In some aspects, the V _L sequence is SEQ ID NO: 226. In some aspects, the V _L sequence is SEQ ID NO: 227. In some aspects, the V _L sequence is SEQ ID NO: 228.

[00187] In some aspects, the V _H sequence is SEQ ID NO: 193, and the V _L sequence is selected from SEQ ID NO: 204-228. In some aspects, the V _L sequence is SEQ ID NO: 204. In some aspects, the V _L sequence is SEQ ID NO: 205. In some aspects, the V _L sequence is SEQ ID NO: 206. In some aspects, the V _L sequence is SEQ ID NO: 207. In some aspects, the V _L sequence is SEQ ID NO: 208. In some aspects, the V _L sequence is SEQ ID NO: 209. In some aspects, the V L sequence is SEQ ID NO: 210. In some aspects, the V _L sequence is SEQ ID NO: 210. In some aspects, the V _L sequence is SEQ ID NO: 211. In some aspects, the V _L sequence is SEQ ID NO: 212. In some aspects, the V _L sequence is SEQ ID NO: 213. In some aspects, the V _L sequence is SEQ ID NO: 214. In some aspects, the sequence V _L is SEQ ID NO: 215. In some aspects, the sequence V _L is SEQ ID NO: 216. In some aspects, the sequence V _L is SEQ ID NO: 217. In some aspects, the sequence V _L is SEQ ID NO: 218. In some aspects, the sequence V _L is SEQ ID NO: 219. In some aspects, the sequence V _L is SEQ ID NO: 220. In some aspects, the sequence V _L is SEQ ID NO: 221. In some aspects, the V _L sequence is SEQ ID NO: 222. In some aspects, the V _L sequence is SEQ ID NO: 223. In some aspects, the V _L sequence is SEQ ID NO: 224. In some aspects, the V _L sequence is is SEQ ID NO: 225. In some aspects, the V _L sequence is SEQ ID NO: 226. In some aspects, the V _L sequence is SEQ ID NO: 227. In some aspects, the V _L sequence is SEQ ID NO: 228.

[00188] In some aspects, the V _H sequence is SEQ ID NO: 194, and the V _L sequence is selected from SEQ ID NO: 204-228. In some aspects, the V _L sequence is SEQ ID NO: 204. In some aspects, the V _L sequence is SEQ ID NO: 205. In some aspects, the V _L sequence is SEQ ID NO: 206. In some aspects, the V _L sequence is SEQ ID NO: 207. In some aspects, the V _L sequence is SEQ ID NO: 208. In some aspects, the V _L sequence is SEQ ID NO: 209. In some aspects, the V _L sequence is SEQ ID NO: 210. In some aspects, In some aspects, the V _L sequence is SEQ ID NO: 211. In some aspects, the V _L sequence is SEQ ID NO: 212. In some aspects, the V _L sequence is SEQ ID NO: 213. In some aspects, the V _L sequence is SEQ ID NO: 214. In some aspects, the sequence V _L is SEQ ID NO: 215. In some aspects, the sequence V _L is SEQ ID NO: 216. In some aspects, the sequence V _L is SEQ ID NO: 217. In some aspects, the sequence V _L is SEQ ID NO: 218. In some aspects, the sequence V _L is SEQ ID NO: 219. In some aspects, the sequence V _L is SEQ ID NO: 220. In some aspects, the sequence V _L is SEQ ID NO: 221. In some aspects, the V _L sequence is SEQ ID NO: 222. In some aspects, the V _L sequence is SEQ ID NO: 223. In some aspects, the V _L sequence is SEQ ID NO: 224. In some aspects, the V _L sequence is is SEQ ID NO: 225. In some aspects, the V _L sequence is SEQ ID NO: 226. In some aspects, the V _L sequence is SEQ ID NO: 227. In some aspects, the V _L sequence is SEQ ID NO: 228.

[00189] In some aspects, the V _H sequence is SEQ ID NO: 195 and the V _L sequence is selected from SEQ ID NO: 204-228. In some aspects, the V _L sequence is SEQ ID NO: 204. In some aspects, the V _L sequence is SEQ ID NO: 205. In some aspects, the V _L sequence is SEQ ID NO: 206. In some aspects, the V _L sequence is SEQ ID NO: 207. In some aspects, the V _L sequence is SEQ ID NO: 208. In some aspects, the V _L sequence is SEQ ID NO: 209. In some aspects, the V _L sequence is SEQ ID NO: 210. In some aspects, In some aspects, the V _L sequence is SEQ ID NO: 211. In some aspects, the V _L sequence is SEQ ID NO: 212. In some aspects, the V _L sequence is SEQ ID NO: 213. In some aspects, the V _L sequence is SEQ ID NO: 214. In some aspects, the sequence V _L is SEQ ID NO: 215. In some aspects, the sequence V _L is SEQ ID NO: 216. In some aspects, the sequence V _L is SEQ ID NO: 217. In some aspects, the sequence V _L is SEQ ID NO: 218. In some aspects, the sequence V _L is SEQ ID NO: 219. In some aspects, the sequence V _L is SEQ ID NO: 220. In some aspects, the sequence V _L is SEQ ID NO: 221. In some aspects, the V _L sequence is SEQ ID NO: 222. In some aspects, the V _L sequence is SEQ ID NO: 223. In some aspects, the V _L sequence is SEQ ID NO: 224. In some aspects, the V _L sequence is is SEQ ID NO: 225. In some aspects, the V _L sequence is SEQ ID NO: 226. In some aspects, the V _L sequence is SEQ ID NO: 227. In some aspects, the V _L sequence is SEQ ID NO: 228.

[00190] In some aspects, the V _H sequence is SEQ ID NO: 196, and the V _L sequence is selected from SEQ ID NO: 204-228. In some aspects, the V _L sequence is SEQ ID NO: 204. In some aspects, the V _L sequence is SEQ ID NO: 205. In some aspects, the V _L sequence is SEQ ID NO: 206. In some aspects, the V _L sequence is SEQ ID NO: 207. In some aspects, the V _L sequence is SEQ ID NO: 208. In some aspects, the V _L sequence is SEQ ID NO: 209. In some aspects, the V _L sequence is SEQ ID NO: 210. In some aspects, In some aspects, the V _L sequence is SEQ ID NO: 211. In some aspects, the V _L sequence is SEQ ID NO: 212. In some aspects, the V _L sequence is SEQ ID NO: 213. In some aspects, the V _L sequence is SEQ ID NO: 214. In some aspects, the sequence V _L is SEQ ID NO: 215. In some aspects, the sequence V _L is SEQ ID NO: 216. In some aspects, the sequence V _L is SEQ ID NO: 217. In some aspects, the sequence V _L is SEQ ID NO: 218. In some aspects, the sequence V _L is SEQ ID NO: 219. In some aspects, the sequence V _L is SEQ ID NO: 220. In some aspects, the sequence V _L is SEQ ID NO: 221. In some aspects, the V _L sequence is SEQ ID NO: 222. In some aspects, the V _L sequence is SEQ ID NO: 223. In some aspects, the V _L sequence is SEQ ID NO: 224. In some aspects, the V _L sequence is is SEQ ID NO: 225. In some aspects, the V _L sequence is SEQ ID NO: 226. In some aspects, the V _L sequence is SEQ ID NO: 227. In some aspects, the V _L sequence is SEQ ID NO: 228.

[00191] In some aspects, the V _H sequence is SEQ ID NO: 197, and the V _L sequence is selected from SEQ ID NO: 204-228. In some aspects, the V _L sequence is SEQ ID NO: 204. In some aspects, the V _L sequence is SEQ ID NO: 205. In some aspects, the V _L sequence is SEQ ID NO: 206. In some aspects, the V _L sequence is SEQ ID NO: 207. In some aspects, the V _L sequence is SEQ ID NO: 208. In some aspects, the V _L sequence is SEQ ID NO: 209. In some aspects, the V _L sequence is SEQ ID NO: 210. In some aspects, In some aspects, the V _L sequence is SEQ ID NO: 211. In some aspects, the V _L sequence is SEQ ID NO: 212. In some aspects, the V _L sequence is SEQ ID NO: 213. In some aspects, the V _L sequence is SEQ ID NO: 214. In some aspects, the sequence V _L is SEQ ID NO: 215. In some aspects, the sequence V _L is SEQ ID NO: 216. In some aspects, the sequence V _L is SEQ ID NO: 217. In some aspects, the sequence V _L is SEQ ID NO: 218. In some aspects, the sequence V _L is SEQ ID NO: 219. In some aspects, the sequence V _L is SEQ ID NO: 220. In some aspects, the sequence V _L is SEQ ID NO: 221. In some aspects, the V _L sequence is SEQ ID NO: 222. In some aspects, the V _L sequence is SEQ ID NO: 223. In some aspects, the V _L sequence is SEQ ID NO: 224. In some aspects, the V _L sequence is is SEQ ID NO: 225. In some aspects, the V _L sequence is SEQ ID NO: 226. In some aspects, the V _L sequence is SEQ ID NO: 227. In some aspects, the V _L sequence is SEQ ID NO: 228.

[00192] In some aspects, the V _H sequence is SEQ ID NO: 198, and the V _L sequence is selected from SEQ ID NO: 204-228. In some aspects, the V _L sequence is SEQ ID NO: 204. In some aspects, the V _L sequence is SEQ ID NO: 205. In some aspects, the V _L sequence is SEQ ID NO: 206. In some aspects, the V _L sequence is SEQ ID NO: 207. In some aspects, the V _L sequence is SEQ ID NO: 208. In some aspects, the V _L sequence is SEQ ID NO: 209. In some aspects, the V _L sequence is SEQ ID NO: 210. In some aspects, In some aspects, the V _L sequence is SEQ ID NO: 211. In some aspects, the V _L sequence is SEQ ID NO: 212. In some aspects, the V _L sequence is SEQ ID NO: 213. In some aspects, the V _L sequence is SEQ ID NO: 214. In some aspects, the sequence V _L is SEQ ID NO: 215. In some aspects, the sequence V _L is SEQ ID NO: 216. In some aspects, the sequence V _L is SEQ ID NO: 217. In some aspects, the sequence V _L is SEQ ID NO: 218. In some aspects, the sequence V _L is SEQ ID NO: 219. In some aspects, the sequence V _L is SEQ ID NO: 220. In some aspects, the sequence V _L is SEQ ID NO: 221. In some aspects, the V _L sequence is SEQ ID NO: 222. In some aspects, the V _L sequence is SEQ ID NO: 223. In some aspects, the V _L sequence is SEQ ID NO: 224. In some aspects, the V _L sequence is is SEQ ID NO: 225. In some aspects, the V _L sequence is SEQ ID NO: 226. In some aspects, the V _L sequence is SEQ ID NO: 227. In some aspects, the V _L sequence is SEQ ID NO: 228.

[00193] In some aspects, the V _H sequence is SEQ ID NO: 199 and the V _L sequence is selected from SEQ ID NO: 204-228. In some aspects, the V _L sequence is SEQ ID NO: 204. In some aspects, the V _L sequence is SEQ ID NO: 205. In some aspects, the V _L sequence is SEQ ID NO: 206. In some aspects, the V _L sequence is SEQ ID NO: 207. In some aspects, the V _L sequence is SEQ ID NO: 208. In some aspects, the V _L sequence is SEQ ID NO: 209. In some aspects, the V _L sequence is SEQ ID NO: 210. In some aspects, In some aspects, the V _L sequence is SEQ ID NO: 211. In some aspects, the V _L sequence is SEQ ID NO: 212. In some aspects, the V _L sequence is SEQ ID NO: 213. In some aspects, the V _L sequence is SEQ ID NO: 214. In some aspects, the sequence V _L is SEQ ID NO: 215. In some aspects, the sequence V _L is SEQ ID NO: 216. In some aspects, the sequence V _L is SEQ ID NO: 217. In some aspects, the sequence V _L is SEQ ID NO: 218. In some aspects, the sequence V _L is SEQ ID NO: 219. In some aspects, the sequence V _L is SEQ ID NO: 220. In some aspects, the sequence V _L is SEQ ID NO: 221. In some aspects, the V _L sequence is SEQ ID NO: 222. In some aspects, the V _L sequence is SEQ ID NO: 223. In some aspects, the V _L sequence is SEQ ID NO: 224. In some aspects, the V _L sequence is is SEQ ID NO: 225. In some aspects, the V _L sequence is SEQ ID NO: 226. In some aspects, the V _L sequence is SEQ ID NO: 227. In some aspects, the V _L sequence is SEQ ID NO: 228.

[00194] In some aspects, the V _H sequence is SEQ ID NO: 200, and the V _L sequence is selected from SEQ ID NO: 204-228. In some aspects, the V _L sequence is SEQ ID NO: 204. In some aspects, the V _L sequence is SEQ ID NO: 205. In some aspects, the V _L sequence is SEQ ID NO: 206. In some aspects, the V _L sequence is SEQ ID NO: 207. In some aspects, the V _L sequence is SEQ ID NO: 208. In some aspects, the V _L sequence is SEQ ID NO: 209. In some aspects, the V _L sequence is SEQ ID NO: 210. In some aspects, In some aspects, the V _L sequence is SEQ ID NO: 211. In some aspects, the V _L sequence is SEQ ID NO: 212. In some aspects, the V _L sequence is SEQ ID NO: 213. In some aspects, the V _L sequence is SEQ ID NO: 214. In some aspects, the sequence V _L is SEQ ID NO: 215. In some aspects, the sequence V _L is SEQ ID NO: 216. In some aspects, the sequence V _L is SEQ ID NO: 217. In some aspects, the sequence V _L is SEQ ID NO: 218. In some aspects, the sequence V _L is SEQ ID NO: 219. In some aspects, the sequence V _L is SEQ ID NO: 220. In some aspects, the sequence V _L is SEQ ID NO: 221. In some aspects, the V _L sequence is SEQ ID NO: 222. In some aspects, the V _L sequence is SEQ ID NO: 223. In some aspects, the V _L sequence is SEQ ID NO: 224. In some aspects, the V _L sequence is is SEQ ID NO: 225. In some aspects, the V _L sequence is SEQ ID NO: 226. In some aspects, the V _L sequence is SEQ ID NO: 227. In some aspects, the V _L sequence is SEQ ID NO: 228.

1.7.3. CDR-H1 + CDR-H2 + CDR-H3 + CDR-L1 + CDR-L2 + CDR-L3

[00195] In some aspects, the antibody comprises a V _H sequence comprising a Kabat CDR-H1 sequence containing SEQ ID NO: 18, a Kabat CDR-H2 sequence containing SEQ ID NO: 54, and a Kabat CDR-H3 sequence, containing SEQ ID NO: 76, and a V _L sequence containing a CDR-L1 sequence containing SEQ ID NO: 105, a CDR-L2 sequence containing SEQ ID NO: 128, and a CDR-L3 sequence SEQ ID NO: 149. According to some In aspects, said antibody comprises a V _H sequence comprising a Kabat CDR-H1 sequence containing SEQ ID NO: 19, a Kabat CDR-H2 sequence containing SEQ ID NO: 55, and a Kabat CDR-H3 sequence containing SEQ ID NO: 77, and a V _L sequence comprising a CDR-L1 sequence containing SEQ ID NO: 105, a CDR-L2 sequence containing SEQ ID NO: 128, and a CDR-L3 sequence SEQ ID NO: 149. In some aspects, said antibody comprises the sequence V _H containing the Kabat CDR-H1 sequence containing SEQ ID NO: 20, the Kabat CDR-H2 sequence containing SEQ ID NO: 56, and the Kabat CDR-H3 sequence containing SEQ ID NO: 78, and the V sequence _L containing the CDR-L1 sequence containing SEQ ID NO: 105, the CDR-L2 sequence containing SEQ ID NO: 128, and the CDR-L3 sequence SEQ ID NO: 149. In some aspects, the antibody contains a V _H sequence containing the sequence Kabat CDR-H1 containing SEQ ID NO: 21, Kabat CDR-H2 sequence containing SEQ ID NO: 57, and Kabat CDR-H3 sequence containing SEQ ID NO: 79, and V _L sequence containing the CDR sequence -L1 comprising SEQ ID NO: 105, a CDR-L2 sequence comprising SEQ ID NO: 128, and a CDR-L3 sequence SEQ ID NO: 149. In some aspects, said antibody comprises a V _H sequence comprising a Kabat CDR-H1 sequence , containing SEQ ID NO: 22, the Kabat CDR-H2 sequence containing SEQ ID NO: 58, and the Kabat CDR-H3 sequence containing SEQ ID NO: 80, and the V _L sequence containing the CDR-L1 sequence containing SEQ ID NO: 105, a CDR-L2 sequence comprising SEQ ID NO: 128, and a CDR-L3 sequence SEQ ID NO: 149. In some aspects, said antibody comprises a V _H sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO : 21, Kabat CDR-H2 sequence containing SEQ ID NO: 57, and Kabat CDR-H3 sequence containing SEQ ID NO: 76, and V _L sequence containing CDR-L1 sequence containing SEQ ID NO: 106, a CDR-L2 sequence comprising SEQ ID NO: 129, and a CDR-L3 sequence SEQ ID NO: 150. In some aspects, said antibody comprises a V _H sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 23, a CDR sequence -H2 by Kabat containing SEQ ID NO: 59, and the sequence CDR-H3 by Kabat containing SEQ ID NO: 76, and the sequence V _L containing the sequence CDR-L1 containing SEQ ID NO: 107, the sequence CDR-L2, comprising SEQ ID NO: 128, and a CDR-L3 sequence of SEQ ID NO: 151. In some aspects, said antibody comprises a V _H sequence comprising a Kabat CDR-H1 sequence, comprising SEQ ID NO: 23, a Kabat CDR-H2 sequence, containing SEQ ID NO: 60, and a Kabat CDR-H3 sequence containing SEQ ID NO: 81, and a V _L sequence containing a CDR-L1 sequence containing SEQ ID NO: 108, a CDR-L2 sequence containing SEQ ID NO: 130, and a CDR-L3 sequence of SEQ ID NO: 151. In some aspects, said antibody comprises a _VH sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 23, a Kabat CDR-H2 sequence comprising SEQ ID NO: 59, and the Kabat CDR-H3 sequence containing SEQ ID NO: 82, and the V _L sequence containing the CDR-L1 sequence containing SEQ ID NO: 109, the CDR-L2 sequence containing SEQ ID NO: 131, and the CDR sequence -L3 SEQ ID NO: 152. In some aspects, said antibody comprises a V _H sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 23, a Kabat CDR-H2 sequence comprising SEQ ID NO: 59, and a CDR sequence -H3 by Kabat containing SEQ ID NO: 76, and the V _L sequence containing the CDR-L1 sequence containing SEQ ID NO: 107, the CDR-L2 sequence containing SEQ ID NO: 132, and the CDR-L3 sequence SEQ ID NO :153. In some aspects, the antibody comprises a _VH sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 23, a Kabat CDR-H2 sequence comprising SEQ ID NO: 59, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 81, and a V _L sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 110, a CDR-L2 sequence comprising SEQ ID NO: 132, and a CDR-L3 sequence SEQ ID NO: 151. In some aspects, the antibody contains a V _H sequence containing a Kabat CDR-H1 sequence containing SEQ ID NO: 21, a Kabat CDR-H2 sequence containing SEQ ID NO: 57, and a Kabat CDR-H3 sequence containing SEQ ID NO: 83, and a V _L sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 111, a CDR-L2 sequence comprising SEQ ID NO: 133, and a CDR-L3 sequence SEQ ID NO: 151. In some aspects, said antibody comprises a V _H sequence. containing the Kabat CDR-H1 sequence containing SEQ ID NO: 21, the Kabat CDR-H2 sequence containing SEQ ID NO: 57, and the Kabat CDR-H3 sequence containing SEQ ID NO: 84, and the V _L sequence containing a CDR-L1 sequence comprising SEQ ID NO: 105, a CDR-L2 sequence comprising SEQ ID NO: 128, and a CDR-L3 sequence SEQ ID NO: 149. In some aspects, said antibody comprises a _VH sequence comprising a CDR-H1 sequence Kabat containing SEQ ID NO: 24, Kabat CDR-H2 sequence containing SEQ ID NO: 61, and Kabat CDR-H3 sequence containing SEQ ID NO: 85, and V _L sequence containing CDR-L1 sequence, comprising SEQ ID NO: 105, a CDR-L2 sequence comprising SEQ ID NO: 128, and a CDR-L3 sequence SEQ ID NO: 154. In some aspects, said antibody comprises a _VH sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 24, a Kabat CDR-H2 sequence containing SEQ ID NO: 61, and a Kabat CDR-H3 sequence containing SEQ ID NO: 86, and a V _L sequence containing a CDR-L1 sequence containing SEQ ID NO: 105, a CDR-L2 sequence comprising SEQ ID NO: 128, and a CDR-L3 sequence SEQ ID NO: 154. In some aspects, said antibody comprises a _VH sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 25, the Kabat CDR-H2 sequence containing SEQ ID NO: 62, and the Kabat CDR-H3 sequence containing SEQ ID NO: 87, and the V _L sequence containing the CDR-L1 sequence containing SEQ ID NO: 112, the sequence CDR- L2 comprising SEQ ID NO: 134, and a CDR-L3 sequence of SEQ ID NO: 155. In some aspects, said antibody comprises a _VH sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 26, a CDR-H2 sequence Kabat containing SEQ ID NO: 63, and the Kabat CDR-H3 sequence containing SEQ ID NO: 88, and the V _L sequence containing the CDR-L1 sequence containing SEQ ID NO: 113, the CDR-L2 sequence containing SEQ ID NO: 135, and a CDR-L3 sequence SEQ ID NO: 156. In some aspects, said antibody comprises a _VH sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 26, a Kabat CDR-H2 sequence comprising SEQ ID NO: 63, and the Kabat CDR-H3 sequence containing SEQ ID NO: 89, and the V _L sequence containing the CDR-L1 sequence containing SEQ ID NO: 114, the CDR-L2 sequence containing SEQ ID NO: 136, and a CDR-L3 sequence of SEQ ID NO: 157. In some aspects, said antibody comprises a _VH sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 25, a Kabat CDR-H2 sequence comprising SEQ ID NO: 63, and the Kabat CDR-H3 sequence containing SEQ ID NO: 90, and the V _L sequence containing the CDR-L1 sequence containing SEQ ID NO: 115, the CDR-L2 sequence containing SEQ ID NO: 135, and the CDR-L3 sequence SEQ ID NO: 157. In some aspects, the antibody comprises a _VH sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 27, a Kabat CDR-H2 sequence comprising SEQ ID NO: 64, and a CDR-H3 sequence Kabat containing SEQ ID NO: 90, and a V _L sequence containing a CDR-L1 sequence containing SEQ ID NO: 116, a CDR-L2 sequence containing SEQ ID NO: 128, and a CDR-L3 sequence SEQ ID NO: 155. In some aspects, the antibody comprises a _VH sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 28, a Kabat CDR-H2 sequence comprising SEQ ID NO: 62, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 91, and a V _L sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 117, a CDR-L2 sequence comprising SEQ ID NO: 137, and a CDR-L3 sequence SEQ ID NO: 155. In some aspects, the antibody contains a V _H sequence containing a Kabat CDR-H1 sequence containing SEQ ID NO: 29, a Kabat CDR-H2 sequence containing SEQ ID NO: 64, and a Kabat CDR-H3 sequence containing SEQ ID NO: 92, and a V _L sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 118, a CDR-L2 sequence comprising SEQ ID NO: 137, and a CDR-L3 sequence SEQ ID NO: 158. In some aspects, said antibody comprises a V _H sequence. containing the Kabat CDR-H1 sequence containing SEQ ID NO: 25, the Kabat CDR-H2 sequence containing SEQ ID NO: 65, and the Kabat CDR-H3 sequence containing SEQ ID NO: 93, and the V _L sequence containing a CDR-L1 sequence comprising SEQ ID NO: 118, a CDR-L2 sequence comprising SEQ ID NO: 138, and a CDR-L3 sequence SEQ ID NO: 155. In some aspects, said antibody comprises a V _H sequence comprising a CDR-H1 sequence Kabat containing SEQ ID NO: 30, Kabat CDR-H2 sequence containing SEQ ID NO: 66, and Kabat CDR-H3 sequence containing SEQ ID NO: 94, and V _L sequence containing CDR-L1 sequence, comprising SEQ ID NO: 119, a CDR-L2 sequence comprising SEQ ID NO: 139, and a CDR-L3 sequence SEQ ID NO: 159. In some aspects, said antibody comprises a _VH sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 31, a Kabat CDR-H2 sequence containing SEQ ID NO: 67, and a Kabat CDR-H3 sequence containing SEQ ID NO: 95, and a V _L sequence containing a CDR-L1 sequence containing SEQ ID NO: 120, a CDR-L2 sequence comprising SEQ ID NO: 140, and a CDR-L3 sequence SEQ ID NO: 160. In some aspects, said antibody comprises a _VH sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 32, the Kabat CDR-H2 sequence containing SEQ ID NO: 68, and the Kabat CDR-H3 sequence containing SEQ ID NO: 96, and the V _L sequence containing the CDR-L1 sequence containing SEQ ID NO: 121, the sequence CDR- L2 comprising SEQ ID NO: 141, and a CDR-L3 sequence of SEQ ID NO: 161. In some aspects, said antibody comprises a _VH sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 33, a CDR-H2 sequence Kabat containing SEQ ID NO: 69, and the Kabat CDR-H3 sequence containing SEQ ID NO: 97, and the V _L sequence containing the CDR-L1 sequence containing SEQ ID NO: 122, the CDR-L2 sequence containing SEQ ID NO: 142, and a CDR-L3 sequence SEQ ID NO: 162. In some aspects, said antibody comprises a _VH sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 34, a Kabat CDR-H2 sequence comprising SEQ ID NO: 70, and the Kabat CDR-H3 sequence containing SEQ ID NO: 98, and the V _L sequence containing the CDR-L1 sequence containing SEQ ID NO: 105, the CDR-L2 sequence containing SEQ ID NO: 143, and a CDR-L3 sequence of SEQ ID NO: 163. In some aspects, said antibody comprises a _VH sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 18, a Kabat CDR-H2 sequence comprising SEQ ID NO: 54, and the Kabat CDR-H3 sequence containing SEQ ID NO: 99, and the V _L sequence containing the CDR-L1 sequence containing SEQ ID NO: 105, the CDR-L2 sequence containing SEQ ID NO: 143, and the CDR-L3 sequence SEQ ID NO: 164. In some aspects, the antibody comprises a V _H sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 31, a Kabat CDR-H2 sequence comprising SEQ ID NO: 71, and a CDR-H3 sequence of Kabat containing SEQ ID NO: 100, and a V _L sequence containing a CDR-L1 sequence containing SEQ ID NO: 123, a CDR-L2 sequence containing SEQ ID NO: 144, and a CDR-L3 sequence SEQ ID NO: 165. In some aspects, the antibody comprises a _VH sequence comprising a Kabat CDR-H1 sequence comprising SEQ ID NO: 24, a Kabat CDR-H2 sequence comprising SEQ ID NO: 61, and a Kabat CDR-H3 sequence comprising SEQ ID NO: 101, and a V _L sequence containing a CDR-L1 sequence containing SEQ ID NO: 124, a CDR-L2 sequence containing SEQ ID NO: 145, and a CDR-L3 sequence SEQ ID NO: 166.

[00196] In some aspects, the antibody comprises a _VH sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO: 1, a Chothia CDR-H2 sequence comprising SEQ ID NO: 38, and a Chothia CDR-H3 sequence, containing SEQ ID NO: 76, and a V _L sequence containing a CDR-L1 sequence containing SEQ ID NO: 105, a CDR-L2 sequence containing SEQ ID NO: 128, and a CDR-L3 sequence SEQ ID NO: 149. According to some In aspects, said antibody comprises a V _H sequence comprising a Chothia CDR-H1 sequence containing SEQ ID NO: 2, a Chothia CDR-H2 sequence containing SEQ ID NO: 39, and a Chothia CDR-H3 sequence containing SEQ ID NO: 77, and a V _L sequence comprising a CDR-L1 sequence containing SEQ ID NO: 105, a CDR-L2 sequence containing SEQ ID NO: 128, and a CDR-L3 sequence SEQ ID NO: 149. In some aspects, said antibody comprises the sequence V _H containing the Chothia CDR-H1 sequence containing SEQ ID NO: 2, the Chothia CDR-H2 sequence containing SEQ ID NO: 40, and the Chothia CDR-H3 sequence containing SEQ ID NO: 78, and the V sequence _L containing the CDR-L1 sequence containing SEQ ID NO: 105, the CDR-L2 sequence containing SEQ ID NO: 128, and the CDR-L3 sequence SEQ ID NO: 149. In some aspects, the antibody contains a V _H sequence containing the sequence Chothia CDR-H1 containing SEQ ID NO: 3, Chothia CDR-H2 sequence containing SEQ ID NO: 41, and Chothia CDR-H3 sequence containing SEQ ID NO: 79, and V _L sequence containing the CDR sequence -L1 comprising SEQ ID NO: 105, a CDR-L2 sequence comprising SEQ ID NO: 128, and a CDR-L3 sequence SEQ ID NO: 149. In some aspects, said antibody comprises a V _H sequence comprising a Chothia CDR-H1 sequence containing SEQ ID NO: 4, a Chothia CDR-H2 sequence containing SEQ ID NO: 41, and a Chothia CDR-H3 sequence containing SEQ ID NO: 80, and a V _L sequence containing a CDR-L1 sequence containing SEQ ID NO: 105, a CDR-L2 sequence comprising SEQ ID NO: 128, and a CDR-L3 sequence SEQ ID NO: 149. In some aspects, said antibody comprises a _VH sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO : 3, a Chothia CDR-H2 sequence containing SEQ ID NO: 41, and a Chothia CDR-H3 sequence containing SEQ ID NO: 76, and a V _L sequence containing a CDR-L1 sequence containing SEQ ID NO: 106, a CDR-L2 sequence comprising SEQ ID NO: 129, and a CDR-L3 sequence SEQ ID NO: 150. In some aspects, said antibody comprises a V _H sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO: 2, a CDR sequence Chothia -H2 containing SEQ ID NO: 42, and the Chothia CDR-H3 sequence containing SEQ ID NO: 76, and the V _L sequence containing the CDR-L1 sequence containing SEQ ID NO: 107, the CDR-L2 sequence, comprising SEQ ID NO: 128, and a CDR-L3 sequence of SEQ ID NO: 151. In some aspects, said antibody comprises a V _H sequence comprising a Chothia CDR-H1 sequence, comprising SEQ ID NO: 2, a Chothia CDR-H2 sequence, containing SEQ ID NO: 43, and a Chothia CDR-H3 sequence containing SEQ ID NO: 81, and a V _L sequence containing a CDR-L1 sequence containing SEQ ID NO: 108, a CDR-L2 sequence containing SEQ ID NO: 130, and a CDR-L3 sequence of SEQ ID NO: 151. In some aspects, said antibody comprises a _VH sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO: 2, a Chothia CDR-H2 sequence comprising SEQ ID NO: 42, and the Chothia CDR-H3 sequence containing SEQ ID NO: 82, and the V _L sequence containing the CDR-L1 sequence containing SEQ ID NO: 109, the CDR-L2 sequence containing SEQ ID NO: 131, and the CDR sequence -L3 SEQ ID NO: 152. In some aspects, said antibody comprises a _VH sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO: 5, a Chothia CDR-H2 sequence comprising SEQ ID NO: 42, and a CDR sequence -H3 by Chothia containing SEQ ID NO: 76, and the V _L sequence containing the CDR-L1 sequence containing SEQ ID NO: 107, the CDR-L2 sequence containing SEQ ID NO: 132, and the CDR-L3 sequence SEQ ID NO : 153. In some aspects, said antibody comprises a _VH sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO: 2, a Chothia CDR-H2 sequence comprising SEQ ID NO: 42, and a Chothia CDR-H3 sequence, containing SEQ ID NO: 81, and a V _L sequence containing a CDR-L1 sequence containing SEQ ID NO: 110, a CDR-L2 sequence containing SEQ ID NO: 132, and a CDR-L3 sequence SEQ ID NO: 151. According to some In aspects, said antibody comprises a V _H sequence comprising a Chothia CDR-H1 sequence containing SEQ ID NO: 3, a Chothia CDR-H2 sequence containing SEQ ID NO: 41, and a Chothia CDR-H3 sequence containing SEQ ID NO: 83, and a V _L sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 111, a CDR-L2 sequence comprising SEQ ID NO: 133, and a CDR-L3 sequence SEQ ID NO: 151. In some aspects, said antibody comprises the sequence V _H containing the Chothia CDR-H1 sequence containing SEQ ID NO: 3, the Chothia CDR-H2 sequence containing SEQ ID NO: 41, and the Chothia CDR-H3 sequence containing SEQ ID NO: 84, and the V sequence _L containing the CDR-L1 sequence containing SEQ ID NO: 105, the CDR-L2 sequence containing SEQ ID NO: 128, and the CDR-L3 sequence SEQ ID NO: 149. In some aspects, the antibody contains a V _H sequence containing the sequence Chothia CDR-H1 containing SEQ ID NO: 6, Chothia CDR-H2 sequence containing SEQ ID NO: 44, and Chothia CDR-H3 sequence containing SEQ ID NO: 85, and V _L sequence containing the CDR sequence -L1 comprising SEQ ID NO: 105, a CDR-L2 sequence comprising SEQ ID NO: 128, and a CDR-L3 sequence SEQ ID NO: 154. In some aspects, said antibody comprises a V _H sequence comprising a Chothia CDR-H1 sequence containing SEQ ID NO: 6, a Chothia CDR-H2 sequence containing SEQ ID NO: 44, and a Chothia CDR-H3 sequence containing SEQ ID NO: 86, and a V _L sequence containing a CDR-L1 sequence containing SEQ ID NO: 105, a CDR-L2 sequence comprising SEQ ID NO: 128, and a CDR-L3 sequence SEQ ID NO: 154. In some aspects, said antibody comprises a V _H sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO : 7, a Chothia CDR-H2 sequence containing SEQ ID NO: 45, and a Chothia CDR-H3 sequence containing SEQ ID NO: 87, and a V _L sequence containing a CDR-L1 sequence containing SEQ ID NO: 112, a CDR-L2 sequence comprising SEQ ID NO: 134, and a CDR-L3 sequence SEQ ID NO: 155. In some aspects, said antibody comprises a _VH sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO: 8, a CDR sequence Chothia -H2 containing SEQ ID NO: 44, and the Chothia CDR-H3 sequence containing SEQ ID NO: 88, and the V _L sequence containing the CDR-L1 sequence containing SEQ ID NO: 113, the CDR-L2 sequence, comprising SEQ ID NO: 135, and a CDR-L3 sequence of SEQ ID NO: 156. In some aspects, said antibody comprises a V _H sequence comprising a Chothia CDR-H1 sequence, comprising SEQ ID NO: 8, a Chothia CDR-H2 sequence, containing SEQ ID NO: 44, and a Chothia CDR-H3 sequence containing SEQ ID NO: 89, and a V _L sequence containing a CDR-L1 sequence containing SEQ ID NO: 114, a CDR-L2 sequence containing SEQ ID NO: 136, and a CDR-L3 sequence of SEQ ID NO: 157. In some aspects, said antibody comprises a _VH sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO: 7, a Chothia CDR-H2 sequence comprising SEQ ID NO: 44, and the Chothia CDR-H3 sequence containing SEQ ID NO: 90, and the V _L sequence containing the CDR-L1 sequence containing SEQ ID NO: 115, the CDR-L2 sequence containing SEQ ID NO: 135, and the CDR sequence -L3 SEQ ID NO: 157. In some aspects, said antibody comprises a _VH sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO: 9, a Chothia CDR-H2 sequence comprising SEQ ID NO: 44, and a CDR sequence -H3 by Chothia containing SEQ ID NO: 90, and the V _L sequence containing the CDR-L1 sequence containing SEQ ID NO: 116, the CDR-L2 sequence containing SEQ ID NO: 128, and the CDR-L3 sequence SEQ ID NO : 155. In some aspects, said antibody comprises a _VH sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO: 6, a Chothia CDR-H2 sequence comprising SEQ ID NO: 45, and a Chothia CDR-H3 sequence, containing SEQ ID NO: 91, and a V _L sequence containing a CDR-L1 sequence containing SEQ ID NO: 117, a CDR-L2 sequence containing SEQ ID NO: 137, and a CDR-L3 sequence SEQ ID NO: 155. According to some In aspects, said antibody comprises a V _H sequence comprising a Chothia CDR-H1 sequence containing SEQ ID NO: 8, a Chothia CDR-H2 sequence containing SEQ ID NO: 44, and a Chothia CDR-H3 sequence containing SEQ ID NO: 92, and a V _L sequence comprising a CDR-L1 sequence comprising SEQ ID NO: 118, a CDR-L2 sequence comprising SEQ ID NO: 137, and a CDR-L3 sequence SEQ ID NO: 158. In some aspects, said antibody comprises the sequence V _H containing the Chothia CDR-H1 sequence containing SEQ ID NO: 7, the Chothia CDR-H2 sequence containing SEQ ID NO: 44, and the Chothia CDR-H3 sequence containing SEQ ID NO: 93, and the V sequence _L containing the CDR-L1 sequence containing SEQ ID NO: 118, the CDR-L2 sequence containing SEQ ID NO: 138, and the CDR-L3 sequence SEQ ID NO: 155. In some aspects, the antibody contains a V _H sequence containing the sequence Chothia CDR-H1 containing SEQ ID NO: 10, Chothia CDR-H2 sequence containing SEQ ID NO: 46, and Chothia CDR-H3 sequence containing SEQ ID NO: 94, and V _L sequence containing the CDR sequence -L1 comprising SEQ ID NO: 119, a CDR-L2 sequence comprising SEQ ID NO: 139, and a CDR-L3 sequence SEQ ID NO: 159. In some aspects, said antibody comprises a V _H sequence comprising a Chothia CDR-H1 sequence containing SEQ ID NO: 11, a Chothia CDR-H2 sequence containing SEQ ID NO: 47, and a Chothia CDR-H3 sequence containing SEQ ID NO: 95, and a V _L sequence containing a CDR-L1 sequence containing SEQ ID NO: 120, a CDR-L2 sequence comprising SEQ ID NO: 140, and a CDR-L3 sequence SEQ ID NO: 160. In some aspects, said antibody comprises a V _H sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO : 12, a Chothia CDR-H2 sequence containing SEQ ID NO: 48, and a Chothia CDR-H3 sequence containing SEQ ID NO: 96, and a V _L sequence containing a CDR-L1 sequence containing SEQ ID NO: 121, a CDR-L2 sequence comprising SEQ ID NO: 141, and a CDR-L3 sequence SEQ ID NO: 161. In some aspects, said antibody comprises a V _H sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO: 13, a CDR sequence Chothia -H2 containing SEQ ID NO: 44, and the Chothia CDR-H3 sequence containing SEQ ID NO: 97, and the V _L sequence containing the CDR-L1 sequence containing SEQ ID NO: 122, the CDR-L2 sequence, comprising SEQ ID NO: 142, and a CDR-L3 sequence of SEQ ID NO: 162. In some aspects, said antibody comprises a V _H sequence comprising a Chothia CDR-H1 sequence, comprising SEQ ID NO: 14, a Chothia CDR-H2 sequence, containing SEQ ID NO: 49, and the Chothia CDR-H3 sequence containing SEQ ID NO: 98, and the V _L sequence containing the CDR-L1 sequence containing SEQ ID NO: 105, the CDR-L2 sequence containing SEQ ID NO: 143, and a CDR-L3 sequence of SEQ ID NO: 163. In some aspects, said antibody comprises a _VH sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO: 1, a Chothia CDR-H2 sequence comprising SEQ ID NO: 38, and the Chothia CDR-H3 sequence containing SEQ ID NO: 99, and the V _L sequence containing the CDR-L1 sequence containing SEQ ID NO: 105, the CDR-L2 sequence containing SEQ ID NO: 143, and the CDR sequence -L3 SEQ ID NO: 164. In some aspects, said antibody comprises a V _H sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO: 11, a Chothia CDR-H2 sequence comprising SEQ ID NO: 50, and a CDR sequence -H3 by Chothia containing SEQ ID NO: 100, and the V _L sequence containing the CDR-L1 sequence containing SEQ ID NO: 123, the CDR-L2 sequence containing SEQ ID NO: 144, and the CDR-L3 sequence SEQ ID NO : 165. In some aspects, said antibody comprises a _VH sequence comprising a Chothia CDR-H1 sequence comprising SEQ ID NO: 6, a Chothia CDR-H2 sequence comprising SEQ ID NO: 44, and a Chothia CDR-H3 sequence, containing SEQ ID NO: 101, and a V _L sequence containing a CDR-L1 sequence containing SEQ ID NO: 124, a CDR-L2 sequence containing SEQ ID NO: 145, and a CDR-L3 sequence SEQ ID NO: 166.

1.7.3.1. Pair options V _H - V _L

[00197] In some embodiments, the V _H - V _L pairs provided by the present invention comprise a variant of the exemplary V _H and/or V _L sequence described herein.

[00198] In some aspects, the V _H sequence comprises, consists of, or consists essentially of a variant of the exemplary V _H sequence described herein. In some aspects, the V _H sequence comprises, consists of, or consists of a sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.1% identical to any of the illustrative V _H sequences given herein.

[00199] In some embodiments, the V _H sequence contains, consists of, or consists essentially of any of the exemplary V _H sequences provided herein, with 20 or less, 19 or less, 18 or less, 17 or less, 16 or less , 15 or less, 14 or less, 13 or less, 12 or less, 11 or less, 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, 2 or less, or 1 or less amino acid substitutions. In some aspects, these amino acid substitutions are conservative amino acid substitutions.

[00200] In some aspects, the V _L sequence comprises, consists of, or consists essentially of a variant of the exemplary V _L sequence described herein. In some aspects, the sequence V _L comprises, consists of, or consists of a sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.05% identical to any of the illustrative sequences V _L given in the present description.

[00201] In some embodiments, the V _L sequence contains, consists of, or consists essentially of any of the exemplary V _L sequences provided herein, with 20 or less, 19 or less, 18 or less, 17 or less, 16 or less , 15 or less, 14 or less, 13 or less, 12 or less, 11 or less, 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, 2 or less, or 1 or less amino acid substitutions. In some aspects, these amino acid substitutions are conservative amino acid substitutions.

1.7.4. HC+LC

[00202] In some aspects, the antibody comprises or consists of one or more heavy chains consisting of an HC sequence and one or more light chains consisting of an LC sequence. In some aspects, the antibody comprises or consists of two identical heavy chains consisting of an HC sequence and two identical light chains consisting of an LC sequence.

[00203] In some aspects, said HC sequence is an HC sequence comprising, consisting of, or essentially consisting of a sequence selected from SEQ ID NOs: 232-262, and said LC sequence is an LC sequence comprising, consisting of, or essentially consisting of from SEQ ID NO: 300-330. In some embodiments, said HC sequence is an HC sequence consisting of a sequence selected from SEQ ID NOs: 232-262, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NOs: 300-330. In some embodiments, said HC sequence is an HC sequence comprising, consisting of, or essentially consisting of a sequence selected from SEQ ID NOs: 266-296, and said LC sequence is an LC sequence comprising, consisting of, or essentially consisting of SEQ ID NO: 300-330. In some embodiments, said HC sequence is an HC sequence consisting of a sequence selected from SEQ ID NOs: 266-296, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NOs: 300-330.

[00204] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 232, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00205] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 233, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00206] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 234, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00207] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 235, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00208] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 236, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00209] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 237, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00210] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 238, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00211] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 239, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00212] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 240, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00213] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 241, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00214] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 242, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00215] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 243, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00216] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 244, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00217] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 245, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00218] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 246, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00219] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 247, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00220] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 248, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00221] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 249, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00222] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 250, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00223] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 251, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00224] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 252, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00225] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 253, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00226] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 254, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00227] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 255, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00228] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 256, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00229] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 257, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00230] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 258, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00231] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 259, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00232] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 260, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00233] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 261, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00234] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 262, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00235] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 266, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00236] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 267, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00237] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 268, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00238] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 269, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00239] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 270, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00240] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 271, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00241] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 272, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00242] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 273, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00243] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 274, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00244] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 275, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00245] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 276, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00246] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 277, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00247] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 278, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00248] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 279, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00249] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 280, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00250] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 281, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00251] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 282, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00252] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 283, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00253] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 284, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00254] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 285, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00255] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 286, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00256] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 287, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00257] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 288, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00258] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 289, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00259] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 290, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00260] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 291, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00261] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 292, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00262] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 293, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00263] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 294, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00264] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 295, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00265] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 296, and said LC sequence is an LC sequence consisting of a sequence selected from SEQ ID NO: 300-330. In some aspects, said LC sequence is SEQ ID NO: 300. In some aspects, said LC sequence is SEQ ID NO: 301. In some aspects, said LC sequence is SEQ ID NO: 302. In some aspects, said LC sequence is SEQ ID NO: 303. In some aspects, said LC sequence is SEQ ID NO: 304. In some aspects, said LC sequence is SEQ ID NO: 305. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 306. In some aspects, said LC sequence is SEQ ID NO: 307. In some aspects, said LC sequence is SEQ ID NO: 308. In some aspects, said LC sequence is SEQ ID NO: 309. In some aspects, said LC sequence is SEQ ID NO: 310. In some aspects, said LC sequence is SEQ ID NO: 311. In some aspects, said LC sequence is SEQ ID NO: 312. In some aspects, said LC sequence is SEQ ID NO: 313. In some aspects, said the LC sequence is SEQ ID NO: 314. In some aspects, the LC sequence is SEQ ID NO: 315. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 316. In some aspects, the LC sequence is SEQ ID NO: 317. In some aspects, said LC sequence is SEQ ID NO: 318. In some aspects, said LC sequence is SEQ ID NO: 319. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. In some aspects, said LC sequence is SEQ ID NO: 320. is SEQ ID NO: 321. In some aspects, said LC sequence is SEQ ID NO: 322. In some aspects, said LC sequence is SEQ ID NO: 323. In some aspects, said LC sequence is SEQ ID NO: 324. In some aspects, said LC sequence is SEQ ID NO: 325. In some aspects, said LC sequence is SEQ ID NO: 326. In some aspects, said LC sequence is SEQ ID NO: 327. In some aspects, said LC sequence is SEQ ID NO: 328. In some aspects, said LC sequence is SEQ ID NO: 329. In some aspects, said LC sequence is SEQ ID NO: 330.

[00266] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 232, and said LC sequence is an LC sequence consisting of SEQ ID NO: 300. In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 233, and the specified LC sequence is an LC sequence consisting of the sequence SEQ ID NO: 301. In some aspects, the specified HC sequence is a HC sequence consisting of SEQ ID NO: 234, and the specified LC sequence is an LC sequence consisting of the sequence SEQ ID NO: 302. In some aspects, said HC sequence is a HC sequence consisting of SEQ ID NO: 235, and said LC sequence is an LC sequence consisting of the sequence SEQ ID NO: 303 In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 236, and said LC sequence is an LC sequence consisting of SEQ ID NO: 304. In some aspects, said HC sequence is an HC sequence consisting of of SEQ ID NO: 237, and said LC sequence is an LC sequence consisting of the sequence SEQ ID NO: 305. In some aspects, said HC sequence is a HC sequence consisting of SEQ ID NO: 238, and said LC sequence is an LC sequence consisting of the sequence SEQ ID NO: 306. In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 239, and said LC sequence is a LC sequence consisting of the sequence SEQ ID NO: 307. According to In some aspects, the HC sequence is the HC sequence consisting of SEQ ID NO: 240, and the LC sequence is the LC sequence consisting of the sequence SEQ ID NO: 308. In some aspects, the HC sequence is the HC sequence consisting of SEQ ID NO: 241, and said LC sequence is an LC sequence consisting of the sequence SEQ ID NO: 309. In some aspects, said HC sequence is a HC sequence consisting of SEQ ID NO: 242, and said LC sequence is an LC sequence consisting of the sequence SEQ ID NO: 310. In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 243, and said LC sequence is an LC sequence consisting of the sequence SEQ ID NO: 311. In some aspects said HC sequence is the HC sequence consisting of SEQ ID NO: 244, and said LC sequence is the LC sequence consisting of the sequence SEQ ID NO: 312. In some aspects, said HC sequence is the HC sequence consisting of SEQ ID NO: : 245, and said LC sequence is an LC sequence consisting of the sequence SEQ ID NO: 313. In some aspects, said HC sequence is a HC sequence consisting of SEQ ID NO: 246, and said LC sequence is an LC sequence consisting from the sequence SEQ ID NO: 314. In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 247, and said LC sequence is an LC sequence consisting of the sequence SEQ ID NO: 315. In some aspects, said sequence The HC is the HC sequence consisting of SEQ ID NO: 248, and the LC sequence is the LC sequence consisting of the sequence SEQ ID NO: 316. In some aspects, the HC sequence is the HC sequence consisting of SEQ ID NO: 249 and said LC sequence is an LC sequence consisting of the sequence SEQ ID NO: 317. In some aspects, said HC sequence is a HC sequence consisting of SEQ ID NO: 250, and said LC sequence is a LC sequence consisting of the sequence SEQ ID NO: 318. In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 251, and said LC sequence is an LC sequence consisting of the sequence SEQ ID NO: 319. In some aspects, said HC sequence is is the HC sequence consisting of SEQ ID NO: 252, and the LC sequence is the LC sequence consisting of the sequence SEQ ID NO: 320. In some aspects, the specified HC sequence is the HC sequence consisting of SEQ ID NO: 253, and said LC sequence is an LC sequence consisting of the sequence SEQ ID NO: 321. In some aspects, said HC sequence is a HC sequence consisting of SEQ ID NO: 254, and said LC sequence is an LC sequence consisting of the sequence SEQ ID NO: 322. In some aspects, said HC sequence is the HC sequence consisting of SEQ ID NO: 255, and said LC sequence is an LC sequence consisting of the sequence SEQ ID NO: 323. In some aspects, said HC sequence is the sequence HC consisting of SEQ ID NO: 256, and the specified LC sequence is an LC sequence consisting of the sequence SEQ ID NO: 324. In some aspects, the specified HC sequence is a HC sequence consisting of SEQ ID NO: 257, and the specified sequence The LC is an LC sequence consisting of the sequence SEQ ID NO: 325. In some aspects, the HC sequence is the HC sequence consisting of SEQ ID NO: 258, and the LC sequence is an LC sequence consisting of the sequence SEQ ID NO: 258. 326. In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 259, and said LC sequence is an LC sequence consisting of the sequence SEQ ID NO: 327. In some aspects, said HC sequence is an HC sequence, consisting of SEQ ID NO: 260, and said LC sequence is an LC sequence consisting of the sequence SEQ ID NO: 328. In some aspects, said HC sequence is a HC sequence consisting of SEQ ID NO: 261, and said LC sequence is is an LC sequence consisting of the sequence SEQ ID NO: 329. In some aspects, said HC sequence is a HC sequence consisting of SEQ ID NO: 262, and said LC sequence is an LC sequence consisting of the sequence SEQ ID NO: 330.

[00267] In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 266, and said LC sequence is an LC sequence consisting of SEQ ID NO: 300. In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 267, and the specified LC sequence is an LC sequence consisting of the sequence SEQ ID NO: 301. In some aspects, the specified HC sequence is a HC sequence consisting of SEQ ID NO: 268, and the specified LC sequence is an LC sequence consisting of the sequence SEQ ID NO: 302. In some aspects, said HC sequence is a HC sequence consisting of SEQ ID NO: 269, and said LC sequence is an LC sequence consisting of the sequence SEQ ID NO: 303 In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 270, and said LC sequence is an LC sequence consisting of SEQ ID NO: 304. In some aspects, said HC sequence is an HC sequence consisting of of SEQ ID NO: 271, and said LC sequence is an LC sequence consisting of the sequence SEQ ID NO: 305. In some aspects, said HC sequence is a HC sequence consisting of SEQ ID NO: 272, and said LC sequence is an LC sequence consisting of the sequence SEQ ID NO: 306. In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 273, and said LC sequence is a LC sequence consisting of the sequence SEQ ID NO: 307. According to In some aspects, the HC sequence is the HC sequence consisting of SEQ ID NO: 274, and the LC sequence is the LC sequence consisting of the sequence SEQ ID NO: 308. In some aspects, the HC sequence is the HC sequence consisting of SEQ ID NO: 275, and said LC sequence is an LC sequence consisting of the sequence SEQ ID NO: 309. In some aspects, said HC sequence is a HC sequence consisting of SEQ ID NO: 276, and said LC sequence is an LC sequence consisting of the sequence SEQ ID NO: 310. In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 277, and said LC sequence is an LC sequence consisting of the sequence SEQ ID NO: 311. In some aspects said HC sequence is the HC sequence consisting of SEQ ID NO: 278, and said LC sequence is the LC sequence consisting of the sequence SEQ ID NO: 312. In some aspects, said HC sequence is the HC sequence consisting of SEQ ID NO: : 279, and said LC sequence is an LC sequence consisting of the sequence SEQ ID NO: 313. In some aspects, said HC sequence is a HC sequence consisting of SEQ ID NO: 280, and said LC sequence is an LC sequence consisting from the sequence SEQ ID NO: 314. In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 281, and said LC sequence is an LC sequence consisting of the sequence SEQ ID NO: 315. In some aspects, said sequence The HC is the HC sequence consisting of SEQ ID NO: 282, and the LC sequence is the LC sequence consisting of the sequence SEQ ID NO: 316. In some aspects, the HC sequence is the HC sequence consisting of SEQ ID NO: 283 and said LC sequence is an LC sequence consisting of the sequence SEQ ID NO: 317. In some aspects, said HC sequence is a HC sequence consisting of SEQ ID NO: 284, and said LC sequence is an LC sequence consisting of the sequence SEQ ID NO: 318. In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 285, and said LC sequence is an LC sequence consisting of SEQ ID NO: 319. In some aspects, said HC sequence is is the HC sequence consisting of SEQ ID NO: 286, and the LC sequence is the LC sequence consisting of the sequence SEQ ID NO: 320. In some aspects, the specified HC sequence is the HC sequence consisting of SEQ ID NO: 287, and said LC sequence is an LC sequence consisting of the sequence SEQ ID NO: 321. In some aspects, said HC sequence is a HC sequence consisting of SEQ ID NO: 288, and said LC sequence is an LC sequence consisting of the sequence SEQ ID NO: 322. In some aspects, said HC sequence is the HC sequence consisting of SEQ ID NO: 289, and said LC sequence is an LC sequence consisting of the sequence SEQ ID NO: 323. In some aspects, said HC sequence is the sequence HC consisting of SEQ ID NO: 290, and the specified LC sequence is an LC sequence consisting of the sequence SEQ ID NO: 324. In some aspects, the specified HC sequence is a HC sequence consisting of SEQ ID NO: 291, and the specified sequence The LC is an LC sequence consisting of the sequence SEQ ID NO: 325. In some aspects, the HC sequence is the HC sequence consisting of SEQ ID NO: 292, and the LC sequence is an LC sequence consisting of the sequence SEQ ID NO: 292. 326. In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 293, and said LC sequence is an LC sequence consisting of the sequence SEQ ID NO: 327. In some aspects, said HC sequence is an HC sequence, consisting of SEQ ID NO: 294, and said LC sequence is an LC sequence consisting of the sequence SEQ ID NO: 328. In some aspects, said HC sequence is a HC sequence consisting of SEQ ID NO: 295, and said LC sequence is is an LC sequence consisting of the sequence SEQ ID NO: 329. In some aspects, said HC sequence is an HC sequence consisting of SEQ ID NO: 296, and said LC sequence is an LC sequence consisting of the sequence SEQ ID NO: 330.

1.8. Consensus sequences

[00268] Some embodiments of the present invention provide anti-HLA-G antibodies comprising one or more sequences defined by consensus sequences. Each consensus sequence is based, at least in part, on one or more alignments of two or more suitable anti-HLA-G CDR sequences presented herein. Based on such alignments, one skilled in the art will appreciate that different amino acid residues may be suitable for use at certain positions of these CDRs. Accordingly, each consensus sequence spans two or more suitable anti-HLA-G CDR sequences.

1.8.1. CDR-H3 consensus sequences

[00269] In some embodiments, the antibody comprises a CDR-H3 sequence defined by the consensus sequence G-Y ₂ -Y ₃ -RAVPF-U ₉ -Y ₁₀ (SEQ ID NO: 76-84), where Y ₂ is I, P, Q, T or V; Y ₃ represents A, F, K or R; Y ₉ represents A, D, Q or V; Y ₁₀ represents D, R or Y.

[00270] According to some aspects, in cases where Y ₂ represents I; Y ₃ represents A or R; Y ₉ represents F; and Y ₁₀ is Y. In some aspects, when Y ₂ is V; _Y3 represents R; Y ₉ represents A, D, Q or V; and Y ₁₀ is D, R or Y. In some aspects, when Y ₃ is R; Y ₂ represents I, T or V; Y ₉ represents A, D or Q; and Y ₁₀ is D, R or Y. In some aspects, when Y ₉ is D; Y ₂ represents I, P, Q or V; Y ₃ represents A, F, K or R; and Y ₁₀ is Y. In some aspects, when Y ₁₀ is Y; Y ₂ represents I, P, R or V; Y ₃ represents A, F, K or R; and Y ₉ is D. In some aspects, when Y ₁₀ is D; Y ₂ represents V; _Y3 represents R; and Y ₉ represents A or V.

[00271] According to some aspects, in cases where Y ₂ is V; Y ₃ represents R; Y ₉ represents D; and Y ₁₀ is Y. In some aspects, in cases where Y ₂ is I; Y ₃ represents A; Y ₉ represents D; and Y ₁₀ is Y. In some aspects, when Y ₂ is P; Y ₃ represents K; Y ₉ represents D; and Y ₁₀ is Y. In some aspects, when Y ₂ is V; Y ₃ represents R; Y ₉ represents V; and Y10 is D. In some aspects, when _Y2 is V; Y ₃ represents R; Y ₉ represents Q; and Y ₁₀ is R. In some aspects, when Y ₂ is T; Y ₃ represents R; Y ₉ represents D; and Y ₁₀ is Y. In some aspects, when Y ₂ is V; Y ₃ represents R; Y ₉ represents A; and Y ₁₀ is D. In some aspects, when Y ₂ is I; Y ₃ represents R; Y ₉ represents D; and Y ₁₀ is Y. In some aspects, when Y ₂ is Q; Y ₃ represents F; Y ₉ represents D; and Y ₁₀ represents Y.

[00272] In some embodiments, the antibody comprises a CDR-H3 sequence defined by the consensus sequence GG-Φ ₃ -Φ ₄ -Φ ₅ -YSRGP-Φ11-DV (SEQ ID NO: 85-93), where Φ ₃ is E , G, Q or T; Φ ₄ represents A, H, P, Q or V; Φ ₅ represents K or T; and Φ ₁₁ represents F, L or M.

[00273] In some aspects, Φ ₃ represents G; in cases where Φ ₄ represents A or Q; Φ ₅ represents T; and Φ ₁₁ represents V. In some aspects, Φ ₃ represents T; in cases where Φ ₄ represents H, P or V; Φ ₅ represents I, T or Y; and Φ ₁₁ is V. In some aspects, Φ ₄ is H; in cases where Φ ₃ represents T; Φ ₅ represents T; and Φ ₁₁ is F, L or M. In some aspects, Φ ₄ is V; in cases where Φ ₃ represents E, T or Q; Φ ₅ represents K or T; and Φ ₁₁ represents L. In some aspects, Φ ₅ represents T; in cases where Φ ₃ represents E, G, T or Q; Φ ₄ represents A, H, Q or V; and Φ ₁₁ is F, L, or M. In some aspects, Φ ₁₁ is L; in cases where Φ ₃ represents E, G, T or Q; Φ ₄ represents A, H, P, Q or V; and Φ ₅ represents I, K or T.

[00274] According to some aspects, in cases where Φ ₃ represents T; in cases where Φ ₄ represents H; Φ ₅ represents T; and Φ ₁₁ represents M. According to some aspects, in cases where Φ ₃ represents T; in cases where Φ ₄ represents H; Φ ₅ represents T; and Φ ₁₁ represents F. According to some aspects, in cases where Φ ₃ represents T; in cases where Φ ₄ represents P; Φ ₅ represents I; and Φ ₁₁ represents L. According to some aspects, in cases where Φ ₃ represents G; in cases where Φ ₄ represents Q; Φ ₅ represents T; and Φ ₁₁ represents L. According to some aspects, in cases where Φ ₃ represents G; in cases where Φ ₄ represents A; Φ ₅ represents T; and Φ ₁₁ represents L. According to some aspects, in cases where Φ ₃ represents T; in cases where Φ ₄ represents H; Φ ₅ represents T; and Φ ₁₁ represents L. According to some aspects, in cases where Φ ₃ represents T; in cases where Φ ₄ represents H; Φ ₅ represents T; and Φ ₁₁ represents L. According to some aspects, in cases where Φ ₃ represents T; in cases where Φ ₄ represents V; Φ ₅ represents K; and Φ ₁₁ represents L. According to some aspects, in cases where Φ ₃ represents Q; in cases where Φ ₄ represents V; Φ ₅ represents T; and Φ ₁₁ represents L. According to some aspects, in cases where Φ ₃ represents E; in cases where Φ ₄ represents V; Φ ₅ represents T; and Φ ₁₁ represents L.

1.8.2. Chothia CDR-H2 consensus sequences

[00275] In some embodiments, the antibody comprises a Chothia CDR-H2 sequence defined by the consensus sequence Y-ε ₂ -S-ε ₄ -S (SEQ ID NOs: 38 and 44-45), where ε ₂ represents H or Y and ε ₄ represents A or G.

[00276] According to some aspects, in cases where ε ₂ represents H; ε ₄ is A or G. In some aspects, when ε ₄ is G, ε ₂ is H or Y.

[00277] According to some aspects, in cases where ε ₂ represents Y; ε ₄ represents G. In some aspects, when ε ₂ represents H; ε ₄ represents G. In some aspects, when ε ₂ represents H; ε ₄ represents A.

[00278] In some embodiments, the antibody comprises a Chothia CDR-H2 sequence defined by the α ₁ -α ₂ -SGS consensus sequence (SEQ ID NOs: 39, 41-42, and 49), wherein α ₁ is A, H, or S; and α ₂ represents S or Y.

[00279] According to some aspects, in cases where α ₁ represents S; α ₂ represents S or Y.

[00280] According to some aspects, in cases where α ₁ represents S; α ₂ represents S. In some aspects, when al represents S; α ₂ represents Y. In some aspects, when α ₁ represents H; α ₂ represents Y. In some aspects, when α ₁ represents A; α ₂ represents Y.

[00281] In some embodiments, the antibody comprises a Chothia CDR-H2 sequence defined by the consensus sequence β ₁ - β ₂ -SG-β ₅ - _{β 6} (SEQ ID NO: 56-60), where β ₁ is A or S; β ₂ represents G or S; β ₅ represents I or S; and β ₆ represents T or V.

[00282] In some aspects, when β ₁ is S, β ₂ is G or S; β ₅ represents I or S; and β ₆ is T or V. In some aspects, when β ₂ is S, β ₁ is A or S; _β5S ; and β ₆ is T or V. In some aspects, when β ₅ is S, β ₁ is A or S; β ₂ represents S; and β ₆ is T or V. In some aspects, when β ₆ is T, β ₁ is S; β ₂ represents G or S; and β ₅ represents I or T.

[00283] According to some aspects, in cases where β ₁ represents A; β ₂ represents S; β ₅ represents S; and β ₆ is V. In some aspects, when β ₁ is S; β ₂ represents G; β ₅ represents I; and β ₆ represents T. In some aspects, when β ₁ represents S; β ₂ represents S; β ₅ represents S; and β ₆ represents T.

1.8.3. Chothia CDR-H1 consensus sequences

[00284] In some embodiments, the antibody comprises a Chothia CDR-H1 sequence defined by the consensus sequence GGSISS-Ω7- _{Ω8 -Ω9} (SEQ ID NOs: 1-4 and 13-14), wherein _Ω7 is S or A; Ω ₈ represents D, S or N; and Ω ₉ is T, N, Y or absent.

[00285] According to some aspects, in cases where Ω ₇ represents S; Ω ₈ represents D, N or S; and Ω ₉ is T, Y or absent.

[00286] According to some aspects, in cases where Ω ₈ represents D; Ω ₇ represents S or A; and Ω ₉ is N, T or Y.

[00287] According to some aspects, in cases where Ω ₉ represents T; Ω ₇ represents S; and Ω ₈ represents D or S. According to some aspects, in cases where Ω ₉ represents Y; Ω ₇ represents S; and Ω ₈ represents D or S.

[00288] According to some aspects, in cases where Ω ₇ represents S; Ω ₈ represents D; and Ω ₉ represents Y. According to some aspects, in cases where Ω ₇ represents S; Ω ₈ represents S; and Ω ₉ represents T. According to some aspects, in cases where Ω ₇ represents S; Ω ₈ represents D; and Ω ₉ represents T. According to some aspects, in cases where Ω ₇ represents A; Ω ₈ represents D; and Ω ₉ represents N. According to some aspects, in cases where Ω ₇ represents S; Ω ₈ represents N; and Ω ₉ is missing. According to some aspects, in cases where Ω ₇ represents S; Ω ₈ represents S; and Ω ₉ represents Y.

[00289] In some embodiments, the antibody comprises a Chothia CDR-H1 sequence defined by the consensus sequence GYSI-ν ₅ -SG- ν ₈ (SEQ ID NO: 6-9), where ν ₅ is S or L and ν ₈ represents F, H or Y.

[00290] In some aspects, when ν ₅ is S, ν ₈ is F, H, or Y.

[00291] In some aspects, in those cases where ν ₅ is S, ν ₈ is F. In some aspects, in those cases where ν ₅ is S, ν ₈ is H. In some aspects, in those cases, when ν ₅ is S, ν ₈ is Y. In some aspects, when ν ₅ is L, ν ₈ is Y.

[00292] In some embodiments, the antibody comprises a Chothia CDR-H1 sequence defined by the consensus sequence GFTF-κ ₅ -κ ₆ -κ ₇ (SEQ ID NO: 10-12), where κ ₅ represents D or s; κ ₆ represents D, N or S; and κ ₇ represents S or Y.

[00293] According to some aspects, in cases where κ ₅ represents S; κ ₆ represents D or S; and κ ₇ is S or Y. In some aspects, when κ ₇ is Y; κ ₅ represents D or S; and κ ₆ represents N or D.

[00294] According to some aspects, in cases where κ ₅ represents D; κ ₆ represents N; and κ ₇ represents Y. According to some aspects, in cases where κ ₅ represents S; κ ₆ represents D; and κ ₇ represents Y. According to some aspects, in cases where κ ₅ represents S; κ ₆ represents S; and κ ₇ represents S.

1.8.4. Kabat CDR-H2 consensus sequences

[00295] In some embodiments, the antibody comprises a Kabat CDR-H2 sequence defined by the consensus sequence β ₁ -I-β ₃ -β ₄ -β ₅ -β ₆ -β ₇ -T-β ₉ -YNPSLKS (SEQ ID NO : 54-65 and 69-70), where β ₁ represents A, E, G or S; β ₃ represents A, H, S or Y; β ₄ represents H, S or Y; β ₅ represents N or S; β ₆ represents A or G; β ₇ represents A, L or S; and β ₉ A, N, L, V or Y.

[00296] According to some aspects, in cases where β ₁ represents S; β ₃ represents A, H, S or Y; β ₄ represents H, S or Y; β ₅ represents N or S; β ₆ represents A or G; β ₇ represents A, L or S; and β ₉ is A, N, L, V or Y. In some aspects, when β ₁ is G; β ₃ represents A or Y; β ₄ represents H or Y; β ₅ represents G or S; β ₆ represents A or G; β ₇ represents S; and β ₉ is A or Y. In some aspects, when β ₃ is Y; β ₁ represents A, E, G or S; β ₄ represents H or Y; β ₅ represents S; β ₆ represents A or G; β ₇ represents S; and β ₉ is A, N, V or Y. In some aspects, when β ₃ is S; β ₁ represents S; β ₄ represents S or Y; β ₅ represents N or S; β ₆ represents A or G; β ₇ represents L or S; and β ₉ is Y. In some aspects, when β ₃ is H; β ₁ represents S; β ₄ represents H or Y; β ₅ represents S; β ₆ represents G; β ₇ represents A or S; and β ₉ is L or Y. In some aspects, when β ₄ is Y; β ₁ represents S or G; β ₃ represents A, H, S or Y; β ₅ represents N or S; β ₆ represents A or G; β ₇ represents L or S; and β ₉ is L or Y. In some aspects, when β ₄ is H; β ₁ represents A, E, G, S; β ₃ represents H or Y; β ₅ represents S; β ₆ represents A or G; β ₇ represents A or S; and β ₉ is A, N, Y or V. In some aspects, when β ₅ is S; β ₁ represents A, E, G or S; β ₃ represents A, H, S or Y; β ₄ represents H, S or Y; β ₆ represents A or G; β ₇ represents A or S; and β ₉ is A, L, N, Y or V. In some aspects, when β ₆ is G; β ₁ represents A, E, G or S; β ₃ represents A, H, S or Y; β ₄ represents H, S or Y; β ₅ represents S; β ₇ represents S; and β ₉ is A, N, L, V, or Y. In some aspects, when β ₆ is A; β ₁ represents G or S; β ₃ represents S or Y; β ₄ represents H or Y; β ₅ represents N or S; β ₇ represents L or S; and β ₉ is A or Y. In some aspects, when β ₇ is S; β ₁ represents A, E, G or S; β ₃ represents A, H, S or Y; β ₄ represents H, S or Y; β ₅ represents S; β ₆ represents A or G; and β ₉ is A, L, N, V, or Y. In some aspects, when β ₉ is Y; β ₁ represents G or S; β ₃ represents A, H, S or Y; β ₄ represents H, S or Y; β ₅ represents N or S; β ₆ represents A or G; and β ₇ is A, L or S. In some aspects, when β ₉ is A; β ₁ represents G; β ₃ represents Y; β ₄ represents H; β ₅ represents S; β ₆ represents A or G; and β ₇ represents S.

[00297] According to some aspects, in cases where β ₁ represents S; β ₃ represents Y; β ₄ represents Y; represents S; β ₆ represents G; and β ₇ represents S; and β9 is Y. In some aspects, when β ₁ is S; β ₃ represents S; β ₄ represents S; β ₅ represents S; β ₆ represents G; and β ₇ represents S; and β ₉ is Y. In some aspects, when β ₁ is S; β ₃ represents H; β ₄ represents H; β ₅ represents S; β ₆ represents G; and β ₇ represents A; and β ₉ is Y. In some aspects, when β ₁ is S; β ₃ represents H; β ₄ represents Y; β ₅ represents S; β ₆ represents G; and β ₇ represents S; and β ₉ is L. In some aspects, when β ₁ is S; β ₃ represents H; β ₄ represents Y; β ₅ represents S; β ₆ represents G; and β ₇ represents S; and β ₉ is Y. In some aspects, when β ₁ is G; β ₃ represents A; β ₄ represents Y; β ₅ represents S; β ₆ represents G; and β ₇ represents S; and β ₉ is Y. In some aspects, when β ₁ is S; β ₃ represents S; β ₄ represents Y; β ₅ represents N; β ₆ represents A; and β ₇ represents L; and β ₉ is Y. In some aspects, when β ₁ is S; β ₃ represents Y; β ₄ represents H; β ₅ represents S; β ₆ represents G; and β ₇ represents S; and β ₉ is Y. In some aspects, when β ₁ is G; β ₃ represents Y; β ₄ represents H; β ₅ represents S; β ₆ represents A; and β ₇ represents S; and β ₉ is A. In some aspects, when β ₁ is G; β ₃ represents Y; β ₄ represents H; β ₅ represents S; β ₆ represents G; and β ₇ represents S; and β ₉ is Y. In some aspects, when β ₁ is A; β ₃ represents Y; β ₄ represents H; β ₅ represents S; β ₆ represents G; and β ₇ represents S; and β ₉ is V. In some aspects, when β ₁ is G; β ₃ represents Y; β ₄ represents H; β ₅ represents S; β ₆ represents G; and β ₇ represents S; and β ₉ is A. In some aspects, when β ₁ is E; β ₃ represents Y; β ₄ represents H; β ₅ represents S; β ₆ represents G; and β ₇ represents S; and β ₉ is N. In some aspects, when β ₁ is S; β ₃ represents S; β ₄ represents Y; β ₅ represents S; β ₆ represents G; and β ₇ represents S; and β ₉ represents Y.

1.8.5. Kabat CDR-H1 consensus sequences

[00298] In some embodiments, the antibody comprises a Kabat CDR-H1 sequence defined by the consensus sequence SS-δ ₃ -δ ₄ -YW-δ ₇ (SEQ ID NOs: 18-21, 23 and 34), where δ ₃ represents is D or S; δ ₄ represents T or Y; and δ ₇ is A, G or S.

[00299] According to some aspects, in cases where δ ₃ represents D; δ ₄ represents T or Y; and δ ₇ is G. In some aspects, when δ ₃ is S; δ ₄ represents T or Y; and δ ₇ is A, G or S. In some aspects, when δ ₄ is T; δ ₃ represents D or S; and δ ₇ is A, G or S. In some aspects, when δ ₄ is Y; δ ₃ represents D or S; and δ ₇ is G. In some aspects, when δ ₇ is G; δ ₃ represents D or S; and δ ₄ represents T or Y.

[00300] According to some aspects, in cases where δ₃ represents D; δ₄ represents Y; and δ₇ represents G. According to some aspects, in cases where δ₃ represents S; δ₄ represents T; and δ₇ represents A. According to some aspects, in cases where δ₃ represents S; δ₄ represents T; and δ₇ represents G. According to some aspects, in cases where δ₃ represents D; δ₄ represents T; and δ₇ represents G. According to some aspects, in cases where δ₃ represents S; δ₄ represents T; and δ₇ represents S. According to some aspects, in cases where δ₃ represents S; δ₄ represents Y; and δ₇ represents G.

[00301] In some embodiments, the antibody comprises a Kabat CDR-H1 sequence defined by the consensus sequence SG-θ ₃ -YW-θ ₆ (SEQ ID NO: 24-29), where θ ₃ is F, H, or Y; and θ ₆ is F, G, I, L or T.

[00302] In some aspects, when θ ₃ is H, θ ₆ is I or T. In some aspects, when θ ₃ is Y, θ ₆ is F, G, or L. According to some aspects in cases where θ ₆ represents T, θ ₃ represents F or H.

[00303] According to some aspects, in those cases where θ ₃ is Y, θ ₆ is G. According to some aspects, in those cases where θ ₃ is Y, θ ₆ is F. According to some aspects, in those cases, when θ ₃ is H, θ ₆ is I. According to some aspects, when θ ₃ is F, θ ₆ is T. According to some aspects, when θ ₃ is Y, θ ₆ is is L. In some aspects, when θ ₃ is H, θ ₆ is T.

1.8.6. CDR-L3 consensus sequences

[00304] In some embodiments, the antibody comprises a CDR-L3 sequence defined by the consensus sequence Q-π ₂ -π ₃ -π ₄ -HSPYT (SEQ ID NOs: 149-153), where π ₂ represents Q or W; π ₃ represents A, T or V; and π ₄ represents I or V.

[00305] According to some aspects, in cases where π ₂ represents Q; π ₃ represents A, T or V; and π ₄ is I or V. In some aspects, when π ₃ is A; π ₂ represents Q or W; and π ₄ is I or V. According to some aspects, in cases where π ₄ is V; π ₂ represents Q or W; and π ₃ represents A, T or V.

[00306] According to some aspects, in cases where π ₂ represents Q; π ₃ represents A; and π ₄ is V. According to some aspects, in cases where π ₂ is W; π ₃ represents A; and π ₄ represents V. According to some aspects, in cases where π ₂ represents Q; π ₃ represents V; and π ₄ represents V. According to some aspects, in cases where π ₂ represents Q; π ₃ represents T; and π ₄ represents V. According to some aspects, in cases where π ₂ represents Q; π ₃ represents A; and π ₄ represents I.

[00307] In some embodiments, the antibody comprises a CDR-L3 sequence defined by the consensus sequence QQ-λ ₃ -S-λ ₅ -YPPT (SEQ ID NOs: 154-158), where λ ₃ is F, H, or V; and λ ₅ represents I, L or S.

[00308] According to some aspects, in cases where λ ₃ represents H; λ ₅ represents I, L or S. In some aspects, when λ ₅ represents H; λ ₃ represents F, H or V.

[00309] In some aspects, when λ ₃ is H, λ ₅ is S. In some aspects, when λ ₃ is H, λ ₅ is L.

According to some aspects, when λ ₃ is F, λ ₅ is S. According to some aspects, when λ ₃ is V, λ ₅ is S. According to some aspects, when λ ₃ represents H, λ ₅ represents I.

[00310] In some embodiments, the antibody comprises a CDR-L3 sequence defined by the consensus sequence QQ-Ω ₃ -Ω ₄ -Ω ₅ -Ω ₆ -PIT (SEQ ID NOs: 160-161 and 163-164), where Ω ₃ is A, L, V or Y; Ω ₄ represents G, P, V or Y; Ω ₅ represents S, L or F; and Ω ₆ is D, L, S or Y.

[00311] According to some aspects, in cases where Ω ₅ represents S; Ω ₃ represents V or Y; Ω ₄ represents G or V; and Ω ₆ represents D or S.

[00312] According to some aspects, in cases where Ω ₃ represents A; Ω ₄ represents Y; Ω ₅ represents L; and Ω ₆ represents Y. According to some aspects, in cases where Ω ₃ represents L; Ω ₄ represents P; Ω ₅ represents F; and Ω ₆ represents L. According to some aspects, in cases where Ω ₃ represents Y; Ω ₄ represents V; Ω ₅ represents S; and Ω ₆ represents D. According to some aspects, in cases where Ω ₃ represents V; Ω ₄ represents G; Ω ₅ represents S; and Ω ₆ represents S.

1.8.7. CDR-L2 consensus sequences

[00313] In some embodiments, the antibody comprises a CDR-L2 sequence defined by the consensus sequence ψ ₁ -AS-ψ ₄ -RA-ψ ₇ (SEQ ID NOs: 128, 130, 132, 134-138, 143 and 145), where ψ ₁ represents D or G; ψ ₄ represents A, D, N, R, S, T or Y; and ψ ₇ is A, N, S or T.

[00314] According to some aspects, in cases where ψ ₁ represents G; ψ ₄ represents A, D, N, R, S, T or Y; and ψ ₇ is A, N, or T. In some aspects, when ψ ₁ is D; ψ ₄ represents S or T; and ψ ₇ is S or T. In some aspects, when ψ ₄ is S; ψ ₁ represents G or D; and ψ ₇ is S or T. In some aspects, when ψ ₄ is N; ψ ₁ represents G or D; and ψ ₇ is A or T. In some aspects, when ψ ₄ is T; ψ ₁ represents G or D; and ψ ₇ is T. According to some aspects, in cases where ψ ₇ is T; ψ ₁ represents G or D; and ψ ₄ is A, N, R, S, T or Y.

[00315] According to some aspects, in cases where ψ ₁ represents G; ψ ₄ represents S; and ψ ₇ represents T. According to some aspects, in cases where ψ ₁ represents G; ψ ₄ represents A; and ψ ₇ represents T. According to some aspects, in cases where ψ ₁ represents N; ψ ₄ represents S; and ψ ₇ represents A. According to some aspects, in cases where ψ ₁ represents G; ψ ₄ represents N; and ψ ₇ represents T. According to some aspects, in cases where ψ ₁ represents D; ψ ₄ represents S; and ψ ₇ represents S. According to some aspects, in cases where ψ ₁ represents D; ψ ₄ represents S; and ψ ₇ represents T. According to some aspects, in cases where ψ ₁ represents G; ψ ₄ represents D; and ψ ₇ represents N. According to some aspects, in cases where ψ ₁ represents G; ψ ₄ represents Y; and ψ ₇ represents T. According to some aspects, in cases where ψ ₁ represents G; ψ ₄ represents R; and ψ ₇ represents T. According to some aspects, in cases where ψ ₁ represents G; ψ ₄ represents T; and ψ ₇ represents T.

1.8.8. CDR-L1 consensus sequences

[00316] In some embodiments, the antibody comprises a CDR-L1 sequence defined by the consensus sequence ϕ ₁ -ASQ-ϕ ₅ -VS-ϕ ₉ -ϕ ₁₀ -LA (SEQ ID NOs: 105-112 and 117), where ϕ ₁ is E, G, K, Q or R; ϕ ₅ represents A or S; ϕ ₉ represents A, D, N, S or T; and ϕ ₁₀ represents P or Y.

[00317] According to some aspects, in cases where ϕ ₁ represents R; ϕ ₅ represents Q or S; ϕ ₉ represents A, S or T; and ϕ ₁₀ represents S or Y. According to some aspects, in cases where ϕ ₁ represents G; ϕ ₅ represents Q or S; ϕ ₉ represents A or D; and ϕ ₁₀ represents P or Y. According to some aspects, in cases where ϕ ₁ represents Q; ϕ ₅ represents A or S; ϕ ₉ represents N or S; and ϕ ₁₀ represents Y. According to some aspects, in cases where ϕ ₅ represents S; ϕ ₁ represents E, G, Q or R; ϕ ₉ represents A, D, S or T; and ϕ ₁₀ represents P or Y. According to some aspects, in cases where ϕ ₅ represents A; ϕ ₁ represents K or Q; ϕ ₉ represents N or S; and ϕ ₁₀ represents Y. According to some aspects, in cases where ϕ ₉ represents S; ϕ ₁ represents E, K, Q or R; ϕ ₅ represents A or S; and ϕ ₁₀ represents Y. According to some aspects, in cases where ϕ ₉ represents A; ϕ ₁ represents G or R; ϕ ₅ represents S; and ϕ ₁₀ is P or Y. According to some aspects, in cases where ϕ ₁₀ is Y; ϕ ₁ represents E, G, K, Q or R; ϕ ₅ represents A or S; and ϕ ₉ is A, D, N, S or T.

[00318] According to some aspects, in cases where ϕ₁ represents R; ϕ₅ represents S; ϕ₉ represents S; and ϕ₁₀ represents Y. According to some aspects, in cases where ϕ₁ represents G; ϕ₅ represents S; ϕ₉ represents D; and ϕ₁₀ represents Y. According to some aspects, in cases where ϕ₁ represents Q; ϕ₅ represents A; ϕ₉ represents N; and ϕ₁₀ represents Y. According to some aspects, in cases where ϕ₁ represents G; ϕ₅ represents S; ϕ₉ represents A; and ϕ₁₀ represents P. According to some aspects, in cases where ϕ₁ represents R; ϕ₅ represents S; ϕ₉ represents T; and ϕ₁₀ represents Y. According to some aspects, in cases where ϕ₁ represents Q; ϕ₅ represents S; ϕ₉ represents S; and ϕ₁₀ represents Y. According to some aspects, in cases where ϕ₁ represents K; ϕ₅ represents A; ϕ₉ represents S; and ϕ₁₀ represents Y. According to some aspects, in cases where ϕ₁ represents E; ϕ₅ represents S; 49 represents S; and ϕ₁₀ represents Y. According to some aspects, in cases where ϕ₁ represents R; ϕ₅represents S; ϕ₉ represents A; and ϕ₁₀ represents Y.

[00319] In some embodiments, the antibody comprises a CDR-L1 sequence defined by the consensus sequence RASQS-Ϭ ₆ -Ϭ ₇ -S-Ϭ ₉ -L-Ϭ ₁₁ (SEQ ID NOs: 119 and 123-124), where Ϭ ₆ represents I or V; Ϭ ₇ represents N or S; Ϭ ₉ represents N, W or Y; Ϭ ₁₁ represents A or N.

[00320] According to some aspects, when Ϭ ₆ is I, Ϭ ₇ is N or S; Ϭ ₉ represents W or Y; and Ϭ ₁₁ is A or N. In some aspects, when Ϭ ₇ is S, Ϭ ₆ is I or V; Ϭ ₉ represents N or Y; and Ϭ ₁₁ is A or N. In some aspects, when Ϭ ₁₁ is A, Ϭ ₆ is I or V; Ϭ ₇ represents N or S; and Ϭ ₉ represents N or W.

[00321] According to some aspects, in cases where Ϭ ₆ represents I; Ϭ ₇ represents N; Ϭ ₉ represents W; and Ϭ ₁₁ represents A. According to some aspects, in cases where Ϭ ₆ represents I; Ϭ ₇ represents S; Ϭ ₉ represents Y; and Ϭ ₁₁ represents N. According to some aspects, in cases where Ϭ ₆ represents V; Ϭ ₇ represents S; Ϭ ₉ represents N; and Ϭ ₁₁ represents A.

[00322] In some embodiments, the antibody comprises a CDR-L1 sequence defined by the consensus sequence γ ₁ -γ ₂ -SQSVS-γ ₈ -γ ₉ -YLA (SEQ ID NO: 113-116), where γ ₁ is E or R; γ ₂ represents A or V; γ ₈ represents A, D or S; and γ ₁₀ is A or S.

[00323] According to some aspects, in cases where γ ₁ represents E; γ ₂ represents A or V; γ ₈ A or S; and γ ₉ is A or S. In some aspects, when γ ₂ is A; γ ₁ represents E; γ ₈ represents A or S; and γ ₉ is A or S. In some aspects, when γ ₂ is V; γ ₁ represents E or R; γ ₈ A or D; and γ ₉ is A or S. In some aspects, when γ ₈ is A; γ ₁ represents E; γ ₂ represents A or V; and γ ₉ is S. In some aspects, when γ ₉ is S; γ ₁ represents E; γ ₂ represents A or V; and γ ₈ is A. In some aspects, when γ ₉ is A; γ ₁ represents E or R; γ ₂ represents A or V; and γ ₈ D or S.

[00324] According to some aspects, in cases where γ ₁ represents E; γ ₂ represents A; γ ₈ represents A; and γ ₉ represents S. According to some aspects, in cases where γ ₁ represents E; γ ₂ represents A; γ ₈ represents S; and γ ₉ represents A. In some aspects, when γ ₁ represents R; γ ₂ represents V; γ ₈ represents A; and γ ₉ represents A. According to some aspects, in cases where γ ₁ represents E; γ ₂ represents V; γ ₈ represents A; and γ ₉ represents S.

2. Germ line

[00325] In some embodiments, an antibody that specifically binds HLA-G is an antibody comprising a variable region encoded by a specific germline, gene, or variant thereof. Exemplary antibodies of the present invention comprise variable regions encoded by the germline heavy chain variable region genes VH3-23, VH4-39, VH3-11 and VH4-0B, or variants thereof; and the light chain variable region germline genes VK1-33, VK3-20, VK1-12 and VK1-05, or variants thereof. One skilled in the art will appreciate that the CDR sequences of the present invention may also be useful in combination with variable regions encoded by other germline variable region genes, or variants thereof. In particular, the CDR sequences of the present invention may be useful in combination with variable regions encoded by germline variable region genes or variants thereof structurally similar to the germline variable region genes described above. For example, in some embodiments, the CDR-H sequence of the present invention may be combined with a variable region encoded by a germline variable region gene selected from the VH1 or VH3 families, or a variant thereof. In some embodiments, the CDR-L sequence of the present invention may be combined with a variable region encoded by a germline variable region gene selected from the Vλ3, Wκ1, Vκ3, and Vκ4 families, or a variant thereof.

3. Affinity

[00326] In some embodiments, the affinity of said antibody for HLA-G, as indicated by KD, is less than about 10 ^-5 M, less than about 10 ^-6 M, less than about 10 ^-7 M, less than about 10 ^{- 8} M, less than about 10 ^-9 M, less than about 10 ^-10 M, less than about 10 ^-11 M, or less than about 10 ^-12 M. In some embodiments, the affinity of the antibody is from about 10 ^-7 M to 10 ^-11 M. In some embodiments, the affinity of the antibody is from about 10 ^-7 M to 10 ^-10 M. In some embodiments, the affinity of the antibody is from about 10 ^-7 M to 10 ^-9 M. In some embodiments, the affinity of the antibody is from about 10 ^-7 M to 10 ^-8 M. In some embodiments, the affinity of the antibody is from about 10 ^-8 M to 10 ^-11 M. In some embodiments, the affinity of the antibody is from about 10 ^-8 M to 10 ^-10 M. In some embodiments, the affinity of the antibody is from about 10 ^-9 M to 10 ^-11 M. In some embodiments, the affinity of the antibody is from about 10 ^-10 M to 10 ^-11 M.

[00327] In some embodiments, the affinity of said antibody for human HLA-G is from about 1.00×10 ^-8 M to 9.43×10 ^-10 M. In certain embodiments, the affinity of said antibody for human HLA-G is approximately 1.00×10 ^-8 M, approximately 1.08×10 ^-8 M, approximately 1.10×10 ^-8 M, approximately 1.13×10 ^-8 M, approximately 1.14×10 ^-8 M, approximately 1.16×10 ^-8 M, approximately 1.29×10 ^-8 M, approximately 1.40×10 ^-8 M, approximately 1.41×10 ^-8 M, approximately 1.46×10 ^-8 M, approximately 1.67×10 ^-8 M, approximately 1.79×10 ^-8 M, approximately 1.81×10 ^-8 M, approximately 2.04×10 ^-8 M, approximately 2.30 10 ^-8 M, approximately 2.49×10 ^-8 M, approximately 2.59×10 ^-8 M, approximately 2.94×10 ^-8 M, approximately 2.95×10 ^-8 M, approximately 3.11× 10 ^-8 M, approximately 3.98×10 ^-9 M, approximately 4.11×10 ^-9 M, approximately 4.20×10 ^-9 M, approximately 4.33×10 ^-9 M, approximately 4.39× 10 ^-9 M, approximately 4.42×10 ^-9 M, approximately 4.72×10 ^-9 M, approximately 5.24×10 ^-9 M, approximately 5.30×10 ^-9 M, approximately 5.35× 10 ^-9 M, approximately 5.40×10 ^-9 M, approximately 5.55×10 ^-9 M, approximately 5.56×10 ^-9 M, approximately 5.80×10 ^-9 M, approximately 5.89× 10 ^-9 M, approximately 5.92×10 ^-9 M, approximately 5.98×10 ^-9 M, approximately 5.99×10 ^-9 M, approximately 6.10×10 ^-9 M, approximately 6.34× 10 ^-9 M, approximately 6.66×10 ^-9 M, approximately 6.75×10 ^-9 M, approximately 7.19×10 ^-9 M, approximately 7.69×10 ^-9 M, approximately 7.93× 10 ^-9 M, approximately 8.23×10 ^-9 M, approximately 8.34×10 ^-9 M, approximately 8.37×10 ^-9 M, approximately 8.62×10 ^-9 M, approximately 8.82× 10 ^-9 M, approximately 9.21×10 ^-9 M, approximately 9.51×10 ^-9 M, approximately 1.62×10 ^-10 M, approximately 1.63×10 ^-10 M, 1.64×10 ^-10 approximately 1.65×10 ^-10 M, approximately 1.66×10 ^-10 M, approximately 1.71×10 ^-10 M, approximately 1.72×10 ^-10 M, approximately 1.86×10 ^-10 M approximately 1.78×10 ^-10 M, approximately 1.97×10 ^-10 M, approximately 1.98×10 ^-10 M, approximately 1.99×10 ^-10 M, approximately 2.29×10 ^-10 M , approximately 3.24×10 ^-10 M, approximately 6.47×10 ^-10 M, approximately 6.96×10 ^-10 M, approximately 7.84×10 ^-10 M, approximately 9.41×10 ^-10 M or approximately 9.43×10 ^-10 M.

[00328] In some embodiments, the antibody, when bound to human HLA-G, has a k _on of from about 1.41×10 ⁵ M ^-1 ×s ^-1 to about 1.07×10 ⁶ M ^-1 ×s ^-1 . In some embodiments, the antibody, when bound to human HLA-G, has a k _{on of} approximately 1.41×10 ⁵ M ^-1 ×s ^-1 , approximately 1.49×10 ⁵ M ^-1 ×s ^-1 , approximately 1.66 ×10 ⁵ M ^-1 ×s ^-1 , approximately 2.90×10 ⁵ M ^-1 ×s ^-1 , approximately 3.60×10 ⁵ M ^-1 ×s ^-1 , approximately 3.74×10 ⁵ M ^{- 1} ×s ^-1 , approximately 3.78×10 ⁵ M ^-1 ×s ^-1 , approximately 4.03×10 ⁵ M ^-1 ×s ^-1 , approximately 4.30×10 ⁵ M ^-1 ×s ^-1 , approximately 4.32×10 ⁵ M ^-1 ×s ^-1 , approximately 4.34×10 ⁵ M ^-1 ×s ^-1 , approximately 4.60×10 ⁵ M ^-1 ×s ^-1 , approximately 4.64 ×10 ⁵ M ^-1 ×s ^-1 , approximately 4.80×10 ⁵ M ^-1 ×s ^-1 , approximately 4.84×10 ⁵ M ^-1 ×s ^-1 , approximately 4.87×10 ⁵ M ^{- 1} ×s ^-1 , approximately 4.91×10 ⁵ M ^-1 ×s ^-1 , approximately 4.96×10 ⁵ M ^-1 ×s ^-1 , approximately 4.97×10 ⁵ M ^-1 ×s ^-1 , approximately 4.98×10 ⁵ M ^-1 ×s ^-1 , approximately 5.01×10 ⁵ M ^-1 ×s ^-1 , approximately 5.14×10 ⁵ M ^-1 ×s ^-1 , approximately 5.19 ×10 ⁵ M ^-1 ×s ^-1 , approximately 5.20×10 ⁵ M ^-1 ×s ^-1 , approximately 5.26×10 ⁵ M ^-1 ×s ^-1 , approximately 5.27×10 ⁵ M ^{- 1} ×s ^-1 , approximately 5.30×10 ⁵ M ^-1 ×s ^-1 , approximately 5.61×10 ⁵ M ^-1 ×s ^-1 , approximately 5.90×10 ⁵ M ^-1 ×s ^-1 , approximately 6.31×10 ⁵ M ^-1 ×s ^-1 , approximately 6.32×10 ⁵ M ^-1 ×s ^-1 , approximately 6.36×10 ⁵ M ^-1 ×s ^-1 , approximately 6.46 ×10 ⁵ M ^-1 ×s ^-1 , approximately 6.53×10 ⁵ M ^-1 ×s ^-1 , approximately 6.66×10 ⁵ M ^-1 ×s ^-1 , approximately 6.84×10 ⁵ M ^{- 1} ×s ^-1 , approximately 7.20×10 ⁵ M ^-1 ×s ^-1 , approximately 7.24×10 ⁵ M ^-1 ×s ^-1 , approximately 7.48×10 ⁵ M ^-1 ×s ^-1 , approximately 7.36×10 ⁵ M ^-1 ×s ^-1 , approximately 7.58×10 ⁵ M ^-1 ×s ^-1 , approximately 7.77×10 ⁵ M ^-1 ×s ^-1 , approximately 7.92 ×10 ⁵ M ^-1 ×s ^-1 , approximately 7.94×10 ⁵ M ^-1 ×s ^-1 , approximately 7.96×10 ⁵ M ^-1 ×s ^-1 , approximately 8.03×10 ⁵ M ^{- 1} ×s ^-1 , approximately 8.24×10 ⁵ M ^-1 ×s ^-1 , approximately 8.26×10 ⁵ M ^-1 ×s ^-1 , approximately 8.55×10 ⁵ M ^-1 ×s ^-1 , approximately 8.63×10 ⁵ M ^-1 ×s ^-1 , approximately 8.66×10 ⁵ M ^-1 ×s ^-1 , approximately 8.74×10 ⁵ M ^-1 ×s ^-1 , approximately 8.79 ×10 ⁵ M ^-1 ×s ^-1 , approximately 8.92×10 ⁵ M ^-1 ×s ^-1 , approximately 8.96×10 ⁵ M ^-1 ×s ^-1 , approximately 9.09×10 ⁵ M ^{- 1} ×s ^-1 , approximately 9.31×10 ⁵ M ^-1 ×s ^-1 , approximately 9.35×10 ⁵ M ^-1 ×s ^-1 , approximately 9.38×10 ⁵ M ^-1 ×s ^-1 , approximately 9.46×10 ⁵ M ^-1 ×s ^-1 , approximately 9.54×10 ⁵ M ^-1 ×s ^-1 , approximately 9.73×10 ⁵ M ^-1 ×s ^-1 , approximately 9.83 ×10 ⁵ M ^-1 ×s ^-1 , approximately 9.84×10 ⁵ M ^-1 ×s ^-1 , approximately 9.91×10 ⁵ M ^-1 ×s ^-1 , approximately 1.05×10 ⁶ M ^{- 1} × s ^-1 or approximately 1.07 × 10 ⁶ M ^-1 × s ^-1 .

[00329] In some embodiments, the antibody, when bound to human HLA-G, has a _koff of from about 1.06 x 10 ² s ^-1 to about 8.55 x 10 ⁵ s ^-1 . In some embodiments, the antibody has a _{koff of} about 1.06×10 ^-2 s ^-1 , about 1.13×10 ^-2 s ^-1 , about 1.87×10 ^-2 s ^-1 , about 2.13× 10 ^-2 s ^-1 , approximately 3.62×10 ^-3 s ^-1 , approximately 3.66×10 ^-3 s ^-1 , approximately 3.75×10 ^-3 s ^-1 , approximately 3.78×10 - ³ s ^-1 , approximately 3.83×10 ^-3 s ^-1 , approximately 3.96×10 ^-3 s ^-1 , approximately 4.17×10 ^-3 s ^-1 , approximately 4.27×10 ^-3 s ^-1 , approximately 4.29×10 ^-3 s ^-1 , approximately 4.41×10 ^-3 s ^-1 , approximately 4.42×10 ^-3 s ^-1 , approximately 4.46×10 ^-3 s ^-1 , approximately 4.54×10 ^-3 s ^-1 , approximately 4.65×10 ^-3 s ^-1 , approximately 4.85×10 ^-3 s ^-1 , approximately 4.88×10 ^-3 s ^-1 , approximately 4.89×10 ^-3 s ^-1 , approximately 4.98×10 ^-3 s ^-1 , approximately 5.26×10 ^-3 s ^-1 , approximately 5.44×10 ^-3 s ^-1 , approximately 5, 47×10 ^-3 s ^-1 , approximately 5.71×10 ^-3 s ^-1 , approximately 5.72×10 ^-3 s ^-1 , approximately 5.84×10 ^-3 s ^-1 , approximately 5.90× 10 ^-3 s ^-1 , approximately 5.92×10 ^-3 s ^-1 , approximately 5.93×10 ^-3 s ^-1 , approximately 6.24×10 ^-3 s ^-1 , approximately 6.25×10 ^{- 3} s ^-1 , approximately 6.28×10 ^-3 s ^-1 , approximately 6.49×10 ^-3 s ^-1 , approximately 6.50×10 ^-3 s ^-1 , approximately 6.71×10 ^-3 s ^-1 , approximately 6.78×10 ^-3 s ^-1 , approximately 6.83×10 ^-3 s ^-1 , approximately 6.98×10 ^-3 s ^-1 , approximately 7.17×10 ^-3 s ^-1 , approximately 7.42×10 ^-3 s ^-1 , approximately 8.12×10 ^-3 s ^-1 , approximately 8.16×10 ^-3 s ^-1 , approximately 8.26×10 ^-3 s ^-1 , approximately 8.64×10 ^-3 s ^-1 , approximately 8.76×10 ^-3 s ^-1 , approximately 8.91×10 ^-3 s ^-1 , approximately 9.31×10 ^-3 s ^-1 , approximately 9, 32×10 ^-3 s ^-1 , approximately 9.87×10 ^-3 s ^-1 , approximately 1.82×10 ^-4 s ^-1 , approximately 4.38×10 ^-4 s ^-1 , approximately 4.59× 10 ^-4 s ^-1 , approximately 4.99×10 ^-4 s ^-1 , approximately 5.73×10 ^-4 s ^-1 , approximately 6.03×10 ^-4 s ^-1 or approximately 8.55×10 ^{- 5} s ^-1 .

[00330] In some aspects, K _D , k _a and k _d are determined at 25°C. In some embodiments, KD, ka, and kd are determined using surface plasmon resonance. In some embodiments, said KD, ka, and kd are determined in accordance with the methods described in the examples.

4. HLA-G inhibition

[00331] In some aspects, the antibody reduces the affinity of HLA-G for its ligand(s). In some aspects, the antibody disrupts the binding of HLA-G to beta-2-microglobulin and/or a cognate peptide thereof. In some aspects, the antibody prevents dimerization or oligomerization of HLA-G.

[00332] In some aspects, the antibody inhibits the function of HLA-G on tumor cells. In some aspects, the antibody inhibits the function of HLA-G on immune cells. In some embodiments, the antibody blocks the interaction and/or binding of HLA-G to an inhibitory ITIM receptor. In some embodiments, the antibody blocks the interaction and/or binding of HLA-G to ILT2. In some embodiments, the antibody blocks the interaction and/or binding of HLA-G to ILT4. In some embodiments, the antibody blocks the interaction and/or binding of HLA-G to KIR2DL4.

[00333] In some embodiments, the antibody inhibits immunosuppressive function. In some embodiments, the antibody inhibits HLA-G-mediated suppression of NK cells. In some embodiments, the antibody inhibits HLA-G-mediated suppression of cytotoxic T lymphocytes. In some embodiments, the antibody inhibits HLA-G-mediated suppression of B cells. In some embodiments, the antibody inhibits HLA-G-mediated suppression of neutrophils. In some embodiments, the antibody inhibits HLA-G-mediated suppression of dendritic cells. In some embodiments, the antibody inhibits HLA-G-mediated suppression of macrophages. In some embodiments, the antibody inhibits HLA-G-mediated suppression of monocytes. In some embodiments, the antibody inhibits HLA-G-mediated suppression of cytolysis and/or proliferation of NK and/or T cells.

[00334] In some embodiments, the antibody prevents or inhibits HLA-G-mediated suppression of phagocytosis. In some embodiments, the antibody mediates HLA-G-mediated induction of regulatory T cells. In some embodiments, the antibody prevents or inhibits the formation or expansion of regulatory T cells. In some embodiments, the antibody inhibits tumor growth through antibody-dependent cellular cytotoxicity (ADCC) or phagocytosis (ADCP).

[00335] In some aspects, the reduction is a reduction of about 10% or less, a reduction of about 20% or less, a reduction of about 30% or less, a reduction of about 40% or less, a reduction of about 50% or less, a decrease of about 60% or less, a decrease of about 70% or less, a decrease of about 80% or less, a decrease of about 90% or less, or a decrease of about 100%. In some aspects, the increase is an increase of about 10% or more, an increase of about 20% or more, an increase of about 30% or more, an increase of about 40% or more, an increase of about 50% or more, an increase of about 60% or more, an increase of about 70% or more, an increase of about or more than 80%, an increase of about 90% or more, or an increase of 100%.

5. HLA-G test

[00336] In some embodiments, the antibody binds to an HLA-G epitope. An epitope often consists of a continuous series of amino acids, such as, but not limited to, 5-6 amino acids. In some embodiments, the epitope contains or consists of a continuous or discontinuous series of amino acids. In some embodiments, the continuous or discontinuous series of amino acids is part of the HLA-G domain. In some embodiments, the domain comprises or consists of an alpha-3 domain.

[00337] In some aspects, HLA-G has a sequence identical to the amino acid sequence set forth in SEQ ID NO: 342. In some aspects, the epitope has an amino acid sequence included in the amino acid sequence set forth in SEQ ID NO: 342. In some aspects said epitope has an amino acid sequence that is 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% identical to the sequence set forth in SEQ ID NO: SEQ ID NO: 342.

[00338] In some aspects, the epitope comprises or consists of a continuous or discontinuous stretch of amino acids comprising residues 195, 197, and/or 198 of the sequence set forth in SEQ ID NO: 342. In some aspects, the epitope comprises a sequence identical to or corresponding to residues 195 , 197 and/or 198 sequence, which is part of the sequence presented in SEQ ID NO: 342. In some aspects, the specified epitope has the sequence of 60%, 65%, 70%, 75%, 80%, 85%, 90 % or 95% identical to the sequence contained in the sequence set forth in SEQ ID NO: 342. In some aspects, the epitope contains 1, 2, 3, 4, 5, 6, 7, 8, or 9 substitutions relative to the sequence contained in sequence set forth in SEQ ID NO: 342. In some aspects, said epitope contains 1, 2, or 3 substitutions relative to residues of the sequence included in the sequence set forth in SEQ ID NO: 342. In some aspects, said antibody contacts any of residues presented in Fig. 9.

[00339] In some aspects, the antibody competes with any of the antibodies provided herein. Competition may be, for example, without limitation, binding competition, inhibition competition, or any other form of competition. In some aspects, said antibody competes with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13 antibodies 38410, 38418, 38422, 38426, 38381, 38358, 37323, 38373, 38375 , 38379, 38389, 33303, or 33357. In some aspects, the antibody competes with any of the antibodies shown in FIG. 2 or fig. 3. In some aspects, said antibody competes with 1, 2, 3, 4, 5, 6, 7, or 8 antibodies 38373, 38375, 38379, 38418, 38422, 38426, 38410, or 38381. In some aspects, said antibody competes with 38358. In some aspects, said antibody competes with 1, 2, 3, 4, 5, 6, 7, 8, or 9 antibodies 38373, 38375, 38379, 38418, 38422, 38426, 38410 or 38381 or 38358. In some aspects, said antibody competes with one or both of antibodies 37323 and/or 38389. In some aspects, said antibody competes with one or both of antibodies 33303 and/or 33357.

6. Glycosylation variants

[00340] In some embodiments, an antibody may be modified to increase, decrease, or eliminate its degree of glycosylation. Glycosylation of polypeptides is typically either "N-linked" or "O-linked".

[00341] "N-linked" glycosylation refers to the attachment of a carbohydrate moiety to the side chain of an asparagine residue. The tripeptide sequences asparagine-X-serine and asparagine-X-threonine, where X is any amino acid other than proline, are recognition sequences for the enzymatic attachment of a carbohydrate moiety to the asparagine side chain. Accordingly, the presence of any of these tripeptide sequences in a polypeptide creates a potential glycosylation site.

[00342] "O-linked" glycosylation refers to the attachment of one of the sugars N-acetylgalactosamine, galactose or xylose to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine may also be used.

[00343] The addition or deletion of N-linked glycosylation sites to an antibody can be accomplished by altering the amino acid sequence so as to create or delete one or more of the tripeptide sequences described above. The addition or deletion of O-linked glycosylation sites can be accomplished by adding, deleting or substituting, as appropriate, one or more serine or threonine residues in the antibody sequence.

[00344] In some embodiments, the antibody is glycosylated. In some embodiments, the antibody is deglycosylated. Carbohydrates can be removed using standard techniques. In some embodiments, the antibody is aglycosylated, for example, through expression in a non-glycosylation system.

7. Fc options

[00345] In some embodiments, amino acid modifications may be introduced into the Fc region of an antibody of the present invention to produce a variant Fc region. In some embodiments, the Fc region variant has some, but not all, effector functions. Such antibodies may be useful, for example, in applications for which the in vivo half-life of the antibody is important, but certain effector functions are unnecessary or detrimental. Examples of effector functions include complement-dependent cytotoxicity (CDC) and antibody-directed complement-mediated cytotoxicity (ADMC). Numerous substitutions or deletions providing measures of effector function are known in the art.

[00346] In some embodiments, Fc is modified. In some embodiments, the hinge of an IgG1 or IgG4 antibody is modified. Modification of the hinge region stabilizes the antibody and prevents the formation of unwanted bispecific antibodies. In some embodiments, the modification comprises L234A, L235A, and/or G237A in accordance with the Kabat numbering scheme, or residues numbered 117, 118, and 120, respectively, wherein residues are numbered in accordance with any of SEQ ID NO: 334. In some embodiments implementation, said modification comprises EU S228P or S241P according to the Kabat numbering scheme or residue number 108 according to SEQ ID NO: 335. In some embodiments, an IgG Fc is engineered to modulate the effector function of an antibody (see Wang et al., Protein Cell, 2018, Jan; 9(1): 63-73), which is incorporated by reference herein in its entirety, including all drawings).

[00347] Non-limiting examples of in vitro assays for assessing the ADCC activity of a molecule of interest are provided in US Pat. No. 5,500,362 and US Pat. No. 5,821,337; in: Hellstrom et al., Proc. Natl. Acad. Sci. USA 1986, 83:7059-7063; Hellstrom et al., Proc. Natl. Acad. Sci. USA 1985, 82:1499-1502; and Bruggemann et al., J. Exp. Med., 1987, 166:1351-1361. Suitable effector cells for such assays include peripheral blood mononuclear cells (PBMCs) and natural killer (NK) cells. In an alternative or additional embodiment, the ADCC activity of a molecule of interest can be assessed in vivo using an animal model such as that described in Clynes et al. Proc. Natl. Acad. Sci. USA, 1998, 95:652-656.

[00348] C1q binding assays can also be performed to confirm that the antibody is unable to bind Clq and therefore does not have CDC activity. Examples of Clq binding assays include those described in WO 2006/029879 and WO 2005/100402.

[00349] Complement activation assays include those described, for example, in Gazzano-Santoro et al., J. Immunol. Methods 1996, 202:163-171; Cragg et al., Blood, 2003, 101:1045-1052; and Cragg and Glennie, Blood, 2004, 103:2738-2743.

[00350] FcRn binding and in vivo clearance (half-life determination) can also be measured, for example, using the methods described in Petkova et al., Intl. Immunol., 2006, 18:1759-1769.

8. Obtaining antibodies

8.1. Obtaining antigens

[00351] The HLA-G antigen for use in antibody production may be intact HLA-G or an HLA-G fragment. Said intact HLA-G or HLA-G fragment may be in the form of an isolated protein or expressed by the cell. Other forms of HLA-G suitable for antibody production will be apparent to those skilled in the art.

8.2. Monoclonal antibodies

[00352] Monoclonal antibodies can be produced, for example, using the hybridoma method first described in Kohler et al., Nature, 1975, 256:495-497, and/or recombinant DNA methods (see, for example , patent US No. 4816567). Monoclonal antibodies can also be produced, for example, using phage or yeast libraries. See, for example, US Pat. No. 8,258,082 and US Pat. No. 8,691,730.

[00353] In the hybridoma method, a mouse or other suitable host animal is immunized to stimulate the production of lymphocytes that produce or are capable of producing antibodies that specifically bind to the protein used for immunization. Alternatively, lymphocytes can be immunized in vitro. The lymphocytes are then fused with the myeloma cells using a suitable fusion agent such as polyethylene glycol to produce a hybridoma cell. See Goding JW, Monoclonal Antibodies: Principles and Practice ^3rd ed. (1986) Academic Press, San Diego, CA.

[00354] Hybridoma cells are seeded and cultured in a suitable culture medium that contains one or more substances that inhibit the growth or survival of unfused parental myeloma cells. For example, if the original myeloma cells lacked the enzyme hypoxanthine guanine phosphoribosyltransferase (HGPRT or HPRT), hybridoma culture medium typically includes hypoxanthine, aminopterin, and thymidine (HAT medium), substances that prevent the growth of HGPRT-deficient cells.

[00355] Suitable myeloma cells are cells that efficiently fuse to support stable production of high levels of antibody by the selected antibody-producing cells; and sensitive to environmental conditions such as the presence or absence of HAT media. Of these cells, preferred myeloma cell lines are murine myeloma lines, such as those derived from MOP-21 and MC-11 mouse tumors (available from the Salk Institute Cell Center, San Diego, Calif.), and SP-2 or X63-Ag8- cells. 653 (available from the American Type Culture Collection, Rockville, MD). Human myeloma and mouse-human heteromyeloma cell lines have also been described for the production of human monoclonal antibodies. See, for example, Kozbor, J. Immunol., 1984, 133:3001.

[00356] Once hybridoma cells that produce antibodies with the desired specificity, affinity, and/or biological activity have been identified, selected clones can be subcloned using serial dilution procedures and cultured by standard methods. See Goding, above. Suitable culture media for this purpose include, for example, D-MEM or RPMI-1640 media. In addition, hybridoma cells can be cultured in vivo as ascites tumors in an animal.

[00357] DNA encoding monoclonal antibodies can be easily isolated and sequenced using standard procedures (eg, using oligonucleotide probes capable of specifically binding to the genes encoding the heavy and light chains of said monoclonal antibodies). Accordingly, hybridoma cells can serve as a suitable source of DNA encoding antibodies with the desired properties. Once isolated, said DNA can be placed into expression vectors, which are then transfected into host cells such as bacteria (eg, E. coli), yeast (eg, Saccharomyces or Pichia species), COS cells, Chinese hamster ovary (CHO) cells, or myelomas that do not otherwise produce antibody, to obtain said monoclonal antibodies.

8.3. Humanized Antibodies

[00358] Humanized antibodies can be produced by replacing most or all of the structural portions of a monoclonal antibody with corresponding human antibody sequences. This creates a hybrid molecule in which only the antigen-specific variable region, or CDR, consists of non-human sequence. Methods for producing humanized antibodies include those described, for example, in Winter and Milstein, Nature, 1991, 349:293-299; Rader et al., Proc. Nat. Acad. Sci. USA 1998, 95:8910-8915; Steinberger et al., J. Biol. Chem., 2000, 275:36073-36078; Queen et al., Proc. Natl. Acad. Sci. USA 1989, 86:10029-10033; and US patents No. 5585089, No. 5693761, No. 5693762 and No. 6180370.

8.4. Human antibodies

[00359] Human antibodies can be produced using various techniques known in the art, for example, using transgenic animals (eg, humanized mice). See, for example, Jakobovits et al., Proc. Natl. Acad. Sci. USA 1993, 90:2551; Jakobovits et al., Nature, 1993, 362:255-258; Bruggermann et al., Year in Immuno., 1993, 7:33; and US Patents No. 5591669, No. 5589369 and No. 5545807. Human antibodies can also be derived from phage display libraries (see, e.g. , Hoogenboom et al., J. Mol. Biol., 1991, 227:381-388; Marks et al., J. Mol. Biol., 1991, 222 :581-597; and US patents No. 5565332 and No. 5573905). Human antibodies can also be produced by in vitro activated B cells (see, e.g. , US Pat. No. 5,567,610 and US Pat. No. 5,229,275). Human antibodies may also be derived from yeast libraries (see, for example , US Pat. No. 8,691,730).

9. Vectors, host cells and recombinant methods

[00360] The present invention also provides isolated nucleic acids encoding anti-HLA-G antibodies, vectors and host cells containing said nucleic acids, and recombinant techniques for producing said antibodies.

[00361] To recombinantly produce an antibody, the nucleic acid encoding it can be isolated and inserted into a replicable vector for further cloning (ie, DNA amplification) or expression. In some aspects, said nucleic acid can be produced by homologous recombination, for example as described in US Pat. No. 5,204,244.

[00362] Many different vectors are known in the art. Vector components typically include, but are not limited to, one or more of the following: a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence, for example as described in US Pat. No. 5,534,615.

[00363] Suitable host cells include any prokaryotic (eg, bacterial), lower eukaryotic (eg, yeast) or higher eukaryotic cells (eg, mammalian cells). Suitable prokaryotes include eubacteria such as gram-negative or gram-positive organisms, for example enterobacteria such as Escherichia (E. coli), Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella (S. typhimurium), Serratia (S. marcescans), Shigella, Bacilli (B. subtilis and B. licheniformis), Pseudomonas (P. aeruginosa) and Streptomyces. One suitable E. coli host for cloning is E. coli 294, but other strains such as E. coli B, E. coli X1776 and E. coli W3110 are also suitable.

[00364] In addition to prokaryotes, eukaryotic microorganisms such as filamentous fungi or yeast are also suitable as hosts for cloning or expression of anti-HLA-G antibody-encoding vectors.Saccharomyces cerevisiae,or common baker's yeast is a commonly used lower eukaryotic host microorganism. However, several other genera, species and strains are also available and suitable for use, such asSchizosaccharomyces pombe, Kluyveromyces (K. lactis, K. fragilis, K. bulgaricus, K. wickeramii, K. waltii, K. drosophilarum, K. thermotoleransAndK. marxianus), Yarrowia, Pichia pastoris, Candida (C. albicans), Trichoderma reesia, Neurospora crassa, Schwanniomyces (S. occidentalis),And such filamentous fungi as, for examplePenicillium, TolypocladiumAndAspergillus (A. nidulansAndA. niger).

[00365] Suitable mammalian host cells include COS-7 cells, HEK293 cells; newborn hamster kidney (BHK) cells; Chinese Hamster Ovary (CHO) cells; mouse Sertoli cells; African green monkey kidney cells (VERO-76); and so on.

[00366] The host cells used to produce the anti-HLA-G antibody of the present invention can be cultured in a variety of media. Commercially available media such as, for example, Ham's P10 medium, minimal essential medium (MEM), RPMI-1640 and Dulbecco's modified Eagle's medium (DMEM) are suitable for culturing host cells. Additionally, any of the media described in Ham et al., Meth. Enz., 1979, 58:44; Barnes et al., Anal. Biochem., 1980, 102:255; and US Pat. Nos. 4,767,704, 4,657,866, 4,927,762, 4,560,655, and 5,122,469, or WO 90/03430 and WO 87/00195.

[00367] Hormones and/or other growth factors (such as insulin, transferrin or epidermal growth factor), salts (such as sodium, calcium, magnesium chloride and phosphate), buffers (such as HEPES), nucleotides (such as adenosine and thymidine), antibiotics, trace elements (by definition, inorganic compounds typically present in final concentrations in the micromolar range), and glucose or an equivalent energy source. Any other necessary additives may also be included in suitable concentrations known to those skilled in the art.

[00368] Culture conditions, such as temperature, pH, and the like, are those previously used for the host cell selected for expression and will be apparent to one skilled in the art.

[00369] Using recombinant techniques, the antibody can be produced intracellularly, in the periplasmic space, or directly secreted into the medium. If the antibody is produced intracellularly, the first step is to remove debris, ie host cells or lysed fragments, for example by centrifugation or ultrafiltration. For example, in the source: Carter et al. ( Bio/Technology, 1992, 10:163-167) describes a procedure for isolating antibodies that are secreted into the periplasmic space of E. coli. Briefly, the cell paste is thawed in the presence of sodium acetate (pH 3.5), EDTA and phenylmethylsulfonyl fluoride (PMSP) for approximately 30 minutes. Cellular debris can be removed by centrifugation.

[00370] In some embodiments, the antibody is produced in a cell-free system. In some aspects, the cell-free system is an in vitro transcription and translation system as described in Yin et al., mAbs, 2012, 4:217-225, incorporated herein by reference in its entirety. In some aspects, the cell-free system uses a cell-free extract of a eukaryotic cell or prokaryotic cell. In some aspects, said prokaryotic cell is E. coli. Cell-free expression of an antibody may be useful, for example, if the antibody accumulates in the cell as an insoluble aggregate, or if the yield from periplasmic expression is negligible.

[00371] If the antibody is secreted into the medium, supernatants from such expression systems are typically first concentrated using a commercially available protein concentration filter, such as an ^Amicon® or ^{Millipore® Pellcon®} ultrafiltration unit. At any of the steps described, a protease inhibitor, such as PMSP, can be added to inhibit proteolysis, as well as antibiotics to prevent the growth of unintended contaminants.

[00372] The antibody composition obtained from cells can be purified using, for example, hydroxyapatite chromatography, gel electrophoresis, dialysis and affinity chromatography; in particular, affinity chromatography is a suitable purification method. The suitability of protein A as an affinity ligand depends on the type and isotype of any immunoglobulin Fc domain in the antibody. Protein A can be used to purify antibodies based on human γ1, γ2 or γ4 heavy chains. (Lindmark et al., J. Immunol. Meth., 1983, 62:1-13). Protein G is suitable for all mouse isotypes and for human γ3 (Guss et al., EMBO J., 1986, 5:1567-1575).

[00373] The matrix to which the affinity ligand is attached is most often agarose, but other matrices are available. Mechanically stable matrices such as controlled pore glass or poly(styrene divinyl)benzene provide higher flow rates and shorter processing times than agarose can provide. If the antibody contains a CH3 domain, BakerBond ABX ^® resin is suitable for purification.

[00374] Other protein purification techniques are also available and can be used by one skilled in the art, such as ion exchange column fractionation, ethanol precipitation, reverse phase HPLC, silica gel chromatography, heparin-Sepharose ^® chromatography, chromatofocusing, SDS-PAGE. electrophoresis and precipitation with ammonium sulfate..

[00375] After any preliminary purification step(s), the mixture containing the antibody of interest and contaminants can be subjected to low pH hydrophobic interaction chromatography using an elution buffer with a pH of about 2.5 to about 4.5, which is typically carried out at low salt concentrations (eg, from about 0 to about 0.25 M salt).

10. Pharmaceutical compositions and methods of administration

[00376] Any of the antibodies of the present invention may be presented in any suitable pharmaceutical composition and administered by any suitable route. Suitable routes of administration include, but are not limited to, inhalation, intra-arterial, intradermal, intramuscular, intraperitoneal, intravenous, nasal, parenteral, pulmonary and subcutaneous administration.

[00377] The pharmaceutical composition may contain one or more pharmaceutical excipients. Any suitable pharmaceutical excipients may be used, and one skilled in the art will be able to select suitable pharmaceutical excipients. Accordingly, the pharmaceutical excipients listed below are intended to be illustrative and not limiting. Additional pharmaceutical excipients include, for example, those described in: Handbook of Pharmaceutical Excipients, Rowe et al. (Eds.) 6th Ed. (2009), incorporated herein by reference in its entirety.

[00378] In some embodiments, the pharmaceutical composition comprises an antifoaming agent. Any suitable antifoaming agent may be used. In some aspects, said antifoam agent is selected from alcohol, ether, oil, wax, silicone, surfactant, and combinations thereof. In some aspects, said antifoam agent is selected from mineral oil, vegetable oil, ethylene bis-stearamide, paraffin wax, ester wax, fatty alcohol wax, long chain fatty alcohol, fatty acid soap, fatty acid ester, silicone glycol, fluorosilicone, polyethylene glycol copolymer, and polypropylene glycol, polydimethylxyloxane-silica, ether, octyl alcohol, caprylic alcohol, sorbitan trioleate, ethyl alcohol, 2-ethyl-hexanol, dimethicone, oleyl alcohol, simethicone and combinations of the above.

[00379] In some embodiments, the pharmaceutical composition comprises a cosolvent. Illustrative examples of co-solvents include ethanol, poly(ethylene) glycol, butylene glycol, dimethylacetamide, glycerin and propylene glycol.

[00380] In some embodiments, the pharmaceutical composition comprises a buffer. Illustrative examples of buffers include acetate, borate, carbonate, lactate, malate, phosphate, citrate, hydroxide, diethanolamine, monoethanolamine, glycine, methionine, guar gum and sodium monoglutamate.

[00381] In some embodiments, the pharmaceutical composition comprises a carrier or excipient. Illustrative examples of carriers or excipients include lactose, maltodextrin, mannitol, sorbitol, chitosan, stearic acid, xanthan gum and guar gum.

[00382] In some embodiments, the pharmaceutical composition comprises a surfactant. Illustrative examples of surfactants include d -alpha tocopherol, benzalkonium chloride, benzethonium chloride, cetrimide, cetylpyridinium chloride, sodium docusate, glyceryl behenate, glyceryl monooleate, lauric acid, macrogol 15 hydroxystearate, myristyl alcohol, phospholipids, polyoxyethylene alkyl ethers, polyoxyethylene sorbitol fatty acid esters, polyoxyethylene stearates, polyoxyyl glycerides, sodium lauryl sulfate, sorbitol esters and polyethylene (glycol) vitamin E succinate.

[00383] In some embodiments, the pharmaceutical composition comprises an anti-caking agent. Illustrative examples of anti-caking agents include calcium phosphate (tribasic), hydroxymethylcellulose, hydroxypropylcellulose and magnesium oxide.

[00384] Other excipients that may be used with these pharmaceutical compositions include, for example, albumin, antioxidants, antibacterial agents, antimycotic agents, biodegradable polymers, chelating agents, controlled release agents, diluents, dispersing agents, dissolution enhancing agents, emulsifying agents agents, gelling agents, ointment bases, penetration enhancing agents, preservatives, solubilizing agents, solvents, stabilizing agents and sugars. Specific examples of each of these agents are described, for example, in the manual: Handbook of Pharmaceutical Excipients, Rowe et al. (Eds.) 6th Ed. (2009), The Pharmaceutical Press, incorporated herein by reference in its entirety.

[00385] In some embodiments, the pharmaceutical composition comprises a solvent. In some aspects, said solvent is a saline solution, such as sterile isotonic saline or dextrose solution. In some aspects, said solvent is water for injection.

[00386] In some embodiments, the pharmaceutical compositions are in the form of particles, such as microparticles or nanoparticles. Microparticles and nanoparticles can be obtained from any suitable material, such as a polymer or lipid. In some aspects, said microparticles or nanoparticles are micelles, liposomes, or polymersomes. In some embodiments, the composition of the present invention is a pharmaceutical composition or a unit dosage form. The pharmaceutical compositions and unit dosage forms of the present invention contain a prophylactically or therapeutically effective amount of one or more prophylactic or therapeutic antibodies.

[00387] Also included herein are anhydrous pharmaceutical compositions and dosage forms containing the antibody, since water may promote degradation of some antibodies.

[00388] The anhydrous pharmaceutical compositions and dosage forms provided by the present invention can be prepared using anhydrous or low moisture ingredients and under low moisture or low humidity conditions. Pharmaceutical compositions and dosage forms that contain lactose and at least one active ingredient that contains a primary or secondary amine may be anhydrous if significant contact with moisture and/or humidity is expected during manufacture, packaging and/or storage.

[00389] The preparation and storage of an anhydrous pharmaceutical composition must be carried out in such a way as to preserve its anhydrous nature. Accordingly, anhydrous compositions can be packaged using materials known to prevent exposure to water, such that they can be included in suitable formulation kits. Examples of suitable packaging include, but are not limited to, hermetically sealed foil, plastic, unit dose containers ( eg vials), blister packs and blister packs.

[00390] In some embodiments, said pharmaceutical composition further comprises one or both antibodies to an immunoinhibitory receptor or ligand and/or an immunostimulatory receptor and/or ligand. In some embodiments, said pharmaceutical composition further comprises an effective amount of at least one of the following: an anti-ILT2 antibody; anti-ILT-4 antibody; anti-ILT4 antibody; anti-KIR2DL4 antibody; anti-HLA-E antibody; anti-NKG2A antibody; anti-HLA-P antibody; anti-PD-L1 antibody; anti-PD-I antibody; anti-CTLA4 antibody; anti-CD38 antibody; anti-CD73 antibody; anti-A2A receptor antibody; anti-A2B receptor antibody; anti-dual A2A/A2B receptor antibody or a combination thereof; anti-CD39 antibody; anti-CD73 antibody; anti-CD47 antibody; and/or a small molecule inhibitor. In some embodiments, the pharmaceutical composition further comprises an anti-Tim-3 antibody; anti-TIGIT antibody; anti-Vista antibody; anti-CD94 antibody; anti-ILT2 antibody, anti-ILT4 antibody, anti-PD-L1 antibody and/or anti-CD47 antibody; small molecule inhibitor; bispecific T cell recruiter, agent for CAR T cell therapy, CAR NK cell therapy, CAR macrophage therapy, engineered cell therapy and/or adoptive T cell therapy; oncolytic virus; chemotherapeutic agent; and/or a therapeutic agent with ADCC function that uses competent effector antibodies, for example, anti-CD19, anti-CD20, anti-EGPR, anti-Her2, anti-SLAMF7, anti-CD52, anti-BCMA, anti-GD2, anti-CD3 and/or anti-CCR4. In some embodiments, the ADCC therapy is an enhanced ADCC therapy. In some embodiments, the effector is enhanced through afucosylation, point mutations, or other means.

10.1. Parenteral dosage forms

[00391] In some embodiments, parenteral dosage forms are provided. Parenteral dosage forms may be administered to subjects by a variety of routes, including, but not limited to, subcutaneous, intravenous (including bolus injection), intramuscular, and intra-arterial. Because their administration typically involves bypassing the subject's natural defenses against contaminants, parenteral dosage forms are generally sterile or may be sterilized prior to administration to the subject. Examples of parenteral dosage forms include, but are not limited to, solutions ready for injection, dry products ready to be dissolved or suspended in a pharmaceutically acceptable injectable base, suspensions ready for injection, and emulsions.

[00392] Suitable bases that can be used to provide parenteral dosage forms are well known to those skilled in the art. Examples include, but are not limited to: USP Water for Injection; aqueous bases such as, but not limited to, sodium chloride injection, Ringer's solution for injection, dextrose injection, dextrose-sodium chloride injection and lactated Ringer's solution for injection; water-miscible bases such as, but not limited to, ethyl alcohol, polyethylene glycol and polypropylene glycol; and non-aqueous bases such as, but not limited to, corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate and benzyl benzoate.

[00393] Excipients that increase the solubility of one or more antibodies as described herein may also be included in these parenteral dosage forms.

10.2. Dosage and unit dosage forms

[00394] For therapy in humans, the physician will determine the dosage regimen he or she deems most appropriate for prophylactic or curative therapy and appropriate to the age, weight, condition, and other factors specific to the patient being treated.

[00395] The amount of antibody or composition that will be effective in preventing or treating a disorder or one or more symptoms thereof depends on the nature and severity of the disease or condition and the route by which the antibody is administered. The frequency and dosage will also vary depending on factors specific to each subject, depending on the specific therapy being administered (eg, therapeutic or prophylactic agents), the severity of the disorder, disease or condition, route of administration, and age, body weight, response and subject's history. Effective doses can be extrapolated from dose response curves obtained in vitro or in animal model test systems.

[00396] In some embodiments, exemplary doses of the composition include milligrams or micrograms of antibody per kilogram of body weight of the subject or sample ( e.g., about 10 μg per kilogram to about 50 milligrams per kilogram, about 100 μg per kilogram to about 25 milligrams per kilogram , or from about 100 micrograms per kilogram to about 10 milligrams per kilogram). In a specific embodiment, the dosage by weight of an antibody of the present invention that is administered to prevent, treat, manage, or alleviate a disorder or one or more symptoms thereof in a subject is 0.1 mg/kg, 1 mg/kg, 2 mg/kg, 3 mg/kg, 4 mg/kg, 5 mg/kg, 6 mg/kg, 10 mg/kg, or 15 mg/kg subject's body weight; or more. In another embodiment, the dosage of said composition or composition of the present invention that is administered to prevent, treat, manage, or alleviate a disorder or one or more symptoms thereof in a subject is from 0.1 mg to 200 mg, from 0.1 mg up to 100 mg, from 0.1 mg to 50 mg, from 0.1 mg to 25 mg, from 0.1 mg to 20 mg, from 0.1 mg to 15 mg, from 0.1 mg to 10 mg, from 0.1 mg to 7.5 mg, from 0.1 mg to 5 mg, from 0.1 to 2.5 mg, from 0.25 mg to 20 mg, from 0.25 to 15 mg, from 0.25 up to 12 mg, from 0.25 to 10 mg, from 0.25 mg to 7.5 mg, from 0.25 mg to 5 mg, from 0.25 mg to 2.5 mg, from 0.5 mg to 20 mg, from 0.5 to 15 mg, from 0.5 to 12 mg, from 0.5 to 10 mg, from 0.5 mg to 7.5 mg, from 0.5 mg to 5 mg, from 0.5 mg to 2.5 mg, from 1 mg to 20 mg, from 1 mg to 15 mg, from 1 mg to 12 mg, from 1 mg to 10 mg, from 1 mg to 7.5 mg, from 1 mg to 5 mg or from 1 mg to 2.5 mg.

[00397] The dose may be administered according to a suitable schedule, for example, once, twice, three times or several times weekly. In some cases, it may be necessary to use antibody dosages beyond the range described herein, as will be apparent to those skilled in the art. Additionally, it should be noted that the clinician or treating physician knows how and when to interrupt, adjust, or discontinue therapy based on the subject's response.

[00398] Other therapeutically effective amounts may be suitable for use in other diseases and conditions, as is well known to those skilled in the art. Likewise, an amount sufficient to prevent, manage, treat, or alleviate such disorders, but not sufficient to cause or sufficient to reduce adverse events associated with the antibodies of the present invention, is also included in the dosages and dosing schedules described herein. In addition, if multiple doses of a composition of the present invention are administered to a subject, not all doses will necessarily be the same. For example, the dose administered may be increased to improve the prophylactic or therapeutic effect of the composition or may be decreased to reduce one or more side effects experienced by a particular subject.

[00399] In some embodiments, treatment or prevention may be initiated by administering one or more loading doses of an antibody or composition of the present invention, followed by one or more maintenance doses.

[00400] In some embodiments, a dose of an antibody or composition of the present invention may be administered to achieve a steady-state concentration of said antibody in the blood or serum of a subject. The steady-state concentration can be determined by measurement in accordance with techniques known to those skilled in the art, or based on the physical characteristics of the subject, such as height, weight and age.

[00401] In some embodiments, administration of the same composition may be repeated and said administrations may be separated in time by at least 1 day, 2 days, 3 days, 5 days, 10 days, 15 days, 30 days, 45 days , 2 months, 75 days, 3 months or 6 months. In other embodiments, administration of the same prophylactic or therapeutic agent may be repeated and said administrations may be separated in time by at least 1 day, 2 days, 3 days, 5 days, 10 days, 15 days, 30 days, 45 days , 2 months, 75 days, 3 months or 6 months.

11. Therapeutic use

[00402] In therapeutic applications, the antibodies of the present invention are administered to a mammal, typically a human, in a pharmaceutically acceptable dosage form such as those known in the art and described above herein. For example, the antibodies of the present invention may be administered to a human intravenously as a bolus, or may be administered by continuous infusion over a period of time, by intramuscular, intraperitoneal, intraspinal, subcutaneous, intraarticular, intrasynovial, intrathecal, or intratumoral routes. Antibodies are also administered by peritumoral, intralesional or perisolate routes in appropriate cases to provide both local and systemic therapeutic effects. Intraperitoneal administration may be particularly suitable, for example, in the treatment of ovarian tumors.

[00403] Antibodies of the present invention may be suitable for treating any disease or condition in which HLA-G is involved, such as cancer, autoimmune disease and infection.

[00404] The antibodies of the present invention can be used to treat any suitable cancer. Exemplary suitable cancers include, for example, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), adrenocortical carcinoma, anal cancer, appendix cancer, astrocytoma, basal cell carcinoma, brain tumor, bile duct cancer, bladder cancer , bone cancer, breast cancer, bronchial tumor, Burkitt's lymphoma, carcinoma of unknown primary origin, cardiac tumor, cervical cancer, chordoma, chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), chronic myeloproliferative neoplasm, colon cancer, colorectal cancer, craniopharyngioma, cutaneous T-cell lymphoma, ductal carcinoma, embryonal tumor, endometrial cancer, ependymoma, esophageal cancer, esthesioneuroblastoma, fibrous histiocytoma, Ewing's sarcoma, eye cancer, germ cell tumor, gallbladder cancer, gastric cancer, carcinoid GI tumor, GI stromal tumor, gestational trophoblastic carcinoma, glioma, head and neck cancer, hairy cell leukemia, hepatocellular carcinoma, histiocytosis, Hodgkin's lymphoma, hypopharyngeal carcinoma, intraocular melanoma, islet cell tumor, Kaposi's sarcoma, kidney cancer, Langerhans cell histiocytosis , laryngeal cancer, leukemia, lip and oral cavity cancer, liver cancer, lobular carcinoma in situ, lung cancer, lymphoma, macroglobulinemia, malignant fibrous histiocytoma, melanoma, Merkel cell carcinoma, mesothelioma, metastatic squamous cell carcinoma of the neck with occult primary midline carcinoma with involving the NUT gene, oral cancer, multiple endocrine neoplasia syndrome, multiple myeloma, mycosis fungoides, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm, nasal and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, non-Hodgkin's lymphoma, non-small cell lung cancer, oropharyngeal cancer, osteosarcoma , ovarian cancer, pancreatic cancer, papillomatosis, paraganglioma, parathyroid cancer, penile cancer, pharyngeal cancer, pheochromocytomas, pituitary tumor, pleuropulmonary blastoma, primary central nervous system lymphoma, prostate cancer, rectal cancer, renal cell cancer, renal pelvis and ureter cancer, retinoblastoma, rhabdoid tumor, salivary gland cancer, Sezary syndrome, skin cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, spinal cord tumor, stomach cancer, T-cell lymphoma, teratoid tumor, testicular cancer , throat cancer, thymoma and thymic carcinoma, thyroid cancer, urethral cancer, uterine cancer, vaginal cancer, vulvar cancer and Wilms tumor. In some embodiments, the cancer is selected from breast cancer, lung cancer, colorectal cancer, gastric cancer, esophageal cancer, neuroblastoma, cervical cancer, and hematologic cancer.

[00405] The antibodies of the present invention can be used to treat any suitable autoimmune disease. Exemplary suitable autoimmune diseases, or diseases with an autoimmune component, include, for example, acute disseminated encephalomyelitis (ADEM), acute necrotizing hemorrhagic leukoencephalitis, Addison's disease, agammaglobulinemia, alopecia areata, amyloidosis, ankylosing spondylitis, anti-CBM/anti-BMK nephritis, antiphospholipid syndrome (APS), autoimmune angioedema, autoimmune aplastic anemia, autoimmune vegetative dystonia, autoimmune hepatitis, autoimmune hyperlipidemia, autoimmune immunodeficiency, autoimmune inner ear disease (AIAD), autoimmune myocarditis, autoimmune oophoritis, autoimmune pancreatitis, autoimmune retinopathy, autoimmune thrombocytopenic purpura ( ATP), autoimmune thyroid disease, autoimmune urticaria, axonal and neuronal neuropathies, Balo's disease, Behçet's disease, bullous pemphigoid, cardiomyopathy, Castleman's disease, celiac disease, Chagas disease, chronic fatigue syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), chronic relapsing multifocal osteomyelitis (CRMS), Churg-Strauss syndrome, cicatricial pemphigoid/benign mucosal pemphigoid, Crohn's disease, Cogan's syndrome, cold agglutinin disease, colitis, congenital heart block, Coxsackie myocarditis, CREST syndrome, essential mixed cryoglobulinemia, demyelinating neuropathies, dermatitis herpetiformis , dermatomyositis, Devic's disease (neuromyelitis of the optic nerve), discoid lupus, Dressler's syndrome, endometriosis, eosinophilic esophagitis, eosinophilic fasciitis, erythema nodosum, experimental allergic encephalomyelitis, Evans syndrome, fibromyalgia, fibrosing alveolitis, giant cell arteritis (temporal arteritis), giant cell myocardium t, glomerulonephritis, Goodpasture's syndrome, granulomatosis with polyangiitis (GPA) (formerly called Wegener's granulomatosis), Graves' disease, Guillain-Barre syndrome, Hashimoto's encephalitis, Hashimoto's thyroiditis, hemolytic anemia, Henoch-Schönlein purpura, gestational herpes, hypogammaglobulinemia, idiopathic thrombocytopenia purpura (ITP ), IgA nephropathy, IgG4-related sclerosing disease, immunoregulatory lipoproteins, inclusion body myositis, inflammatory bowel disease, interstitial cystitis, juvenile arthritis, juvenile diabetes (type 1 diabetes), juvenile myositis, Kawasaki syndrome, Lambert-Eaton syndrome, leukocytoclastic vasculitis, lichen planus, lichen sclerosis, woody conjunctivitis, linear IgA dermatosis (LAD), lupus (SLE), Lyme disease (chronic), Meniere's disease, microscopic polyangiitis, mixed connective tissue disease (MCTD), Moray's ulcer, Mukha- Habermann, multiple sclerosis, myasthenia gravis, myositis, narcolepsy, neuromyelitis of the optic nerve (Devic's neuromyelitis), neutropenia, ocular cicatricial pemphigoid, optic neuritis, palindromic rheumatism, PANDAS (pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections), paraneoplastic cerebellar degeneration , nocturnal paroxysmal hemoglobinuria (PNH), Parry-Romberg syndrome, Personage-Turner syndrome, pars plana inflammation (peripheral uveitis), pemphigus, peripheral neuropathy, perivenous encephalomyelitis, pernicious anemia, POEMS syndrome, polyarteritis nodosa, autoimmune polyglandular syndromes type I, II and III, polymyalgia rheumatica, polymyositis, post-infarction syndrome, post-cardiotomy syndrome, progesterone dermatitis, primary biliary cirrhosis, primary sclerosing cholangitis, psoriasis, psoriatic arthritis, idiopathic pulmonary fibrosis, pyoderma gangrenosum, true erythrocyte aplasia, Raynaud's phenomenon, reactive arthritis, sympathetic reflex vector dystrophy, Reiter's syndrome, relapsing polychondritis, restless legs syndrome, retroperitoneal fibrosis, rheumatic fever, rheumatoid arthritis, sarcoidosis, Schmidt's syndrome, scleritis, scleroderma, Sjogren's syndrome, autoimmunity against testicular and/or sperm antigens, stiff man syndrome, subacute bacterial endocarditis ( PIE), Susak syndrome, sympathetic ophthalmia, Takayasu arteritis, temporal arteritis/giant cell arteritis, thrombotic disease, thrombocytopenic purpura (TTP), Tolosa-Hunt syndrome, transverse myelitis, type 1 diabetes, ulcerative colitis, undifferentiated connective tissue disease (UCTD), uveitis, vasculitis, vesiculobullous dermatosis, vitiligo and Wegener's granulomatosis (now called granulomatosis with polyangiitis (GPA).

[00406] The antibodies of the present invention can be used to treat any suitable infection. Exemplary suitable infections include, for example, hepatitis A virus, hepatitis B virus, hepatitis C virus (HCV), human immunodeficiency virus (HIV), and other viral infections.

[00407] Some embodiments provide for treating a subject suffering from cancer, chronic infection, or inflammatory disease, comprising the step of administering to said subject a pharmaceutical composition containing an effective amount of any of the antibodies provided herein. Some embodiments include treating a subject suffering from cancer with a chronic infection; or an inflammatory disease, comprising the step of administering to said subject a pharmaceutical composition comprising an effective amount of any of the antibodies provided herein in combination with an effective amount of another antibody provided herein. In some embodiments, the cancer is a hematologic cancer.

[00408] Some embodiments provide a method of modulating the function of the immune system in a subject in need thereof, comprising the step of contacting a population of immune cells of the subject with a pharmaceutical composition containing an effective amount of an antibody provided herein under conditions that modulate the immune system. Some embodiments provide a method of modulating immune system function in a subject in need thereof, comprising the step of contacting a population of immune cells of the subject with an effective amount of any of the antibodies provided herein in combination with an effective amount of another antibody provided herein. In some embodiments, the antibody comprises a bispecific antibody or a complexing antibody.

[00409] In some embodiments, the bispecific antibody or complexing antibody is administered in an amount sufficient to achieve 1, 2, 3, 4, 5, 6, 7, or 8 of:

a) inhibition of immune suppression;

b) decreasing levels of regulatory T cells;

c) increased activity of myeloid cells;

d) increasing the activity of cytotoxic T lymphocytes, NK cells, B cells, neutrophils, monocytes, macrophages and/or dendritic cells;

e) increasing phagocytic activity;

f) inhibiting metastasis;

g) inhibiting tumor growth; and/or

h) induction of tumor regression.

In some embodiments, the bispecific antibody binds HLA-G and HLA-E.

[00410] In some embodiments, the method of modulating immune system function in a subject in need thereof further comprises administering chemotherapy, administering radiation therapy, and/or administering one or more additional therapeutic agents. In some embodiments, the one or more additional therapeutic agents comprise one or more immunostimulating agents. In some embodiments, the one or more immunostimulating agents comprise an inhibitory immune cell receptor antagonist. In some embodiments, the inhibitory receptor is at least one of ILT2, ILT3, ILT4, KIR2DL4, CTLA-4, PD-1, CD39, CD73, PD-L1, PD-L2, LAG-3, TIGIT, B7 -H3, B7-H4, Tim3, neuritin, BTLA, CECAM-1, CECAM-5, VISTA, LAIR1, CD160, 2B4, TGP-B, NKG2A and/or killer cell immunoglobulin-like receptor (KIR).

[00411] In some embodiments, the one or more immunostimulatory agents comprise an immune cell co-stimulatory receptor agonist. In some embodiments, said co-stimulatory receptor comprises any one or more of OX40, CD2, CD27, ICAM-1, LPA-1, ICOS (CD278), 4-1BB (CD137), GITR, CD28, CD30, CD40, BAPPR , HVEM, CD7, LIGHT, NKG2C, SLAMP7, NKp30, NKp46, NKp80, CD160 and/or CD83 ligand.

[00412] In some embodiments, the one or more immunostimulating agents comprise a cytokine. In some embodiments, said cytokine is at least one of IL-1, IL-2, IL-5, IL-7, IL-10, IL-12, IL-15, IL-21, and/or IL-27 . In some embodiments, the one or more immunostimulating agents comprise an oncolytic virus. In some embodiments, the oncolytic virus includes one or more oncolytic viruses from herpes simplex virus, vesicular stomatitis virus, adenovirus, Newcastle disease virus, vaccinia virus, or Maraba virus. In some embodiments, the one or more immunostimulating agents comprise a chimeric antigen receptor T cell. In some embodiments, the immunostimulating agents comprise a bispecific or multispecific T cell-directed antibody. In some embodiments, the one or more immunostimulatory agents comprise or consist of an ADCC-competent antibody that may target CD19, CD20, EGPR, Her2, SLAMP7, CD52, BCMA, GD2, CD38, or CCR4. In some embodiments, the ADCC-competent antibody is an effector antibody enhanced by afucosylation, point mutations, or other means.

[00413] In some embodiments, the one or more immunostimulatory agents comprise a bispecific T cell recruiter of a bispecific T cell recruiter, an agent for CART therapy, CAR NK cell therapy, CAR macrophage therapy, adoptive T cell therapy

12. Diagnostic application options and diagnostic methods

[00414] In some embodiments, the antibodies of the present invention are used in diagnostic applications and/or diagnostic methods. For example, an anti-HLA-G antibody may be suitable for use in HLA-G protein assays. In some aspects, the antibody can be used to detect HLA-G expression in various cells and tissues. In some embodiments, the antibody can be used to detect soluble HLA-G in liquids. In some embodiments, the fluids comprise or consist of blood, serum, ascites, and/or other fluids. These tests may be useful, for example, in the evaluation of cancer and autoimmune disease.

[00415] In some embodiments, the diagnostic method includes or consists of detecting tumor-expressed HLA-G. In some embodiments, the diagnostic method includes or consists of detecting soluble HLA-G. In some embodiments, the detection method includes or consists of detecting HLA-G expression on immune cells.

[00416] In some diagnostic applications, the antibody may be labeled with a detectable moiety. Suitable detectable moieties include, but are not limited to, radioisotopes, fluorescent tags, and enzyme-substrate tags. According to another embodiment of the present invention, the anti-HLA-G antibody does not need to be labeled, and its presence can be detected using a labeled antibody that specifically binds to the anti-HLA-G antibody.

13. Reagents for affinity purification

[00417] The antibodies of the present invention can be used as affinity purification agents. During this process, antibodies can be immobilized on a solid support, such as resin or filter paper, using methods well known in the art. The immobilized antibody is brought into contact with a sample containing the HLA-G protein (or fragment thereof) to be purified, after which the support is washed with a suitable solvent that removes substantially all of the material in the sample except the HLA-G protein, which is bound to the immobilized antibody. antibody. Finally, the support is washed with another suitable solvent, such as glycine buffer, pH 5.0, which dissociates the HLA-G protein from the antibody.

14. Sets

[00418] In some embodiments, the anti-HLA-G antibody of the present invention is provided in kit form, i.e. a packaged combination of reagents in predetermined quantities with instructions for performing the procedure. In some embodiments, the procedure is a diagnostic assay. In other embodiments, the procedure is a therapeutic procedure.

[00419] In some embodiments, the kit further comprises a solvent for reconstituting the anti-HLA-G antibody. In some embodiments, the anti-HLA-G antibody is provided in the form of a pharmaceutical composition.

EXAMPLES

Example 1: Selection of antibodies to HLA-G

[00420] Antibodies to HLA-G were selected from a synthetic library of human antibodies present on the surface of yeast cells in IgG format, as generally described, for example, in references: WO2009036379; WO2010105256; WO2012009568; and Xu et al., Protein Eng. Des. Sel., 2013, 26:663-670 (each of which is incorporated herein by reference in its entirety), and more specifically described below. The sequences and characteristics of antibodies isolated from the indicated recombinant library are presented in Table S.

[00421] Eight untrained synthetic yeast human antibody libraries, each with ^~ 10E+09 diversity, were propagated as described in references: WO2009036379; WO2010105256; WO2012009568; and Xu et al., Protein Eng. Des. Sel., 2013, 26:663-670; each of which is incorporated herein by reference in its entirety. The first two rounds of selection were carried out using the magnetic bead sorting method on the Miltenyi MACS ^® system as described in Siegel et al., J. Immunol. Meth., 2004, 286:141-153. Subsequent rounds of selection were performed using flow cytometry-based sorting. For all rounds of selection, the antigen was biotinylated human HLA-G, and decreasing concentrations of antigen were used in each subsequent round. In addition to selection on antigen, several rounds of selection have been used to reduce the amount of nonspecific binding agents using soluble membrane proteins from CHO cells (see WO2014179363 and Xu et al., Protein Eng. Des. Sel., 2013, 26:663-670, each which are incorporated herein by reference in their entirety). Along with CHO cell proteins, recombinant HLA-A/B/C proteins were deselected to preserve specific binding to HLA-G. After the final round of sorting, yeasts were plated and individual colonies were recovered for characterization and assignment of clones for affinity maturation.

[00422] Antibody variable domains of interest were synthesized, codon-optimized to maximize transient expression in host cells. These variable regions were cloned into expression vectors containing human immunoglobulin constant domains and their sequences were confirmed. Paired antibody heavy and light chain vectors were transfected into Expi293 cells using the ExpiFectamine system (Invitrogen). On day 4, transient cultures were harvested and the IgG titer in the clarified cell culture supernatant was assessed using biolayer interferometry (BLI) using Octet (ForteBio) in addition to standards. The antibodies were then purified on a protein A column and eluted using low pH glycine. Purified antibody samples were then buffer exchanged or dialyzed into buffers compatible with the subsequent assay.

[00423] Antibody purity was assessed by passing samples through SDS-PAGE and through an analytical size exclusion chromatography column.

[00424] Light chain shuffling: Heavy chain plasmids were extracted from the untrained products (described herein) and transformed into a prepared untrained light chain library of 10E+06 diversity. Selection was performed as described above using one round of MACS sorting and three rounds of FACS sorting with decreasing amounts of biotinylated HLA-G antigen for the respective rounds.

Example 2: Affinity Maturation

[00425] Optimization of untrained clones was performed using four maturation strategies; diversification of CDR-H1 and CDR-H2; CDR-H3 diversification; diversification of CDR-L1, L2 and L3; rearrangements of diversified heavy and light chains.

[00426] Selection of CDR-H1 and CDR-H2: CDR-H3 regions from clones selected by bulk light chain diversification, light chain diversification, and clones from screened untrained libraries were independently recombined into finished libraries with CDR-H1 and CDR-H2 variants with diversity >10E+8. Selection was carried out using the HLA-G antigen. Decreasing antigen concentrations were used for affinity pressure, and HLA-G specificity was maintained by deselection against HLA-A/B/C antigens.

[00427] CDR-H3 Selection: After characterization of the CDR-H1 and CDR-H2 variants, clones binding to non-HLA-G HLA antigens were removed. Also, if necessary, undesirable chemical properties of the variable regions were eliminated. The remaining clones obtained from the CDR-H1 and CDR-H2 selection procedure were subjected to additional rounds of affinity maturation via CDR-H3 dimer scanning mutagenesis. Selection using HLA-G as the antigen was performed generally as described above, except for the use of FACS sorting for all selection rounds.

[00428] Selection of CDR-L1, L2, L3: Clones obtained from the CDR-H1 and CDR-H2 selection procedure were subjected to additional rounds of affinity maturation via light chain mutagenesis. The CDR-L1 and CDR-L2 diversity were obtained from a ready-made library, and the CDR-L3 diversity was obtained by scanning monomeric mutagenesis. Selection was carried out using HLA-G as the antigen, starting with one round of MACS followed by three rounds of FACS using the method for CDR-L1, L2, L3 described herein.

[00429] Rearrangement of diversified heavy and light chains: the products of the CDR-H3 diversification and the CDR-L1, L2, L3 diversification described above were recombined and selected using HLA-G as the antigen generally as described above, except for the use of sorting FACS for all selection rounds.

Example 3: Binding affinity of anti-HLA-G antibodies to recombinant HLA-G

[00430] Binding kinetics were measured using the Octet Red96 system (Pall ForteBio) at 30°C in running buffer (1× Pall ForteBio Kinetics Buffer, diluted in 1× PBS, pH 7.4). Briefly, 0.16 μg/mL biotinylated recombinant HLA-G/β2m/peptide heterotrimer was loaded onto streptavidin (SA) biosensors to a binding reaction of approximately 0.25 nm. After a short baseline step in running buffer, the biosensors were exposed to full-length anti-HLA-G mAbs at varying concentrations (1.5, 3.0, or 30 nM) for the binding step. The dissociation of the complex was monitored by repeated immersion of the sensors in the running buffer for up to 30 min. Data were processed using ForteBio Octet DataAnalysis software (version 10) with background subtraction of non-HLA-G biosensors. Each sensorgram was fitted to a 1:1 Langmuir binding model to determine binding and dissociation rates by full local or partial local fitting. K _D was calculated from the ratio of k _d to k _a . Monovalent affinity values were obtained using identical methods, except that Fabs were used instead of IgG.

[00431] In FIG. 1 shows a table with the avidity and monovalent affinity values of anti-HLA-G antibodies for the recombinant HLA-G protein. For the data in FIG. 1 R ² value >0.98. BUT. = undefined when using Fab. K _D values for avidity ranged from 11.7 nM to sub-picomolar with dissociation rates (k _off ) ranging from 0.007 s ^-1 to the Octet dissociation rate limit (1.0 × 10 -7 s ^-1 ). Monovalent KD values ranged from 0.187 nM to 208 nM, but monovalent affinity values for clones with lower avidity were not determined.

Example 4: Antibodies that bind to HLA-G and are sorted separately from other antibodies

[00432] Recombinant HLA-G heterotrimer binding during epitope binning was determined using the Octet Red96 system (Pall ForteBio) at 30°C in running buffer (1× Pall ForteBio Kinetics Buffer, diluted in 1× PBS, pH 7.4). Briefly, 0.16 μg/mL biotinylated recombinant HLA-G/β2m/peptide heterotrimer was loaded onto streptavidin (SA) biosensors to a binding reaction of approximately 0.25 nm. After a short baseline step in running buffer, the biosensor was immersed in 20 μg/mL of each mAb and allowed to saturate the HLA-G binding reaction. For the competitive binding step, concentrations of each mAb equimolar to the saturating mAb concentrations were used.

[00433] Epitope binning was performed in all directions (each mAb was used as both a saturating mAb (binding step 1) and a competing mAb (binding step 2)). Sensograms reflecting auto-blocking are shown in gray. Sensograms without auto-blocking are shown in black; black sensorgrams correspond to pairwise mAb binning. Sensograms only for the second stage of binding are shown in Fig. 2.

[00434] In FIG. 2A shows sensorgrams obtained by biolayer interferometry, showing that the tested antibodies that bind HLA-G can be divided into three different chemical groups, one of which can be further divided. Gray sensorgrams indicate autoblocking; black sensorgrams indicate pairwise binning. The Y-axis indicates the amount of saturating antibody; The X-axis indicates the amount of competing antibody.

[00435] In FIG. Figure 2B shows biolayer sensograms for antibodies (Fabs) that bind HLA-G and can be divided into two subgroups of the broader group 1. Group 1a Fabs do not block competing Group 1b Fabs. However, group 1b Fabs block group 1a Fabs. As described above, gray sensorgrams indicate auto-blocking, and black sensorgrams indicate pairwise binning. The Y axis corresponds to the saturating Fab, and the X axis corresponds to the competing Fab.

Example 5: Antibodies against HLA-G that block the interaction/binding of HLA-G with recombinant ILT2 and ILT4

[00436] Binding block assays for recombinant HLA-G heterotrimer and recombinant extracellular domain proteins ILT2 or ILT4 were performed using the Octet Red96 system (Pall ForteBio) at 30°C in running buffer (1× Pall ForteBio Kinetics Buffer, diluted in 1× PBS, pH 7.4). Briefly, 0.16 μg/mL biotinylated recombinant HLA-G/β2m/peptide heterotrimer was loaded onto streptavidin (SA) biosensors to a binding reaction of approximately 0.25 nm. After a short baseline run in running buffer, the biosensor was immersed in a solution of each mAb at a concentration of at least 200 nM (up to 0.5 μM for weakly binding mAbs) and allowed to saturate the HLA-G binding reaction. Immediately after this, a second coupling step was performed by dipping into wells containing dimerized ILT2 or ILT4. Dimers were prepared by preincubating His-tagged ILT2 or ILT4 with anti-His mAb (MAB050, R&D Systems). The binding response of ILT2/ILT4 with saturated HLA-G mAb (black sensograms) was compared with HLA-G binding in the absence of anti-HLA-G mAb (gray sensograms).

[00437] Sensograms from the second binding step are shown in FIG. 3. The given sensograms correspond to antibodies that bind and completely block the interaction of HLA-G with ILT2 and ILT4, for example, group la and group 1b antibodies 38381 and 38358, respectively. As indicated, gray sensograms correspond to ILT2 or ILT4 binding in the absence of antibody; Black sensorgrams correspond to ILT2 or ILT4 binding in the presence of antibody.

[00438] In FIG. 3 also shows sensorgrams obtained by biolayer interferometry for antibodies that bind but do not block the interaction of HLA-G with ILT2 or ILT4, for example, group 3 antibodies, such as 33357. Sensograms in gray correspond to the binding reaction of ILT2 or ILT4 in the absence of the antibody; Black sensorgrams correspond to ILT2 or ILT4 binding in the presence of antibody.

[00439] Also shown in the sensorgrams are antibodies that bind and block the interaction of HLA-G with ILT2 or ILT4 with intermediate effect, such as group 2 antibody 38389.

Example 6: Anti-HLA-G Antibodies Bind to HLA-G Naturally Expressed on JEG-3 Cells

[00440] Parental JEG-3 cells or HLA-G knockout cells (JEG-3 KO) were incubated with 100 nM anti-HLA-G antibodies for 2 hours at 4°C in wash buffer (phosphate buffered saline (PBS), 2% fetal bovine serum (FBS) and 2 mM EDTA). Cells were then washed in wash buffer and incubated with AFC-conjugated secondary antibody (goat anti-human IgG kappa chain) at a dilution of 1:500 in wash buffer for 30 min at 4°C. Cells were then washed and resuspended in 1% paraformaldehyde/wash buffer, followed by sample collection using a BD Fortessa X-20 flow cytometer (Becton Dickinson). Sample data were exported as FCS files and analyzed using FlowJo v10 software (Tree Star, Inc.).

[00441] The results are shown in FIG. 4. The shaded histogram represents the binding of the isotype control to JEG-3 cells at the same concentration.

Example 7: Antibodies against HLA-G neutralize suppression mediated by interaction of HLA-G with ILT2 or ILT4 in an NKL killing assay

[00442] Antibodies against HLA-G neutralize the inhibition of NKL cytotoxicity through ILT2-HLA-G or ILT4-HLA-G interaction. NKL cells (effector cells) were co-incubated with 721.221 cells (target cells) expressing or not expressing (+/-) HLA-G at an E:T ratio of 4:1 overnight at 37°C. 721.221 cells were preincubated with Fab fragments or full-length intact anti-HLA-G antibodies at a nanomolar concentration (200 nM) for 60 minutes at 37°C. Before antibody pretreatment, 721.221 cells were labeled with 1:1000 CellTrace Violet (CTV) (Invitrogen) in PBS at 37°C.

[00443] After overnight co-incubation, cells were washed once in 4°C wash buffer (phosphate buffered saline, 2% FBS, 2 mM EDTA) and then stained with 1:2000 irreversible viability dye Fixable Viability Dye eFluor ™ 780 (Invitrogen) for 30 minutes at 4°C. Cells were washed again in wash buffer at 4°C, resuspended in wash buffer, and % 721.221 cell death was analyzed by flow cytometric analysis on a BD Celesta flow cytometer. The percentage of dead 721,221 cells was determined by gating on CTV-positive cells and then dividing the Fixable Viability Dye-positive portion of these cells by the total number of CTV-positive cells.

[00444] Antibody MEM-G/9 is a commercially available antibody (cm. source: Fournel et al., Tissue Antigens 200: 55: 510-518 (1999), which is incorporated by reference herein in its entirety, with all drawings).

[00445] In FIG. 5A (Fab fragments) and FIG. 5B (intact IgG) shows the effect on NKL cells endogenously expressing ILT2. For each antibody, the percentage of dead cells (indicated in the figures as a unique clone number) is shown along with control values corresponding to minimum and maximum killing in the presence and absence of HLA-G, respectively. As can be seen in FIG. 5, Group 1 antibodies demonstrated the best blockade of the antibodies tested.

[00446] In FIG. 5C demonstrates dose-dependent blockade of HLA-G-mediated suppression of NKL killing by endogenously expressed ILT2 for a specific anti-HLA-G Group 1 Fab.

[00447] In FIG. 5D demonstrates dose-dependent blockade of HLA-G-mediated suppression of NKL killing by engineered ILT4 expression (an engineered cell line modified by ILT2 knockout and retroviral transduction to express ILT4) for a specific anti-HLA-G Group 1 Fab fragment.

Example 8: Anti-HLA-G Fab Fragments Reverse HLA-G-Mediated Suppression of Macrophage Phagocytosis, NK Cell Cytotoxicity, and CD8 ⁺ T Cell Activity

[00448] The CD14 ⁺ cell-enriched population was differentiated into adherent macrophages by incubation at 37°C with 5% CO ₂ for 7 days in complete RPMI medium (cRPMI) with recombinant human M-CSF. Cells were harvested after 7 days, washed, and resuspended in cRPMI. Cells were seeded into a 96-well round bottom plate at a density of 50,000 cells/well in 50 μl cRPMI and incubated at 37°C, 5% CO ₂ before combining with target cells.

[00449] Target cells consisting of either 721.221 parent cells or 721.221-HLA-G cells were stained with CTV (1:1000) at 37°C in PBS, washed and plated in cRPMI at a density of 25,000 cells per well. Cells were then incubated with anti-CD47 antibody in the presence or absence of anti-HLA-G Fab for 1 hour at 37°C with 5% CO ₂ . The 721.221 and antibody mixture was then combined with macrophages and incubated either for 2 hours or overnight at 37°C with 5% CO ₂ . The final ratio of macrophages to target cells 721.221 was 2:1. After 2 hours or overnight incubation, cells were blocked with wash buffer/BD Fc Block™/2% mouse serum for 20 minutes and then stained with anti-CD11b and live/dead dye for 20 minutes. Cells were then washed, resuspended in wash buffer, and analyzed on a BD Fortessa flow cytometer. Sample data were exported as FCS files and analyzed using FlowJo v10 software.

[00450] In a 2-hour assay format, macrophages were assayed for the presence of CTV as an indicator of phagocyte uptake of target CTV ⁺ cells. Live cells were gated for CD11b ⁺ /CTV ⁺ and their number was reported as a percentage of the total number of living macrophages. The overnight assay assessed macrophage killing activity by measuring the absolute number of remaining live CTV ⁺ cells per well.

[00451] In FIG. 6A compares 2-hour and overnight assay results using anti-HLA-G (Fab) antibody. The overnight assay produced similar results to the 2-hour assay with direct measurement of phagocytosis of target cells. In fig. 6B shows the results for Fab fragments of each anti-HLA-G antibody that were tested in an overnight assay to determine the level of restored phagocytic activity.

[00452] To demonstrate that anti-HLA-G antibody neutralizes the inhibition of cytotoxicity of primary human NK cells, HLA-G-expressing target cells (721.221-HLA-G) were preincubated with a representative Group 1 antibody (Fab fragment) and then co-cultured with primary (effector) human NK cells from 3 different donors at an E:T ratio of 4:1 overnight at 37°C. Before antibody pretreatment, 721.221 cells were labeled with 1:1000 CellTrace Violet (CTV) (Invitrogen) in PBS at 37°C.

[00453] After overnight co-incubation, cells were washed once in 4°C wash buffer (phosphate buffered saline, 2% FBS, 2 mM EDTA) and then stained and then stained with 1:2000 irreversible Fixable viability dye Viability Dye eFluor 780 (Invitrogen) for 30 minutes at 4°C. Cells were washed, resuspended in wash buffer, and % 721.221 cell dead was analyzed by flow cytometric analysis on a BD Celesta flow cytometer. The percentage of dead 721,221 cells was determined by gating on CTV-positive cells and then dividing the Fixable Viability Dye-positive portion of these cells by the total number of CTV-positive cells.

[00454] The results are shown in FIG. 6C. The percentage of dead target cells for Group 1 antibody (Fab) is shown along with control values corresponding to co-cultures of 721.221 target cells expressing and not expressing HLA-G (denoted in the figures as “HLA-G” and “non-HLA-G”, respectively . ). Isotype control Fab (Ctrl Fab) was used as a negative control.

[00455] To demonstrate anti-HLA-G antibody reversal of HLA-G-mediated suppression of cytotoxic function of primary CD8 ⁺ T cells, human CD8 ⁺ T cells treated with CD3/CD28 activator (ImmunoCultTM, Stem Cell Technologies) were mixed for 1 hour with antibody-pretreated 721.221 cells (HLA-G expressing and non-expressing) and co-cultured overnight at 37°C. After overnight co-incubation, monensin solution (ThermoFisher) and eFluor 450-CD107a (ThermoFisher) were added; the final amount of each reagent was 0.5 μg/ml for antibody and 2 μM for monensin. The assay mixture was incubated for 4 hours.

[00456] After incubation, cells were washed and stained in several steps, including the following: (1) live/dead cell staining using Fixable Viability Dye eFluor 780 (ThermoFisher); (2) Fc blocking with staining buffer (phosphate buffered saline, 2% FBS, 2 mM EDTA) containing 6% normal mouse serum and 5 μl of Human TruStain FcX™ Fc blocker per sample (Biolegend), for 15 minutes at 4°C; (3) CD8 and ILT2 staining with Alexa Fluor 700-CD8 (Biolegend, clone SK1) and PE-CD85j/ILT2 (Biolegend, clone HP-F1, ThermoFisher); fixation and permeabilization using fixation/permeabilization reagent (ThermoFisher); (5) intracellular staining with Brilliant Violet 711-conjugated anti-IFN-γ antibody (Biolegend, clone 4S.B3) and AFC-conjugated anti-TNF-α antibody (Biolegend, clone MAb11), diluted in permeabilization buffer (ThermoFisher) for 20 minutes at 4°C. Following the staining steps, cells were washed, centrifuged, and resuspended in staining buffer, followed by sample collection on a BD Fortessa X-20 flow cytometer using a high-throughput sampler.

[00457] FCS data was analyzed using FlowJo analysis software version 10 (FlowJo, LLC). Gates were set to select single cells, live cells, and cell types of interest. CD8 ⁺ T cell populations were defined based on CD8 ⁺ ILT2 ⁺ or CD8 ⁺ ILT2 ⁻ . To determine the percentage of cells positive for CD107a, IFN-γ, or TNF-α, all CD8 ⁺ T cell populations were gated and determined using cells with all but one fluorescent detectable label and unstimulated cells.

[00458] The results shown in FIG. 6D demonstrate that blockade of HLA-G with an anti-HLA-G antibody (a representative clone of Group 1) restored the expression of CD107a, IFN-γ, and TNF-α in CD8 ⁺ ILT2 ⁺ T cells in a dose-dependent manner. There was no effect of HLA-G expression on target cells or anti-HLA-G antibody treatment on CD8 ⁺ ILT2 ⁻ cells (data not shown).

Example 9: Anti-HLA-G antibodies that selectively bind HLA-G and do not bind to classical HLA class I antigens

[00459] Antibody binding to HLA antigens (97 different antigens spanning haplotypes HLA-A, -B, and -C) was determined using a combination HLA class I LABScreen Single Antigen (One Lambda) screening assay. Antibodies at concentrations greater than 300 nM were incubated with single antigen-coated LABScreen beads in binding buffer (phosphate buffered saline, 10% FBS, 2 mM EDTA) for 45 minutes in the dark at room temperature with gentle shaking. The beads were washed twice with 200 μl of 1X LABScreen wash buffer in a 96-well V-bottom plate by centrifugation at 1500 g and removal of the buffer by aspiration. The beads were then incubated with PE-conjugated secondary antibodies (goat anti-human or anti-mouse polyclonal antibody in 1X wash buffer) for 30 minutes at room temperature in the dark with gentle shaking. After incubation, the beads were washed twice, resuspended in 90 μl of wash buffer, and then transferred to a 96-well flat-bottom plate. Capture was performed on a Luminex 100 instrument and the data was output as a CSV file. The results based on the average fluorescent intensity values for all individual groups of HLA antigen beads were tabulated.

[00460] Antibody 87G is a commercially available antibody and is a blocking antibody (See Odum et al., Eur . J. Immunol. 22: 2121-2131 (1991) and Lee et al., Immunity, 591-600 Volume 3, Issue 5 (1995), each of which is incorporated by reference herein in its entirety, with all drawings).

[00461] The results are shown in FIG. 7. Binding values (average fluorescence signal) to each individual HLA antigen for each anti-HLA-G antibody are shown.

Example 10: Antibodies against HLA-G that do not bind to classical HLA class antigens expressed at physiological levels on B-LCL cells

[00462] Antibody binding to native HLA class Ia proteins at physiological levels was assessed by flow cytometry in a population of 28 B-LCL cell lines (shown in Table X). Cells were obtained from the International Histocompatibility Working Group cell collection, which includes a pool of B-LCL cell lines that have been HLA-typed. Cells were maintained in supplemented RPMI-1640 medium containing 15% fetal bovine serum.

[00463] For antibody binding, anti-HLA antibodies were first conjugated to DyLight 650 (Thermo Fisher) by tagging primary amines through the NHS ester moiety. Unconjugated dye was removed by passing the antibody formulation through a resin to remove the dye. Conjugation efficiency ranged from 1 to 3 moles of DyLight 650 per mole of antibody. B-LCL cells (ranging from 10,000 to 100,000 cells per well) were incubated with 300 nM labeled antibodies in cold PBS containing 10% FBS and human Fc blocker (BD Biosciences). After 2 hours at 4°C, cells were washed twice in cold wash buffer (phosphate buffered saline, 2% FBS, 2 mM EDTA) followed by sample collection with a BD FACS Celesta instrument. To assess overall HLA class I expression, anti-HLA class I antibody clone W6/32 conjugated to FITC was incubated separately with each individual cell line. All cell lines were strongly positive for class I expression (data not shown). Data were exported as FCS files and analyzed using FlowJo v10 software. Gating was performed on live singlet cells using DAPI to distinguish live/dead cells. The geometric mean MFI is shown for each B-LCL cell line.

Table X

IHW ID Alternate ID Floor Ethnicity/Population Group Use in IHW HLA A* HLA B* HLA Cw* IHW09367 LCK Asians 13 0203 1102 4601 380201 0702 1202 IHW09458 FH70EY M 13 3002 6802 0801 5301 0401 07 IHW09383 FH9 M Other 13 2402 3303 4801 44032 0801 0701 IHW09397 DUG150 Unknown 13 02 680101 5802 4501 0602 1601 IHW09057 TEM M Jews 10, 12 6601 3801 1203 IHW09010 A.M.A. M Algerians 10, 12 6802 5301 0401 IHW09436 FH48 M White Caucasians 13 2402 0201 4427 070201 070201 0704 IHW01167 1413-1090 M White Caucasians CEPH 680102 0201 0801 4402 0701 0501 IHW01075 1344-8354 AND White Caucasians CEPH 2402 0301 4001 5101 030401 0102 IHW01185 1416-1337 M White Caucasians CEPH 0205 2501 4901 4402 0701 0501 IHW09431 FH43 M African Americans 13 3001 3301 5301 8101 04 08 IHW01124 1362-8563 M White Caucasians CEPH 0201 2902 3501 4403 0401 1601 IHW01133 1362-8572 AND White Caucasians CEPH 2902 2601 4403 4402 1601 0501 IHW01092 1346-8603 M White Caucasians CEPH 0201 1101 0702 3501 0702 0401 IHW09371 ISH4 Asians 13 0218 1101 1501 4601 0102 040101 IHW09433 FH45 M Asians 13 1101 02 3802 4101 0702 17 IHW09380 FH6 M Latin Americans 13 2402 2901 2702 0705 1505 020202 IHW09411 FH29 AND Latin Americans 13 0201 2902 1516 440301 1402 1601 IHW09401 TER-259 White/American Indian, USA 13 3201 6802 0801 44020101 0102 07 IHW09398 FH18 AND African Americans 13 3601 7401 5301 5703 0401 0701 IHW09382 FH8 AND African Americans 13 110101 3402 8201 270502 0302 0102 IHW01026 1332-8257 AND White Caucasians CEPH 0301 3001 3501 0702 0401 0702 IHW09409 FH27 M Native Americans 13 310102 3401 350101 380201 0401 0702 IHW09452 FH64 Unknown 13 02 3201 44 1801 05 07 IHW01028 1332-8259 AND White Caucasians CEPH 0301 0301 3501 2705 0401 020202 IHW01061 1341-8465 AND White Caucasians CEPH 0201 680102 0702 0702 0702 0702 IHW01099 1347-8434 M White Caucasians CEPH 2501 0101 0801 1501 0701 0602 IHW01136 1362-8575 M White Caucasians CEPH 0101 1101 0702 5101 0702 1502

[00464] The results are shown in FIG. 8. Binding levels are presented as geometric mean fluorescence intensities. Cells of the class I negative cell line 721.221, expressing or not expressing HLA-G, were used as controls.

Example 11: Critical HLA-G Amino Acid Determinants Required for Anti-HLA-G Antibody Binding

[00465] LCL 721.221 cells transiently expressing various HLA-G point mutants were generated using the ^Neon® Transfection System (ThermoFisher Scientific). Cells were transfected with 1 μg of plasmid per point mutation in a 10 μl reaction format. Cells were cultured for 72 hours before staining with anti-HLA-G antibodies.

[00466] LCL 721.221 cells (expressing various point mutants or a domain swap variant where the primary amino acid sequence encoding the alpha 3 domain was replaced with the same sequence from HLA-A*1101) were incubated with each antibody (100 nM) at wash buffer (phosphate buffered saline, 2% FBS, 2 mM EDTA) for 60 minutes at 4 °C. Cells were then washed with cold wash buffer and incubated with fluorescently labeled secondary antibody at 4°C for 30 minutes. Numbered antibodies were incubated with 1:500 R-phycoerythrin-labeled goat anti-human IgG antibody (Jackson ImmunoResearch). W6/32 was incubated with 1:500 Alexa Fluor 488 goat anti-mouse IgG antibody (Jackson ImmunoResearch). MEMG/9 (Invitrogen) was preconjugated to allophycocyanin. After incubation with the secondary antibody, cells were washed and resuspended in cold wash buffer before analysis by flow cytometry on a BD Celesta instrument. Sample data were exported as FCS files and analyzed using FlowJo v10 software. As shown in FIG. 9, mutation of residues 195, 197 and/or 198 results in loss of binding by anti-HLA-G group 1 antibodies, indicating that these residues are critically important, although it is unlikely that they represent the sole determinants for group 1 antibody binding. Interestingly, the biochemical group defined in Octet as group 1a (Figure 2B) can be further subdivided based on either sensitivity to mutation of residue 197 (e.g., 38379) or mutation of residue 198 (e.g., 38410)

[00467] In FIG. 9A shows an assessment of the binding of anti-HLA-G antibodies to various forms of HLA-G after site-directed mutagenesis. In fig. 9B shows representative histograms for antibody binding to each of the three point mutants (P195S, Y197A, Y197H, E198A).

Example 12: Tumor growth inhibition by anti-HLA-G antibody with and without effector function in a xenograft mouse model using HLA-G-expressing 721.221 cells

[00468] NOD/SCID mice were implanted subcutaneously in the right flank with 10 million HLA-G expressing 721.221 cells in Matrigel. On day 29 postimplantation, mice were randomly assigned to groups based on tumor volume and dosed intraperitoneally with 300 μg of either effector-competent anti-human HLA-G IgG1 antibody (hIgG1 WT) or the same anti-HLA-G antibody with Fc domain mutations , neutralizing interactions with the Fc receptor (hIgG1_AAA), or were left without treatment. The second dose of antibody was administered three days later. The data presented in Fig. 10 show the percentage change in tumor volume six days after initial treatment. These results demonstrate that anti-HLA-G antibody can inhibit the growth of tumors expressing HLA-G by engaging Fc receptor-dependent effector mechanisms, which may include antibody-dependent cellular cytotoxicity (ADCC) or phagocytosis (ADCP).

Example S: Sequences

[00469] Table S lists the sequences mentioned herein.

Table S. Sequences.

SEQ ID NO: Region Scheme/Clone Subsequence 1 CDR-H1 Chothia GGSISSSDY 2 CDR-H1 Chothia GGSISSSST 3 CDR-H1 Chothia GGSISSSDT 4 CDR-H1 Chothia GGSISSADN 5 CDR-H1 Chothia GGSVSSSST 6 CDR-H1 Chothia GYSISSGY 7 CDR-H1 Chothia GYSILSGY 8 CDR-H1 Chothia GYSISSGH 9 CDR-H1 Chothia GYSISSGF 10 CDR-H1 Chothia GFTFDNY eleven CDR-H1 Chothia GFTFSDY 12 CDR-H1 Chothia GFTFSSS 13 CDR-H1 Chothia GGSISSSN 14 CDR-H1 Chothia GGSISSSSY 15 16 17 18 CDR-H1 Kabat SSDYYWG 19 CDR-H1 Kabat SSSTYWA 20 CDR-H1 Kabat SSSTYWG 21 CDR-H1 Kabat SSDTYWG 22 CDR-H1 Kabat SADNYWG 23 CDR-H1 Kabat SSSTYWS 24 CDR-H1 Kabat SGYYWG 25 CDR-H1 Kabat SGYYWF 26 CDR-H1 Kabat SGHYWI 27 CDR-H1 Kabat SGFYWT 28 CDR-H1 Kabat SGYYWL 29 CDR-H1 Kabat SGHYWT thirty CDR-H1 Kabat NYAMH 31 CDR-H1 Kabat DYYMS 32 CDR-H1 Kabat SSAMA 33 CDR-H1 Kabat SSNWWS 34 CDR-H1 Kabat SSSYYWG 35 36 37 38 CDR-H2 Chothia YYSGS 39 CDR-H2 Chothia SSSGS 40 CDR-H2 Chothia HHSGA 41 CDR-H2 Chothia HYSGS 42 CDR-H2 Chothia AYSGS 43 CDR-H2 Chothia SYNAL 44 CDR-H2 Chothia YHSGS 45 CDR-H2 Chothia YHSAS 46 CDR-H2 Chothia SARAGI 47 CDR-H2 Chothia ASSGSV 48 CDR-H2 Chothia SGSGIT 49 CDR-H2 Chothia SYSGS 50 CDR-H2 Chothia SSSGST 51 52 53 54 CDR-H2 Kabat SIYYSGSTYYNPSLKS 55 CDR-H2 Kabat SISSSGSTYYNPSLKS 56 CDR-H2 Kabat SIHHSGATYYNPSLKS 57 CDR-H2 Kabat SIHYSGSTLYNPSLKS 58 CDR-H2 Kabat SIHYSGSTYYNPSLKS 59 CDR-H2 Kabat GIAYSGSTYYNPSLKS 60 CDR-H2 Kabat SISYNALTYYNPSLKS 61 CDR-H2 Kabat SIYHSGSTYYNPSLKS 62 CDR-H2 Kabat GIYHSASTAYNPSLKS 63 CDR-H2 Kabat GIYHSGSTYYNPSLKS 64 CDR-H2 Kabat AIYHSGSTVYNPSLKS 65 CDR-H2 Kabat GIYHSGSTAYNPSLKS 66 CDR-H2 Kabat AISARAGITYYADSVKG 67 CDR-H2 Kabat YIASSGSVIYYADSVKG 68 CDR-H2 Kabat TISGSGITTWYADSVKG 69 CDR-H2 Kabat EIYHSGSTNYNPSLKS 70 CDR-H2 Kabat SISYSGSTYYNPSLKS 71 CDR-H2 Kabat YISSSGSTIYYADSVKG 72 73 74 75 76 CDR-H3 GVRRAVPFDY 77 CDR-H3 GIARAVPFDY 78 CDR-H3 GPKRAVPFDY 79 CDR-H3 GVRRAVPFVD 80 CDR-H3 GVRRAVPFQR 81 CDR-H3 GTRRAVPFDY 82 CDR-H3 GVRRAVPFAD 83 CDR-H3 GIRRAVPFDY 84 CDR-H3 GQFRAVPFDY 85 CDR-H3 GGTHTYSRGPMDV 86 CDR-H3 GGTHTYSRGPDFDV 87 CDR-H3 GGTPIYSRGPLDV 88 CDR-H3 GGGQTYSRGPLDV 89 CDR-H3 GGGATYSRGPLDV 90 CDR-H3 GGTHTYSRGPLDV 91 CDR-H3 GGTVKYSRGPLDV 92 CDR-H3 GGQVTYSRGPLDV 93 CDR-H3 GGEVTYSRGPLDV 94 CDR-H3 RIGYSYGTAPPFDV 95 CDR-H3 HGTPRADFDI 96 CDR-H3 GSRHLNAFNR 97 CDR-H3 GVYHYDPYGMDV 98 CDR-H3 TELGKMHFDY 99 CDR-H3 GSPRYMQD 100 CDR-H3 HSSLGTHNWFDP 101 CDR-H3 EGALSYSWLAAFDI 102 103 104 105 CDR-L1 RASQSVSSSYLA 106 CDR-L1 GASQSVSSDYLA 107 CDR-L1 QASQAVSSNYLA 108 CDR-L1 GASQSVSSAFLA 109 CDR-L1 RASQSVSSTYLA 110 CDR-L1 QASQSVSSSYLA 111 CDR-L1 KASQAVSSSYLA 112 CDR-L1 EASQSVSSSYLA 113 CDR-L1 EASQSVSASYLA 114 CDR-L1 EASQSVSSAYLA 115 CDR-L1 RVSQSVSDAYLA 116 CDR-L1 EVSQSVSASYLA 117 CDR-L1 RASQSVSSAYLA 118 CDR-L1 RASNAVSSSYLA 119 CDR-L1 RASQSINSWLA 120 CDR-L1 AASQGISSDLA 121 CDR-L1 RASQDISTYLN 122 CDR-L1 RSSQSLLHSNGYNYLD 123 CDR-L1 RASQSISSYLN 124 CDR-L1 RASQSVSSNLA 125 126 127 128 CDR-L2 GASSRAT 129 CDR-L2 GAYSLAT 130 CDR-L2 GASARAT 131 CDR-L2 GASSREA 132 CDR-L2 GASNRAA 133 CDR-L2 GASSRQD 134 CDR-L2 GASNRAT 135 CDR-L2 DASSRAS 136 CDR-L2 DASTRAT 137 CDR-L2 GASDRAN 138 CDR-L2 GASYRAT 139 CDR-L2 DASSLES 140 CDR-L2 SASSTQS 141 CDR-L2 DAFNLET 142 CDR-L2 LGSNRAS 143 CDR-L2 GASRRAT 144 CDR-L2 AASSLQS 145 CDR-L2 GASTRAT 146 147 148 149 CDR-L3 QQAVHSPYT 150 CDR-L3 QWAVHSPYT 151 CDR-L3 QQVVHSPYT 152 CDR-L3 QQTVHSPYT 153 CDR-L3 QQAIHSPYT 154 CDR-L3 QQHSSYPPT 155 CDR-L3 QQHSLYPPT 156 CDR-L3 QQFSSYPPT 157 CDR-L3 QQVSSYPPT 158 CDR-L3 QQHSIYPPT 159 CDR-L3 QQYDSHIT 160 CDR-L3 QQAYLYPIT 161 CDR-L3 QQLPFLPIT 162 CDR-L3 MQALGGPWT 163 CDR-L3 QQYVSDPIT 164 CDR-L3 QQVGSSPIT 165 CDR-L3 QQSHLVPRT 166 CDR-L3 QQANHHPPFT 167 168 169 170 VH QLQLQESGPGLVKPSETLSLTCTVSGGSISSSDYYWGWIRQPPGKGLEWIGSIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGVRRAVPFDYWGQGTLVTVSS 171 VH QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSTYWAWIRQPPGKGLEWIGSISSSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGIARAVPFDYWGQGTLVTVSS 172 VH QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSTYWGWIRQSPGKGLEWIGSIHHSGATYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGPKRAVPFDYWGQGTLVTVSS 173 VH QLQLQESGPGLVKPSETLSLTCTVSGGSISSSDTYWGWIRQPPGKGLEWIGSIHYSGSTLYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGVRRAVPFVDWGQGTLVTVSS 174 VH QLQLQESGPGLVKPSETLSLTCTVSGGSISSADNYWGWIRQPPGKGLEWIGSIHYSGSTYYNPSLKSRVTISVDTSKNTQFSLKLSSVTAADTAVYYCARGVRRAVPFQRWGQGTLVTVSS 175 VH QLQLQESGPGLVKPSETLSLTCTVSGGSISSSDTYWGWIRQPPGKGPEWIGSIHYSGSTLYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGVRRAVPFDYWGQGTLVTVSS 176 VH QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSTYWSWIRQPPGKGLEWIGGIAYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGVRRAVPFDYWGQGTLVTVSS 177 VH QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSTYWSWIRQPPGKGLEWIGSISYNALTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGTRRAVPFDYWGQGTLVTVSS 178 VH QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSTYWSWIRQPPGKGLEWIGGIAYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGVRRAVPFADWGQGTLVTVSS 179 VH QLQLQESGPGLVKPSETLSLTCTVSGGSVSSSSTYWSWIRQPPGKGLEWIGGIAYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGVRRAVPFDYWGQGTLVTVSS 180 VH QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSTYWSWIRQPPGKGLEWIGGIAYSGSTYYNPSLKSRVTISVDTSICNQFSLKLSSVTAADTAVYYCARGTRRAVPFDYWGQGTLVTVSS 181 VH QLQLQESGPGLVKPSETLSLTCTVSGGSISSSDTYWGWIRQPPGKGLEWIGSIHYSGSTLYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGIRRAVPFDYWGQGTLVTVSS 182 VH 183 VH QVQLQESGPGLVKPSETLSLTCAVSGYSISSGYYWGWIRQPPGKGLEWIGSIYHSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGGTHTYSRGPMDVWGQGTTVTVSS 184 VH QLQLQESGPRLVKPSETLSLTCAVSGYSISSGYYWGWIRQPPGKGLEWIGSIYHSGSTYYNPSLKSRVTISVDTS1CNQFSLKLSSVTAADTAVYYCARGGTHTYSRGPFDVWGQGTTVTVSS 185 VH LVQLQESGPGLVKPSETLSLTCAVSGYSILSGYYWFWIRQPPGKGLEWIGGIYHSASTAYNPSLKSRVTISVDTSICNQFSLKLSSVTAADTAVYYCARGGTPIYSRGPLDVWGQGTTVTVSS 186 VH QVQLQESGPGLVKPSETLSLTCAVSGYSISSGHYWIWIRQPPGKGLEWIGGIYHSGSTYYNPSLKSRVTISVDTSKDQFSLKLSSVTAADTAVYYCARGGGQTYSRGPLDVWGQGTTVTVSS 187 VH QVQLQESGPGLVKPPETLSLTCAVSGYSISSGHYWIWIRQPPGKGLEWIGGIYHSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGGGATYSRGPLDVWGQGTTVTVSS 188 VH QVQLQESGPGLVKPSETLSLTCAVSGYSILSGYYWFWIRQPPGKGLEWIGGIYHSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGGTHTYSRGPLDVWGQGTTVTVSS 189 VH QVQLQESGPGLVKPSETLSLTCAVSGYSISSGFYWTWIRQPPGKGLEWIGAIYHSGSTVYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGGTHTYSRGPLDVWGQGTTVTVSS 190 VH QVQLQESGPGLVKPSETLSLTCAVSGYSISSGYYWLWIRQPPGKGLEWIGGIYHSASTAYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGGTVKYSRGPLDVWGQGTTVTVSS 191 VH QVQLQESGPGLVKPSETLSLTCAVSGYSISSGHYWTWIRQPPGKGLEWIGAIYHSGSTVYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGGQVTYSRGPLDVWGQGTTVTVSS 192 VH QVQLQESGPGLVKPSETLSLTCAVSGYSILSGYYWFWIRQPPGKGLEWIGGIYHSGSTAYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGGEVTYSRGPLDVWGQGTTVTVSS 193 VH EVQLLESGGGLVQPGGSLRLSCAASGFTFDNYAMHWVRQAPGKGLEWVSAISARAGITYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRIGYSYGTAPPFDVWGQGTTVTVSS 194 VH QVQLVESGGGLVQPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYIASSGSVIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARHGTPRAFDIWGQGTTVTVSS 195 VH EVQLLESGGGLVQPGGSLRLSCAASGFTFSSSAMAWVRQAPGKGLEWVSTISGSGITTWYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGSRHLNAFNRWGQGTTVTVSS 196 VH QVQLQESGPGLVKPSGTLSLTCAVSGGSISSSNWWSWVRQPPGKGLEWIGEIYHSGSTNYNPSLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCARGVYHYDPYGMDVWGQGTTVTVSS 197 VH QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSYYWGWIRQPPGKGLEWIGSISYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARTELGKMHFDYWGQGTLVTVSS 198 VH QLQLQESGPGLVKPSETLSLTCTVSGGSISSSDYYWGWIRQPPGKGLEWIGSIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGSPRYMQDWGQGTLVTVSS 199 VH QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNAICNSLYLQMNSLRAEDTAVYYCARHSSLGTHNWFDPWGQGTLVTVSS 200 VH QVQLQESGPGLVKPSETLSLTCAVSGYSISSGYYWGWIRQPPGKGLEWIGSIYHSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREGALSYSWLAAFDIWGQGTMVTVSS 201 202 203 204 V _L EIVLTQSPGTLLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQAVHSPYTFGGGTKVEIK 205 V _L EIVLTQSPGTLLSLPGERATLSCGASQSVSSDYLAWYQQKPGQAPRLLIYGAYSLATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQWAVHSPYTFGGGTKVEIK 206 V _L EIVLTQSPGTLSLSPGERATLSCQASQAVSSNYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQVVHSPYTFGGGTKVEIK 207 V _L EIVLTQSPGTLLSLSPGERATLSCGASQSVSSAFLAWYQQKPGQAPRLLIYGASARATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQVVHSPYTFGGGTKVEIK 208 V _L EIVLTQSPGTLLSLSPGERATLSCRASQSVSSTYLAWYQQKPGQAPRLLIYGASSREAGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQTVHSPYTFGGGTKVEIK 209 V _L EIVLTQSPGTLSLSPGERATLSCQASQAVSSNYLAWYQQKPGQAPRLLIYGASNRAAGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQAIHSPYTFGGGTKVEIK 210 V _L EIVLTQSPGTLSLSPGERATLSCQASQSVSSSYLAWYQQKPGQAPRLLIYGASNRAAGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQVVHSPYTFGGGTKVEIK 211 V _L EIVLTQSPGTLLSLPGERATLSCKASQAVSSSYLAWYQQKPGQAPRLLIYGASSRQDGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQVVHSPYTFGGGTKVEIK 212 V _L EIVLTQSPGTLLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQHSSYPPTFGGGTKVEIK 213 V _L EIVLTQSPGTLLSLSPGERATLSCEASQSVSSSYLAWYQQKPGQAPRLLIYGASNRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQHSLYPPTFGGGTKVEIK 214 V _L EIVLTQSPGTLLSLSPGERATLSCEASQSVSASYLAWYQQKPGQAPRLLIYDASSRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFSSYPPTFGGGTKVEIK 215 V _L EIVLTQSPGTLLSLSPGERATLSCEASQSVSSAYLAWYQQKPGQAPRLLIYDASTRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQVSSYPPTFGGGTKVEIK 216 V _L EIVLTQSPGTLSLSPGERAALSCRVSQSVSDAYLAWYQQKPGQAPRLLIYDASSRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQVSSYPPTFGGGTKVEIK 217 V _L EIVLTQSPGTLSLSPGERATLSCEVSQSVSASYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQHSLYPPTFGGGTKVEIK 218 V _L EIVLTQSPGTLLSLSPGERATLSCRASQSVSSAYLAWYQQKPGQAPRLLIYGASDRANGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQHSLYPPTFGGGTKVEIK 219 V _L EIVLTQSPGTLSLSPGERATLSCRASNAVSSSYLAWYQQKPGQAPRLLIYGASDRANGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQHSIYPPTFGGGTKVEIK 220 V _L EIVLTQSPGTLSLSPGERATLSCRASNAVSSSYLAWYQQKPGQAPRLLIYGASYRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQHSLYPPTFGGGTKVEIK 221 V _L DIQMTQSPSTLSASVGDRVTITCRASQSINSWLAWYQQKPGICAPKLLISDASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYDSHITFGGGTKVEIK 222 V _L DIQMTQSPSSVSASVGDRVTITCAASQGISSDLAWYQQKPGICAPKLLIYSASSTQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQAYLYPITFGGGTKVEIK 223 V _L GVQMTQSPSSSLSASVGDRVTITCRASQDISTYLNWYQQKPGKAPKLLIYDAFNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQLPFLPITFGGGTKVEIK 224 V _L DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALGGPWTFGGGTKVEIK 225 V _L EIVLTQSPGTLLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASRRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYVSDPITFGGGTKVEIK 226 V _L EIVLTQSPGTLLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASRRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQVGSSPITFGGGTKVEIK 227 V _L DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSHLVPRTFGGGTKVEIK 228 V _L EIVMTQSPATLSVSPGERATLLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQANHHPPFTFGGGTKVEIK 229 230 231 232 IGG1AAAHC 33343 QLQLQESGPGLVKPSETLSLTCTVSGGSISSSDYYWGWIRQPPGKGLEWIGSIYYSGSTYYNPSLKSRVTISVDTSKIIQFSLKLSSVTAADTAVYYCARGVRRAVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ TYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPICDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISICAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 233 IGG1 AAA HC 37268 QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSTYWAWIRQPPGKGLEWIGSISSSGSTYYNPSLKSRVTISVDTSICNIQFSLKLSSVTAADTAVYYCARGIARAVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVN HKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 234 IGGI AAA HC 37269 QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSTYWGWIRQSPGKGLEWIGSIHHSGATYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGPKRAVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQP ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 235 IGG1 AAA HC 37271 QLQLQESGPGLVKPSETLSLTCTVSGGSISSSDTYWGWIRQPPGKGLEWIGSIHYSGSTLYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGVRRAVPFVDWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQP ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 236 IGG1 AAA HC 37272 QLQLQESGPGLVKPSETLSLTCTVSGGSISSADNYWGWIRQPPGKGLEWIGSIHYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGVRRAVPFQRWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ TYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 237 IGG1 AAA HC 37277 QLQLQESGPGLVKPSETLSLTCTVSGGSISSSDTYWGWIRQPPGKGPEWIGSIHYSGSTLYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGVRRAVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC NVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 238 IGG1 AAA HC 38373 QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSTYWSWIRQPPGKGLEWIGGIAYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGVRRAVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNV NHKPSNTICVDKKVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 239 IGG1 AAA HC 38375 QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSTYWSWIRQPPGKGLEWIGSISYNALTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGTRRAVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNV NHKPSNTICVDKKVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISICAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 240 IGG1 AAA HC 38379 QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSTYWSWIRQPPGKGLEWIGGIAYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGVRRAVPFADWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNV NHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 241 IGG1 AAA HC 38381 QLQLQESGPGLVKPSETLSLTCTVSGGSVSSSSTYWSWIRQPPGKGLEWIGGIAYSGSTYYNPSLKSRVTISVDTSICNQFSLKLSSVTAADTAVYYCARGVRRAVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNV NHKPSNTICVDKKVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 242 IGG1 AAA HC 38383 QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSTYWSWIRQPPGKGLEWIGGIAYSGSTYYNPSLKSRVTISVDTSICNQFSLKLSSVTAADTAVYYCARGTRRAVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVICDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVN HKPSNTICVDKKVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 243 IGG1 AAA HC 38386 QLQLQESGPGLVKPSETLSLTCTVSGGSISSSDTYWGWIRQPPGKGLEWIGSIHYSGSTLYNPSLKSRVTISVDTSKNIQFSLKLSSVTAADTAVYYCARGIRRAVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC NVNHKPSNTICVDKKVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPICDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 244 IGG1 AAA HC 37273 QLQLQESGPGLVKPSETLSLTCTVSGGSISSSDTYWGWIRQPPGKGLEWIGSIHYSGSTLYNPSLKSRVTISVDTSICNQFSLKLSSVTAADTAVYYCARGQFRAVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVICDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC NVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGICEYKCKVSNICALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQP ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 245 IGG1 AAA HC 33361 QVQLQESGPGLVKPSETLSLTCAVSGYSISSGYYWGWIRQPPGKGLEWIGSIYHSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGGTHTYSRGPMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT QTYICNVNHKPSNTKVDKICVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPICDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNG QPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 246 IGG1 AAA HC 35624 QLQLQESGPRLVKPSETLSLTCAVSGYSISSGYYWGWIRQPPGKGLEWIGSIYHSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGGTHTYSRGPFDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT QTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNG QPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 247 IGG1 AAA HC 38410 LVQLQESGPGLVKPSETLSLTCAVSGYSILSGYYWFWIRQPPGKGLEWIGGIYHSASTAYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGGTPIYSRGPLDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLG TQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPICDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWES NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 248 IGG1 AAA HC 38418 QVQLQESGPGLVKPSETLSLTCAVSGYSISSGHYWIWIRQPPGKGLEWIGGIYHSGSTYYNPSLKSRVTISVDTSKDQFSLKLSSVTAADTAVYYCARGGGQTYSRGPLDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ TYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKL\TQVSLTCLVKGFYPSDIAVEWES NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 249 IG G1 AAA HC 38420 QVQLQESGPGLVKPPETLSLTCAVSGYSISSGHYWIWIRQPPGKGLEWIGGIYHSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGGGATYSRGPLDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ TYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 250 IGG1 AAA HC 38421 QVQLQESGPGLVKPSETLSLTCAVSGYSILSGYYWFWIRQPPGKGLEWIGGIYHSGSTYYNPSLKSRVTISVDTSICNQFSLKLSSVTAADTAVYYCARGGTHTYSRGPLDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT QTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNG QPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 251 IGG1 AAA HC 38422 QVQLQESGPGLVKPSETLSLTCAVSGYSISSGFYWTWIRQPPGKGLEWIGAIYHSGSTVYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGGTHTYSRGPLDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ TYICNVNHKPSNTICVDKKVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 252 IGG1 AAA HC 38424 QVQLQESGPGLVKPSETLSLTCAVSGYSISSGYYWLWIRQPPGKGLEWIGGIYHSASTAYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGGTVKYSRGPLDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT QTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNG QPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 253 IGG1 AAA HC 38425 QVQLQESGPGLVKPSETLSLTCAVSGYSISSGHYWTWIRQPPGKGLEWIGAIYHSGSTVYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGGQVTYSRGPLDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT QTYICNVNHKPSNTKVDKICVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPICDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNG QPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 254 IGG1 AAA HC 38426 QVQLQESGPGLVKPSETLSLTCAVSGYSILSGYYWFWIRQPPGKGLEWIGGIYHSGSTAYNPSLKSRVTISVDTSICNQFSLKLSSVTAADTAVYYCARGGEVTYSRGPLDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT QTYICNVNHKPSNTICVDKKVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNG QPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 255 IGG1 AAA HC 37323 EVQLLESGGGLVQPGGSLRLSCAASGFTFDNYAMHWVRQAPGKGLEWVSAISARAGITYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRIGYSYGTAPPFDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTA.ALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNV NHKPSNTICVDKKVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTICNQVSLTCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 256 IGG1 AAA HC 38389 QVQLVESGGGLVQPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYIASSGSVIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARHGTPRAFDIWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVN HKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPICDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 257 IGG1 AAA HC 38358 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSSAMAWVRQAPGKGLEWVSTISGSGITTWYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGSRHLNAFNRWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVICDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHK PSNTICVDKICVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 258 IGG1 AAA HC 33303 QVQLQESGPGLVKPSGTLSLTCAVSGGSISSSNWWSWVRQPPGKGLEWIGEIYHSGSTNYNPSLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCARGVYHYDPYGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT QTYICNVNHKPSNTKVDICKVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPICDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 259 IGG1 AAA HC 33342 QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSYYWGWIRQPPGKGLEWIGSISYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARTELGKMHFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ TYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 260 IGG1 AAA HC 33299 QLQLQESGPGLVKPSETLSLTCTVSGGSISSSDYYWGWIRQPPGKGLEWIGSIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGSPRYMQDWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ TYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPICDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 261 IGG1 AAA HC 33351 QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARHSSLGTHNWFDPWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC NVNHKPSNTICVDKKVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPICDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 262 IGG1 AAA HC 33357 QVQLQESGPGLVKPSETLSLTCAVSGYSISSGYYWGWIRQPPGKGLEWIGSIYHSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREGALSYSWLAAFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT QTYICNVNHKPSNTICVDKKVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNG QPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 263 264 265 266 IGG4 HC 33343 QLQLQESGPGLVKPSETLSLTCTVSGGSISSSDYYWGWIRQPPGKGLEWIGSIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGVRRAVPFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTK TYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWES NGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSPGK 267 IGG4 HC 37268 QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSTYWAWIRQPPGKGLEWIGSISSSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGIARAVPFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDH KPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN NYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSPGK 268 IGG4HC 37269 QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSTYWGWIRQSPGKGLEWIGSIHHSGATYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGPKRAVPFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTY TCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPICDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNG QPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSPGK 269 IGG4 HC 37271 QLQLQESGPGLVKPSETLSLTCTVSGGSISSSDTYWGWIRQPPGKGLEWIGSIHYSGSTLYNPSLKSRVTISVDTSKNTQFSLKLSSVTAADTAVYYCARGVRRAVPFVDWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTY TCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPICDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNG QPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSPGK 270 IGG4 HC 37272 QLQLQESGPGLVKPSETLSLTCTVSGGSISSADNYWGWIRQPPGKGLEWIGSIHYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGVRRAVPFQRWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTK TYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTICNQVSLTCLVKGFYPSDIAVEWES NGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSPGK 271 IGG4 HC 37277 QLQLQESGPGLVKPSETLSLTCTVSGGSISSSDTYWGWIRQPPGKGPEWIGSIHYSGSTLYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGVRRAVPFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTC NVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPICDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTICNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSPGK 272 IGG4 HC 38373 QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSTYWSWIRQPPGKGLEWIGGIAYSGSTYYNPSLKSRVTISVDTSICNIQFSLKLSSVTAADTAVYYCARGVRRAVPFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNV DHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQP ENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSPGK 273 IGG4 HC 38375 QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSTYWSWIRQPPGKGLEWIGSISYNALTYYNPSLKSRVTISVDTSKNIQFSLKLSSVTAADTAVYYCARGTRRAVPFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNV DHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQP ENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSPGK 274 IGG4 HC 38379 QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSTYWSWIRQPPGKGLEWIGGIAYSGSTYYNPSLKSRVTISVDTSICNQFSLKLSSVTAADTAVYYCARGVRRAVPFADWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDH KPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPICDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN NYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSPGK 275 IGG4 HC 38381 QLQLQESGPGLVKPSETLSLTCTVSGGSVSSSSTYWSWIRQPPGKGLEWIGGIAYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGVRRAVPFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTC NVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSPGK 276 IGG4 HC 38383 QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSTYWSWIRQPPGKGLEWIGGIAYSGSTYYNPSLKSRVTISVDTSKITQFSLKLSSVTAADTAVYYCARGTRRAVPFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNV DHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTICNQVSLTCLVKGFYPSDIAVEWESNGQP ENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSPGK 277 IGG4 HC 38386 QLQLQESGPGLVKPSETLSLTCTVSGGSISSSDTYWGWIRQPPGKGLEWIGSIHYSGSTLYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGIRRAVPFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTC NVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPICDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSPGK 278 IGG4 HC 37273 QLQLQESGPGLVKPSETLSLTCTVSGGSISSSDTYWGWIRQPPGKGLEWIGSIHYSGSTLYNPSLKSRVTISVDTSICNTQFSLKLSSVTAADTAVYYCARGQFRAVPFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTY TCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNG QPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSPGK 279 IGG4 HC 33361 QVQLQESGPGLVKPSETLSLTCAVSGYSISSGYYWGWIRQPPGKGLEWIGSIYHSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGGTHTYSRGPMDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT KTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEW ESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSPGK 280 IGG4 HC 35624 QLQLQESGPRLVKPSETLSLTCAVSGYSISSGYYWGWIRQPPGKGLEWIGSIYHSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGGTHTYSRGPFDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT KTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEW ESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSPGK 281 IGG4 HC 38410 LVQLQESGPGLVKPSETLSLTCAVSGYSILSGYYWFWIRQPPGKGLEWIGGIYHSASTAYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGGTPIYSRGPLDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS’VVTVPSSSL GTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPICDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDI AVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSPGK 282 IGG4 HC 38418 QVQLQESGPGLVKPSETLSLTCAVSGYSISSGHYWIWIRQPPGKGLEWIGGIYHSGSTYYNPSLKSRVTISVDTSKDQFSLKLSSVTAADTAVYYCARGGGQTYSRGPLDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTK TYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPICDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTICNQVSLTCLVKGFYPSDIAVEWES NGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSPGK 283 IGG4 HC 38420 QVQLQESGPGLVKPPETLSLTCAVSGYSISSGHYWIWIRQPPGKGLEWIGGIYHSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGGGATYSRGPLDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTK TYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWES NGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSPGK 284 IGG4 HC 38421 QVQLQESGPGLVKPSETLSLTCAVSGYSILSGYYWFWIRQPPGKGLEWIGGIYHSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGGTHTYSRGPLDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLG TKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVE WESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSPGK 285 IGG4 HC 38422 QVQLQESGPGLVKPSETLSLTCAVSGYSISSGFYWTWIRQPPGKGLEWIGAIYHSGSTVYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGGTHTYSRGPLDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTK TYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPICDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWES NGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSPGK 286 IGG4 HC 38424 QVQLQESGPGLVKPSETLSLTCAVSGYSISSGYYWLWIRQPPGKGLEWIGGIYHSASTAYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGGTVKYSRGPLDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT KTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEW ESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSPGK 287 IGG4 HC 38425 QVQLQESGPGLVKPSETLSLTCAVSGYSISSGHYWTWIRQPPGKGLEWIGAIYHSGSTVYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGGQVTYSRGPLDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT KTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEW ESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSPGK 288 IGG4 HC 38426 QVQLQESGPGLVKPSETLSLTCAVSGYSILSGYYWFWIRQPPGKGLEWIGGIYHSGSTAYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGGEVTYSRGPLDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLG TKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPICDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVE WESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSPGK 289 IGG4 HC 37323 EVQLLESGGGLVQPGGSLRLSCAASGFTFDNYAMHWVRQAPGKGLEWVSAISARAGITYYADSVKGRFTISRDNSICNTLYLQMNSLRAEDTAVYYCARRIGYSYGTAPPFDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDH KPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN NYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSPGK 290 IGG4 HC 38389 MSWIRQAPGKGLEWVSYIASSGSVIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARHGTPRAFDIWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGG PSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTICNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNV FSCSVMHEALHNHYTQKSLSLSPGK 291 IGG4 HC 38358 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSSAMAWVRQAPGKGLEWVSTISGSGITTWYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGSRHLNAFNRWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPS NTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSPGK 292 IGG4 HC 33303 QVQLQESGPGLVKPSGTLSLTCAVSGGSISSSNWWSWVRQPPGKGLEWIGEIYHSGSTNYNPSLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCARGVYHYDPYGMDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT KTYTCNVDHKPSNTICVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTICNQVSLTCLVKGFYPSDIAVEW ESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSPGK 293 IG G4 HC 33342 QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSYYWGWIRQPPGKGLEWIGSISYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARTELGKMHFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTK TYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWES NGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSPGK 294 IG G4 HC 33329 QLQLQESGPGLVKPSETLSLTCTVSGGSISSSDYYWGWIRQPPGKGLEWIGSIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGSPRYMQDWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTK TYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTICNQVSLTCLVKGFYPSDIAVEWES NGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSPGK 295 IGG4 HC 33351 QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARHSSLGTHNWFDPWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTC NVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSPGK 296 IGG4 HC 33357 QVQLQESGPGLVKPSETLSLTCAVSGYSISSGYYWGWIRQPPGKGLEWIGSIYHSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREGALSYSWLAAFDIWGQGTMVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT KTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEW ESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSPGK 297 298 299 300 L.C. 33343 EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQAVHSPYTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEV THQGLSSPVTKSFNRGEC 301 L.C. 37268 EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQAVHSPYTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEV THQGLSSPVTKSFNRGEC 302 L.C. 37269 EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQAVHSPYTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEV THQGLSSPVTKSFNRGEC 303 L.C. 37271 EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQAVHSPYTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEV THQGLSSPVTKSFNRGEC 304 L.C. 37272 EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQAVHSPYTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEV THQGLSSPVTKSFNRGEC 305 L.C. 37277 EIVLTQSPGTLSLSPGERATLSCGASQSVSSDYLAWYQQKPGQAPRLLIYGAYSLATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQWAVHSPYTFGGGTICVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACE VTHQGLSSPVTKSFNRGEC 306 L.C. 38373 EIVLTQSPGTLSLSPGERATLSCQASQAVSSNYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQVVHSPYTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACE VTHQGLSSPVTKSFNRGEC 307 L.C. 38375 EIVLTQSPGTLSLSPGERATLSCGASQSVSSAFLAWYQQKPGQAPRLLIYGASARATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQVVHSPYTFGGGTKVEIK.RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY ACEVTHQGLSSPVTKSFNRGEC 308 L.C. 38379 EIVLTQSPGTLSLSPGERATLSCRASQSVSSTYLAWYQQKPGQAPRLLIYGASSREAGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQTVHSPYTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEV THQGLSSPVTKSFNRGEC 309 L.C. 38381 EIVLTQSPGTLSLSPGERATLSCQASQAVSSNYLAWYQQKPGQAPRLLIYGASNRAAGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQAIHSPYTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEV THQGLSSPVTKSFNRGEC 310 L.C. 38383 EIVLTQSPGTLSLSPGERATLSCQASQSVSSSYLAWYQQKPGQAPRLLIYGASNRAAGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQVVHSPYTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACE VTHQGLSSPVTKSFNRGEC 311 L.C. 38386 EIVLTQSPGTLSLSPGERATLSCKASQAVSSSYLAWYQQKPGQAPRLLIYGASSRQDGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQVVHSPYTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY ACEVTHQGLSSPVTKSFNRGEC 312 L.C. 37273 EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQAVHSPYTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEV THQGLSSPVTKSFNRGEC 313 L.C. 33361 EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQHSSYPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTH QGLSSPVTKSFNRGEC 314 L.C. 35624 EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQHSSYPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTH QGLSSPVTKSFNRGEC 315 L.C. 38410 EIVLTQSPGTLSLSPGERATLSCEASQSVSSSYLAWYQQKPGQAPRLLIYGASNRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQHSLYPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTH QGLSSPVTKSFNRGEC 316 L.C. 38418 EIVLTQSPGTLSLSPGERATLSCEASQSVSASYLAWYQQKPGQAPRLLIYDASSRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFSSYPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTH QGLSSPVTKSFNRGEC 317 L.C. 38420 EIVLTQSPGTLSLSPGERATLSCEASQSVSSAYLAWYQQKPGQAPRLLIYDASTRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQVSSYPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEV THQGLSSPVTKSFNRGEC 318 L.C. 38421 EIVLTQSPGTLSLSPGERAALSCRVSQSVSDAYLAWYQQKPGQAPRLLIYDASSRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQVSSYPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACE VTHQGLSSPVTKSFNRGEC 319 L.C. 38422 EIVLTQSPGTLSLSPGERATLSCEVSQSVSASYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQHSLYPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTH QGLSSPVTKSFNRGEC 320 L.C. 38424 EIVLTQSPGTLSLSPGERATLSCRASQSVSSAYLAWYQQKPGQAPRLLIYGASDRANGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQHSLYPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQ GLSSPVTKSFNRGEC 321 L.C. 38425 EIVLTQSPGTLSLSPGERATLSCRASNAVSSSYLAWYQQKPGQAPRLLIYGASDRANGIPDRFSGSGTDFTLTISRLEPEDFAVYYCQQHSIYPPTFGGGTICVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQ GLSSPVTKSFNRGEC 322 L.C. 38426 EIVLTQSPGTLSLSPGERATLSCRASNAVSSSYLAWYQQKPGQAPRLLIYGASYRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQHSLYPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQ GLSSPVTKSFNRGEC 323 L.C. 37323 DIQMTQSPSTLSASVGDRVTITCRASQSINSWLAWYQQKPGKAPKLLISDASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYDSHITFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSICDSTYSLSSTLTLSKADYEKHKVYACEV THQGLSSPVTKSFNRGEC 324 L.C. 38389 DIQMTQSPSSVSASVGDRVTITCAASQGISSDLAWYQQKPGKAPKLLIYSASSTQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQAYLYPITFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACE VTHQGLSSPVTKSFNRGEC 325 L.C. 38358 GVQMTQSPSSLSASVGDRVTITCRASQDISTYLNWYQQKPGKAPKLLIYDAFNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQLPFLPITFGGGTICVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKV YACEVTHQGLSSPVTKSFNRGEC 326 L.C. 33303 DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALGGPWTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSICDSTYSLSSTLTLSKADYEK HICVYACEVTHQGLSSPVTKSFNRGEC 327 L.C. 33342 EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASRRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYVSDPITFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEV THQGLSSPVTKSFNRGEC 328 L.C. 33299 EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASRRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQVGSSPITFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAICVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEV THQGLSSPVTKSFNRGEC 329 L.C. 33351 DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSHLVPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY ACEVTHQGLSSPVTKSFNRGEC 330 L.C. 33357 EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQANHHPPFTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTH QGLSSPVTKSFNRGEC 331 332 333 334 Fc for IGG1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 335 Fc region for IGG4 ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQ DWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSPGK 336 Kappa region for LC RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 337 hHLA-G1 MVVMAPRTLFLLLSGALTLTETWAGSHSMRYFSAAVSRPGRGEPRFIAMGYVDDTQFVRFDSDSACPRMEPRAPWVEQEGPEYWEEETRNTKAHAQTDRMNLQTLRGYYNQSEASSHTLQWMIGCDLGSDGRLLRGYEQYAYDGKDYLALNEDLRSWTAADTAAQISKRKCEAANVAEQRRAYLEGTCVEWLHRYLENGKEM LQRADPPKTHVTHHPVFDYEATLRCWALGFYPAEIILTWQRDGEDQTQDVELVETRPAGDGTFQKWAAVVVPSGEEQRYTCHVQHEGLPEPLMLRWKQSSLPTIPIMGIVAGLVVLAAVVTGAAVAAVLWRKKSSD 338 hHLA-G5 MVVMAPRTLFLLLSGALTLTETWAGSHSMRYFSAAVSRPGRGEPRFIAMGYVDDTQFVRFDSDSACPRMEPRAPWVEQEGPEYWEEETRNTKAHAQTDRMNLQTLRGYYNQSEASSHTLQWMIGCDLGSDGRLLRGYEQYAYDGKDYLALNEDLRSWTAADTAAQISKRKCEAANVAEQRRAYLEGTCVEWLHRYLENGKEM LQRADPPKTHVTHHPVFDYEATLRCWALGFYPAEIILTWQRDGEDQTQDVELVETRPAGDGTFQKWAAVVVPSGEEQRYTCHVQHEGLPEPLMLRWSKEGDGGIMSVRESRSLSEDL 339 Cynomolgus macaque, HLA-AG MAVMAPRTLLLVLSGVLALTQPRAGSHSMRYFYTAVSRPGRGQPRFIAVGYVDDTQFVRFDSDAESPRMEPRAPWVEQEGPEYWDRETQNMKTATQTYQANLRTLLRYYNQSEAGSHTFQKMYGCDLGPDGRLLRGYEQFAYDGRDYIILNEDLRSWTAADMAAQNTQRKWEAAGAAEQHRTYLEGECLEWLRRYLENGKET LQRADPPKTNVTHHPVSDYEATLRCWALGFYPAEITLTWQRDGEEQTEDTELVETRPTGDGTFQKWAAVVVPSGEEQRYTCHVQHEGLPKPLTLRWEPSSQSTILIVGIIAGLVLLGTVVTGAVVAAVMWRRKS 340 Rhesus monkey HLA-AG MAVMAPRTLLLVLSGVLALTQTRAGSHSMRYFYTSMSRPGRGQPRFIAVGYVDDTQFVRFDSDAESPRMEPRAPWVEQEGPEYWDRETQNMKTATQTYRENLRTLLRYYNQSEAGSHTIQKMYGCDLGPDGRLLRGYEQFAYDGRDYIALNEDLRSWTAADMAAQFTQRKWEAAGAAEQHRTYLEGECLEWLRRYLENGKETLQ RADPPKTNVTHHPVSDYEATLRCWALGFYPAEITLTWQRDGEEQTEDTELVETRPTGDGTFQKWAAVVVPSGEEQRYTCHVQHEGLPEPLTLRWEPSSQSTILIVGIIAGLVLLGTVVTGAVVAAVMWRRKSSDR 341 ECD hHLA-G with signal peptide MVVMAPRTLFLLLSGALTLTETWAGSHSMRYFS AAVSRPGRGEPRFIAMGYVDDTQFVRFDSDSAC PRMEPRAPWVEQEGPEYWEEETRNTKAHAQTDR MNLQTLRGYYNQSEASSHTLQWMIGCDLGSDGR LLRGYEQYAYDGKDYLALNEDLRSWTAADTAAQ ISKRKCEAANVAEQRRAYLEGTCVEWLHRYLEN GKEMLQRADPPKTHVTHHPVFDYEATLRCWALG FYPAEIILTWQRDGEDQTQDVELVETRPAGDGT FQKWAAVVVPSGEEQRYTCHVQHEGLPEPLMLR W 342 ECD hHLA-G without signal peptide GSHSMRYFSAAVSRPGRGEPRFIAMGYVDDTQFVRFDSDSACPRMEPRAPWVEQEGPEYWEEETRNTKAHAQTDRMNLQTLRGYYNQSEASSHTLQWMIGCDLGSDGRLLRGYEQYAYDGKDYLALNEDLRSWTAADTAAQISKRKCEAANVAEQRRAYLEGTCVEWLHRYLENGKEMLQRADPPKTHVTHHPVFDY EATLRCWALGFYPAEIILTWQRDGEDQTQDVELVETRPAGDGTFQKWAAVVVPSGEEQRYTCHVQHEGLPEPLMLRW

Equivalents

[00470] The description above may cover several separate inventions of independent utility. Although each of these inventions has been disclosed in its preferred form (or forms), the specific embodiments disclosed and illustrated herein are not to be construed as limiting as numerous variations are possible. The subject matter of the present inventions includes all new and non-obvious combinations and subcombinations of various elements, features, functions and/or properties described herein. The following claims contain certain specific combinations and subcombinations that are considered novel and non-obvious. Inventions embodied in other combinations and subcombinations of features, functions, elements and/or properties may be within the scope claimed herein; in applications claiming priority based on this application; or in related applications. Such claims, whether they are directed to another invention or to the same invention, or whether they are broader, narrower, equal or different in scope from the original claims, are also considered to be included in the subject matter of the invention, described in this document.

--->

LIST OF SEQUENCES

<110> TIZONA THERAPEUTICS/ TIZONA THERAPEUTICS

ADIMAB, LLC / ADIMAB, LLC

BEERS, Courtney, et al./BEERS, Courtney et al.

<120> ANTI-HLA-G ANTIBODIES, COMPOSITIONS COMPRISING ANTI-HLA-G

ANTIBODIES AND METHODS OF USING ANTI-HLA-G ANTIBODIES /

ANTIBODIES AGAINST HLA-G, COMPOSITIONS CONTAINING ANTIBODIES AGAINST

HLA-G

AND METHODS OF USING ANTIBODIES AGAINST HLA-G

<130> 117851.00047

<150> US 62/737666

<151> 2018-09-27

<160> 342

<170> PatentIn, version 3.5

<210> 1

<211> 9

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 1

Gly Gly Ser Ile Ser Ser Ser Asp Tyr

15

<210> 2

<211> 9

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 2

Gly Gly Ser Ile Ser Ser Ser Ser Thr

15

<210> 3

<211> 9

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 3

Gly Gly Ser Ile Ser Ser Ser Asp Thr

15

<210> 4

<211> 9

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 4

Gly Gly Ser Ile Ser Ser Ala Asp Asn

15

<210> 5

<211> 9

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 5

Gly Gly Ser Val Ser Ser Ser Ser Thr

15

<210> 6

<211> 8

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 6

Gly Tyr Ser Ile Ser Ser Gly Tyr

15

<210> 7

<211> 8

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 7

Gly Tyr Ser Ile Leu Ser Gly Tyr

15

<210> 8

<211> 8

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 8

Gly Tyr Ser Ile Ser Ser Gly His

15

<210> 9

<211> 8

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 9

Gly Tyr Ser Ile Ser Ser Gly Phe

15

<210> 10

<211> 7

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 10

Gly Phe Thr Phe Asp Asn Tyr

15

<210> 11

<211> 7

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 11

Gly Phe Thr Phe Ser Asp Tyr

15

<210> 12

<211> 7

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 12

Gly Phe Thr Phe Ser Ser Ser

15

<210> 13

<211> 8

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 13

Gly Gly Ser Ile Ser Ser Ser Asn

15

<210> 14

<211> 9

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 14

Gly Gly Ser Ile Ser Ser Ser Tyr

15

<210> 15

<400> 15

000

<210> 16

<400> 16

000

<210> 17

<400> 17

000

<210> 18

<211> 7

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 18

Ser Ser Asp Tyr Tyr Trp Gly

15

<210> 19

<211> 7

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 19

Ser Ser Ser Thr Tyr Trp Ala

15

<210> 20

<211> 7

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 20

Ser Ser Ser Thr Tyr Trp Gly

15

<210> 21

<211> 7

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 21

Ser Ser Asp Thr Tyr Trp Gly

15

<210> 22

<211> 7

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 22

Ser Ala Asp Asn Tyr Trp Gly

15

<210> 23

<211> 7

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 23

Ser Ser Ser Thr Tyr Trp Ser

15

<210> 24

<211> 6

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 24

Ser Gly Tyr Tyr Trp Gly

15

<210> 25

<211> 6

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 25

Ser Gly Tyr Tyr Trp Phe

15

<210> 26

<211> 6

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 26

Ser Gly His Tyr Trp Ile

15

<210> 27

<211> 6

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 27

Ser Gly Phe Tyr Trp Thr

15

<210> 28

<211> 6

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 28

Ser Gly Tyr Tyr Trp Leu

15

<210> 29

<211> 6

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 29

Ser Gly His Tyr Trp Thr

15

<210> 30

<211> 5

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 30

Asn Tyr Ala Met His

15

<210> 31

<211> 5

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 31

Asp Tyr Tyr Met Ser

15

<210> 32

<211> 5

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 32

Ser Ser Ala Met Ala

15

<210> 33

<211> 6

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 33

Ser Ser Asn Trp Trp Ser

15

<210> 34

<211> 7

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 34

Ser Ser Ser Tyr Tyr Trp Gly

15

<210> 35

<400> 35

000

<210> 36

<400> 36

000

<210> 37

<400> 37

000

<210> 38

<211> 5

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 38

Tyr Tyr Ser Gly Ser

15

<210> 39

<211> 5

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 39

Ser Ser Ser Gly Ser

15

<210> 40

<211> 5

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 40

His His Ser Gly Ala

15

<210> 41

<211> 5

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 41

His Tyr Ser Gly Ser

15

<210> 42

<211> 5

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 42

Ala Tyr Ser Gly Ser

15

<210> 43

<211> 5

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 43

Ser Tyr Asn Ala Leu

15

<210> 44

<211> 5

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 44

Tyr His Ser Gly Ser

15

<210> 45

<211> 5

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 45

Tyr His Ser Ala Ser

15

<210> 46

<211> 6

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 46

Ser Ala Arg Ala Gly Ile

15

<210> 47

<211> 6

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 47

Ala Ser Ser Gly Ser Val

15

<210> 48

<211> 6

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 48

Ser Gly Ser Gly Ile Thr

15

<210> 49

<211> 5

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 49

Ser Tyr Ser Gly Ser

15

<210> 50

<211> 6

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 50

Ser Ser Ser Gly Ser Thr

15

<210> 51

<400> 51

000

<210> 52

<400> 52

000

<210> 53

<400> 53

000

<210> 54

<211> 16

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 54

Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser

1 5 10 15

<210> 55

<211> 16

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 55

Ser Ile Ser Ser Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser

1 5 10 15

<210> 56

<211> 16

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 56

Ser Ile His His Ser Gly Ala Thr Tyr Tyr Asn Pro Ser Leu Lys Ser

1 5 10 15

<210> 57

<211> 16

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 57

Ser Ile His Tyr Ser Gly Ser Thr Leu Tyr Asn Pro Ser Leu Lys Ser

1 5 10 15

<210> 58

<211> 16

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 58

Ser Ile His Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser

1 5 10 15

<210> 59

<211> 16

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 59

Gly Ile Ala Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser

1 5 10 15

<210> 60

<211> 16

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 60

Ser Ile Ser Tyr Asn Ala Leu Thr Tyr Tyr Asn Pro Ser Leu Lys Ser

1 5 10 15

<210> 61

<211> 16

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 61

Ser Ile Tyr His Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser

1 5 10 15

<210> 62

<211> 16

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 62

Gly Ile Tyr His Ser Ala Ser Thr Ala Tyr Asn Pro Ser Leu Lys Ser

1 5 10 15

<210> 63

<211> 16

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 63

Gly Ile Tyr His Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser

1 5 10 15

<210> 64

<211> 16

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 64

Ala Ile Tyr His Ser Gly Ser Thr Val Tyr Asn Pro Ser Leu Lys Ser

1 5 10 15

<210> 65

<211> 16

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 65

Gly Ile Tyr His Ser Gly Ser Thr Ala Tyr Asn Pro Ser Leu Lys Ser

1 5 10 15

<210> 66

<211> 17

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 66

Ala Ile Ser Ala Arg Ala Gly Ile Thr Tyr Tyr Ala Asp Ser Val Lys

1 5 10 15

Gly

<210> 67

<211> 17

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 67

Tyr Ile Ala Ser Ser Gly Ser Val Ile Tyr Tyr Ala Asp Ser Val Lys

1 5 10 15

Gly

<210> 68

<211> 17

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 68

Thr Ile Ser Gly Ser Gly Ile Thr Thr Trp Tyr Ala Asp Ser Val Lys

1 5 10 15

Gly

<210> 69

<211> 16

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 69

Glu Ile Tyr His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser

1 5 10 15

<210> 70

<211> 16

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 70

Ser Ile Ser Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser

1 5 10 15

<210> 71

<211> 17

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 71

Tyr Ile Ser Ser Ser Gly Ser Thr Ile Tyr Tyr Ala Asp Ser Val Lys

1 5 10 15

Gly

<210> 72

<400> 72

000

<210> 73

<400> 73

000

<210> 74

<400> 74

000

<210> 75

<400> 75

000

<210> 76

<211> 10

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 76

Gly Val Arg Arg Ala Val Pro Phe Asp Tyr

1 5 10

<210> 77

<211> 10

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 77

Gly Ile Ala Arg Ala Val Pro Phe Asp Tyr

1 5 10

<210> 78

<211> 10

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 78

Gly Pro Lys Arg Ala Val Pro Phe Asp Tyr

1 5 10

<210> 79

<211> 10

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 79

Gly Val Arg Arg Ala Val Pro Phe Val Asp

1 5 10

<210> 80

<211> 10

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 80

Gly Val Arg Arg Ala Val Pro Phe Gln Arg

1 5 10

<210> 81

<211> 10

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 81

Gly Thr Arg Arg Ala Val Pro Phe Asp Tyr

1 5 10

<210> 82

<211> 10

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 82

Gly Val Arg Arg Ala Val Pro Phe Ala Asp

1 5 10

<210> 83

<211> 10

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 83

Gly Ile Arg Arg Ala Val Pro Phe Asp Tyr

1 5 10

<210> 84

<211> 10

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 84

Gly Gln Phe Arg Ala Val Pro Phe Asp Tyr

1 5 10

<210> 85

<211> 13

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 85

Gly Gly Thr His Thr Tyr Ser Arg Gly Pro Met Asp Val

1 5 10

<210> 86

<211> 13

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 86

Gly Gly Thr His Thr Tyr Ser Arg Gly Pro Phe Asp Val

1 5 10

<210> 87

<211> 13

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 87

Gly Gly Thr Pro Ile Tyr Ser Arg Gly Pro Leu Asp Val

1 5 10

<210> 88

<211> 13

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 88

Gly Gly Gly Gln Thr Tyr Ser Arg Gly Pro Leu Asp Val

1 5 10

<210> 89

<211> 13

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 89

Gly Gly Gly Ala Thr Tyr Ser Arg Gly Pro Leu Asp Val

1 5 10

<210> 90

<211> 13

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 90

Gly Gly Thr His Thr Tyr Ser Arg Gly Pro Leu Asp Val

1 5 10

<210> 91

<211> 13

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 91

Gly Gly Thr Val Lys Tyr Ser Arg Gly Pro Leu Asp Val

1 5 10

<210> 92

<211> 13

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 92

Gly Gly Gln Val Thr Tyr Ser Arg Gly Pro Leu Asp Val

1 5 10

<210> 93

<211> 13

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 93

Gly Gly Glu Val Thr Tyr Ser Arg Gly Pro Leu Asp Val

1 5 10

<210> 94

<211> 14

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 94

Arg Ile Gly Tyr Ser Tyr Gly Thr Ala Pro Pro Phe Asp Val

1 5 10

<210> 95

<211> 9

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 95

His Gly Thr Pro Arg Ala Phe Asp Ile

15

<210> 96

<211> 10

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 96

Gly Ser Arg His Leu Asn Ala Phe Asn Arg

1 5 10

<210> 97

<211> 12

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 97

Gly Val Tyr His Tyr Asp Pro Tyr Gly Met Asp Val

1 5 10

<210> 98

<211> 10

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 98

Thr Glu Leu Gly Lys Met His Phe Asp Tyr

1 5 10

<210> 99

<211> 8

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 99

Gly Ser Pro Arg Tyr Met Gln Asp

15

<210> 100

<211> 12

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 100

His Ser Ser Leu Gly Thr His Asn Trp Phe Asp Pro

1 5 10

<210> 101

<211> 14

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 101

Glu Gly Ala Leu Ser Tyr Ser Trp Leu Ala Ala Phe Asp Ile

1 5 10

<210> 102

<400> 102

000

<210> 103

<400> 103

000

<210> 104

<400> 104

000

<210> 105

<211> 12

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 105

Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala

1 5 10

<210> 106

<211> 12

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 106

Gly Ala Ser Gln Ser Val Ser Ser Asp Tyr Leu Ala

1 5 10

<210> 107

<211> 12

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 107

Gln Ala Ser Gln Ala Val Ser Ser Asn Tyr Leu Ala

1 5 10

<210> 108

<211> 12

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 108

Gly Ala Ser Gln Ser Val Ser Ser Ala Phe Leu Ala

1 5 10

<210> 109

<211> 12

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 109

Arg Ala Ser Gln Ser Val Ser Ser Thr Tyr Leu Ala

1 5 10

<210> 110

<211> 12

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 110

Gln Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala

1 5 10

<210> 111

<211> 12

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 111

Lys Ala Ser Gln Ala Val Ser Ser Ser Tyr Leu Ala

1 5 10

<210> 112

<211> 12

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 112

Glu Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala

1 5 10

<210> 113

<211> 12

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 113

Glu Ala Ser Gln Ser Val Ser Ala Ser Tyr Leu Ala

1 5 10

<210> 114

<211> 12

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 114

Glu Ala Ser Gln Ser Val Ser Ser Ala Tyr Leu Ala

1 5 10

<210> 115

<211> 12

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 115

Arg Val Ser Gln Ser Val Ser Asp Ala Tyr Leu Ala

1 5 10

<210> 116

<211> 12

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 116

Glu Val Ser Gln Ser Val Ser Ala Ser Tyr Leu Ala

1 5 10

<210> 117

<211> 12

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 117

Arg Ala Ser Gln Ser Val Ser Ser Ala Tyr Leu Ala

1 5 10

<210> 118

<211> 12

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 118

Arg Ala Ser Asn Ala Val Ser Ser Ser Tyr Leu Ala

1 5 10

<210> 119

<211> 11

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 119

Arg Ala Ser Gln Ser Ile Asn Ser Trp Leu Ala

1 5 10

<210> 120

<211> 11

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 120

Ala Ala Ser Gln Gly Ile Ser Ser Asp Leu Ala

1 5 10

<210> 121

<211> 11

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 121

Arg Ala Ser Gln Asp Ile Ser Thr Tyr Leu Asn

1 5 10

<210> 122

<211> 16

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 122

Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp

1 5 10 15

<210> 123

<211> 11

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 123

Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn

1 5 10

<210> 124

<211> 11

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 124

Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala

1 5 10

<210> 125

<400> 125

000

<210> 126

<400> 126

000

<210> 127

<400> 127

000

<210> 128

<211> 7

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 128

Gly Ala Ser Ser Arg Ala Thr

15

<210> 129

<211> 7

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 129

Gly Ala Tyr Ser Leu Ala Thr

15

<210> 130

<211> 7

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 130

Gly Ala Ser Ala Arg Ala Thr

15

<210> 131

<211> 7

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 131

Gly Ala Ser Ser Arg Glu Ala

15

<210> 132

<211> 7

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 132

Gly Ala Ser Asn Arg Ala Ala

15

<210> 133

<211> 7

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 133

Gly Ala Ser Ser Arg Gln Asp

15

<210> 134

<211> 7

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 134

Gly Ala Ser Asn Arg Ala Thr

15

<210> 135

<211> 7

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 135

Asp Ala Ser Ser Arg Ala Ser

15

<210> 136

<211> 7

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 136

Asp Ala Ser Thr Arg Ala Thr

15

<210> 137

<211> 7

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 137

Gly Ala Ser Asp Arg Ala Asn

15

<210> 138

<211> 7

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 138

Gly Ala Ser Tyr Arg Ala Thr

15

<210> 139

<211> 7

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 139

Asp Ala Ser Ser Leu Glu Ser

15

<210> 140

<211> 7

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 140

Ser Ala Ser Ser Thr Gln Ser

15

<210> 141

<211> 7

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 141

Asp Ala Phe Asn Leu Glu Thr

15

<210> 142

<211> 7

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 142

Leu Gly Ser Asn Arg Ala Ser

15

<210> 143

<211> 7

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 143

Gly Ala Ser Arg Arg Ala Thr

15

<210> 144

<211> 7

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 144

Ala Ala Ser Ser Leu Gln Ser

15

<210> 145

<211> 7

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 145

Gly Ala Ser Thr Arg Ala Thr

15

<210> 146

<400> 146

000

<210> 147

<400> 147

000

<210> 148

<400> 148

000

<210> 149

<211> 9

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 149

Gln Gln Ala Val His Ser Pro Tyr Thr

15

<210> 150

<211> 9

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 150

Gln Trp Ala Val His Ser Pro Tyr Thr

15

<210> 151

<211> 9

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 151

Gln Gln Val Val His Ser Pro Tyr Thr

15

<210> 152

<211> 9

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 152

Gln Gln Thr Val His Ser Pro Tyr Thr

15

<210> 153

<211> 9

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 153

Gln Gln Ala Ile His Ser Pro Tyr Thr

15

<210> 154

<211> 9

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 154

Gln Gln His Ser Ser Tyr Pro Pro Thr

15

<210> 155

<211> 9

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 155

Gln Gln His Ser Leu Tyr Pro Pro Thr

15

<210> 156

<211> 9

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 156

Gln Gln Phe Ser Ser Tyr Pro Pro Thr

15

<210> 157

<211> 9

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 157

Gln Gln Val Ser Ser Tyr Pro Pro Thr

15

<210> 158

<211> 9

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 158

Gln Gln His Ser Ile Tyr Pro Pro Thr

15

<210> 159

<211> 8

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 159

Gln Gln Tyr Asp Ser His Ile Thr

15

<210> 160

<211> 9

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 160

Gln Gln Ala Tyr Leu Tyr Pro Ile Thr

15

<210> 161

<211> 9

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 161

Gln Gln Leu Pro Phe Leu Pro Ile Thr

15

<210> 162

<211> 9

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 162

Met Gln Ala Leu Gly Gly Pro Trp Thr

15

<210> 163

<211> 9

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 163

Gln Gln Tyr Val Ser Asp Pro Ile Thr

15

<210> 164

<211> 9

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 164

Gln Gln Val Gly Ser Ser Pro Ile Thr

15

<210> 165

<211> 9

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 165

Gln Gln Ser His Leu Val Pro Arg Thr

15

<210> 166

<211> 10

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 166

Gln Gln Ala Asn His His Pro Pro Phe Thr

1 5 10

<210> 167

<400> 167

000

<210> 168

<400> 168

000

<210> 169

<400> 169

000

<210> 170

<211> 120

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 170

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser

20 25 30

Asp Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu

35 40 45

Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg Gly Val Arg Arg Ala Val Pro Phe Asp Tyr Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser

115 120

<210> 171

<211> 120

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 171

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser

20 25 30

Ser Thr Tyr Trp Ala Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu

35 40 45

Trp Ile Gly Ser Ile Ser Ser Ser Gly Ser Thr Tyr Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg Gly Ile Ala Arg Ala Val Pro Phe Asp Tyr Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser

115 120

<210> 172

<211> 120

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 172

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser

20 25 30

Ser Thr Tyr Trp Gly Trp Ile Arg Gln Ser Pro Gly Lys Gly Leu Glu

35 40 45

Trp Ile Gly Ser Ile His His Ser Gly Ala Thr Tyr Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg Gly Pro Lys Arg Ala Val Pro Phe Asp Tyr Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser

115 120

<210> 173

<211> 120

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 173

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser

20 25 30

Asp Thr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu

35 40 45

Trp Ile Gly Ser Ile His Tyr Ser Gly Ser Thr Leu Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg Gly Val Arg Arg Ala Val Pro Phe Val Asp Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser

115 120

<210> 174

<211> 120

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 174

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ala

20 25 30

Asp Asn Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu

35 40 45

Trp Ile Gly Ser Ile His Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg Gly Val Arg Arg Ala Val Pro Phe Gln Arg Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser

115 120

<210> 175

<211> 120

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 175

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser

20 25 30

Asp Thr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Pro Glu

35 40 45

Trp Ile Gly Ser Ile His Tyr Ser Gly Ser Thr Leu Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg Gly Val Arg Arg Ala Val Pro Phe Asp Tyr Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser

115 120

<210> 176

<211> 120

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 176

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser

20 25 30

Ser Thr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu

35 40 45

Trp Ile Gly Gly Ile Ala Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg Gly Val Arg Arg Ala Val Pro Phe Asp Tyr Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser

115 120

<210> 177

<211> 120

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 177

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser

20 25 30

Ser Thr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu

35 40 45

Trp Ile Gly Ser Ile Ser Tyr Asn Ala Leu Thr Tyr Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg Gly Thr Arg Arg Ala Val Pro Phe Asp Tyr Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser

115 120

<210> 178

<211> 120

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 178

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser

20 25 30

Ser Thr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu

35 40 45

Trp Ile Gly Gly Ile Ala Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg Gly Val Arg Arg Ala Val Pro Phe Ala Asp Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser

115 120

<210> 179

<211> 120

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 179

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Val Ser Ser Ser

20 25 30

Ser Thr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu

35 40 45

Trp Ile Gly Gly Ile Ala Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg Gly Val Arg Arg Ala Val Pro Phe Asp Tyr Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser

115 120

<210> 180

<211> 120

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 180

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser

20 25 30

Ser Thr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu

35 40 45

Trp Ile Gly Gly Ile Ala Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg Gly Thr Arg Arg Ala Val Pro Phe Asp Tyr Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser

115 120

<210> 181

<211> 120

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 181

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser

20 25 30

Asp Thr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu

35 40 45

Trp Ile Gly Ser Ile His Tyr Ser Gly Ser Thr Leu Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg Gly Ile Arg Arg Ala Val Pro Phe Asp Tyr Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser

115 120

<210> 182

<211> 120

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 182

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser

20 25 30

Asp Thr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu

35 40 45

Trp Ile Gly Ser Ile His Tyr Ser Gly Ser Thr Leu Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg Gly Gln Phe Arg Ala Val Pro Phe Asp Tyr Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser

115 120

<210> 183

<211> 122

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 183

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Tyr Ser Ile Ser Ser Gly

20 25 30

Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp

35 40 45

Ile Gly Ser Ile Tyr His Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu

50 55 60

Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser

65 70 75 80

Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Thr His Thr Tyr Ser Arg Gly Pro Met Asp Val Trp

100 105 110

Gly Gln Gly Thr Thr Val Thr Val Ser Ser

115 120

<210> 184

<211> 122

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 184

Gln Leu Gln Leu Gln Glu Ser Gly Pro Arg Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Tyr Ser Ile Ser Ser Gly

20 25 30

Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp

35 40 45

Ile Gly Ser Ile Tyr His Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu

50 55 60

Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser

65 70 75 80

Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Thr His Thr Tyr Ser Arg Gly Pro Phe Asp Val Trp

100 105 110

Gly Gln Gly Thr Thr Val Thr Val Ser Ser

115 120

<210> 185

<211> 122

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 185

Leu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Tyr Ser Ile Leu Ser Gly

20 25 30

Tyr Tyr Trp Phe Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp

35 40 45

Ile Gly Gly Ile Tyr His Ser Ala Ser Thr Ala Tyr Asn Pro Ser Leu

50 55 60

Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser

65 70 75 80

Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Thr Pro Ile Tyr Ser Arg Gly Pro Leu Asp Val Trp

100 105 110

Gly Gln Gly Thr Thr Val Thr Val Ser Ser

115 120

<210> 186

<211> 122

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 186

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Tyr Ser Ile Ser Ser Gly

20 25 30

His Tyr Trp Ile Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp

35 40 45

Ile Gly Gly Ile Tyr His Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu

50 55 60

Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asp Gln Phe Ser

65 70 75 80

Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Gly Gln Thr Tyr Ser Arg Gly Pro Leu Asp Val Trp

100 105 110

Gly Gln Gly Thr Thr Val Thr Val Ser Ser

115 120

<210> 187

<211> 122

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 187

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Pro Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Tyr Ser Ile Ser Ser Gly

20 25 30

His Tyr Trp Ile Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp

35 40 45

Ile Gly Gly Ile Tyr His Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu

50 55 60

Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser

65 70 75 80

Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Gly Ala Thr Tyr Ser Arg Gly Pro Leu Asp Val Trp

100 105 110

Gly Gln Gly Thr Thr Val Thr Val Ser Ser

115 120

<210> 188

<211> 122

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 188

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Tyr Ser Ile Leu Ser Gly

20 25 30

Tyr Tyr Trp Phe Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp

35 40 45

Ile Gly Gly Ile Tyr His Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu

50 55 60

Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser

65 70 75 80

Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Thr His Thr Tyr Ser Arg Gly Pro Leu Asp Val Trp

100 105 110

Gly Gln Gly Thr Thr Val Thr Val Ser Ser

115 120

<210> 189

<211> 122

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 189

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Tyr Ser Ile Ser Ser Gly

20 25 30

Phe Tyr Trp Thr Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp

35 40 45

Ile Gly Ala Ile Tyr His Ser Gly Ser Thr Val Tyr Asn Pro Ser Leu

50 55 60

Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser

65 70 75 80

Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Thr His Thr Tyr Ser Arg Gly Pro Leu Asp Val Trp

100 105 110

Gly Gln Gly Thr Thr Val Thr Val Ser Ser

115 120

<210> 190

<211> 122

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 190

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Tyr Ser Ile Ser Ser Gly

20 25 30

Tyr Tyr Trp Leu Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp

35 40 45

Ile Gly Gly Ile Tyr His Ser Ala Ser Thr Ala Tyr Asn Pro Ser Leu

50 55 60

Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser

65 70 75 80

Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Thr Val Lys Tyr Ser Arg Gly Pro Leu Asp Val Trp

100 105 110

Gly Gln Gly Thr Thr Val Thr Val Ser Ser

115 120

<210> 191

<211> 122

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 191

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Tyr Ser Ile Ser Ser Gly

20 25 30

His Tyr Trp Thr Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp

35 40 45

Ile Gly Ala Ile Tyr His Ser Gly Ser Thr Val Tyr Asn Pro Ser Leu

50 55 60

Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser

65 70 75 80

Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Gln Val Thr Tyr Ser Arg Gly Pro Leu Asp Val Trp

100 105 110

Gly Gln Gly Thr Thr Val Thr Val Ser Ser

115 120

<210> 192

<211> 122

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 192

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Tyr Ser Ile Leu Ser Gly

20 25 30

Tyr Tyr Trp Phe Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp

35 40 45

Ile Gly Gly Ile Tyr His Ser Gly Ser Thr Ala Tyr Asn Pro Ser Leu

50 55 60

Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser

65 70 75 80

Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Glu Val Thr Tyr Ser Arg Gly Pro Leu Asp Val Trp

100 105 110

Gly Gln Gly Thr Thr Val Thr Val Ser Ser

115 120

<210> 193

<211> 123

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 193

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asn Tyr

20 25 30

Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Ala Ile Ser Ala Arg Ala Gly Ile Thr Tyr Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Arg Ile Gly Tyr Ser Tyr Gly Thr Ala Pro Pro Phe Asp Val

100 105 110

Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser

115 120

<210> 194

<211> 118

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 194

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr

20 25 30

Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Tyr Ile Ala Ser Ser Gly Ser Val Ile Tyr Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg His Gly Thr Pro Arg Ala Phe Asp Ile Trp Gly Gln Gly Thr

100 105 110

Thr Val Thr Val Ser Ser

115

<210> 195

<211> 119

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 195

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Ser

20 25 30

Ala Met Ala Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Thr Ile Ser Gly Ser Gly Ile Thr Thr Trp Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Lys Gly Ser Arg His Leu Asn Ala Phe Asn Arg Trp Gly Gln Gly

100 105 110

Thr Thr Val Thr Val Ser Ser

115

<210> 196

<211> 121

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 196

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gly

1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Gly Ser Ile Ser Ser Ser

20 25 30

Asn Trp Trp Ser Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp

35 40 45

Ile Gly Glu Ile Tyr His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu

50 55 60

Lys Ser Arg Val Thr Ile Ser Val Asp Lys Ser Lys Asn Gln Phe Ser

65 70 75 80

Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Val Tyr His Tyr Asp Pro Tyr Gly Met Asp Val Trp Gly

100 105 110

Gln Gly Thr Thr Val Thr Val Ser Ser

115 120

<210> 197

<211> 120

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 197

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser

20 25 30

Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu

35 40 45

Trp Ile Gly Ser Ile Ser Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg Thr Glu Leu Gly Lys Met His Phe Asp Tyr Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser

115 120

<210> 198

<211> 118

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 198

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser

20 25 30

Asp Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu

35 40 45

Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg Gly Ser Pro Arg Tyr Met Gln Asp Trp Gly Gln Gly Thr

100 105 110

Leu Val Thr Val Ser Ser

115

<210> 199

<211> 121

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 199

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr

20 25 30

Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Tyr Ile Ser Ser Ser Gly Ser Thr Ile Tyr Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg His Ser Ser Leu Gly Thr His Asn Trp Phe Asp Pro Trp Gly

100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser

115 120

<210> 200

<211> 123

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 200

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Tyr Ser Ile Ser Ser Gly

20 25 30

Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp

35 40 45

Ile Gly Ser Ile Tyr His Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu

50 55 60

Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser

65 70 75 80

Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Glu Gly Ala Leu Ser Tyr Ser Trp Leu Ala Ala Phe Asp Ile

100 105 110

Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser

115 120

<210> 201

<400> 201

000

<210> 202

<400> 202

000

<210> 203

<400> 203

000

<210> 204

<211> 108

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 204

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ala Val His Ser Pro

85 90 95

Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys

100 105

<210> 205

<211> 108

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 205

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Gly Ala Ser Gln Ser Val Ser Ser Asp

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Gly Ala Tyr Ser Leu Ala Thr Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Trp Ala Val His Ser Pro

85 90 95

Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys

100 105

<210> 206

<211> 108

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 206

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Gln Ala Ser Gln Ala Val Ser Ser Asn

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Val Val His Ser Pro

85 90 95

Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys

100 105

<210> 207

<211> 108

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 207

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Gly Ala Ser Gln Ser Val Ser Ser Ala

20 25 30

Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Gly Ala Ser Ala Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Val Val His Ser Pro

85 90 95

Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys

100 105

<210> 208

<211> 108

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 208

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Thr

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Gly Ala Ser Ser Arg Glu Ala Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Thr Val His Ser Pro

85 90 95

Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys

100 105

<210> 209

<211> 108

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 209

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Gln Ala Ser Gln Ala Val Ser Ser Asn

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Gly Ala Ser Asn Arg Ala Ala Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ala Ile His Ser Pro

85 90 95

Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys

100 105

<210> 210

<211> 108

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 210

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Gln Ala Ser Gln Ser Val Ser Ser Ser

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Gly Ala Ser Asn Arg Ala Ala Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Val Val His Ser Pro

85 90 95

Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys

100 105

<210> 211

<211> 108

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 211

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Lys Ala Ser Gln Ala Val Ser Ser Ser

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Gly Ala Ser Ser Arg Gln Asp Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Val Val His Ser Pro

85 90 95

Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys

100 105

<210> 212

<211> 108

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 212

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln His Ser Ser Tyr Pro

85 90 95

Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys

100 105

<210> 213

<211> 108

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 213

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Glu Ala Ser Gln Ser Val Ser Ser Ser

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Gly Ala Ser Asn Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln His Ser Leu Tyr Pro

85 90 95

Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys

100 105

<210> 214

<211> 108

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 214

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Glu Ala Ser Gln Ser Val Ser Ala Ser

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Asp Ala Ser Ser Arg Ala Ser Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Phe Ser Ser Tyr Pro

85 90 95

Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys

100 105

<210> 215

<211> 108

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 215

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Glu Ala Ser Gln Ser Val Ser Ser Ala

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Asp Ala Ser Thr Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Val Ser Ser Tyr Pro

85 90 95

Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys

100 105

<210> 216

<211> 108

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 216

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Ala Leu Ser Cys Arg Val Ser Gln Ser Val Ser Asp Ala

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Asp Ala Ser Ser Arg Ala Ser Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Val Ser Ser Tyr Pro

85 90 95

Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys

100 105

<210> 217

<211> 108

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 217

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Glu Val Ser Gln Ser Val Ser Ala Ser

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln His Ser Leu Tyr Pro

85 90 95

Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys

100 105

<210> 218

<211> 108

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 218

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ala

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Gly Ala Ser Asp Arg Ala Asn Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln His Ser Leu Tyr Pro

85 90 95

Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys

100 105

<210> 219

<211> 108

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 219

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Asn Ala Val Ser Ser Ser

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Gly Ala Ser Asp Arg Ala Asn Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln His Ser Ile Tyr Pro

85 90 95

Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys

100 105

<210> 220

<211> 108

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 220

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Asn Ala Val Ser Ser Ser

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Gly Ala Ser Tyr Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln His Ser Leu Tyr Pro

85 90 95

Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys

100 105

<210> 221

<211> 106

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 221

Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly

1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Asn Ser Trp

20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile

35 40 45

Ser Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly

50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro

65 70 75 80

Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Ser His Ile Thr

85 90 95

Phe Gly Gly Gly Thr Lys Val Glu Ile Lys

100 105

<210> 222

<211> 107

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 222

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly

1 5 10 15

Asp Arg Val Thr Ile Thr Cys Ala Ala Ser Gln Gly Ile Ser Ser Asp

20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile

35 40 45

Tyr Ser Ala Ser Ser Thr Gln Ser Gly Val Pro Ser Arg Phe Ser Gly

50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro

65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Tyr Leu Tyr Pro Ile

85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys

100 105

<210> 223

<211> 107

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 223

Gly Val Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly

1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Thr Tyr

20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile

35 40 45

Tyr Asp Ala Phe Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly

50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro

65 70 75 80

Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Leu Pro Phe Leu Pro Ile

85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys

100 105

<210> 224

<211> 112

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 224

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly

1 5 10 15

Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser

20 25 30

Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser

35 40 45

Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro

50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile

65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala

85 90 95

Leu Gly Gly Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys

100 105 110

<210> 225

<211> 108

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 225

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Gly Ala Ser Arg Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Val Ser Asp Pro

85 90 95

Ile Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys

100 105

<210> 226

<211> 108

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 226

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Gly Ala Ser Arg Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Val Gly Ser Ser Pro

85 90 95

Ile Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys

100 105

<210> 227

<211> 107

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 227

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly

1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr

20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile

35 40 45

Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly

50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro

65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser His Leu Val Pro Arg

85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys

100 105

<210> 228

<211> 108

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 228

Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn

20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile

35 40 45

Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly

50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser

65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ala Asn His His Pro Pro

85 90 95

Phe Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys

100 105

<210> 229

<400> 229

000

<210> 230

<400> 230

000

<210> 231

<400> 231

000

<210> 232

<211> 450

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 232

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser

20 25 30

Asp Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu

35 40 45

Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg Gly Val Arg Arg Ala Val Pro Phe Asp Tyr Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val

115 120 125

Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala

130 135 140

Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser

145 150 155 160

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val

165 170 175

Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro

180 185 190

Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys

195 200 205

Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp

210 215 220

Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Ala

225 230 235 240

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile

245 250 255

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu

260 265 270

Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His

275 280 285

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg

290 295 300

Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys

305 310 315 320

Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu

325 330 335

Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr

340 345 350

Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu

355 360 365

Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp

370 375 380

Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val

385 390 395 400

Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp

405 410 415

Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His

420 425 430

Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro

435 440 445

Gly Lys

450

<210> 233

<211> 450

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 233

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser

20 25 30

Ser Thr Tyr Trp Ala Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu

35 40 45

Trp Ile Gly Ser Ile Ser Ser Ser Gly Ser Thr Tyr Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg Gly Ile Ala Arg Ala Val Pro Phe Asp Tyr Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val

115 120 125

Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala

130 135 140

Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser

145 150 155 160

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val

165 170 175

Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro

180 185 190

Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys

195 200 205

Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp

210 215 220

Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Ala

225 230 235 240

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile

245 250 255

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu

260 265 270

Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His

275 280 285

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg

290 295 300

Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys

305 310 315 320

Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu

325 330 335

Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr

340 345 350

Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu

355 360 365

Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp

370 375 380

Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val

385 390 395 400

Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp

405 410 415

Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His

420 425 430

Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro

435 440 445

Gly Lys

450

<210> 234

<211> 450

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 234

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser

20 25 30

Ser Thr Tyr Trp Gly Trp Ile Arg Gln Ser Pro Gly Lys Gly Leu Glu

35 40 45

Trp Ile Gly Ser Ile His His Ser Gly Ala Thr Tyr Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg Gly Pro Lys Arg Ala Val Pro Phe Asp Tyr Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val

115 120 125

Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala

130 135 140

Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser

145 150 155 160

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val

165 170 175

Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro

180 185 190

Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys

195 200 205

Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp

210 215 220

Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Ala

225 230 235 240

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile

245 250 255

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu

260 265 270

Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His

275 280 285

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg

290 295 300

Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys

305 310 315 320

Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu

325 330 335

Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr

340 345 350

Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu

355 360 365

Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp

370 375 380

Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val

385 390 395 400

Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp

405 410 415

Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His

420 425 430

Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro

435 440 445

Gly Lys

450

<210> 235

<211> 450

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 235

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser

20 25 30

Asp Thr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu

35 40 45

Trp Ile Gly Ser Ile His Tyr Ser Gly Ser Thr Leu Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg Gly Val Arg Arg Ala Val Pro Phe Val Asp Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val

115 120 125

Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala

130 135 140

Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser

145 150 155 160

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val

165 170 175

Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro

180 185 190

Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys

195 200 205

Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp

210 215 220

Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Ala

225 230 235 240

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile

245 250 255

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu

260 265 270

Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His

275 280 285

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg

290 295 300

Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys

305 310 315 320

Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu

325 330 335

Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr

340 345 350

Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu

355 360 365

Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp

370 375 380

Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val

385 390 395 400

Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp

405 410 415

Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His

420 425 430

Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro

435 440 445

Gly Lys

450

<210> 236

<211> 450

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 236

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ala

20 25 30

Asp Asn Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu

35 40 45

Trp Ile Gly Ser Ile His Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg Gly Val Arg Arg Ala Val Pro Phe Gln Arg Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val

115 120 125

Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala

130 135 140

Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser

145 150 155 160

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val

165 170 175

Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro

180 185 190

Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys

195 200 205

Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp

210 215 220

Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Ala

225 230 235 240

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile

245 250 255

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu

260 265 270

Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His

275 280 285

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg

290 295 300

Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys

305 310 315 320

Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu

325 330 335

Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr

340 345 350

Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu

355 360 365

Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp

370 375 380

Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val

385 390 395 400

Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp

405 410 415

Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His

420 425 430

Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro

435 440 445

Gly Lys

450

<210> 237

<211> 450

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 237

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser

20 25 30

Asp Thr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Pro Glu

35 40 45

Trp Ile Gly Ser Ile His Tyr Ser Gly Ser Thr Leu Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg Gly Val Arg Arg Ala Val Pro Phe Asp Tyr Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val

115 120 125

Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala

130 135 140

Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser

145 150 155 160

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val

165 170 175

Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro

180 185 190

Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys

195 200 205

Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp

210 215 220

Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Ala

225 230 235 240

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile

245 250 255

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu

260 265 270

Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His

275 280 285

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg

290 295 300

Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys

305 310 315 320

Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu

325 330 335

Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr

340 345 350

Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu

355 360 365

Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp

370 375 380

Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val

385 390 395 400

Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp

405 410 415

Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His

420 425 430

Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro

435 440 445

Gly Lys

450

<210> 238

<211> 450

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 238

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser

20 25 30

Ser Thr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu

35 40 45

Trp Ile Gly Gly Ile Ala Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg Gly Val Arg Arg Ala Val Pro Phe Asp Tyr Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val

115 120 125

Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala

130 135 140

Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser

145 150 155 160

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val

165 170 175

Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro

180 185 190

Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys

195 200 205

Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp

210 215 220

Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Ala

225 230 235 240

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile

245 250 255

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu

260 265 270

Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His

275 280 285

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg

290 295 300

Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys

305 310 315 320

Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu

325 330 335

Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr

340 345 350

Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu

355 360 365

Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp

370 375 380

Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val

385 390 395 400

Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp

405 410 415

Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His

420 425 430

Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro

435 440 445

Gly Lys

450

<210> 239

<211> 450

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 239

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser

20 25 30

Ser Thr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu

35 40 45

Trp Ile Gly Ser Ile Ser Tyr Asn Ala Leu Thr Tyr Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg Gly Thr Arg Arg Ala Val Pro Phe Asp Tyr Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val

115 120 125

Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala

130 135 140

Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser

145 150 155 160

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val

165 170 175

Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro

180 185 190

Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys

195 200 205

Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp

210 215 220

Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Ala

225 230 235 240

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile

245 250 255

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu

260 265 270

Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His

275 280 285

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg

290 295 300

Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys

305 310 315 320

Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu

325 330 335

Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr

340 345 350

Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu

355 360 365

Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp

370 375 380

Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val

385 390 395 400

Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp

405 410 415

Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His

420 425 430

Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro

435 440 445

Gly Lys

450

<210> 240

<211> 450

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 240

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser

20 25 30

Ser Thr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu

35 40 45

Trp Ile Gly Gly Ile Ala Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg Gly Val Arg Arg Ala Val Pro Phe Ala Asp Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val

115 120 125

Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala

130 135 140

Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser

145 150 155 160

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val

165 170 175

Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro

180 185 190

Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys

195 200 205

Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp

210 215 220

Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Ala

225 230 235 240

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile

245 250 255

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu

260 265 270

Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His

275 280 285

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg

290 295 300

Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys

305 310 315 320

Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu

325 330 335

Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr

340 345 350

Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu

355 360 365

Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp

370 375 380

Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val

385 390 395 400

Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp

405 410 415

Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His

420 425 430

Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro

435 440 445

Gly Lys

450

<210> 241

<211> 450

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 241

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Val Ser Ser Ser

20 25 30

Ser Thr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu

35 40 45

Trp Ile Gly Gly Ile Ala Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg Gly Val Arg Arg Ala Val Pro Phe Asp Tyr Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val

115 120 125

Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala

130 135 140

Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser

145 150 155 160

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val

165 170 175

Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro

180 185 190

Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys

195 200 205

Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp

210 215 220

Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Ala

225 230 235 240

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile

245 250 255

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu

260 265 270

Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His

275 280 285

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg

290 295 300

Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys

305 310 315 320

Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu

325 330 335

Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr

340 345 350

Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu

355 360 365

Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp

370 375 380

Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val

385 390 395 400

Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp

405 410 415

Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His

420 425 430

Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro

435 440 445

Gly Lys

450

<210> 242

<211> 450

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 242

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser

20 25 30

Ser Thr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu

35 40 45

Trp Ile Gly Gly Ile Ala Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg Gly Thr Arg Arg Ala Val Pro Phe Asp Tyr Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val

115 120 125

Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala

130 135 140

Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser

145 150 155 160

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val

165 170 175

Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro

180 185 190

Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys

195 200 205

Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp

210 215 220

Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Ala

225 230 235 240

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile

245 250 255

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu

260 265 270

Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His

275 280 285

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg

290 295 300

Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys

305 310 315 320

Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu

325 330 335

Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr

340 345 350

Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu

355 360 365

Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp

370 375 380

Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val

385 390 395 400

Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp

405 410 415

Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His

420 425 430

Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro

435 440 445

Gly Lys

450

<210> 243

<211> 450

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 243

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser

20 25 30

Asp Thr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu

35 40 45

Trp Ile Gly Ser Ile His Tyr Ser Gly Ser Thr Leu Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg Gly Ile Arg Arg Ala Val Pro Phe Asp Tyr Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val

115 120 125

Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala

130 135 140

Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser

145 150 155 160

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val

165 170 175

Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro

180 185 190

Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys

195 200 205

Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp

210 215 220

Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Ala

225 230 235 240

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile

245 250 255

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu

260 265 270

Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His

275 280 285

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg

290 295 300

Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys

305 310 315 320

Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu

325 330 335

Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr

340 345 350

Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu

355 360 365

Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp

370 375 380

Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val

385 390 395 400

Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp

405 410 415

Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His

420 425 430

Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro

435 440 445

Gly Lys

450

<210> 244

<211> 450

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 244

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser

20 25 30

Asp Thr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu

35 40 45

Trp Ile Gly Ser Ile His Tyr Ser Gly Ser Thr Leu Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg Gly Gln Phe Arg Ala Val Pro Phe Asp Tyr Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val

115 120 125

Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala

130 135 140

Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser

145 150 155 160

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val

165 170 175

Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro

180 185 190

Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys

195 200 205

Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp

210 215 220

Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Ala

225 230 235 240

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile

245 250 255

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu

260 265 270

Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His

275 280 285

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg

290 295 300

Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys

305 310 315 320

Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu

325 330 335

Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr

340 345 350

Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu

355 360 365

Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp

370 375 380

Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val

385 390 395 400

Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp

405 410 415

Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His

420 425 430

Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro

435 440 445

Gly Lys

450

<210> 245

<211> 452

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 245

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Tyr Ser Ile Ser Ser Gly

20 25 30

Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp

35 40 45

Ile Gly Ser Ile Tyr His Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu

50 55 60

Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser

65 70 75 80

Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Thr His Thr Tyr Ser Arg Gly Pro Met Asp Val Trp

100 105 110

Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro

115 120 125

Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr

130 135 140

Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr

145 150 155 160

Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro

165 170 175

Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr

180 185 190

Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn

195 200 205

His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser

210 215 220

Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala

225 230 235 240

Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu

245 250 255

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser

260 265 270

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu

275 280 285

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr

290 295 300

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn

305 310 315 320

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro

325 330 335

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln

340 345 350

Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val

355 360 365

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val

370 375 380

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro

385 390 395 400

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr

405 410 415

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val

420 425 430

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu

435 440 445

Ser Pro Gly Lys

450

<210> 246

<211> 452

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 246

Gln Leu Gln Leu Gln Glu Ser Gly Pro Arg Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Tyr Ser Ile Ser Ser Gly

20 25 30

Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp

35 40 45

Ile Gly Ser Ile Tyr His Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu

50 55 60

Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser

65 70 75 80

Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Thr His Thr Tyr Ser Arg Gly Pro Phe Asp Val Trp

100 105 110

Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro

115 120 125

Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr

130 135 140

Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr

145 150 155 160

Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro

165 170 175

Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr

180 185 190

Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn

195 200 205

His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser

210 215 220

Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala

225 230 235 240

Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu

245 250 255

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser

260 265 270

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu

275 280 285

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr

290 295 300

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn

305 310 315 320

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro

325 330 335

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln

340 345 350

Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val

355 360 365

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val

370 375 380

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro

385 390 395 400

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr

405 410 415

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val

420 425 430

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu

435 440 445

Ser Pro Gly Lys

450

<210> 247

<211> 452

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 247

Leu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Tyr Ser Ile Leu Ser Gly

20 25 30

Tyr Tyr Trp Phe Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp

35 40 45

Ile Gly Gly Ile Tyr His Ser Ala Ser Thr Ala Tyr Asn Pro Ser Leu

50 55 60

Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser

65 70 75 80

Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Thr Pro Ile Tyr Ser Arg Gly Pro Leu Asp Val Trp

100 105 110

Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro

115 120 125

Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr

130 135 140

Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr

145 150 155 160

Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro

165 170 175

Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr

180 185 190

Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn

195 200 205

His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser

210 215 220

Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala

225 230 235 240

Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu

245 250 255

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser

260 265 270

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu

275 280 285

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr

290 295 300

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn

305 310 315 320

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro

325 330 335

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln

340 345 350

Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val

355 360 365

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val

370 375 380

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro

385 390 395 400

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr

405 410 415

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val

420 425 430

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu

435 440 445

Ser Pro Gly Lys

450

<210> 248

<211> 452

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 248

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Tyr Ser Ile Ser Ser Gly

20 25 30

His Tyr Trp Ile Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp

35 40 45

Ile Gly Gly Ile Tyr His Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu

50 55 60

Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asp Gln Phe Ser

65 70 75 80

Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Gly Gln Thr Tyr Ser Arg Gly Pro Leu Asp Val Trp

100 105 110

Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro

115 120 125

Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr

130 135 140

Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr

145 150 155 160

Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro

165 170 175

Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr

180 185 190

Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn

195 200 205

His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser

210 215 220

Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala

225 230 235 240

Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu

245 250 255

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser

260 265 270

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu

275 280 285

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr

290 295 300

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn

305 310 315 320

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro

325 330 335

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln

340 345 350

Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val

355 360 365

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val

370 375 380

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro

385 390 395 400

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr

405 410 415

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val

420 425 430

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu

435 440 445

Ser Pro Gly Lys

450

<210> 249

<211> 452

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 249

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Pro Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Tyr Ser Ile Ser Ser Gly

20 25 30

His Tyr Trp Ile Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp

35 40 45

Ile Gly Gly Ile Tyr His Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu

50 55 60

Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser

65 70 75 80

Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Gly Ala Thr Tyr Ser Arg Gly Pro Leu Asp Val Trp

100 105 110

Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro

115 120 125

Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr

130 135 140

Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr

145 150 155 160

Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro

165 170 175

Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr

180 185 190

Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn

195 200 205

His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser

210 215 220

Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala

225 230 235 240

Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu

245 250 255

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser

260 265 270

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu

275 280 285

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr

290 295 300

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn

305 310 315 320

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro

325 330 335

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln

340 345 350

Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val

355 360 365

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val

370 375 380

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro

385 390 395 400

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr

405 410 415

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val

420 425 430

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu

435 440 445

Ser Pro Gly Lys

450

<210> 250

<211> 452

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 250

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Tyr Ser Ile Leu Ser Gly

20 25 30

Tyr Tyr Trp Phe Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp

35 40 45

Ile Gly Gly Ile Tyr His Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu

50 55 60

Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser

65 70 75 80

Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Thr His Thr Tyr Ser Arg Gly Pro Leu Asp Val Trp

100 105 110

Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro

115 120 125

Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr

130 135 140

Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr

145 150 155 160

Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro

165 170 175

Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr

180 185 190

Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn

195 200 205

His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser

210 215 220

Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala

225 230 235 240

Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu

245 250 255

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser

260 265 270

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu

275 280 285

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr

290 295 300

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn

305 310 315 320

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro

325 330 335

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln

340 345 350

Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val

355 360 365

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val

370 375 380

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro

385 390 395 400

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr

405 410 415

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val

420 425 430

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu

435 440 445

Ser Pro Gly Lys

450

<210> 251

<211> 452

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 251

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Tyr Ser Ile Ser Ser Gly

20 25 30

Phe Tyr Trp Thr Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp

35 40 45

Ile Gly Ala Ile Tyr His Ser Gly Ser Thr Val Tyr Asn Pro Ser Leu

50 55 60

Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser

65 70 75 80

Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Thr His Thr Tyr Ser Arg Gly Pro Leu Asp Val Trp

100 105 110

Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro

115 120 125

Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr

130 135 140

Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr

145 150 155 160

Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro

165 170 175

Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr

180 185 190

Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn

195 200 205

His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser

210 215 220

Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala

225 230 235 240

Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu

245 250 255

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser

260 265 270

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu

275 280 285

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr

290 295 300

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn

305 310 315 320

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro

325 330 335

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln

340 345 350

Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val

355 360 365

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val

370 375 380

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro

385 390 395 400

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr

405 410 415

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val

420 425 430

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu

435 440 445

Ser Pro Gly Lys

450

<210> 252

<211> 452

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 252

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Tyr Ser Ile Ser Ser Gly

20 25 30

Tyr Tyr Trp Leu Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp

35 40 45

Ile Gly Gly Ile Tyr His Ser Ala Ser Thr Ala Tyr Asn Pro Ser Leu

50 55 60

Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser

65 70 75 80

Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Thr Val Lys Tyr Ser Arg Gly Pro Leu Asp Val Trp

100 105 110

Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro

115 120 125

Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr

130 135 140

Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr

145 150 155 160

Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro

165 170 175

Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr

180 185 190

Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn

195 200 205

His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser

210 215 220

Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala

225 230 235 240

Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu

245 250 255

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser

260 265 270

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu

275 280 285

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr

290 295 300

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn

305 310 315 320

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro

325 330 335

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln

340 345 350

Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val

355 360 365

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val

370 375 380

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro

385 390 395 400

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr

405 410 415

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val

420 425 430

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu

435 440 445

Ser Pro Gly Lys

450

<210> 253

<211> 452

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 253

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Tyr Ser Ile Ser Ser Gly

20 25 30

His Tyr Trp Thr Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp

35 40 45

Ile Gly Ala Ile Tyr His Ser Gly Ser Thr Val Tyr Asn Pro Ser Leu

50 55 60

Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser

65 70 75 80

Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Gln Val Thr Tyr Ser Arg Gly Pro Leu Asp Val Trp

100 105 110

Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro

115 120 125

Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr

130 135 140

Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr

145 150 155 160

Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro

165 170 175

Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr

180 185 190

Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn

195 200 205

His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser

210 215 220

Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala

225 230 235 240

Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu

245 250 255

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser

260 265 270

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu

275 280 285

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr

290 295 300

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn

305 310 315 320

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro

325 330 335

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln

340 345 350

Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val

355 360 365

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val

370 375 380

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro

385 390 395 400

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr

405 410 415

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val

420 425 430

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu

435 440 445

Ser Pro Gly Lys

450

<210> 254

<211> 452

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 254

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Tyr Ser Ile Leu Ser Gly

20 25 30

Tyr Tyr Trp Phe Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp

35 40 45

Ile Gly Gly Ile Tyr His Ser Gly Ser Thr Ala Tyr Asn Pro Ser Leu

50 55 60

Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser

65 70 75 80

Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Glu Val Thr Tyr Ser Arg Gly Pro Leu Asp Val Trp

100 105 110

Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro

115 120 125

Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr

130 135 140

Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr

145 150 155 160

Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro

165 170 175

Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr

180 185 190

Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn

195 200 205

His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser

210 215 220

Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala

225 230 235 240

Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu

245 250 255

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser

260 265 270

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu

275 280 285

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr

290 295 300

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn

305 310 315 320

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro

325 330 335

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln

340 345 350

Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val

355 360 365

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val

370 375 380

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro

385 390 395 400

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr

405 410 415

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val

420 425 430

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu

435 440 445

Ser Pro Gly Lys

450

<210> 255

<211> 453

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 255

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asn Tyr

20 25 30

Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Ala Ile Ser Ala Arg Ala Gly Ile Thr Tyr Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Arg Ile Gly Tyr Ser Tyr Gly Thr Ala Pro Pro Phe Asp Val

100 105 110

Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly

115 120 125

Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly

130 135 140

Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val

145 150 155 160

Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe

165 170 175

Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val

180 185 190

Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val

195 200 205

Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys

210 215 220

Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala

225 230 235 240

Ala Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr

245 250 255

Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val

260 265 270

Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val

275 280 285

Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser

290 295 300

Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu

305 310 315 320

Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala

325 330 335

Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro

340 345 350

Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln

355 360 365

Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala

370 375 380

Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr

385 390 395 400

Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu

405 410 415

Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser

420 425 430

Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser

435 440 445

Leu Ser Pro Gly Lys

450

<210> 256

<211> 448

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 256

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr

20 25 30

Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Tyr Ile Ala Ser Ser Gly Ser Val Ile Tyr Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg His Gly Thr Pro Arg Ala Phe Asp Ile Trp Gly Gln Gly Thr

100 105 110

Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro

115 120 125

Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly

130 135 140

Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn

145 150 155 160

Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln

165 170 175

Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser

180 185 190

Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser

195 200 205

Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr

210 215 220

His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Ala Pro Ser

225 230 235 240

Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg

245 250 255

Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro

260 265 270

Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala

275 280 285

Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val

290 295 300

Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr

305 310 315 320

Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr

325 330 335

Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu

340 345 350

Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys

355 360 365

Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser

370 375 380

Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp

385 390 395 400

Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser

405 410 415

Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala

420 425 430

Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys

435 440 445

<210> 257

<211> 449

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 257

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Ser

20 25 30

Ala Met Ala Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Thr Ile Ser Gly Ser Gly Ile Thr Thr Trp Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Lys Gly Ser Arg His Leu Asn Ala Phe Asn Arg Trp Gly Gln Gly

100 105 110

Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe

115 120 125

Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu

130 135 140

Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp

145 150 155 160

Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu

165 170 175

Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser

180 185 190

Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro

195 200 205

Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys

210 215 220

Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Ala Pro

225 230 235 240

Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser

245 250 255

Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp

260 265 270

Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn

275 280 285

Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val

290 295 300

Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu

305 310 315 320

Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys

325 330 335

Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr

340 345 350

Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr

355 360 365

Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu

370 375 380

Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu

385 390 395 400

Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys

405 410 415

Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu

420 425 430

Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly

435 440 445

Lys

<210> 258

<211> 451

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 258

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gly

1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Gly Ser Ile Ser Ser Ser

20 25 30

Asn Trp Trp Ser Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp

35 40 45

Ile Gly Glu Ile Tyr His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu

50 55 60

Lys Ser Arg Val Thr Ile Ser Val Asp Lys Ser Lys Asn Gln Phe Ser

65 70 75 80

Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Val Tyr His Tyr Asp Pro Tyr Gly Met Asp Val Trp Gly

100 105 110

Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser

115 120 125

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala

130 135 140

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val

145 150 155 160

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala

165 170 175

Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val

180 185 190

Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His

195 200 205

Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys

210 215 220

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly

225 230 235 240

Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met

245 250 255

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His

260 265 270

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val

275 280 285

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr

290 295 300

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly

305 310 315 320

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile

325 330 335

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val

340 345 350

Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser

355 360 365

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu

370 375 380

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro

385 390 395 400

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val

405 410 415

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met

420 425 430

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser

435 440 445

Pro Gly Lys

450

<210> 259

<211> 450

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 259

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser

20 25 30

Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu

35 40 45

Trp Ile Gly Ser Ile Ser Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg Thr Glu Leu Gly Lys Met His Phe Asp Tyr Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val

115 120 125

Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala

130 135 140

Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser

145 150 155 160

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val

165 170 175

Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro

180 185 190

Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys

195 200 205

Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp

210 215 220

Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Ala

225 230 235 240

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile

245 250 255

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu

260 265 270

Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His

275 280 285

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg

290 295 300

Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys

305 310 315 320

Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu

325 330 335

Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr

340 345 350

Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu

355 360 365

Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp

370 375 380

Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val

385 390 395 400

Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp

405 410 415

Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His

420 425 430

Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro

435 440 445

Gly Lys

450

<210> 260

<211> 448

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 260

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser

20 25 30

Asp Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu

35 40 45

Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg Gly Ser Pro Arg Tyr Met Gln Asp Trp Gly Gln Gly Thr

100 105 110

Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro

115 120 125

Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly

130 135 140

Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn

145 150 155 160

Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln

165 170 175

Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser

180 185 190

Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser

195 200 205

Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr

210 215 220

His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Ala Pro Ser

225 230 235 240

Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg

245 250 255

Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro

260 265 270

Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala

275 280 285

Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val

290 295 300

Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr

305 310 315 320

Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr

325 330 335

Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu

340 345 350

Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys

355 360 365

Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser

370 375 380

Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp

385 390 395 400

Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser

405 410 415

Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala

420 425 430

Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys

435 440 445

<210> 261

<211> 451

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 261

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr

20 25 30

Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Tyr Ile Ser Ser Ser Gly Ser Thr Ile Tyr Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg His Ser Ser Leu Gly Thr His Asn Trp Phe Asp Pro Trp Gly

100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser

115 120 125

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala

130 135 140

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val

145 150 155 160

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala

165 170 175

Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val

180 185 190

Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His

195 200 205

Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys

210 215 220

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly

225 230 235 240

Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met

245 250 255

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His

260 265 270

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val

275 280 285

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr

290 295 300

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly

305 310 315 320

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile

325 330 335

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val

340 345 350

Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser

355 360 365

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu

370 375 380

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro

385 390 395 400

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val

405 410 415

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met

420 425 430

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser

435 440 445

Pro Gly Lys

450

<210> 262

<211> 453

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 262

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Tyr Ser Ile Ser Ser Gly

20 25 30

Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp

35 40 45

Ile Gly Ser Ile Tyr His Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu

50 55 60

Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser

65 70 75 80

Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Glu Gly Ala Leu Ser Tyr Ser Trp Leu Ala Ala Phe Asp Ile

100 105 110

Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly

115 120 125

Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly

130 135 140

Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val

145 150 155 160

Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe

165 170 175

Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val

180 185 190

Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val

195 200 205

Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys

210 215 220

Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala

225 230 235 240

Ala Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr

245 250 255

Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val

260 265 270

Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val

275 280 285

Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser

290 295 300

Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu

305 310 315 320

Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala

325 330 335

Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro

340 345 350

Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln

355 360 365

Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala

370 375 380

Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr

385 390 395 400

Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu

405 410 415

Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser

420 425 430

Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser

435 440 445

Leu Ser Pro Gly Lys

450

<210> 263

<400> 263

000

<210> 264

<400> 264

000

<210> 265

<400> 265

000

<210> 266

<211> 447

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 266

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser

20 25 30

Asp Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu

35 40 45

Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg Gly Val Arg Arg Ala Val Pro Phe Asp Tyr Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val

115 120 125

Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala

130 135 140

Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser

145 150 155 160

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val

165 170 175

Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro

180 185 190

Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys

195 200 205

Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro

210 215 220

Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val

225 230 235 240

Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr

245 250 255

Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu

260 265 270

Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys

275 280 285

Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser

290 295 300

Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys

305 310 315 320

Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile

325 330 335

Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro

340 345 350

Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu

355 360 365

Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn

370 375 380

Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser

385 390 395 400

Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg

405 410 415

Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu

420 425 430

His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys

435 440 445

<210> 267

<211> 447

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 267

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser

20 25 30

Ser Thr Tyr Trp Ala Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu

35 40 45

Trp Ile Gly Ser Ile Ser Ser Ser Gly Ser Thr Tyr Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg Gly Ile Ala Arg Ala Val Pro Phe Asp Tyr Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val

115 120 125

Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala

130 135 140

Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser

145 150 155 160

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val

165 170 175

Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro

180 185 190

Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys

195 200 205

Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro

210 215 220

Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val

225 230 235 240

Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr

245 250 255

Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu

260 265 270

Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys

275 280 285

Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser

290 295 300

Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys

305 310 315 320

Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile

325 330 335

Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro

340 345 350

Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu

355 360 365

Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn

370 375 380

Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser

385 390 395 400

Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg

405 410 415

Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu

420 425 430

His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys

435 440 445

<210> 268

<211> 447

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 268

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser

20 25 30

Ser Thr Tyr Trp Gly Trp Ile Arg Gln Ser Pro Gly Lys Gly Leu Glu

35 40 45

Trp Ile Gly Ser Ile His His Ser Gly Ala Thr Tyr Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg Gly Pro Lys Arg Ala Val Pro Phe Asp Tyr Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val

115 120 125

Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala

130 135 140

Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser

145 150 155 160

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val

165 170 175

Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro

180 185 190

Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys

195 200 205

Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro

210 215 220

Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val

225 230 235 240

Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr

245 250 255

Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu

260 265 270

Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys

275 280 285

Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser

290 295 300

Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys

305 310 315 320

Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile

325 330 335

Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro

340 345 350

Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu

355 360 365

Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn

370 375 380

Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser

385 390 395 400

Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg

405 410 415

Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu

420 425 430

His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys

435 440 445

<210> 269

<211> 447

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 269

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser

20 25 30

Asp Thr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu

35 40 45

Trp Ile Gly Ser Ile His Tyr Ser Gly Ser Thr Leu Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg Gly Val Arg Arg Ala Val Pro Phe Val Asp Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val

115 120 125

Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala

130 135 140

Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser

145 150 155 160

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val

165 170 175

Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro

180 185 190

Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys

195 200 205

Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro

210 215 220

Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val

225 230 235 240

Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr

245 250 255

Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu

260 265 270

Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys

275 280 285

Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser

290 295 300

Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys

305 310 315 320

Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile

325 330 335

Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro

340 345 350

Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu

355 360 365

Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn

370 375 380

Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser

385 390 395 400

Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg

405 410 415

Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu

420 425 430

His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys

435 440 445

<210> 270

<211> 447

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 270

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ala

20 25 30

Asp Asn Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu

35 40 45

Trp Ile Gly Ser Ile His Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg Gly Val Arg Arg Ala Val Pro Phe Gln Arg Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val

115 120 125

Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala

130 135 140

Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser

145 150 155 160

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val

165 170 175

Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro

180 185 190

Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys

195 200 205

Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro

210 215 220

Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val

225 230 235 240

Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr

245 250 255

Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu

260 265 270

Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys

275 280 285

Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser

290 295 300

Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys

305 310 315 320

Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile

325 330 335

Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro

340 345 350

Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu

355 360 365

Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn

370 375 380

Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser

385 390 395 400

Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg

405 410 415

Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu

420 425 430

His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys

435 440 445

<210> 271

<211> 447

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 271

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser

20 25 30

Asp Thr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Pro Glu

35 40 45

Trp Ile Gly Ser Ile His Tyr Ser Gly Ser Thr Leu Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg Gly Val Arg Arg Ala Val Pro Phe Asp Tyr Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val

115 120 125

Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala

130 135 140

Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser

145 150 155 160

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val

165 170 175

Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro

180 185 190

Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys

195 200 205

Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro

210 215 220

Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val

225 230 235 240

Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr

245 250 255

Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu

260 265 270

Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys

275 280 285

Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser

290 295 300

Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys

305 310 315 320

Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile

325 330 335

Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro

340 345 350

Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu

355 360 365

Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn

370 375 380

Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser

385 390 395 400

Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg

405 410 415

Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu

420 425 430

His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys

435 440 445

<210> 272

<211> 447

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 272

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser

20 25 30

Ser Thr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu

35 40 45

Trp Ile Gly Gly Ile Ala Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg Gly Val Arg Arg Ala Val Pro Phe Asp Tyr Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val

115 120 125

Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala

130 135 140

Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser

145 150 155 160

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val

165 170 175

Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro

180 185 190

Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys

195 200 205

Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro

210 215 220

Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val

225 230 235 240

Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr

245 250 255

Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu

260 265 270

Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys

275 280 285

Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser

290 295 300

Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys

305 310 315 320

Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile

325 330 335

Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro

340 345 350

Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu

355 360 365

Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn

370 375 380

Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser

385 390 395 400

Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg

405 410 415

Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu

420 425 430

His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys

435 440 445

<210> 273

<211> 447

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 273

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser

20 25 30

Ser Thr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu

35 40 45

Trp Ile Gly Ser Ile Ser Tyr Asn Ala Leu Thr Tyr Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg Gly Thr Arg Arg Ala Val Pro Phe Asp Tyr Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val

115 120 125

Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala

130 135 140

Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser

145 150 155 160

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val

165 170 175

Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro

180 185 190

Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys

195 200 205

Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro

210 215 220

Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val

225 230 235 240

Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr

245 250 255

Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu

260 265 270

Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys

275 280 285

Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser

290 295 300

Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys

305 310 315 320

Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile

325 330 335

Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro

340 345 350

Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu

355 360 365

Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn

370 375 380

Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser

385 390 395 400

Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg

405 410 415

Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu

420 425 430

His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys

435 440 445

<210> 274

<211> 447

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 274

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser

20 25 30

Ser Thr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu

35 40 45

Trp Ile Gly Gly Ile Ala Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg Gly Val Arg Arg Ala Val Pro Phe Ala Asp Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val

115 120 125

Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala

130 135 140

Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser

145 150 155 160

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val

165 170 175

Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro

180 185 190

Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys

195 200 205

Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro

210 215 220

Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val

225 230 235 240

Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr

245 250 255

Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu

260 265 270

Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys

275 280 285

Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser

290 295 300

Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys

305 310 315 320

Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile

325 330 335

Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro

340 345 350

Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu

355 360 365

Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn

370 375 380

Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser

385 390 395 400

Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg

405 410 415

Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu

420 425 430

His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys

435 440 445

<210> 275

<211> 447

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 275

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Val Ser Ser Ser

20 25 30

Ser Thr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu

35 40 45

Trp Ile Gly Gly Ile Ala Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg Gly Val Arg Arg Ala Val Pro Phe Asp Tyr Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val

115 120 125

Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala

130 135 140

Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser

145 150 155 160

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val

165 170 175

Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro

180 185 190

Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys

195 200 205

Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro

210 215 220

Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val

225 230 235 240

Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr

245 250 255

Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu

260 265 270

Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys

275 280 285

Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser

290 295 300

Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys

305 310 315 320

Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile

325 330 335

Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro

340 345 350

Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu

355 360 365

Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn

370 375 380

Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser

385 390 395 400

Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg

405 410 415

Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu

420 425 430

His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys

435 440 445

<210> 276

<211> 447

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 276

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser

20 25 30

Ser Thr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu

35 40 45

Trp Ile Gly Gly Ile Ala Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg Gly Thr Arg Arg Ala Val Pro Phe Asp Tyr Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val

115 120 125

Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala

130 135 140

Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser

145 150 155 160

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val

165 170 175

Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro

180 185 190

Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys

195 200 205

Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro

210 215 220

Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val

225 230 235 240

Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr

245 250 255

Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu

260 265 270

Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys

275 280 285

Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser

290 295 300

Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys

305 310 315 320

Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile

325 330 335

Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro

340 345 350

Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu

355 360 365

Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn

370 375 380

Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser

385 390 395 400

Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg

405 410 415

Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu

420 425 430

His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys

435 440 445

<210> 277

<211> 447

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 277

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser

20 25 30

Asp Thr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu

35 40 45

Trp Ile Gly Ser Ile His Tyr Ser Gly Ser Thr Leu Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg Gly Ile Arg Arg Ala Val Pro Phe Asp Tyr Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val

115 120 125

Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala

130 135 140

Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser

145 150 155 160

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val

165 170 175

Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro

180 185 190

Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys

195 200 205

Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro

210 215 220

Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val

225 230 235 240

Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr

245 250 255

Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu

260 265 270

Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys

275 280 285

Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser

290 295 300

Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys

305 310 315 320

Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile

325 330 335

Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro

340 345 350

Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu

355 360 365

Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn

370 375 380

Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser

385 390 395 400

Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg

405 410 415

Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu

420 425 430

His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys

435 440 445

<210> 278

<211> 447

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 278

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser

20 25 30

Asp Thr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu

35 40 45

Trp Ile Gly Ser Ile His Tyr Ser Gly Ser Thr Leu Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg Gly Gln Phe Arg Ala Val Pro Phe Asp Tyr Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val

115 120 125

Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala

130 135 140

Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser

145 150 155 160

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val

165 170 175

Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro

180 185 190

Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys

195 200 205

Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro

210 215 220

Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val

225 230 235 240

Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr

245 250 255

Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu

260 265 270

Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys

275 280 285

Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser

290 295 300

Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys

305 310 315 320

Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile

325 330 335

Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro

340 345 350

Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu

355 360 365

Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn

370 375 380

Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser

385 390 395 400

Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg

405 410 415

Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu

420 425 430

His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys

435 440 445

<210> 279

<211> 449

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 279

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Tyr Ser Ile Ser Ser Gly

20 25 30

Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp

35 40 45

Ile Gly Ser Ile Tyr His Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu

50 55 60

Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser

65 70 75 80

Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Thr His Thr Tyr Ser Arg Gly Pro Met Asp Val Trp

100 105 110

Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro

115 120 125

Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr

130 135 140

Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr

145 150 155 160

Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro

165 170 175

Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr

180 185 190

Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp

195 200 205

His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr

210 215 220

Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro

225 230 235 240

Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser

245 250 255

Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp

260 265 270

Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn

275 280 285

Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val

290 295 300

Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu

305 310 315 320

Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys

325 330 335

Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr

340 345 350

Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr

355 360 365

Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu

370 375 380

Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu

385 390 395 400

Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys

405 410 415

Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu

420 425 430

Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly

435 440 445

Lys

<210> 280

<211> 449

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 280

Gln Leu Gln Leu Gln Glu Ser Gly Pro Arg Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Tyr Ser Ile Ser Ser Gly

20 25 30

Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp

35 40 45

Ile Gly Ser Ile Tyr His Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu

50 55 60

Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser

65 70 75 80

Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Thr His Thr Tyr Ser Arg Gly Pro Phe Asp Val Trp

100 105 110

Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro

115 120 125

Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr

130 135 140

Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr

145 150 155 160

Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro

165 170 175

Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr

180 185 190

Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp

195 200 205

His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr

210 215 220

Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro

225 230 235 240

Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser

245 250 255

Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp

260 265 270

Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn

275 280 285

Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val

290 295 300

Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu

305 310 315 320

Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys

325 330 335

Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr

340 345 350

Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr

355 360 365

Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu

370 375 380

Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu

385 390 395 400

Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys

405 410 415

Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu

420 425 430

Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly

435 440 445

Lys

<210> 281

<211> 449

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 281

Leu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Tyr Ser Ile Leu Ser Gly

20 25 30

Tyr Tyr Trp Phe Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp

35 40 45

Ile Gly Gly Ile Tyr His Ser Ala Ser Thr Ala Tyr Asn Pro Ser Leu

50 55 60

Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser

65 70 75 80

Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Thr Pro Ile Tyr Ser Arg Gly Pro Leu Asp Val Trp

100 105 110

Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro

115 120 125

Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr

130 135 140

Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr

145 150 155 160

Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro

165 170 175

Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr

180 185 190

Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp

195 200 205

His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr

210 215 220

Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro

225 230 235 240

Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser

245 250 255

Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp

260 265 270

Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn

275 280 285

Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val

290 295 300

Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu

305 310 315 320

Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys

325 330 335

Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr

340 345 350

Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr

355 360 365

Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu

370 375 380

Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu

385 390 395 400

Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys

405 410 415

Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu

420 425 430

Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly

435 440 445

Lys

<210> 282

<211> 449

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 282

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Tyr Ser Ile Ser Ser Gly

20 25 30

His Tyr Trp Ile Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp

35 40 45

Ile Gly Gly Ile Tyr His Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu

50 55 60

Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asp Gln Phe Ser

65 70 75 80

Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Gly Gln Thr Tyr Ser Arg Gly Pro Leu Asp Val Trp

100 105 110

Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro

115 120 125

Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr

130 135 140

Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr

145 150 155 160

Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro

165 170 175

Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr

180 185 190

Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp

195 200 205

His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr

210 215 220

Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro

225 230 235 240

Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser

245 250 255

Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp

260 265 270

Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn

275 280 285

Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val

290 295 300

Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu

305 310 315 320

Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys

325 330 335

Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr

340 345 350

Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr

355 360 365

Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu

370 375 380

Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu

385 390 395 400

Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys

405 410 415

Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu

420 425 430

Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly

435 440 445

Lys

<210> 283

<211> 449

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 283

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Pro Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Tyr Ser Ile Ser Ser Gly

20 25 30

His Tyr Trp Ile Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp

35 40 45

Ile Gly Gly Ile Tyr His Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu

50 55 60

Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser

65 70 75 80

Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Gly Ala Thr Tyr Ser Arg Gly Pro Leu Asp Val Trp

100 105 110

Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro

115 120 125

Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr

130 135 140

Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr

145 150 155 160

Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro

165 170 175

Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr

180 185 190

Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp

195 200 205

His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr

210 215 220

Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro

225 230 235 240

Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser

245 250 255

Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp

260 265 270

Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn

275 280 285

Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val

290 295 300

Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu

305 310 315 320

Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys

325 330 335

Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr

340 345 350

Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr

355 360 365

Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu

370 375 380

Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu

385 390 395 400

Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys

405 410 415

Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu

420 425 430

Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly

435 440 445

Lys

<210> 284

<211> 449

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 284

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Tyr Ser Ile Leu Ser Gly

20 25 30

Tyr Tyr Trp Phe Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp

35 40 45

Ile Gly Gly Ile Tyr His Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu

50 55 60

Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser

65 70 75 80

Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Thr His Thr Tyr Ser Arg Gly Pro Leu Asp Val Trp

100 105 110

Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro

115 120 125

Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr

130 135 140

Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr

145 150 155 160

Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro

165 170 175

Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr

180 185 190

Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp

195 200 205

His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr

210 215 220

Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro

225 230 235 240

Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser

245 250 255

Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp

260 265 270

Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn

275 280 285

Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val

290 295 300

Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu

305 310 315 320

Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys

325 330 335

Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr

340 345 350

Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr

355 360 365

Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu

370 375 380

Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu

385 390 395 400

Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys

405 410 415

Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu

420 425 430

Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly

435 440 445

Lys

<210> 285

<211> 449

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 285

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Tyr Ser Ile Ser Ser Gly

20 25 30

Phe Tyr Trp Thr Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp

35 40 45

Ile Gly Ala Ile Tyr His Ser Gly Ser Thr Val Tyr Asn Pro Ser Leu

50 55 60

Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser

65 70 75 80

Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Thr His Thr Tyr Ser Arg Gly Pro Leu Asp Val Trp

100 105 110

Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro

115 120 125

Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr

130 135 140

Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr

145 150 155 160

Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro

165 170 175

Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr

180 185 190

Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp

195 200 205

His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr

210 215 220

Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro

225 230 235 240

Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser

245 250 255

Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp

260 265 270

Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn

275 280 285

Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val

290 295 300

Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu

305 310 315 320

Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys

325 330 335

Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr

340 345 350

Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr

355 360 365

Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu

370 375 380

Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu

385 390 395 400

Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys

405 410 415

Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu

420 425 430

Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly

435 440 445

Lys

<210> 286

<211> 449

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 286

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Tyr Ser Ile Ser Ser Gly

20 25 30

Tyr Tyr Trp Leu Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp

35 40 45

Ile Gly Gly Ile Tyr His Ser Ala Ser Thr Ala Tyr Asn Pro Ser Leu

50 55 60

Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser

65 70 75 80

Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Thr Val Lys Tyr Ser Arg Gly Pro Leu Asp Val Trp

100 105 110

Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro

115 120 125

Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr

130 135 140

Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr

145 150 155 160

Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro

165 170 175

Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr

180 185 190

Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp

195 200 205

His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr

210 215 220

Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro

225 230 235 240

Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser

245 250 255

Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp

260 265 270

Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn

275 280 285

Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val

290 295 300

Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu

305 310 315 320

Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys

325 330 335

Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr

340 345 350

Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr

355 360 365

Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu

370 375 380

Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu

385 390 395 400

Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys

405 410 415

Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu

420 425 430

Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly

435 440 445

Lys

<210> 287

<211> 449

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 287

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Tyr Ser Ile Ser Ser Gly

20 25 30

His Tyr Trp Thr Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp

35 40 45

Ile Gly Ala Ile Tyr His Ser Gly Ser Thr Val Tyr Asn Pro Ser Leu

50 55 60

Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser

65 70 75 80

Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Gln Val Thr Tyr Ser Arg Gly Pro Leu Asp Val Trp

100 105 110

Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro

115 120 125

Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr

130 135 140

Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr

145 150 155 160

Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro

165 170 175

Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr

180 185 190

Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp

195 200 205

His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr

210 215 220

Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro

225 230 235 240

Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser

245 250 255

Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp

260 265 270

Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn

275 280 285

Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val

290 295 300

Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu

305 310 315 320

Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys

325 330 335

Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr

340 345 350

Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr

355 360 365

Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu

370 375 380

Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu

385 390 395 400

Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys

405 410 415

Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu

420 425 430

Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly

435 440 445

Lys

<210> 288

<211> 449

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 288

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Tyr Ser Ile Leu Ser Gly

20 25 30

Tyr Tyr Trp Phe Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp

35 40 45

Ile Gly Gly Ile Tyr His Ser Gly Ser Thr Ala Tyr Asn Pro Ser Leu

50 55 60

Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser

65 70 75 80

Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Glu Val Thr Tyr Ser Arg Gly Pro Leu Asp Val Trp

100 105 110

Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro

115 120 125

Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr

130 135 140

Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr

145 150 155 160

Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro

165 170 175

Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr

180 185 190

Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp

195 200 205

His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr

210 215 220

Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro

225 230 235 240

Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser

245 250 255

Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp

260 265 270

Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn

275 280 285

Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val

290 295 300

Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu

305 310 315 320

Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys

325 330 335

Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr

340 345 350

Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr

355 360 365

Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu

370 375 380

Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu

385 390 395 400

Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys

405 410 415

Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu

420 425 430

Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly

435 440 445

Lys

<210> 289

<211> 450

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 289

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asn Tyr

20 25 30

Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Ala Ile Ser Ala Arg Ala Gly Ile Thr Tyr Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Arg Ile Gly Tyr Ser Tyr Gly Thr Ala Pro Pro Phe Asp Val

100 105 110

Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly

115 120 125

Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser

130 135 140

Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val

145 150 155 160

Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe

165 170 175

Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val

180 185 190

Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val

195 200 205

Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys

210 215 220

Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly

225 230 235 240

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile

245 250 255

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu

260 265 270

Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His

275 280 285

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg

290 295 300

Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys

305 310 315 320

Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu

325 330 335

Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr

340 345 350

Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu

355 360 365

Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp

370 375 380

Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val

385 390 395 400

Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp

405 410 415

Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His

420 425 430

Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro

435 440 445

Gly Lys

450

<210> 290

<211> 445

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 290

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr

20 25 30

Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Tyr Ile Ala Ser Ser Gly Ser Val Ile Tyr Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg His Gly Thr Pro Arg Ala Phe Asp Ile Trp Gly Gln Gly Thr

100 105 110

Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro

115 120 125

Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly

130 135 140

Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn

145 150 155 160

Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln

165 170 175

Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser

180 185 190

Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser

195 200 205

Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys

210 215 220

Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val Phe Leu

225 230 235 240

Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu

245 250 255

Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln

260 265 270

Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys

275 280 285

Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu

290 295 300

Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys

305 310 315 320

Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys

325 330 335

Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser

340 345 350

Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys

355 360 365

Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln

370 375 380

Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly

385 390 395 400

Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln

405 410 415

Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn

420 425 430

His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys

435 440 445

<210> 291

<211> 446

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 291

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Ser

20 25 30

Ala Met Ala Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Thr Ile Ser Gly Ser Gly Ile Thr Thr Trp Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Lys Gly Ser Arg His Leu Asn Ala Phe Asn Arg Trp Gly Gln Gly

100 105 110

Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe

115 120 125

Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu

130 135 140

Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp

145 150 155 160

Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu

165 170 175

Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser

180 185 190

Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro

195 200 205

Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro

210 215 220

Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val Phe

225 230 235 240

Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro

245 250 255

Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val

260 265 270

Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr

275 280 285

Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val

290 295 300

Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys

305 310 315 320

Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser

325 330 335

Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro

340 345 350

Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val

355 360 365

Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly

370 375 380

Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp

385 390 395 400

Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp

405 410 415

Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His

420 425 430

Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys

435 440 445

<210> 292

<211> 448

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 292

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gly

1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Gly Ser Ile Ser Ser Ser

20 25 30

Asn Trp Trp Ser Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp

35 40 45

Ile Gly Glu Ile Tyr His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu

50 55 60

Lys Ser Arg Val Thr Ile Ser Val Asp Lys Ser Lys Asn Gln Phe Ser

65 70 75 80

Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Val Tyr His Tyr Asp Pro Tyr Gly Met Asp Val Trp Gly

100 105 110

Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser

115 120 125

Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala

130 135 140

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val

145 150 155 160

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala

165 170 175

Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val

180 185 190

Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His

195 200 205

Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly

210 215 220

Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser

225 230 235 240

Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg

245 250 255

Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro

260 265 270

Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala

275 280 285

Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val

290 295 300

Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr

305 310 315 320

Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr

325 330 335

Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu

340 345 350

Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys

355 360 365

Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser

370 375 380

Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp

385 390 395 400

Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser

405 410 415

Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala

420 425 430

Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys

435 440 445

<210> 293

<211> 447

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 293

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser

20 25 30

Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu

35 40 45

Trp Ile Gly Ser Ile Ser Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg Thr Glu Leu Gly Lys Met His Phe Asp Tyr Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val

115 120 125

Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala

130 135 140

Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser

145 150 155 160

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val

165 170 175

Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro

180 185 190

Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys

195 200 205

Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro

210 215 220

Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val

225 230 235 240

Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr

245 250 255

Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu

260 265 270

Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys

275 280 285

Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser

290 295 300

Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys

305 310 315 320

Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile

325 330 335

Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro

340 345 350

Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu

355 360 365

Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn

370 375 380

Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser

385 390 395 400

Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg

405 410 415

Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu

420 425 430

His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys

435 440 445

<210> 294

<211> 445

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 294

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser

20 25 30

Asp Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu

35 40 45

Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg Gly Ser Pro Arg Tyr Met Gln Asp Trp Gly Gln Gly Thr

100 105 110

Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro

115 120 125

Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly

130 135 140

Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn

145 150 155 160

Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln

165 170 175

Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser

180 185 190

Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser

195 200 205

Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys

210 215 220

Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val Phe Leu

225 230 235 240

Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu

245 250 255

Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln

260 265 270

Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys

275 280 285

Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu

290 295 300

Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys

305 310 315 320

Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys

325 330 335

Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser

340 345 350

Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys

355 360 365

Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln

370 375 380

Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly

385 390 395 400

Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln

405 410 415

Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn

420 425 430

His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys

435 440 445

<210> 295

<211> 448

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 295

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr

20 25 30

Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Tyr Ile Ser Ser Ser Gly Ser Thr Ile Tyr Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg His Ser Ser Leu Gly Thr His Asn Trp Phe Asp Pro Trp Gly

100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser

115 120 125

Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala

130 135 140

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val

145 150 155 160

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala

165 170 175

Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val

180 185 190

Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His

195 200 205

Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly

210 215 220

Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser

225 230 235 240

Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg

245 250 255

Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro

260 265 270

Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala

275 280 285

Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val

290 295 300

Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr

305 310 315 320

Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr

325 330 335

Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu

340 345 350

Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys

355 360 365

Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser

370 375 380

Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp

385 390 395 400

Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser

405 410 415

Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala

420 425 430

Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys

435 440 445

<210> 296

<211> 450

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 296

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Tyr Ser Ile Ser Ser Gly

20 25 30

Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp

35 40 45

Ile Gly Ser Ile Tyr His Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu

50 55 60

Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser

65 70 75 80

Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Glu Gly Ala Leu Ser Tyr Ser Trp Leu Ala Ala Phe Asp Ile

100 105 110

Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly

115 120 125

Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser

130 135 140

Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val

145 150 155 160

Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe

165 170 175

Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val

180 185 190

Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val

195 200 205

Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys

210 215 220

Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly

225 230 235 240

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile

245 250 255

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu

260 265 270

Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His

275 280 285

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg

290 295 300

Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys

305 310 315 320

Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu

325 330 335

Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr

340 345 350

Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu

355 360 365

Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp

370 375 380

Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val

385 390 395 400

Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp

405 410 415

Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His

420 425 430

Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro

435 440 445

Gly Lys

450

<210> 297

<400> 297

000

<210> 298

<400> 298

000

<210> 299

<400> 299

000

<210> 300

<211> 215

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 300

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ala Val His Ser Pro

85 90 95

Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala

100 105 110

Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser

115 120 125

Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu

130 135 140

Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser

145 150 155 160

Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu

165 170 175

Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val

180 185 190

Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys

195 200 205

Ser Phe Asn Arg Gly Glu Cys

210 215

<210> 301

<211> 215

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 301

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ala Val His Ser Pro

85 90 95

Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala

100 105 110

Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser

115 120 125

Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu

130 135 140

Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser

145 150 155 160

Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu

165 170 175

Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val

180 185 190

Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys

195 200 205

Ser Phe Asn Arg Gly Glu Cys

210 215

<210> 302

<211> 215

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 302

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ala Val His Ser Pro

85 90 95

Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala

100 105 110

Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser

115 120 125

Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu

130 135 140

Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser

145 150 155 160

Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu

165 170 175

Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val

180 185 190

Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys

195 200 205

Ser Phe Asn Arg Gly Glu Cys

210 215

<210> 303

<211> 215

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 303

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ala Val His Ser Pro

85 90 95

Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala

100 105 110

Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser

115 120 125

Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu

130 135 140

Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser

145 150 155 160

Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu

165 170 175

Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val

180 185 190

Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys

195 200 205

Ser Phe Asn Arg Gly Glu Cys

210 215

<210> 304

<211> 215

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 304

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ala Val His Ser Pro

85 90 95

Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala

100 105 110

Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser

115 120 125

Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu

130 135 140

Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser

145 150 155 160

Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu

165 170 175

Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val

180 185 190

Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys

195 200 205

Ser Phe Asn Arg Gly Glu Cys

210 215

<210> 305

<211> 215

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 305

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Gly Ala Ser Gln Ser Val Ser Ser Asp

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Gly Ala Tyr Ser Leu Ala Thr Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Trp Ala Val His Ser Pro

85 90 95

Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala

100 105 110

Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser

115 120 125

Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu

130 135 140

Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser

145 150 155 160

Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu

165 170 175

Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val

180 185 190

Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys

195 200 205

Ser Phe Asn Arg Gly Glu Cys

210 215

<210> 306

<211> 215

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 306

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Gln Ala Ser Gln Ala Val Ser Ser Asn

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Val Val His Ser Pro

85 90 95

Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala

100 105 110

Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser

115 120 125

Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu

130 135 140

Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser

145 150 155 160

Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu

165 170 175

Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val

180 185 190

Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys

195 200 205

Ser Phe Asn Arg Gly Glu Cys

210 215

<210> 307

<211> 215

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 307

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Gly Ala Ser Gln Ser Val Ser Ser Ala

20 25 30

Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Gly Ala Ser Ala Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Val Val His Ser Pro

85 90 95

Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala

100 105 110

Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser

115 120 125

Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu

130 135 140

Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser

145 150 155 160

Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu

165 170 175

Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val

180 185 190

Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys

195 200 205

Ser Phe Asn Arg Gly Glu Cys

210 215

<210> 308

<211> 215

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 308

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Thr

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Gly Ala Ser Ser Arg Glu Ala Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Thr Val His Ser Pro

85 90 95

Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala

100 105 110

Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser

115 120 125

Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu

130 135 140

Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser

145 150 155 160

Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu

165 170 175

Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val

180 185 190

Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys

195 200 205

Ser Phe Asn Arg Gly Glu Cys

210 215

<210> 309

<211> 215

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 309

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Gln Ala Ser Gln Ala Val Ser Ser Asn

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Gly Ala Ser Asn Arg Ala Ala Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ala Ile His Ser Pro

85 90 95

Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala

100 105 110

Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser

115 120 125

Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu

130 135 140

Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser

145 150 155 160

Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu

165 170 175

Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val

180 185 190

Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys

195 200 205

Ser Phe Asn Arg Gly Glu Cys

210 215

<210> 310

<211> 215

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 310

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Gln Ala Ser Gln Ser Val Ser Ser Ser

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Gly Ala Ser Asn Arg Ala Ala Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Val Val His Ser Pro

85 90 95

Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala

100 105 110

Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser

115 120 125

Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu

130 135 140

Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser

145 150 155 160

Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu

165 170 175

Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val

180 185 190

Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys

195 200 205

Ser Phe Asn Arg Gly Glu Cys

210 215

<210> 311

<211> 215

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 311

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Lys Ala Ser Gln Ala Val Ser Ser Ser

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Gly Ala Ser Ser Arg Gln Asp Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Val Val His Ser Pro

85 90 95

Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala

100 105 110

Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser

115 120 125

Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu

130 135 140

Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser

145 150 155 160

Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu

165 170 175

Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val

180 185 190

Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys

195 200 205

Ser Phe Asn Arg Gly Glu Cys

210 215

<210> 312

<211> 215

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 312

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ala Val His Ser Pro

85 90 95

Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala

100 105 110

Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser

115 120 125

Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu

130 135 140

Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser

145 150 155 160

Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu

165 170 175

Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val

180 185 190

Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys

195 200 205

Ser Phe Asn Arg Gly Glu Cys

210 215

<210> 313

<211> 215

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 313

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln His Ser Ser Tyr Pro

85 90 95

Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala

100 105 110

Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser

115 120 125

Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu

130 135 140

Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser

145 150 155 160

Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu

165 170 175

Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val

180 185 190

Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys

195 200 205

Ser Phe Asn Arg Gly Glu Cys

210 215

<210> 314

<211> 215

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 314

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln His Ser Ser Tyr Pro

85 90 95

Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala

100 105 110

Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser

115 120 125

Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu

130 135 140

Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser

145 150 155 160

Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu

165 170 175

Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val

180 185 190

Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys

195 200 205

Ser Phe Asn Arg Gly Glu Cys

210 215

<210> 315

<211> 215

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 315

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Glu Ala Ser Gln Ser Val Ser Ser Ser

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Gly Ala Ser Asn Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln His Ser Leu Tyr Pro

85 90 95

Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala

100 105 110

Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser

115 120 125

Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu

130 135 140

Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser

145 150 155 160

Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu

165 170 175

Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val

180 185 190

Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys

195 200 205

Ser Phe Asn Arg Gly Glu Cys

210 215

<210> 316

<211> 215

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 316

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Glu Ala Ser Gln Ser Val Ser Ala Ser

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Asp Ala Ser Ser Arg Ala Ser Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Phe Ser Ser Tyr Pro

85 90 95

Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala

100 105 110

Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser

115 120 125

Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu

130 135 140

Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser

145 150 155 160

Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu

165 170 175

Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val

180 185 190

Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys

195 200 205

Ser Phe Asn Arg Gly Glu Cys

210 215

<210> 317

<211> 215

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 317

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Glu Ala Ser Gln Ser Val Ser Ser Ala

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Asp Ala Ser Thr Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Val Ser Ser Tyr Pro

85 90 95

Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala

100 105 110

Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser

115 120 125

Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu

130 135 140

Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser

145 150 155 160

Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu

165 170 175

Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val

180 185 190

Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys

195 200 205

Ser Phe Asn Arg Gly Glu Cys

210 215

<210> 318

<211> 215

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 318

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Ala Leu Ser Cys Arg Val Ser Gln Ser Val Ser Asp Ala

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Asp Ala Ser Ser Arg Ala Ser Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Val Ser Ser Tyr Pro

85 90 95

Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala

100 105 110

Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser

115 120 125

Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu

130 135 140

Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser

145 150 155 160

Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu

165 170 175

Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val

180 185 190

Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys

195 200 205

Ser Phe Asn Arg Gly Glu Cys

210 215

<210> 319

<211> 215

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 319

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Glu Val Ser Gln Ser Val Ser Ala Ser

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln His Ser Leu Tyr Pro

85 90 95

Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala

100 105 110

Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser

115 120 125

Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu

130 135 140

Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser

145 150 155 160

Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu

165 170 175

Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val

180 185 190

Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys

195 200 205

Ser Phe Asn Arg Gly Glu Cys

210 215

<210> 320

<211> 215

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 320

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ala

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Gly Ala Ser Asp Arg Ala Asn Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln His Ser Leu Tyr Pro

85 90 95

Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala

100 105 110

Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser

115 120 125

Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu

130 135 140

Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser

145 150 155 160

Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu

165 170 175

Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val

180 185 190

Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys

195 200 205

Ser Phe Asn Arg Gly Glu Cys

210 215

<210> 321

<211> 215

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 321

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Asn Ala Val Ser Ser Ser

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Gly Ala Ser Asp Arg Ala Asn Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln His Ser Ile Tyr Pro

85 90 95

Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala

100 105 110

Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser

115 120 125

Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu

130 135 140

Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser

145 150 155 160

Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu

165 170 175

Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val

180 185 190

Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys

195 200 205

Ser Phe Asn Arg Gly Glu Cys

210 215

<210> 322

<211> 215

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 322

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Asn Ala Val Ser Ser Ser

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Gly Ala Ser Tyr Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln His Ser Leu Tyr Pro

85 90 95

Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala

100 105 110

Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser

115 120 125

Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu

130 135 140

Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser

145 150 155 160

Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu

165 170 175

Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val

180 185 190

Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys

195 200 205

Ser Phe Asn Arg Gly Glu Cys

210 215

<210> 323

<211> 213

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 323

Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly

1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Asn Ser Trp

20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile

35 40 45

Ser Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly

50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro

65 70 75 80

Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Ser His Ile Thr

85 90 95

Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro

100 105 110

Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr

115 120 125

Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys

130 135 140

Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu

145 150 155 160

Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser

165 170 175

Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala

180 185 190

Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe

195 200 205

Asn Arg Gly Glu Cys

210

<210> 324

<211> 214

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 324

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly

1 5 10 15

Asp Arg Val Thr Ile Thr Cys Ala Ala Ser Gln Gly Ile Ser Ser Asp

20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile

35 40 45

Tyr Ser Ala Ser Ser Thr Gln Ser Gly Val Pro Ser Arg Phe Ser Gly

50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro

65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Tyr Leu Tyr Pro Ile

85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala

100 105 110

Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly

115 120 125

Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala

130 135 140

Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln

145 150 155 160

Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser

165 170 175

Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr

180 185 190

Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser

195 200 205

Phe Asn Arg Gly Glu Cys

210

<210> 325

<211> 214

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 325

Gly Val Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly

1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Thr Tyr

20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile

35 40 45

Tyr Asp Ala Phe Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly

50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro

65 70 75 80

Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Leu Pro Phe Leu Pro Ile

85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala

100 105 110

Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly

115 120 125

Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala

130 135 140

Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln

145 150 155 160

Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser

165 170 175

Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr

180 185 190

Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser

195 200 205

Phe Asn Arg Gly Glu Cys

210

<210> 326

<211> 219

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 326

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly

1 5 10 15

Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser

20 25 30

Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser

35 40 45

Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro

50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile

65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala

85 90 95

Leu Gly Gly Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys

100 105 110

Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu

115 120 125

Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe

130 135 140

Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln

145 150 155 160

Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser

165 170 175

Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu

180 185 190

Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser

195 200 205

Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys

210 215

<210> 327

<211> 215

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 327

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Gly Ala Ser Arg Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Val Ser Asp Pro

85 90 95

Ile Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala

100 105 110

Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser

115 120 125

Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu

130 135 140

Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser

145 150 155 160

Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu

165 170 175

Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val

180 185 190

Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys

195 200 205

Ser Phe Asn Arg Gly Glu Cys

210 215

<210> 328

<211> 215

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 328

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Gly Ala Ser Arg Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Val Gly Ser Ser Pro

85 90 95

Ile Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala

100 105 110

Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser

115 120 125

Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu

130 135 140

Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser

145 150 155 160

Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu

165 170 175

Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val

180 185 190

Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys

195 200 205

Ser Phe Asn Arg Gly Glu Cys

210 215

<210> 329

<211> 214

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 329

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly

1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr

20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile

35 40 45

Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly

50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro

65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser His Leu Val Pro Arg

85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala

100 105 110

Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly

115 120 125

Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala

130 135 140

Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln

145 150 155 160

Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser

165 170 175

Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr

180 185 190

Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser

195 200 205

Phe Asn Arg Gly Glu Cys

210

<210> 330

<211> 215

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 330

Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn

20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile

35 40 45

Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly

50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser

65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ala Asn His His Pro Pro

85 90 95

Phe Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala

100 105 110

Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser

115 120 125

Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu

130 135 140

Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser

145 150 155 160

Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu

165 170 175

Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val

180 185 190

Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys

195 200 205

Ser Phe Asn Arg Gly Glu Cys

210 215

<210> 331

<400> 331

000

<210> 332

<400> 332

000

<210> 333

<400> 333

000

<210> 334

<211> 330

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 334

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys

1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr

20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser

35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser

50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr

65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys

85 90 95

Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys

100 105 110

Pro Ala Pro Glu Ala Ala Gly Ala Pro Ser Val Phe Leu Phe Pro Pro

115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys

130 135 140

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp

145 150 155 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu

165 170 175

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu

180 185 190

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn

195 200 205

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly

210 215 220

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu

225 230 235 240

Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr

245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn

260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe

275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn

290 295 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr

305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys

325 330

<210> 335

<211> 327

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 335

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg

1 5 10 15

Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr

20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser

35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser

50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr

65 70 75 80

Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys

85 90 95

Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro

100 105 110

Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys

115 120 125

Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val

130 135 140

Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp

145 150 155 160

Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe

165 170 175

Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp

180 185 190

Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu

195 200 205

Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg

210 215 220

Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys

225 230 235 240

Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp

245 250 255

Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys

260 265 270

Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser

275 280 285

Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser

290 295 300

Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser

305 310 315 320

Leu Ser Leu Ser Pro Gly Lys

325

<210> 336

<211> 107

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 336

Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu

1 5 10 15

Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe

20 25 30

Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln

35 40 45

Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser

50 55 60

Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu

65 70 75 80

Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser

85 90 95

Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys

100 105

<210> 337

<211> 338

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 337

Met Val Val Met Ala Pro Arg Thr Leu Phe Leu Leu Leu Ser Gly Ala

1 5 10 15

Leu Thr Leu Thr Glu Thr Trp Ala Gly Ser His Ser Met Arg Tyr Phe

20 25 30

Ser Ala Ala Val Ser Arg Pro Gly Arg Gly Glu Pro Arg Phe Ile Ala

35 40 45

Met Gly Tyr Val Asp Asp Thr Gln Phe Val Arg Phe Asp Ser Asp Ser

50 55 60

Ala Cys Pro Arg Met Glu Pro Arg Ala Pro Trp Val Glu Gln Glu Gly

65 70 75 80

Pro Glu Tyr Trp Glu Glu Glu Thr Arg Asn Thr Lys Ala His Ala Gln

85 90 95

Thr Asp Arg Met Asn Leu Gln Thr Leu Arg Gly Tyr Tyr Asn Gln Ser

100 105 110

Glu Ala Ser Ser His Thr Leu Gln Trp Met Ile Gly Cys Asp Leu Gly

115 120 125

Ser Asp Gly Arg Leu Leu Arg Gly Tyr Glu Gln Tyr Ala Tyr Asp Gly

130 135 140

Lys Asp Tyr Leu Ala Leu Asn Glu Asp Leu Arg Ser Trp Thr Ala Ala

145 150 155 160

Asp Thr Ala Ala Gln Ile Ser Lys Arg Lys Cys Glu Ala Ala Asn Val

165 170 175

Ala Glu Gln Arg Arg Ala Tyr Leu Glu Gly Thr Cys Val Glu Trp Leu

180 185 190

His Arg Tyr Leu Glu Asn Gly Lys Glu Met Leu Gln Arg Ala Asp Pro

195 200 205

Pro Lys Thr His Val Thr His His Pro Val Phe Asp Tyr Glu Ala Thr

210 215 220

Leu Arg Cys Trp Ala Leu Gly Phe Tyr Pro Ala Glu Ile Ile Leu Thr

225 230 235 240

Trp Gln Arg Asp Gly Glu Asp Gln Thr Gln Asp Val Glu Leu Val Glu

245 250 255

Thr Arg Pro Ala Gly Asp Gly Thr Phe Gln Lys Trp Ala Ala Val Val

260 265 270

Val Pro Ser Gly Glu Glu Gln Arg Tyr Thr Cys His Val Gln His Glu

275 280 285

Gly Leu Pro Glu Pro Leu Met Leu Arg Trp Lys Gln Ser Ser Leu Pro

290 295 300

Thr Ile Pro Ile Met Gly Ile Val Ala Gly Leu Val Val Leu Ala Ala

305 310 315 320

Val Val Thr Gly Ala Ala Val Ala Ala Val Leu Trp Arg Lys Lys Ser

325 330 335

Ser Asp

<210> 338

<211> 319

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 338

Met Val Val Met Ala Pro Arg Thr Leu Phe Leu Leu Leu Ser Gly Ala

1 5 10 15

Leu Thr Leu Thr Glu Thr Trp Ala Gly Ser His Ser Met Arg Tyr Phe

20 25 30

Ser Ala Ala Val Ser Arg Pro Gly Arg Gly Glu Pro Arg Phe Ile Ala

35 40 45

Met Gly Tyr Val Asp Asp Thr Gln Phe Val Arg Phe Asp Ser Asp Ser

50 55 60

Ala Cys Pro Arg Met Glu Pro Arg Ala Pro Trp Val Glu Gln Glu Gly

65 70 75 80

Pro Glu Tyr Trp Glu Glu Glu Thr Arg Asn Thr Lys Ala His Ala Gln

85 90 95

Thr Asp Arg Met Asn Leu Gln Thr Leu Arg Gly Tyr Tyr Asn Gln Ser

100 105 110

Glu Ala Ser Ser His Thr Leu Gln Trp Met Ile Gly Cys Asp Leu Gly

115 120 125

Ser Asp Gly Arg Leu Leu Arg Gly Tyr Glu Gln Tyr Ala Tyr Asp Gly

130 135 140

Lys Asp Tyr Leu Ala Leu Asn Glu Asp Leu Arg Ser Trp Thr Ala Ala

145 150 155 160

Asp Thr Ala Ala Gln Ile Ser Lys Arg Lys Cys Glu Ala Ala Asn Val

165 170 175

Ala Glu Gln Arg Arg Ala Tyr Leu Glu Gly Thr Cys Val Glu Trp Leu

180 185 190

His Arg Tyr Leu Glu Asn Gly Lys Glu Met Leu Gln Arg Ala Asp Pro

195 200 205

Pro Lys Thr His Val Thr His His Pro Val Phe Asp Tyr Glu Ala Thr

210 215 220

Leu Arg Cys Trp Ala Leu Gly Phe Tyr Pro Ala Glu Ile Ile Leu Thr

225 230 235 240

Trp Gln Arg Asp Gly Glu Asp Gln Thr Gln Asp Val Glu Leu Val Glu

245 250 255

Thr Arg Pro Ala Gly Asp Gly Thr Phe Gln Lys Trp Ala Ala Val Val

260 265 270

Val Pro Ser Gly Glu Glu Gln Arg Tyr Thr Cys His Val Gln His Glu

275 280 285

Gly Leu Pro Glu Pro Leu Met Leu Arg Trp Ser Lys Glu Gly Asp Gly

290 295 300

Gly Ile Met Ser Val Arg Glu Ser Arg Ser Leu Ser Glu Asp Leu

305 310 315

<210> 339

<211> 336

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 339

Met Ala Val Met Ala Pro Arg Thr Leu Leu Leu Val Leu Ser Gly Val

1 5 10 15

Leu Ala Leu Thr Gln Pro Arg Ala Gly Ser His Ser Met Arg Tyr Phe

20 25 30

Tyr Thr Ala Val Ser Arg Pro Gly Arg Gly Gln Pro Arg Phe Ile Ala

35 40 45

Val Gly Tyr Val Asp Asp Thr Gln Phe Val Arg Phe Asp Ser Asp Ala

50 55 60

Glu Ser Pro Arg Met Glu Pro Arg Ala Pro Trp Val Glu Gln Glu Gly

65 70 75 80

Pro Glu Tyr Trp Asp Arg Glu Thr Gln Asn Met Lys Thr Ala Thr Gln

85 90 95

Thr Tyr Gln Ala Asn Leu Arg Thr Leu Leu Arg Tyr Tyr Asn Gln Ser

100 105 110

Glu Ala Gly Ser His Thr Phe Gln Lys Met Tyr Gly Cys Asp Leu Gly

115 120 125

Pro Asp Gly Arg Leu Leu Arg Gly Tyr Glu Gln Phe Ala Tyr Asp Gly

130 135 140

Arg Asp Tyr Ile Ile Leu Asn Glu Asp Leu Arg Ser Trp Thr Ala Ala

145 150 155 160

Asp Met Ala Ala Gln Asn Thr Gln Arg Lys Trp Glu Ala Ala Gly Ala

165 170 175

Ala Glu Gln His Arg Thr Tyr Leu Glu Gly Glu Cys Leu Glu Trp Leu

180 185 190

Arg Arg Tyr Leu Glu Asn Gly Lys Glu Thr Leu Gln Arg Ala Asp Pro

195 200 205

Pro Lys Thr Asn Val Thr His His Pro Val Ser Asp Tyr Glu Ala Thr

210 215 220

Leu Arg Cys Trp Ala Leu Gly Phe Tyr Pro Ala Glu Ile Thr Leu Thr

225 230 235 240

Trp Gln Arg Asp Gly Glu Glu Gln Thr Glu Asp Thr Glu Leu Val Glu

245 250 255

Thr Arg Pro Thr Gly Asp Gly Thr Phe Gln Lys Trp Ala Ala Val Val

260 265 270

Val Pro Ser Gly Glu Glu Gln Arg Tyr Thr Cys His Val Gln His Glu

275 280 285

Gly Leu Pro Lys Pro Leu Thr Leu Arg Trp Glu Pro Ser Ser Gln Ser

290 295 300

Thr Ile Leu Ile Val Gly Ile Ile Ala Gly Leu Val Leu Leu Gly Thr

305 310 315 320

Val Val Thr Gly Ala Val Val Ala Ala Val Met Trp Arg Arg Lys Ser

325 330 335

<210> 340

<211> 331

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 340

Leu Leu Leu Val Leu Ser Gly Val Leu Ala Leu Thr Gln Thr Arg Ala

1 5 10 15

Gly Ser His Ser Met Arg Tyr Phe Tyr Thr Ser Met Ser Arg Pro Gly

20 25 30

Arg Gly Gln Pro Arg Phe Ile Ala Val Gly Tyr Val Asp Asp Thr Gln

35 40 45

Phe Val Arg Phe Asp Ser Asp Ala Glu Ser Pro Arg Met Glu Pro Arg

50 55 60

Ala Pro Trp Val Glu Gln Glu Gly Pro Glu Tyr Trp Asp Arg Glu Thr

65 70 75 80

Gln Asn Met Lys Thr Ala Thr Gln Thr Tyr Arg Glu Asn Leu Arg Thr

85 90 95

Leu Leu Arg Tyr Tyr Asn Gln Ser Glu Ala Gly Ser His Thr Ile Gln

100 105 110

Lys Met Tyr Gly Cys Asp Leu Gly Pro Asp Gly Arg Leu Leu Arg Gly

115 120 125

Tyr Glu Gln Phe Ala Tyr Asp Gly Arg Asp Tyr Ile Ala Leu Asn Glu

130 135 140

Asp Leu Arg Ser Trp Thr Ala Ala Asp Met Ala Ala Gln Phe Thr Gln

145 150 155 160

Arg Lys Trp Glu Ala Ala Gly Ala Ala Glu Gln His Arg Thr Tyr Leu

165 170 175

Glu Gly Glu Cys Leu Glu Trp Leu Arg Arg Tyr Leu Glu Asn Gly Lys

180 185 190

Glu Thr Leu Gln Arg Ala Asp Pro Pro Lys Thr Asn Val Thr His His

195 200 205

Pro Val Ser Asp Tyr Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly Phe

210 215 220

Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Glu Gln

225 230 235 240

Thr Glu Asp Thr Glu Leu Val Glu Thr Arg Pro Thr Gly Asp Gly Thr

245 250 255

Phe Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Glu Glu Gln Arg

260 265 270

Tyr Thr Cys His Val Gln His Glu Gly Leu Pro Glu Pro Leu Thr Leu

275 280 285

Arg Trp Glu Pro Ser Ser Gln Ser Thr Ile Leu Ile Val Gly Ile Ile

290 295 300

Ala Gly Leu Val Leu Leu Gly Thr Val Val Thr Gly Ala Val Val Ala

305 310 315 320

Ala Val Met Trp Arg Arg Lys Ser Ser Asp Arg

325 330

<210> 341

<211> 298

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 341

Met Val Val Met Ala Pro Arg Thr Leu Phe Leu Leu Leu Ser Gly Ala

1 5 10 15

Leu Thr Leu Thr Glu Thr Trp Ala Gly Ser His Ser Met Arg Tyr Phe

20 25 30

Ser Ala Ala Val Ser Arg Pro Gly Arg Gly Glu Pro Arg Phe Ile Ala

35 40 45

Met Gly Tyr Val Asp Asp Thr Gln Phe Val Arg Phe Asp Ser Asp Ser

50 55 60

Ala Cys Pro Arg Met Glu Pro Arg Ala Pro Trp Val Glu Gln Glu Gly

65 70 75 80

Pro Glu Tyr Trp Glu Glu Glu Thr Arg Asn Thr Lys Ala His Ala Gln

85 90 95

Thr Asp Arg Met Asn Leu Gln Thr Leu Arg Gly Tyr Tyr Asn Gln Ser

100 105 110

Glu Ala Ser Ser His Thr Leu Gln Trp Met Ile Gly Cys Asp Leu Gly

115 120 125

Ser Asp Gly Arg Leu Leu Arg Gly Tyr Glu Gln Tyr Ala Tyr Asp Gly

130 135 140

Lys Asp Tyr Leu Ala Leu Asn Glu Asp Leu Arg Ser Trp Thr Ala Ala

145 150 155 160

Asp Thr Ala Ala Gln Ile Ser Lys Arg Lys Cys Glu Ala Ala Asn Val

165 170 175

Ala Glu Gln Arg Arg Ala Tyr Leu Glu Gly Thr Cys Val Glu Trp Leu

180 185 190

His Arg Tyr Leu Glu Asn Gly Lys Glu Met Leu Gln Arg Ala Asp Pro

195 200 205

Pro Lys Thr His Val Thr His His Pro Val Phe Asp Tyr Glu Ala Thr

210 215 220

Leu Arg Cys Trp Ala Leu Gly Phe Tyr Pro Ala Glu Ile Ile Leu Thr

225 230 235 240

Trp Gln Arg Asp Gly Glu Asp Gln Thr Gln Asp Val Glu Leu Val Glu

245 250 255

Thr Arg Pro Ala Gly Asp Gly Thr Phe Gln Lys Trp Ala Ala Val Val

260 265 270

Val Pro Ser Gly Glu Glu Gln Arg Tyr Thr Cys His Val Gln His Glu

275 280 285

Gly Leu Pro Glu Pro Leu Met Leu Arg Trp

290 295

<210> 342

<211> 274

<212> PRT/Protein

<213> Artificial sequence

<220>

<213> Synthetic

<400> 342

Gly Ser His Ser Met Arg Tyr Phe Ser Ala Ala Val Ser Arg Pro Gly

1 5 10 15

Arg Gly Glu Pro Arg Phe Ile Ala Met Gly Tyr Val Asp Asp Thr Gln

20 25 30

Phe Val Arg Phe Asp Ser Asp Ser Ala Cys Pro Arg Met Glu Pro Arg

35 40 45

Ala Pro Trp Val Glu Gln Glu Gly Pro Glu Tyr Trp Glu Glu Glu Thr

50 55 60

Arg Asn Thr Lys Ala His Ala Gln Thr Asp Arg Met Asn Leu Gln Thr

65 70 75 80

Leu Arg Gly Tyr Tyr Asn Gln Ser Glu Ala Ser Ser His Thr Leu Gln

85 90 95

Trp Met Ile Gly Cys Asp Leu Gly Ser Asp Gly Arg Leu Leu Arg Gly

100 105 110

Tyr Glu Gln Tyr Ala Tyr Asp Gly Lys Asp Tyr Leu Ala Leu Asn Glu

115 120 125

Asp Leu Arg Ser Trp Thr Ala Ala Asp Thr Ala Ala Gln Ile Ser Lys

130 135 140

Arg Lys Cys Glu Ala Ala Asn Val Ala Glu Gln Arg Arg Ala Tyr Leu

145 150 155 160

Glu Gly Thr Cys Val Glu Trp Leu His Arg Tyr Leu Glu Asn Gly Lys

165 170 175

Glu Met Leu Gln Arg Ala Asp Pro Pro Lys Thr His Val Thr His His

180 185 190

Pro Val Phe Asp Tyr Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly Phe

195 200 205

Tyr Pro Ala Glu Ile Ile Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln

210 215 220

Thr Gln Asp Val Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Gly Thr

225 230 235 240

Phe Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Glu Glu Gln Arg

245 250 255

Tyr Thr Cys His Val Gln His Glu Gly Leu Pro Glu Pro Leu Met Leu

260 265 270

Arg Trp

<---

Claims (80)

1. An antibody that specifically binds to human HLA-G (hHLA-G), comprising a heavy chain variable region (VH) and a light chain variable region ( _VL ), where a) VH contains: i) VH complementarity determining region (CDR) 1 - VHCDR1, containing the amino acid sequence presented in SEQ ID NO: 7; VHCDR2 containing the amino acid sequence presented in SEQ ID NO: 44; and VHCDR3, containing the amino acid sequence presented in SEQ ID NO: 93, and these CDRs are defined by Chothia; or ii) VHCDR1 containing the amino acid sequence presented in SEQ ID NO: 25; VHCDR2, containing the amino acid sequence presented in SEQ ID NO: 65; and VHCDR3, containing the amino acid sequence presented in SEQ ID NO: 93, and these CDRs are defined by Kabat; And b) VL contains: i) VLCDR1 containing the amino acid sequence presented in SEQ ID NO: 118; VLCDR2 containing the amino acid sequence presented in SEQ ID NO: 138; and VLCDR3, containing the amino acid sequence presented in SEQ ID NO: 155, and these CDRs are determined by Chothia and Kabat. 2. The antibody of claim 1, comprising a VH sequence that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 192 and a VL sequence that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 220. 3. The antibody of claim 1, comprising a VH sequence that is at least 95% identical to the amino acid sequence set forth in SEQ ID NO: 192 and a VL sequence that is at least 95% identical to the amino acid sequence set forth in SEQ ID NO: 220 . 4. The antibody of claim 1, comprising a heavy chain of the sequence SEQ ID NO: 254 and a light chain of the sequence SEQ ID NO: 322. 5. The antibody of claim 1, comprising a heavy chain of the sequence SEQ ID NO: 288 and a light chain of the sequence SEQ ID NO: 322. 6. The antibody according to claim 1, which is a monoclonal antibody. 7. A pharmaceutical composition for treating a disease or condition in which HLA-G is involved, comprising an effective amount of an antibody according to claim 1 and a pharmaceutically acceptable carrier or excipient. 8. The pharmaceutical composition according to claim 7, further containing at least one of the following: a) anti-ILT2 antibody; b) anti-ILT4 antibody; c) anti-KIR2DL4 antibody; d) anti-HLA-E antibody; e) anti-NKG2A antibody f) anti-HLA-F antibody g) anti-PD-L1 antibody; h) anti-PD-l antibody; i) anti-CD38 antibody; j) anti-CD39 antibody; k) anti-CD73 antibody; l) anti-A2A receptor antibody; m) anti-A2B receptor antibody; n) antibody against dual A2A/A2B receptor or combination thereof; o) anti-CD47 antibody; p) anti-CTLA-4 antibody; q) anti-TIM-3 antibody; r) anti-TIGIT antibody; s) anti-VISTA antibody; t) anti-CD94 antibody; u) small molecule inhibitor; v) bispecific T cell recruiter, agents for CART therapy, CAR NK cell therapy, CAR macrophage therapy, engineered cell therapy and/or adoptive T cell therapy; w) oncolytic virus; x) chemotherapeutic agent; and/or y) an ADCC therapeutic agent that uses competent effector antibodies such as anti-CD19, anti-CD20, anti-eGF, anti-Her2, anti-SLAMF7, anti-CD52, anti-BCMA, anti-GD2 and/or anti-CCR4. 9. The pharmaceutical composition according to claim 7 or 8, further containing one or both of: a) antibodies to an immunoinhibitory receptor or ligand and/or b) antibodies to an immunostimulating receptor or ligand. 10. An isolated nucleic acid molecule encoding the antibody according to claim 1. 11. An expression vector containing a nucleic acid molecule according to claim 10. 12. A prokaryotic or eukaryotic host cell for expressing an antibody that specifically binds to hHLA-G, comprising the vector of claim 11. 13. A kit for detecting the presence of HLA-G, containing the antibody according to claim 1 and a packaged combination of reagents in predetermined quantities with instructions for carrying out the procedure. 14. A method of producing an antibody that specifically binds to hHLA-G, comprising i) providing nucleic acids encoding the antibody of claim 1, ii) placing said nucleic acids into expression vectors, and iii) transfecting said expression vectors into host cells, to production of an antibody that specifically binds to hHLA-G. 15. A method of treating a disease or condition involving HLA-G in a subject suffering from said disease, comprising the step of administering to the subject a pharmaceutical composition containing an effective amount of an antibody according to claim 1. 16. The method of treatment according to claim 15, wherein said disease is selected from cancer, an autoimmune disease, an infection, a chronic infection or an inflammatory disease. 17. The method of claim 15, further comprising administering one or more of the following: a) antibodies against ILT2; b) antibodies against ILT4; c) antibodies against KIR2DL4; d) antibodies against HLA-E; e) antibodies against NKG2A f) antibodies against HLA-F g) antibodies against PD-L1; h) antibodies against PD-1; i) antibodies against CD38; j) antibodies against CD39; k) antibodies against CD73; l) antibodies against the A2A receptor; m) antibodies against the A2B receptor; n) antibodies against dual receptor A2A/A2B or combinations thereof; o) antibodies against CD47; p) antibodies against CTLA-4; q) antibodies against TIM-3; r) antibodies against TIGIT; s) antibodies against VISTA; t) antibodies against CD94; u) low molecular weight inhibitor; v) a bispecific T cell recruiter, an agent for CART therapy, CAR NK cell therapy, CAR macrophage therapy, engineered cell therapy and/or adoptive T cell therapy; w) oncolytic virus; x) chemotherapy; and/or y) a therapeutic agent with ADCC function, which uses competent effector antibodies, such as anti-CD19, anti-CD20, anti-eGF, anti-Her2, anti-SLAMF7, anti-CD52, anti-BCMA, anti-GD2 and/or anti-CCR4 antibodies. 18. The method of claim 15, wherein said method further includes one or more of the following: i) administering chemotherapy; ii) administering radiation therapy; and/or iii) administration of one or more additional therapeutic agents. 19. The method of claim 18, wherein said one or more additional therapeutic agents include one or more immunostimulating agents. 20. A method of modulating the function of the immune system in a subject in need thereof, comprising the step of bringing a population of immune cells of said subject into contact with a pharmaceutical composition containing an effective amount of an antibody according to claim 1 under conditions that provide modulation of the immune system.

Images